---
document_datetime: 2025-02-04 16:33:34
document_pages: 127
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/kisqali-h-c-004213-ii-0045-epar-assessment-report-variation_en.pdf
document_name: kisqali-h-c-004213-ii-0045-epar-assessment-report-variation_en.pdf
version: success
processing_time: 258.8165045
conversion_datetime: 2025-12-24 17:14:04.50107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
17 October 2024 EMA/CHMP/512303/2024

Committee for Medicinal Products for Human Use (CHMP) Corr.1 1

## Assessment report

## Kisqali

International non-proprietary name: Ribociclib

Procedure No. EMEA/H/C/004213/II/0045

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

1  3 February 2025 to correct a statement in section 3.3 'Uncertainties and limitations about favourable effects'

Official address

Domenico Scarlattilaan 6

Address for visits and deliveries

●

1083 HS Amsterdam

●

The Netherlands

Refer to www.ema.europa.eu/how-to-find-us

+31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................6                                                 |
| 2. Scientific discussion................................................................................                   | 8                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................8 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................8             |
| 2.1.2. About the product                                                                                                   | .............................................................................................9            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 10                                                                                                        |
| 2.1.4. General comments on compliance with                                                                                 | GCP........................................................ 12                                            |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Introduction....................................................................................................    | 12                                                                                                        |
| 2.2.2. Toxicology......................................................................................................    | 12                                                                                                        |
| 2.2.3. Ecotoxicity/environmental risk assessment.........................................................                  | 16                                                                                                        |
| 2.2.4. Discussion on non-clinical aspects .....................................................................            | 18                                                                                                        |
| 2.2.5. Conclusion on the non-clinical aspects                                                                              | ............................................................... 19                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 19     |
| 2.3.1. Introduction....................................................................................................    | 19                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 20           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 33                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 33          |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 35                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 37                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 37     |
| 2.4.1. Dose response study(ies)                                                                                            | ................................................................................. 37                      |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 37  |
| 2.4.1. Discussion on clinical efficacy............................................................................         | 66                                                                                                        |
| 2.4.2. Conclusions on the clinical efficacy                                                                                | .................................................................... 70                                   |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 71   |
| 2.5.1. Introduction....................................................................................................    | 71                                                                                                        |
| 2.5.2. Patient exposure                                                                                                    | ............................................................................................. 71          |
| 2.5.3. Adverse events                                                                                                      | ............................................................................................... 73        |
| 2.5.4. Serious adverse event/deaths/other significant events.......................................                        | 107                                                                                                       |
| 2.5.5. Laboratory findings........................................................................................         | 109                                                                                                       |
| 2.5.6. Safety in special populations...........................................................................            | 113                                                                                                       |
| 2.5.7. Discontinuation due to adverse events.............................................................                  | 114                                                                                                       |
| 2.5.8. Post marketing experience                                                                                           | ............................................................................. 116                         |
| 2.5.9. Discussion on clinical safety............................................................................           | 116                                                                                                       |
| 2.5.10. Conclusions on clinical safety ........................................................................            | 119                                                                                                       |
| 2.5.11. PSUR cycle .................................................................................................       | 119                                                                                                       |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 119                 |
| 2.7. Update of the Product information......................................................................               | 120                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 121                                                                                                       |

<div style=\"page-break-after: always\"></div>

3. Benefit-Risk Balance ........................................................................... 121

3.1. Therapeutic Context ......................................................................................... 121

3.1.1. Disease or condition ...................................................................................... 121

3.1.2. Available therapies and unmet medical need  ..................................................... 121

3.1.3. Main clinical studies  ....................................................................................... 121

3.2. Favourable effects  ............................................................................................ 122

3.3. Uncertainties and limitations about favourable effects  ........................................... 122

3.4. Unfavourable effects  ......................................................................................... 123

3.5. Uncertainties and limitations about unfavourable effects ....................................... 124

3.6. Effects Table  .................................................................................................... 124

3.7. Benefit-risk assessment and discussion  ............................................................... 125

3.7.1. Importance of favourable and unfavourable effects  ............................................ 125

3.7.2. Balance of benefits and risks .......................................................................... 125

3.7.3. Additional considerations on the benefit-risk balance ......................................... 125

3.8. Conclusions  ..................................................................................................... 126

4. Recommendations  ............................................................................... 126

<div style=\"page-break-after: always\"></div>

## List of abbreviations

aBC

Advanced breast cancer

ADR

Adverse drug reaction

AE

Adverse event

AI

Aromatase inhibitor

ANC

Absolute neutrophil count

AUC

Area under the concentration-time curve

BC

Breast cancer

CDK4/6

Cyclin-dependent kinase 4/6

CHMP

Committee for Medicinal Products for Human Use

CI

Confidence interval

CL

Clearance

CRO

Contract research organization

CTCAE

Common Terminology Criteria for Adverse Events

DCO

Data cut-off date

DDFS

Distant disease-free survival

DFS

Disease-free survival

DMC

Data Monitoring Committee

DRFS

Distant recurrence-free survival

eBC

Early breast cancer

ECOG

Eastern Cooperative Oncology Group

eCRS

Electronic Case Retrieval Strategy

EMA

European Medicines Agency

EORTC

European Organisation for Research and Treatment of Cancer

ET

Endocrine therapy

ET only

arm/group

Letrozole or anastrozole, plus goserelin (if applicable)

FAS

Full Analysis Set

FDA

Food and Drug Administration

HADS

Hospital Anxiety and Depression Scales

HER2

Human epidermal growth factor receptor 2

HR

Hormone receptor

iDFS

Invasive disease-free survival

ILD

Interstitial lung disease

IRT

Interactive response technology

LRRFS

Loco-regional recurrence-free survival

MedDRA

Medical Dictionary for Regulatory Activities

NSAI

Nonsteroidal aromatase inhibitor

OS

Overall survival

PAES

Post Approval Efficacy Study

PARP

Poly (ADP-ribose) polymerase

PD

Pharmacodynamics

PFS

Progression-free survival

PgR

Progesterone receptor

PK

Pharmacokinetics

popPK

Population pharmacokinetics

PPS

Per-protocol set

PRO

Patient-reported outcome

PSUR

Periodic Safety Update Report

<div style=\"page-break-after: always\"></div>

| RFS   | Recurrence-free survival                                                            |
|-------|-------------------------------------------------------------------------------------|
| RMM   | Repeated measures model                                                             |
| SAE   | Serious adverse event                                                               |
| SC    | Steering Committee                                                                  |
| SCE   | Summary of Clinical Efficacy                                                        |
| SCP   | Summary of Clinical Pharmacology                                                    |
| SCS   | Summary of Clinical Safety                                                          |
| SEER  | Surveillance, Epidemiology, and End Results                                         |
| STEEP | Standardized Definitions for Efficacy End Points (in Adjuvant Breast Cancer Trials) |
| TTR   | Time to response                                                                    |
| VAS   | Visual analog scale                                                                 |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Novartis Europharm Limited submitted to the European Medicines Agency on 25 August 2023 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include the adjuvant treatment of adult patients with hormone receptor (HR)positive, human epidermal growth factor receptor 2 (HER2)-negative, Stage II or Stage III early breast cancer, irrespective of nodal status, in combination with an AI for Kisqali based on study CLEE011O12301C (NATALEE); This is a global, Phase III, multicentre, randomized, open-label trial to evaluate efficacy and safety of ribociclib with ET versus ET alone as adjuvant treatment in patients with HR-positive, HER2-negative, early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH sought advice at the CHMP on 23 Nov 2016 and 01 Nov 2018.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

Co-Rapporteur:

N/A

<div style=\"page-break-after: always\"></div>

| Timetable                                                            | Actual dates      |
|----------------------------------------------------------------------|-------------------|
| Submission date                                                      | 25 August 2023    |
| Start of procedure:                                                  | 16 September 2023 |
| CHMP Rapporteur Assessment Report                                    | 10 November 2023  |
| PRAC Rapporteur Assessment Report                                    | 16 November 2023  |
| CHMP Co-Rapporteur Assessment                                        | 22 November 2023  |
| PRAC members comments                                                | 22 November 2023  |
| PRAC Outcome                                                         | 30 November 2023  |
| CHMP members comments                                                | 04 December 2024  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                 | 7 December 2023   |
| Request for supplementary information (RSI)                          | 14 December 2023  |
| MAH's responses submitted to the CHMP on:                            | 18 January 2024   |
| CHMP Rapporteur Assessment Report                                    | 20 February 2024  |
| PRAC Rapporteur Assessment Report                                    | 23 February 2024  |
| PRAC members comments                                                | 28 February 2024  |
| Updated PRAC Rapporteur Assessment Report                            | n/a               |
| PRAC Outcome                                                         | 07 March 2024     |
| CHMP members comments                                                | 11 March 2024     |
| Updated CHMP Rapporteur Assessment Report                            | 14 March 2024     |
| Request for supplementary information (RSI)                          | 21 March 2024     |
| MAH's responses submitted to the CHMP on:                            | 23 May 2024       |
| Rapporteur's assessment report on the MAH's responses circulated on: | 01 July 2024      |
| CHMP members comments                                                | 15 July 2024      |
| Rapporteur's updated assessment report circulated on:                | 18 July 2024      |
| Request for supplementary information (RSI)                          | 25 July 2024      |
| MAH's responses submitted to the CHMP on:                            | 13 August 2024    |
| Rapporteur's assessment report on the MAH's responses circulated on: | 23 September 2024 |
| CHMP members comments                                                | 07 October 2024   |
| Rapporteur's updated assessment report circulated on:                | 10 October 2024   |
| CHMP opinion:                                                        | 17 October 2024   |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The claimed indication is:

Kisqali is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer, irrespective of nodal status, in combination with an aromatase inhibitor.

The final indication has been amended as follows:

Kisqali in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)negative early breast cancer at high risk of recurrence (see section 5.1 for selection criteria).

In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

## Epidemiology

Breast cancer (BC) is the most frequently diagnosed cancer among women worldwide. Approximately 2.3 million new cases of BC and 685,000 deaths attributed to this disease were estimated to occur in 2020 worldwide. BC incidence varies between individuals of different ethnicities and in different geographic locations around the world. In Europe, the estimated incidence of BC in 2020 was approximately 531,000, with 142,000 deaths (GLOBOCAN 2020). Breast cancer in men is uncommon, with a reported frequency of approximately 1% of all BC (Eggemann et al 2013).

## Biologic features

BC is a molecularly diverse disease with several clearly defined molecular subgroups (Perou et al 2000). Clinically, the three therapeutic subgroups are HR-positive breast cancer (oestrogen and/or progesterone receptor-positive with normal HER2 expression), HER2-positive breast cancer characterized by HER2 gene amplification or overexpression (approximately 45% of these cancers are HR-positive), and triplenegative breast cancer characterized by low or absent hormone receptors and absence of HER2 alteration.

Approximately 60-65% of new BC cases are HR-positive and benefit from adjuvant endocrine therapy (ET), which reduces the risk of recurrence and, ultimately, cancer death. Resistance to ET, however, continues to be a clinical problem.

The cyclin-dependent kinase (CDK) 4/6 complex is involved in DNA synthesis and cell cycle progression via interaction with cyclin D1 and the retinoblastoma protein (pRb). Oestrogen receptor (ER)-positive BC seems to be particularly dependent on the CDK4/cyclin D1/Rb interaction, which, concurrently, is often dysregulated in BC. CDK4/6/cyclin D1/Rb interaction thus constitutes a potential target for targeted therapies in HR-positive BC.

<div style=\"page-break-after: always\"></div>

## Clinical presentation, diagnosis

Almost all newly diagnosed BC cases are early BC (eBC), localised to the breast tissue and regional lymphatics, which are potentially curable with surgical resection and a variety of treatment modalities. Among all HR-positive, HER2-negative BC cases in females diagnosed between 2010 and 2019, 94.8% of the cases were eBC, with 68.9% localised to the breast tissue and 25.9% within both the breast tissue and regional lymph nodes (SEER 2022).

## Management

The treatment goal for patients with eBC is prevention of both early and late recurrences and, subsequently, death due to BC.

Treatment of patients with HR-positive, HER2-negative eBC consists of surgery and combinations of adjuvant ET, radiotherapy, and neoadjuvant and/or adjuvant chemotherapy. The systemic treatments are typically considered for patients at risk for recurrence, including stage II and III disease with larger tumour size and/or metastases in multiple regional lymph nodes, high tumour grade, and high recurrence genomic score, or a combination of these. Adjuvant systemic treatments in patients with eBC have been shown to decrease locoregional and distant recurrences, reduce the risk of recurrence and BC deaths, and to improve 15-year breast cancer mortality (Clarke et al 2005). According to current ESMO and NCCN clinical guidelines, pre- and postmenopausal women with HR-positive eBC are recommended adjuvant ET. For premenopausal women and for men, standard adjuvant ET consists of tamoxifen or an aromatase inhibitor (AI) + a luteinizing hormone-releasing hormone (LHRH). For postmenopausal women, adjuvant ET consists of either an AI (letrozole, anastrozole, or exemestane) or tamoxifen, alone or sequential treatment.

Despite adjuvant ET, recurrences are still common. Approximately 30-60% of patients with stage II and III BC suffer from recurrent disease. The risk of recurrence in patients with HR-positive, HER-2 negative eBC is highest during the first 5 years after diagnosis, but still more than half of those who recur experience late recurrences (≥ 5 years from diagnosis). In women with ER -positive eBC who were disease-free after 5 years of adjuvant ET, the cumulative 20-year risk of distant recurrence is approximately 22% for patients without lymph node metastases and 31-52% for those with nodal disease. The corresponding cumulative 20-year risks of death from BC based on nodal status (N0, N1-3, N4-9) are 15%, 28%, and 49%, respectively (Pan et al 2017). Currently, abemaciclib in combination with ET is the only CDK4/6 inhibitor indicated for adjuvant treatment of HR-positive, HER2-negative eBC with high risk of recurrence (see Verzenios EPAR).

## 2.1.2. About the product

Ribociclib is an oral, selective small molecule inhibitor of the CDK4/6 enzyme complex, which targets the pRb to block cell cycle progression. The inhibition of CDK4/6 can delay or overcome endocrine resistance and thereby enhance the effectiveness of ET.

## The current submitted indication is in Early breast cancer

The recommended dose is 400 mg (two 200 mg film-coated tablets) of ribociclib once daily for 21 consecutive days followed by 7 days off treatment, resulting in a complete cycle of 28 days. In patients with early breast cancer, Kisqali should be taken until completion of 3 years of treatment or until disease recurrence or unacceptable toxicity occur.

Previously the product was approved for Advanced or metastatic breast cancer

<div style=\"page-break-after: always\"></div>

The recommended dose is 600 mg (three 200 mg film-coated tablets) of ribociclib once daily for 21 consecutive days followed by 7 days off treatment, resulting in a complete cycle of 28 days. In patients with advanced or metastatic breast cancer, the treatment should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.

Ribociclib as well as the CDK4/6 inhibitors abemaciclib and palbociclib are indicated for treatment of advanced or metastatic BC in combination with ET (see Kisqali EPAR).

Ribociclib has been studied in combination with various hormonal and other agents in cancer patients.

- Ribociclib + letrozole vs. letrozole monotherapy was investigated in the phase III study MONALEESA-2 in postmenopausal women with HR-positive, HER2-negative, advanced BC (aBC) without prior therapy for advanced disease.
- Ribociclib in combination with either a non-steroidal AI (NSAI) or tamoxifen and goserelin vs. placebo in combination with either an NSAI or tamoxifen and goserelin was investigated in the phase III study MONALEESA-7 in pre- and perimenopausal women with HR-positive, HER2-negative aBC without prior ET for advanced disease.
- Ribociclib + fulvestrant vs. fulvestrant monotherapy was investigated in the phase III study MONALEESA-3 in postmenopausal women with HR-positive, HER2-negative aBC who had received no or only one line of prior ET.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## Development programme

The primary claim for treatment of HR-positive, HER2-negative eBC with ribociclib + AI is based on the pivotal study CLEE011O12301C (`study O12301C´). Ribociclib is not indicated in combination with tamoxifen, and in study O12301C all patients were treated with the AIs letrozole or anastrozole. Premenopausal women plus men also received the gonadotropin-releasing hormone (GnRH) agonist goserelin for gonadal suppression.

## Scientific advice

On 23 Nov 2016 the Applicant Novartis requested scientific advice for their product ribociclib. At that time, Novartis sought advice from the CHMP and SAWP concerning the pre-clinical and clinical development of their intended phase III study in eBC patients with high risk of recurrence.

In summary, the CHMP agreed on the Applicant's approach to assess the carcinogenic potential of ribociclib using a stepwise procedure in a 2-year rat carcinogenicity study. The outcome of the rat carcinogenicity study was requested to be included in the application for extension of indication for adjuvant treatment. It was noted that, eventually, a study in a transgenic mouse model should be considered before MAA.

Furthermore, the Applicant proposed two clinical studies, one in eBC patients with high risk of recurrence and one in eBC patients with intermediate risk of recurrence. For both the CHMP overall agreed on the target population and study design. The endpoints were endorsed with some recommendations. Furthermore, the Applicant was advised to plan adequate collection of OS data.

The proposed dosage (600 mg daily orally in a 3 weeks on/1 week off schedule) was endorsed but a justification of the proposed treatment duration was requested and different treatment durations (e.g., one and two years) in the phase 3 study was advised.

<div style=\"page-break-after: always\"></div>

On 01 Nov 2018 Novartis requested scientific advice for their product ribociclib (EMA/CHMP/SAWP/113188/2019) as follow-up to the previous advice where two different studies were suggested, one in stage II and one in stage III. The Applicant proposed to evaluate both study populations in one pivotal study. No detailed reasons were given, but the Applicant stated that the change was not due to safety reasons.

Because of the changed study design, the overall sample size was proposed to be reduced. It was noted by the CHMP that study heterogeneity may be further increased when different target populations are combined. The approach evaluating an overall population within one pivotal study was not rejected but the Applicant was requested to ensure sufficiently high recruitment numbers to allow the demonstration of internal consistency of efficacy and safety across the relevant subpopulations in this heterogeneous overall population. As a consequence of the CHMP critique, the MAH amended the overall sample size of the study from 4,000 to 5,000 in protocol amendment 4.0, 27-Aug-2020 (addition of 1,000 patients with stage III disease).

Furthermore, the Applicant proposed to cap enrolment of stage II and III patients at 40% and 60%, respectively. The CHMP highlighted that from a clinical perspective this study population would not be representative for the population being treated in clinical practice out of trials. The weighting of stage II and stage III in the statistical analysis will depend on the proportion of events that are contributed by each stratum such that it is counterintuitive to even increase the proportion of stage III patients with a higher event risk compared to the natural distribution. The Applicant expected a consistent treatment effect in terms of hazard ratio for stage II and stage III patients and justified the capping by an expected shorter study duration. The assessment of the consistency assumption will be of paramount importance to justify that the results as observed in the study population can be generalised to the overall patient population.

The Applicant furthermore proposed a lower ribociclib dosage (400 mg) and longer treatment duration (36 months) than previously discussed. It was considered that the dose reduction may not be well underpinned and that the treatment duration needed further justification, not least taking into account that the long-term safety of ribociclib was undetermined.

The endpoints were endorsed but the Applicant was recommended to continue collecting iDFS data to provide analyses in line with EMA censoring rules. Furthermore, the Applicant was advised to plan adequate collection of OS data.

On 29 June 2023 a pre-submission with the Applicant and the Rapporteurs was held. The Rapporteurs noted that given the adjuvant setting of the indication and the high percentage of patients still on treatment at the time of the presented data lock-point, a longer follow up period will be required to sufficiently assess the benefit/risk. The applicant anticipated a data update at 500 events, probably available at the time of responses to the first round of questions. The MAH was informed that these data will be required for decision-making.

Furthermore, the MAH has received scientific advice from the FDA regarding the endpoint overall survival (OS) and regarding treatment duration. The FDA asked if the study O12301C SAP would include formal testing for OS but given the stage II and stage III eBC patient population the event rate for OS was expected to be low, and so it was considered impractical to statistically power an analysis of OS. OS was, however, added as a secondary endpoint.

The optimal duration of ribociclib treatment in the adjuvant setting was discussed but ultimately left for the Sponsor decision. Data supported a higher risk of disease recurrence during the first three years after surgical resection. According to the Applicant, an extended duration of treatment is critical to prolong cell cycle arrest and drive more tumour cells into senescence/death and, thus, a 3-year duration of treatment was chosen for the study.

<div style=\"page-break-after: always\"></div>

The following recommendation is not considered completely met in the application:

- Study O12301C is an open-label study. Radiologic review is assessed locally, and not centrally reviewed. As was stated in the scientific advice on 23 Nov 2016, this was not agreed upon. All efforts must be made to keep the strictest parallelism in the assessments between arms to minimise the risk of bias when the study is not double-blinded.

## 2.1.4. General comments on compliance with GCP

The MAH states that the study is conducted in compliance with GCP. The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

Kisqali contains a nitrosamine impurity (N-NRib) which levels, have been so far regulated by ICH Q3B in accordance with ICH S9 for the currently approved indication of locally advanced and metastatic breast cancer.

The current extension of indication application aims to treat early breast cancer in an adjuvant setting hence the exception in ICH S9 is not applicable and would need to follow ICH M7 guidance for non-clinical development.

## 2.2.2. Toxicology

## Genotoxicity

The N-nitrosoribociclib impurity (N-NRib) is present in trace amounts in ribociclib succinate drug substance and in Ribociclib 200 mg film-coated tablet. N-NRib was tested in three separate Ames tests, all concluding that N-NRib did not induce mutations under the test conditions. However, N-NRib was determined to be mutagenic in an in vivo transgenic rodent (TGR) gene mutation assay (Muta™Mouse study). N-NRib limits need to be controlled using the carcinogenic potency categorization approach (CPCA) by applying a maximum acceptable intake (AI) of 400 ng/day (category 3).

The applicant proposed changes to the quality module to include measures to minimize the formation of the N-NRib impurity and to ensure control of N-NRib in compliance with the acceptable intake of 400 ng/day for early breast cancer and considering a Maximum Daily Dose (MDD) of 400 mg for the proposed early breast cancer indication which are assessed in procedure EMEA/H/C/004213/II/0054/G.

N-NRib was tested in three separate Ames tests: one enhanced Ames test (EAT) applying EAT conditions and two supportive tests, one standard Ames test (not an EAT) and one externally conducted Ames (partly EAT conditions).

<div style=\"page-break-after: always\"></div>

Table 1. Tabular summary of in vitro and in vivo mutagenicity assays performed for N-NRib

| Novartis Ref. 2371003   | N-NRib: Transgenic Gene Mutation Assay in Muta™Mice (the objective of this study is to evaluate the induction of gene mutation in the lacZ transgene in bone marrow, liver, kidney and duodenum from Muta™Mice (CD2-lacZ80/HazfBR strain)).                                                                                                                                                                                                                                                       |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Novartis Ref. 2370992   | Bacterial Reverse Mutation Assay using the Enhanced Ames protocol (the objective of this study is to evaluate the ability of N-NRib to induce reverse mutations in histidine-requiring strains of Salmonella typhimurium and one tryptophan-requiring strain of Escherichia coli in the absence and presence of a 30% rat and 30% hamster liver metabolising system (S-9))                                                                                                                        |
| Novartis Ref. 2112503   | Bacterial Reverse Mutation Assay (The objective of the Salmonella/microsome assay is to evaluate the mutagenic potential of a test item by its effects on one or more histidine-requiring strains of Salmonella typhimurium in the absence and presence of a 10% rat liver metabolising system) non-regulatory study for which a claim of GLP compliance was not made. However, the laboratory procedures were conducted in accordance with the current GLP requirements of the UK MHRA and OECD. |

Table 2. Summary of Bacterial Reverse Mutation Assay in vitro using the Enhanced Ames Test protocol (23709992)

| Genotoxicity: in vitro (23709992): Bacterial Reverse Mutation Assay   | Genotoxicity: in vitro (23709992): Bacterial Reverse Mutation Assay                                                                             |
|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Test for induction of                                                 | Reverse Mutations (Enhanced Ames Test)                                                                                                          |
| Strains                                                               | Salmonella typhimurium TA98, TA100, TA1535 and TA1537 and Escherichia coli WP2 uvrA pKM101                                                      |
| Metabolizing System                                                   | β -Naphthoflavone/Phenobarbital induced rat or hamster liver S-9 (30%)                                                                          |
| Vehicles:                                                             | Vehicles:                                                                                                                                       |
| For Test item: For Positive Controls:                                 | Dimethyl formamide (DMF) Dimethyl Sulphoxide (DMSO) (2NF, AAC, AAN, B[a]P, NQO, NDEA, MNPA), Purified water (NAN3)                              |
| No. of Independent Assays:                                            | 1                                                                                                                                               |
| No. of Replicates:                                                    | 3                                                                                                                                               |
| No. Cells/Analysed/Culture:                                           | 10 8 /plate                                                                                                                                     |
| Treatment:                                                            | Pre-incubation (30 minutes)                                                                                                                     |
| Date of Treatment:                                                    | 12 December 2023                                                                                                                                |
| Novartis Reference No:                                                | 2370992                                                                                                                                         |
| GLP Compliance:                                                       | Yes                                                                                                                                             |
| Toxic Effects:                                                        | Evidence of toxicity in the form of a reduction in revertant numbers was observed at 750 μ g/plate and above in strain TA100 in the presence of |

<div style=\"page-break-after: always\"></div>

## Genotoxicity: in vitro (23709992): Bacterial Reverse Mutation Assay

hamster S-9 and at 1000 μ g/plate in strain TA1537 in the presence of hamster S-9

None

Genotoxic Effects:

Table 3. Raw plate counts without activation

|                      |                 |                          | MutationExperiment   | MutationExperiment   | MutationExperiment            | MutationExperiment   | MutationExperiment   |
|----------------------|-----------------|--------------------------|----------------------|----------------------|-------------------------------|----------------------|----------------------|
| Metabolic Activation | Test Item       | Concentration (μg/plate) |                      |                      | Revertants/Plate(Mean) TA1535 | TA1537               | WP2uvrApKM101        |
|                      | DMF             | 0                        | 17                   | 115                  | 20                            | 8                    | 190                  |
| Without              | DMP433          | 5                        | 18                   | 118                  | 11                            | 8                    | 182                  |
| Activation           | DMP433          | 16                       | 15                   | 108                  | 9                             | 8                    | 149                  |
|                      | DMP433          | 50                       | 15                   | 117                  | 13                            | 11                   | 164                  |
|                      | DMP433          | 160                      | 14                   | 128                  | 12                            | 7                    | 145                  |
|                      | DMP433          | 500                      | 17                   | 134                  | 12                            | 9                    | 160                  |
|                      | DMP433          | 750                      | 18P                  | 107 P                | 12 P                          | 10P                  | 142 P                |
|                      | DMP433          | 1000                     | 18P                  | 113P                 | 14 P                          | 10P                  | 167 P                |
|                      | PositiveControl | Compound                 | 2NF                  | NaN3                 | NaN3                          | AAC                  | NQO                  |
|                      |                 | Concentration            | 5                    | 2                    | 2                             | 50                   | 2                    |
|                      |                 | (μg/plate) Revertants    | 1832                 | 1070                 | 891                           | 277                  | 1726                 |

Table 4. Raw plate counts without activation

|                      |                 |                          | MutationExperiment   | MutationExperiment   | MutationExperiment            | MutationExperiment   | MutationExperiment   |
|----------------------|-----------------|--------------------------|----------------------|----------------------|-------------------------------|----------------------|----------------------|
| Metabolic Activation | Test Item       | Concentration (μg/plate) | TA98                 | TA100                | Revertants/Plate(Mean) TA1535 | TA1537               | WP2uvrApKM101        |
|                      | DMF             | 0                        | 36                   | 156                  | 19                            | 25                   | 203                  |
| With                 | DMP433          | 5                        | 39                   | 143                  | 21                            | 18                   | 212                  |
| Activation           | DMP433          | 16                       | 33                   | 137                  | 19                            | 20                   | 229                  |
| 30%Rat               | DMP433          | 50                       | 39                   | 123                  | 16                            | 18                   | 211                  |
| S-9                  | DMP433          | 160                      | 40                   | 122                  | 18                            | 27                   | 201                  |
|                      | DMP433          | 500                      | 31                   | 121                  | 24                            | 20                   | 220                  |
|                      | DMP433          | 750                      | 38P                  | 121 P                | 17 P                          | 23 P                 | 201 P                |
|                      | DMP433          | 1000                     | 39P                  | 117 P                | 19P                           | 25 P                 | 186P                 |
|                      | DMSO            | 0                        | 62                   | 184                  | 26 M                          | 18CM                 | 192                  |
|                      | NDEA            | 1250                     | 54                   | 235                  | 23                            | 20                   | 518                  |
|                      | NDEA            | 2500                     | 59                   | 270                  | 31                            | 32                   | 702                  |
|                      | NDEA            | 5000                     | 65                   | 311                  | 26                            | 15                   | 928                  |
|                      | MNPA            | 500                      | 51CM                 | 1041                 | 558                           | 16                   | 903                  |
|                      | MNPA            | 1600                     | 61                   | 1116                 | 413                           | 22                   | 875                  |
|                      | PositiveControl | Compound                 | B[a]P                | AAN                  | AAN                           | AAN                  | AAN                  |
|                      |                 | Concentration(μg/plate)  | 10                   | 5                    | 5                             | 5                    | 10                   |
|                      |                 | Revertants               | 269                  | 1568                 | 184                           | 31                   | 643                  |

<div style=\"page-break-after: always\"></div>

| MutationExperiment   | MutationExperiment   | MutationExperiment       | MutationExperiment                                                   | MutationExperiment                                                   | MutationExperiment                                                   | MutationExperiment                                                   | MutationExperiment                                                   |
|----------------------|----------------------|--------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                      |                      | (μg/plate)               | Metabolic Test Item Concentration Revertants/Plate (Mean) Activation | Metabolic Test Item Concentration Revertants/Plate (Mean) Activation | Metabolic Test Item Concentration Revertants/Plate (Mean) Activation | Metabolic Test Item Concentration Revertants/Plate (Mean) Activation | Metabolic Test Item Concentration Revertants/Plate (Mean) Activation |
|                      |                      |                          |                                                                      | TA1537                                                               | WP2uvrApKM101                                                        |                                                                      |                                                                      |
| With                 | Positive Control     | Compound                 |                                                                      | AAN                                                                  |                                                                      |                                                                      |                                                                      |
| Activation           |                      | Concentration (μg/plate) |                                                                      | 8                                                                    |                                                                      |                                                                      |                                                                      |
| 30% Rat              |                      | Revertants               |                                                                      | 42                                                                   |                                                                      |                                                                      |                                                                      |
| S-9                  | Positive Control     | Compound                 |                                                                      | AAN                                                                  |                                                                      |                                                                      |                                                                      |
| (continued)          |                      | Concentration (μg/plate) |                                                                      | 1.25                                                                 |                                                                      |                                                                      |                                                                      |
|                      |                      | Revertants               |                                                                      | 32 M                                                                 |                                                                      |                                                                      |                                                                      |
|                      | Positive Control     | Compound                 |                                                                      | B[a]P                                                                |                                                                      |                                                                      |                                                                      |
|                      |                      | Concentration (μg/plate) |                                                                      | 7.5                                                                  |                                                                      |                                                                      |                                                                      |
|                      |                      | Revertants               |                                                                      | 85M                                                                  |                                                                      |                                                                      |                                                                      |
|                      | Positive Control     | Compound                 |                                                                      | B[a]P                                                                |                                                                      |                                                                      |                                                                      |
|                      |                      | Concentration (μg/plate) |                                                                      | 10                                                                   |                                                                      |                                                                      |                                                                      |
|                      |                      | Revertants               |                                                                      | 88                                                                   |                                                                      |                                                                      |                                                                      |

MutationExperiment

| Metabolic Activation   | Test Item        | Concentration (μg/plate)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   |
|------------------------|------------------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                        |                  |                            | TA98                      | TA100                     | TA1535                    | TA1537                    | WP2uvrA pKM101            |
|                        | DMF              | 0                          | 47                        | 180CM                     | 30                        | 23                        | 228                       |
| With                   | DMP433           | 5                          | 36                        | 117WCM                    | 31                        | 22                        | 304                       |
| Activation             | DMP433           | 16                         | 39                        | 103WM                     | 25 W M                    | 19                        | 225                       |
| 30%                    | DMP433           | 50                         | 41                        | 115 W M                   | 23 W M                    | 20                        | 221                       |
| Hamster S-9            | DMP433           | 160                        | 40                        | 102W M                    | 18 W M                    | 16                        | 242                       |
|                        | DMP433           | 500                        | 40                        | 107W M                    | 17 W M                    | 22                        | 214                       |
|                        | DMP433           | 750                        | 36P                       | 98WPM                     | 17WP M                    | 16P                       | 172 P                     |
|                        | DMP433           | 1000                       | 41 P                      | 97WPM                     | 21WPM                     | 12 P                      | 194 P                     |
|                        | DMSO             | 0                          | 38M                       | 145                       | 26                        | 19                        | 188                       |
|                        | NDEA             | 1250                       | 87                        | 570                       | 103                       | 24                        | 966                       |
|                        | NDEA             | 2500                       | 116                       | 1048                      | 109                       | 20                        | 1306                      |
|                        | NDEA             | 5000                       | 157                       | 1449                      | 177                       | 28                        | 1392                      |
|                        | MNPA             | 500                        | 89                        | 1535                      | 1304                      | 21                        | 736                       |
|                        | MNPA             | 1600                       | 116                       | 1460                      | 1361                      | 25                        | 805                       |
|                        | Positive Control | Compound                   | B[a)P                     | AAN                       | AAN                       | AAN                       | AAN                       |
|                        |                  | Concentration (μg/plate)   | 10                        | 5                         | 5                         | 5                         | 10                        |
|                        |                  | Revertants                 | 657                       | 2862                      | 392                       | 38                        | 804                       |

## MutationExperiment

2NF

2-Nitrofluorene

NaN3

Sodium azide

AAC

9-Aminoacridine

NQO

4-Nitroquinoline-1-oxide

B[a]P

Benzo[a]pyrene

AAN

2-Aminoanthracene

| Metabolic Activation    | Test Item        | Concentration (μg/plate)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   | Revertants/Plate (Mean)   |
|-------------------------|------------------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| With                    |                  | TA98                       |                           | TA1537                    |                           |                           |                           |
| Activation              | Positive         | Compound                   |                           | AAN                       |                           |                           |                           |
| 30%                     | Control          | Concentration (μg/plate)   |                           | 8                         |                           |                           |                           |
| Hamster S-9 (continued) |                  | Revertants                 |                           | 121                       |                           |                           |                           |
| Hamster S-9 (continued) | Positive         | Compound                   |                           | AAN                       |                           |                           |                           |
| Hamster S-9 (continued) | Control          | Concentration (μg/plate)   |                           | 1.25                      |                           |                           |                           |
| Hamster S-9 (continued) |                  | Revertants                 |                           | 35                        |                           |                           |                           |
| Hamster S-9 (continued) | Positive         | Compound                   |                           | B[a]P                     |                           |                           |                           |
| Hamster S-9 (continued) | Control          | Concentration (μg/plate)   |                           | 7.5                       |                           |                           |                           |
| Hamster S-9 (continued) |                  | Revertants                 |                           | 139                       |                           |                           |                           |
| Hamster S-9 (continued) | Positive Control | Compound                   |                           | B[a]P                     |                           |                           |                           |
| Hamster S-9 (continued) |                  | Concentration (μg/plate)   |                           | 10                        |                           |                           |                           |
| Hamster S-9 (continued) |                  | Revertants                 |                           | 155                       |                           |                           |                           |

Footnotes to tables:

Key to postfixes:

P:

Precipitationoftestitemobserved

M:

Plate counted manually

C: Contaminated plate

W: Wet plate

Meansvaluesaregeneratedfromunroundedvaluesexporteddirectlyfromdata capturesoftware,andsomay appeartovaryfromthosepresented to 1 decimal place in the study report.

<div style=\"page-break-after: always\"></div>

In vivo Muta™Mouse study with the the nitrosamine impurity N-NRib

N-NRib induced dose dependent mutations in the lacZ transgene at all doses tested (25, 50 or 100/80 mg/kg/day) in liver and duodenum of male mice. An increase in mutant frequency (MF) was also noted in duodenum in female high dose mice (below tables). No biological relevant increases of mutant frequencies were noted in bone marrow and kidneys of either sex.

Table 5. Mutant frequency in liver from male mice male mice

| Group   | Treatment       | Dose (mg/kg/day)   |   Group Mean MF (x 10-6) |      SD | P-value           |
|---------|-----------------|--------------------|--------------------------|---------|-------------------|
| 1       | Vehiclecontrol  | 0                  |                    45.17 |  15.407 |                   |
| ２3      | DMP433          | 25                 |                    81.05 |  27.843 | 0.0286 (P≤0.05)   |
|         | DMP433          | 50                 |                   117.71 |  51.243 | 0.0010 (P≤0.001)  |
| 4       | DMP433          | 100/80t            |                   180.3  | 116.303 | 0.0005(P≤0.001)   |
| N/A     | PositiveControl | 50                 |                   278.18 |  36.408 | <0.0001 (P≤0.001) |

Table 6 Mutant frequency in duodenum from male mice

| Group   | Treatment        | Dose (mg/kg/day)   |   GroupMean MF (x 10-6) |      SD | P-value          |
|---------|------------------|--------------------|-------------------------|---------|------------------|
| 1       | Vehiclecontrol   | 0                  |                   46.02 |   8.825 |                  |
| 2       | DMP433           | 25                 |                  115.91 |  22.14  | 0.0002(P≤0.001)  |
| 3       | DMP433           | 50                 |                  127.28 |  44.3   | <0.0001(P≤0.001) |
| 4       | DMP433           | 100/80t            |                  203.88 |  53.694 | <0.0001(P≤0.001) |
| N/A     | Positive Control | 50                 |                 1058.93 | 139.852 | <0.0001(P≤0.001) |

Table 7. Mutant frequency in duodenum from female mice

| Group   | Treatment       |   Dose (mg/kg/day) |   Group Mean MF (x 10-6) |     SD | P-value           |
|---------|-----------------|--------------------|--------------------------|--------|-------------------|
| 5       | Vehiclecontrol  |                  0 |                    40.21 |  9.569 |                   |
| 6       | DMP433          |                100 |                   236.21 | 74.466 | <0.0001 (P≤0.001) |
| N/A     | PositiveControl |                 50 |                  1035.5  | 88.774 | 0.0028 (P≤0.01)   |

## 2.2.3. Ecotoxicity/environmental risk assessment

Ribociclib is an orally bioavailable, highly selective small molecule inhibitor of CDK4/6 that induces G1 arrest at sub-micromolar concentrations in a variety of pRb-positive cancer cells in vitro.

The ERA initially submitted in the context of the initial MAA has been updated by means of newly calculated Predicted Exposure Concentrations (PECs), which are based on prevalence data for the target indication.

<div style=\"page-break-after: always\"></div>

Table 8. Summary of main study results

| Substance (INN): ribociclib                                                                                         | Substance (INN): ribociclib                                                        | Substance (INN): ribociclib                                                                                                            | Substance (INN): ribociclib                                                        |
|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| CAS-number (if available): 1211441-98-3 (free base); 1374639-75-4 (succinate salt)                                  | CAS-number (if available): 1211441-98-3 (free base); 1374639-75-4 (succinate salt) | CAS-number (if available): 1211441-98-3 (free base); 1374639-75-4 (succinate salt)                                                     | CAS-number (if available): 1211441-98-3 (free base); 1374639-75-4 (succinate salt) |
| PBT screening                                                                                                       |                                                                                    | Result                                                                                                                                 | Conclusion                                                                         |
| Bioaccumulation potential- log K ow                                                                                 | OECD107                                                                            | log D at pH 4 < -0.8 log D at pH 7 = 0.6 log D at pH 9 = 2.2                                                                           | Potential PBT: N                                                                   |
| PBT-assessment                                                                                                      | PBT-assessment                                                                     | PBT-assessment                                                                                                                         | PBT-assessment                                                                     |
| Parameter                                                                                                           | Result relevant for conclusion                                                     |                                                                                                                                        | Conclusion                                                                         |
| Bioaccumulation                                                                                                     | log D ow (highest in pH range 4 to 9)                                              | 2.2                                                                                                                                    | not B                                                                              |
|                                                                                                                     | BCF                                                                                | N/A                                                                                                                                    | -                                                                                  |
| Persistence                                                                                                         | DT50 (OECD 308; recalculated to 12°C)                                              | 0.66 to 0.74 days                                                                                                                      | not P                                                                              |
| Toxicity                                                                                                            | NOEC                                                                               |                                                                                                                                        | T                                                                                  |
| PBT-statement :                                                                                                     | The compound is considered as not PBT nor vPvB                                     | The compound is considered as not PBT nor vPvB                                                                                         | The compound is considered as not PBT nor vPvB                                     |
| Phase I                                                                                                             | Phase I                                                                            | Phase I                                                                                                                                | Phase I                                                                            |
| Calculation                                                                                                         | Value                                                                              | Unit                                                                                                                                   | Conclusion                                                                         |
| PEC surfacewater refined (e.g. prevalence, literature)                                                              | 0.147                                                                              | µ g/L                                                                                                                                  | > 0.01 threshold Y                                                                 |
| Other concerns (e.g. chemical class)                                                                                |                                                                                    |                                                                                                                                        | N                                                                                  |
| Phase II Physical-chemical properties and fate                                                                      | Phase II Physical-chemical properties and fate                                     | Phase II Physical-chemical properties and fate                                                                                         | Phase II Physical-chemical properties and fate                                     |
| Study type                                                                                                          | Test protocol                                                                      | Results                                                                                                                                | Remarks                                                                            |
| Adsorption-Desorption Soil 1 = Loamy sand Soil 2 = Sandy loam Soil 3 = Clay Sludge 1 = Tilburg Sludge 2 = Aa & Maas | OECD 106                                                                           | K oc Soil1 = 41886 L/kgoc K oc Soil2 = 69250 L/kg oc K oc Soil3 = 301755 L/kg oc K oc Sludge1 =1873 L/kg oc K oc Sludge2 = 993 L/kg oc | K oc,sludge < 10000 L/kg does not trigger terrestrial testing                      |
| Ready Biodegradability Test                                                                                         | OECD 301                                                                           | 5 - 14%, not readily biodegradable                                                                                                     |                                                                                    |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems Sediment 1 Sandy Sediment 2 = Silty Clay Loam      | OECD 308                                                                           | DT50, whole system = 0.66 / 0.74 d % shifting to sediment = 77 / 80% CO 2 = 11% / 2% NER = 34% / 44%                                   | DT 50s at 12°C triggers sediment testing at test end at test end                   |

<div style=\"page-break-after: always\"></div>

|                                                                |               | >10% = 3, TP1 = 10 / 10% TP2 = 1% / 2% TP3 = N/A / 15%   | >10% = 3, TP1 = 10 / 10% TP2 = 1% / 2% TP3 = N/A / 15%   | >10% = 3, TP1 = 10 / 10% TP2 = 1% / 2% TP3 = N/A / 15%   | at test end at test end at test end   |
|----------------------------------------------------------------|---------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|---------------------------------------|
| Phase IIa Effect studies                                       |               |                                                          |                                                          |                                                          |                                       |
| Study type                                                     | Test protocol | Endpoint                                                 | value                                                    | Unit                                                     | Remarks                               |
| Algae, Growth Inhibition Test/ Pseudokirchneriella subcapitata | OECD 201      | EC 10                                                    | 0.71                                                     | µg/L                                                     | Growth rate                           |
| Daphnia magna, Reproduction Test                               | OECD 211      | NOEC                                                     | 1.1                                                      | µg/L                                                     | Growth                                |
| Fish, Early Life Stage Toxicity Test/ Pimephales promelas      | OECD 210      | NOEC                                                     | 0.79                                                     | µg/L                                                     | Growth (length)                       |
| Activated Sludge, Respiration Inhibition Test                  | OECD 209      | NOEC                                                     | ≥ 10                                                     | µg/L                                                     | Respiration                           |
| Phase IIb Studies                                              |               |                                                          |                                                          |                                                          |                                       |
| Bioaccumulation                                                | OECD 305      | BCF                                                      | N/A                                                      |                                                          |                                       |
| Sediment dwelling organism/ Chironomus riparius                | OECD 218      | NOEC                                                     | 787                                                      | mg/k g dw                                                |                                       |

The highest risk ratio for ribociclib has been found for sediment compartments with 0.118. Based on the available information on partition behavior and adsorption to sludge and soil, ribociclib is neither expected to bioaccumulate, nor to show any significant transfer to sludge and soil.

## 2.2.4. Discussion on non-clinical aspects

The current extension of indication application aims to treat early breast cancer in an adjuvant setting and would need to follow ICH M7 guidance for non-clinical development. The non-clinical development supporting the initial MA was conducted according to ICH S9 as ribociclib was intended for the treatment of advanced breast cancer. The N-nitrosoribociclib impurity (N-NRib) is present in trace amounts in ribociclib succinate drug substance and in Ribociclib 200 mg film-coated tablet. N-NRib was tested in three separate Ames tests, including a test applying enhanced Ames test conditions, all concluding that N-NRib did not induce mutations under the test conditions. However, N-NRib was determined to be mutagenic in an in vivo transgenic rodent (TGR) gene mutation assay (Muta™Mouse study). N-NRib limits need to be controlled using the carcinogenic potency categorization approach (CPCA) by applying a maximum acceptable intake (AI) of 400 ng/day (category 3).

The applicant proposed changes to the quality module in a separate procedure (EMEA/H/C/004213/II/54/G) to include measures to minimize the formation of the N-NRib impurity and to ensure control of N-NRib in compliance with the acceptable intake of 400 ng/day for early breast cancer and considering a Maximum Daily Dose (MDD) of 400 mg for the proposed early breast cancer indication.

In order to ensure the N-NRib content remains below the acceptable intake throughout its shelf-life, changes are made to the storage conditions and shelf-life. The product information has been updated accordingly.

This includes a restriction in shelf life and storage conditions from '36 months without special conditions'

<div style=\"page-break-after: always\"></div>

to 'refrigerated for up to 10 months at the pharmacy + up to 2 months below 25 °C with the patient. Information on the updated storage conditions are included in the PI and will be disseminated via a Direct Healthcare Professional Communication (DHPC).

The ERA initially submitted in the context of the initial MAA has been updated by means of newly calculated Predicted Exposure Concentrations (PECs), which are based on prevalence data for the target indication.

## 2.2.5. Conclusion on the non-clinical aspects

In the context of the extension of the indication to early breast cancer setting, additional data were provided to assess the potential mutagenicity of the nitrosamine impurity (N-NRib) in line with ICH M7. Risk mitigation measures were set up including storage conditions amendment, Reference is made to EMEA/H/C/004213/II/0054/G for quality aspects. The product information was amended to reflect: Shelf life: 12 months. Special precautions of storage: Pharmacy: store in a refrigerator (2⁰C -8⁰C) for up to 10 months . Patient: Store below 25⁰C for up to 2 months. Store in original package.

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of ribociclib. Ribociclib should be used according to the precautions stated in the SmPC to minimize any potential risks to the environment.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Study CLEE011 no. Status                             | Study design/ Study description/ Objectives                                                              | Study population (No. of patients on ribociclib)                                                                         | Treatment Details (Drug, Dose, Frequency, Duration, Formulation)                                                                                                                                                                                                                                                                                                                    | PK sampling timepoints (PAS)                                 |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| [Study O12301C Primary Analysis CSR] Ongoing NATALEE | Phase III, randomized, open- label/Study of ribociclib in combination with NSAI/Safety, efficacy, and PK | Pre- and postmenopausal women, plus men, with HR-positive, HER2-negative eBC (N=2549 (patients randomized)/2526 treated) | Ribociclib 400 mg orally QD on Days 1 to 21 of a 28 day cycle (up to 36 months of treatment) Endocrine therapy (NSAI): Letrozole: 2.5 mg orally QD. [b] given continuously or anastrozole 1 mg orally QD [b] given continuously (plus goserelin 3.6 mg subcutaneously once every 4 weeks in premenopausal women, and men) (up to 60 months of treatment) Formulation: Tablet 200 mg | Sampling time points: Pre-dose, 2 and 4 hr post dose (N=108) |

<div style=\"page-break-after: always\"></div>

| Study CLEE011 no. Status                          | Study design/ Study description/ Objectives                                                             | Study population (No. of patients on ribociclib)                                                                                              | Treatment Details (Drug, Dose, Frequency, Duration, Formulation)                                                                                                                                                                                                                                                                      | PK sampling timepoints (PAS)                                                                                                                                                                                                                                                                                                    |
|---------------------------------------------------|---------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [Study A2207 Primary Analysis CSR] Ongoing AMALEE | Phase II, randomized, open- label/Study of ribociclib in combination with NSAI/Safety, efficacy, and PK | Pre- and postmenopausal women with HR- positive, HER2- negative advanced (i.e. loco-regionally recurrent or metastatic) breast cancer (N=376) | Ribociclib 400 mg, 600 mg orally QD 3 weeks on/1week off (until disease progression) Endocrine therapy (NSAI): Letrozole 2.5 mg orally QD. [b] given continuously or anastrozole: 1 mg orally QD. [b] given continuously (plus goserelin: 3.6 mg subcutaneously once every 4 weeks in premenopausal women) Formulation: Tablet 200 mg | 400 mg dose: N=167 (PAS) For patients on extensive PK collection: C1D15: 0, 2, 4, 6, 24 hr (N=20) For patients on non- extensive PK collection: C1D15: 0, 2, 4 hr 600 mg dose: (N=168) For patients on extensive PK collection: C1D15: 0, 2, 4, 6, 24 hr (N=16) For patients on non- extensive PK collection: C1D15: 0, 2, 4 hr |

Data cut-offs: Study O12301C: 11-Jan-2023; Study A2207: 11-Jun-2021 Source: [Study O12301C Primary Analysis CSR], [Study A2207

Primary Analysis CSR]

In support of this application the MAH provided the following information:

- PK data of ribociclib and/or its combination partners from Study CLEE011O12301C (NATALEE). A Phase III study to evaluate the efficacy and safety of ribociclib 400 mg in combination with ET (NSAI; anastrozole or letrozole) versus ET alone as an adjuvant treatment in pre- and postmenopausal women plus men with HR-positive, HER2-negative eBC.
- PK data of ribociclib from Study CLEE011A2207 (hereafter A2207 or AMALEE), an open-label, randomized, Phase II study to evaluate the safety and efficacy of ribociclib 400 mg + NSAI/AI (letrozole or anastrozole) vs ribociclib 600 mg + AI (letrozole or anastrozole) in the treatment of pre- and postmenopausal women with HR-positive, HER2-negative aBC.
- An updated population PK (popPK) analysis using Study O12301C data, comparison of PK data of Study O12301C and historical studies, updated PK-QT analysis of pooled clinical data, exposureefficacy, exposure-neutropenia analyses of Study O12301C.
- Drug-drug interaction data based on PBPK report DMPK R2300859 which form the basis for the updated assessment of drug-drug interaction (DDI) at the dose of 400 mg.

## 2.3.2. Pharmacokinetics

## Introduction

A new oral dose of 400 mg once daily for 21 days followed by 7 days off treatment, repeated for 3 years or until disease recurrence or unacceptable toxicity, is proposed for early breast cancer in this application, supported primarily by data from Study O12301C and Study A2207. For reference, the recommended dose in the currently approved indications is 600 mg (three 200 mg film coated tablets) of ribociclib once daily.

Ribociclib is eliminated primarily via CYP3A4 mediated hepatic metabolism. At 600 mg dose ribociclib is a strong time-dependent CYP3A4 inhibitor with auto-inhibition leading to time-dependent pharmacokinetics. Co-administration of the strong CYP3A4 inhibitor ritonavir (100 mg twice daily for 14 days) with a single

<div style=\"page-break-after: always\"></div>

400 mg dose of ribociclib increased ribociclib AUCinf and Cmax in healthy subjects 3.2 and 1.7-fold, respectively, compared to a single 400 mg ribociclib dose given alone. Cmax and AUClast for LEQ803 (a prominent metabolite of ribociclib accounting for less than 10% of parent exposure) decreased by 96% and 98%, respectively.

At the time of MAA, it was concluded that the contribution of CYP3A4 to the overall elimination is likely smaller at steady state than after a single dose due to time-dependent auto-inhibition of the CYP3A4mediated metabolism of ribociclib. Thus, in the ritonavir study the effect of ritonavir on ribociclib at steady state might have been overestimated. The effect of a strong and moderate CYP3A4 inhibitors on ribociclib at steady state was therefore simulated using physiologically based pharmacokinetic modelling (PBPK) to inform on dose reductions needs. The same model is updated and proposed to be used here to inform on interactions in early breast cancer patients.

No new information on absorption, distribution, metabolism or elimination was provided in support of this application.

## Bioanalysis

The concentrations of ribociclib and its metabolite LEQ803 in K3EDTA plasma was determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The method was first validated (report DMPKR1300147), and was later re-validated, including a cross-validation of the two sites (DMPKR1300457). The method was transferred and revalidated (DMPK R1600666a) before study sample analysis of both study A2207 and O12301C.

## Population PK analysis for Study O12301C

## Objectives

The objectives of the popPK analysis were:

- To simulate ribociclib PK in patients in Study O12301C based on the final popPK model and to compare it with the observed PK data;
- To generate individual post hoc longitudinal trough concentrations (Ctrough) of ribociclib in patients in Study O12301C to support the exposure-efficacy analysis of Study O12301C;
- To provide summary of popPK-predicted PK metrics for patients on 400 mg in Study O12301C to support the PK-QT analysis (Cmax at steady-state).

## Data

The PopPK analysis was based on PK observations measured in Study O12301C. In Study O12301C, approximately 130 patients from the Investigational arm were to be considered as the PK subset. Plasma samples for ribociclib determination were to be obtained from these patients at the following time points on Day 15 of Cycle 1: pre-dose, 2h post-dose (± 15 min) and 4h post-dose (± 30 min).

The final PopPK dataset included 348 concentrations from 123 patients. The baseline covariates in these patients are summarized in Table 9 .

Table 9 Distribution of intrinsic factors in popPK dataset

<div style=\"page-break-after: always\"></div>

| Covariate            | Category                    | N   |
|----------------------|-----------------------------|-----|
| BW#                  | <50kg                       |     |
|                      | 50-60kg                     | 24  |
|                      | 60-70kg                     | 34  |
|                      | 70-80kg                     | 26  |
|                      | 80-90kg                     | 19  |
|                      | >=90kg                      | 12  |
| Menopausal status    | Premenopausal women and men | 42  |
|                      | Postmenopausal women        | 81  |
| Anatomic stage group | Stage group II              | 68  |
|                      | Stage group II              | 55  |

A summary of the observed ribociclib concentrations from Study O12301C compared to subjects from other parts of the clinical development programme are shown in Figure 1 .

Figure 1 Steady-state mean concentration of ribociclib in eBC, aBC, and advanced cancer patients and HV at the dose of 400 mg ribociclib (PK-Safety Set)

<!-- image -->

Hoursafterdose

Data included steady-state dosesfromstudies:A2106(Day10),X2101(Day18/Day21),A2207(Cycle1Day 15),O12301C（Cycle1Day15)

## Methods

The popPK model from the previous submission (initial MA, EMEA/H/C/4213) was first updated based on the observed PK data collected from the 123 patients included in the PK analysis dataset. No pooling

<div style=\"page-break-after: always\"></div>

between studies was performed in the popPK analysis for Study O12301C. The analysis was performed using Monolix Suite version 2021R.

The popPK model from the previous submission (initial MA, EMEA/H/C/4213) was a two-compartment model with delayed zero-order oral absorption, using linear clearance from the central compartment. The model included dose as a covariate on clearance, inter-compartment clearance, and peripheral volume, and BW on intercompartmental clearance and peripheral volume.

Figure 2 Structure of PopPK model

<!-- image -->

A reduced model development scheme was applied to describe the PK data in O12301C. The same structure as the previous model was assumed. A base model was defined, where all population parameters were fixed to the previously estimated value. A sensitivity analysis was then performed by estimating one by one all population parameters (including fixed effects, random effect variances and residual variability variances), to identify the closest model which would describe PK in the eBC population.

The predictive performance of the PopPK model was evaluated using a visual predictive check (VPC).

The popPK model was updated to describe the lower exposure observed in patients with eBC in Study O12301C in comparison with aBC patients. In the updated popPK model, inter-individual variability was included in the parameter describing the zero-order absorption process (Tk0), along with re-estimation of the clearance parameter. The residual error model was also adjusted to reflect the new study data (the residual error distribution was modified from constant in the log-normal space to constant in the normal space. Mathematically, this is equivalent to changing the residual error model from proportional to additive.). The model simulations (prediction-corrected VPCs) vs observed data are presented in Figure 3. The empirical percentiles (lines) are within the prediction interval of each corresponding theoretical percentiles (areas), indicating the updated popPK model describes data from Study O12301C

## Results

The population mean estimate of the apparent clearance of ribociclib at the 600 mg dose was 32.7 L/hr (95% CI: 30.1 - 35.6) in patients with eBC, approximately 19% higher than that in aBC (26.8; 95% CI: 25.8 - 27.7). At a 400 mg dose, population mean estimate of the apparent clearance of ribociclib in patient with eBC was 38.4 L/hr (95% CI: 35.5 - 41.9). Based on the updated popPK model, the estimated population mean steady-state CL/F in eBC patients is approximately 20% higher than that in aBC patients at the dose level of 400 mg (38.4 and 31.5 L/hr, respectively) as well as at the dose level of 600 mg (32.7 and 26.8 L/hr, respectively).

<div style=\"page-break-after: always\"></div>

Figure 3 Prediction-corrected visual predictive check (VPC) of the updated PopPK model compared with observed PK concentrations in Study O12301C.

<!-- image -->

Dots represent the observed concentrations in the PK-iDFS dataset. Upper and lower borders of the blue area represent the 90% CI of the 5th and 95th percentiles of the simulations, while the red area represents the 90% CI of the median. Similarly, the upper and lower dashed line represent the 5th and 95th percentile of the observations, while the solid line represents the median of the observations. The simulations are based on 500 replicates.

## Study A2207

PK data are available from study A2207. The purpose of the study was to evaluate if the reduced dosing regimen of 400 mg in combination with an NSAI maintains the efficacy while decreasing the risk of QTc prolongation as well as the frequency of other adverse events in pre- and postmenopausal women with HR-positive, HER2-negative aBC who have received no prior therapy for advanced disease. The study consisted of two arms where arm 1 had 400 mg ribociclib while arm 2 had 600 mg ribociclib. In both ribociclib was taken once daily day 1 to 21, with 7 days off within a 28 day cycle and in combination with endocrine therapy. Extensive PK sampling was performed in approximately 20 patients per arm on C1D15, with sparse sampling in the remaining patients.

<div style=\"page-break-after: always\"></div>

Strong inhibitors or inducers of CYP3A4/5 were prohibited in the study, while moderate inhibitors or inducers of CYP3A4/5 were to be used with caution.

The study included 376 female patients randomised 1:1. PK data were available for 167 subjects in the 400 mg group and 168 in the 600 mg group. 162 subjects of the 400 mg did not require any dose reduction, while 26 reduced their dose once. In the 600 mg group, 113 patients did not require a dose reduction, while 57 required one dose reduction and 17 required two. There were no protocol deviations affecting PK. PK parameters in the subjects with extensive sampling are presented in Table 10 .

Table 10: Ribociclib PK parameters on C1D15 - Study A2207

<!-- image -->

| Dose group              | Statistics   | Cmax(ng/mL)   | Tmax (h)   | AUC0-24h (ngxh/mL)   | AUClast (ngxh/mL)   | Cmin (ng/mL)   | CL/F (L/h)   | Vz/F (L)   |
|-------------------------|--------------|---------------|------------|----------------------|---------------------|----------------|--------------|------------|
| Ribociclib400 mg (N=20) | n            | 20            | 20         | 17                   | 19                  | 19             | 17           | 17         |
|                         | Mean (SD)    | 1240 (739)    | N/A        | 18700 (11600)        | 16800 (11700)       | 347 (314)      | 26.7 (9.70)  | 468 (162)  |
|                         | CV%          | 59.5          | N/A        | 62.2                 | 69.3                | 90.5           | 36.3         | 34.6       |
|                         | Geo-mean     | 1080          | N/A        | 16400                | 13500               | 253            | 24.4         | 438        |
|                         | Geo-CV%      | 57.8          | N/A        | 51.8                 | 86.0                | 101.4          | 51.8         | 41.3       |
|                         | Median       | 983           | 2.08       | 12300                | 12100               | 218            | 32.4         | 472        |
|                         | Min-max      | 353-3070      | 1.83-4.38  | 11200-46100          | 1620-44400          | 29.3-1200      | 8.68-35.7    | 208-718    |
| Ribociclib600 mg (N=16) | n            | 16            | 16         | 13                   | 15                  | 15             | 13           | 13         |
|                         | Mean (SD)    | 1740 (918)    | N/A        | 31600(14300)         | 28500 (15100)       | 691 (405)      | 23.3 (11.9)  | 655 (601)  |
|                         | CV%          | 52.7          | N/A        | 45.3                 | 53.1                | 58.5           | 51.1         | 91.7       |
|                         | Geo-mean     | 1500          | N/A        | 28600                | 24100               | 584            | 21.0         | 523        |
|                         | Geo-CV%      | 67.0          | N/A        | 50.0                 | 74.1                | 71.2           | 50.0         | 69.6       |
|                         | Median       | 1640          | 4.00       | 29800                | 26100               | 525            | 20.1         | 460        |
|                         | Min-max      | 374-3290      | 1.83-23.8  | 11100-58800          | 4240-58300          | 111-1500       | 10.2-53.9    | 225-2540   |

n = number of patients with corresponding evaluablePK parameters.

Ribociclib 400 and 600 mg dose groups consist of allpatients who provided evaluable parameters after receiving at least 10 consecutive daily ribociclib doses of 400 and 6o0 respectively,. immediately prior to and on the PK collection day.

Source:Table14.2-4.2

Following daily oral administration of ribociclib with 3 weeks on/1 week off, the median (range) of Tmax on C1D15 was 2.1 (1.8-4.4) h and 4 (1.8-23.8) h for the ribociclib 400 mg and 600 mg arms, respectively. The geometric mean of ribociclib Cmax and AUC0-24h at C1D15 were approximately 28% and 43% lower in the ribociclib 400 mg arm as compared to the 600 mg arm (Cmax 1080 vs 1500 ng/mL and AUC0 24h 16400 vs. 28600 ng×h/mL).

## Special populations

Based on the dedicated hepatic impairment study A2109 (submitted at the time of MAA) with 400 mg ribociclib, the AUC for ribociclib was increased by 1.32 and 1.29 fold respectively, in patients with moderate and severe hepatic impairment compared to subjects with normal hepatic function.

## Pharmacokinetic interaction studies

No new DDI studies are provided as part of this submission. Results of drug-drug interaction studies were assessed in the original MAA submission and are described in the approved SmPC.

Details of PBPK predictions for eBC and aBC populations are summarized in DMPK R2300859 report submitted. The focus lies on the victim interaction with CYP3A4 inhibitors or inducers thus the assessment is limited to that part of the model. SmPC has been updated based on the model.

## PBPK report DMPK R2300859

The observed pharmacokinetics (PK) for ribociclib was different in healthy volunteers and metastatic breast cancer patients, mainly due to the lower clearance (CL/F) observed for patients. Therefore, the use of two physiologically based pharmacokinetic (PBPK) population models for healthy volunteers and metastatic breast cancer, described by Samant et al (2020), were combined with the same compound model for ribociclib. Simcyp V22 was used for all simulations, as compared to V18 earlier. The only

<div style=\"page-break-after: always\"></div>

changes applied to the ribociclib compound file were the following: the absorption model was changed from ADAM to first order absorption to simplify the model. Consequently, the fa, ka and lag time were adapted from 0.942, 1.052 h-1 and 0 h to values of 1.00, 0.700 h-1 and 1.10 h. The remaining compound files were used unchanged and are provided in the report.

The early breast cancer population, was actually represented by the Simcyp healthy volunteer population file from V22 with some modifications

The Simcyp healthy volunteers population file was modified by reducing the amount of microsomal protein per gram of liver to 12% and the CV for the hepatic CYP3A4 abundance was reduced to 23.8% to match the clinically observed PK variability of ribociclib for both populations. Furthermore, for a metastatic breast cancer population model the hepatic and intestinal CYP3A4 abundance was also reduced to account for the disease-related reduction. The abundance values of these two parameters were reduced by 40% to 82.2 pmol/mg protein and 39.2 pmol/mg protein, respectively, as described in the supporting information of Samant et al (2020).

The PK of ribociclib was predicted following single dose administrations of 150 mg i.v. and 600 mg p.o. to healthy volunteers and multiple dose administration of 400 mg QD to metastatic breast cancer patients ( Table 11 , Figure 4).

Table 11: Predicted and observed PK parameters for ribociclib in healthy subjects or metastatic breast cancer patients

| Population               | Ribociclib dose regimen1   | Observed median Tmax (h-1) 3.4   |   Predicted median Tmax (h-1) | Observed Cmax (%CV) Geometric Mean (ng/mL) 3.4   | Predicted Cmax (%CV) GeometricMean (ng*h/mL)   | Observed GeometricMean AUC (%CV) (ng*h/mL) 3.4   | PredictedGeometric Mean AUC (%CV) (ng*h/mL)   |
|--------------------------|----------------------------|----------------------------------|-------------------------------|--------------------------------------------------|------------------------------------------------|--------------------------------------------------|-----------------------------------------------|
| HV                       | 150 mg SD i.v.             | 3.52                             |                          4    | 347 (22.8)                                       | 363 (19.3)                                     | 3781 (27.4)                                      | 3781 (21.2)                                   |
| HV                       | 600 mg SD p.0.             | 2.99                             |                          2.45 | 624 (42.5)                                       | 728 (35.9)                                     | 9840 (44.4)                                      | 8865 (36.5)                                   |
| Metastatic breast cancer | 400 mg QD p.o.             |                                  |                          2.7  | 1040 (49.3)                                      | 1071 (32.4)                                    | 11400 (57.8)                                     | 13814 (42.7)                                  |

%CV, percent coefficient of variance; HV, healthy volunteer; i.v., intravenous; p.o. per oral; QD, once a day; SD, single dose

waseither the\"adapted healthy volunteer(HV)\"or the\"metastaticbreast cancerpatient\"population model.Detailsofthe trial design canbe found in Table 3-1.

2Reported AUC values and ratios were AUCinf for ribociclib single dose and AUCtau for ribociclib at steady-state.

3 observed HV ribociclib Cmax and AUCinf at day 1 for a 150 and 600 mg SD dose taken from (CLEE011A2117)

4observedHVribociclibCmaxandAUCtau at day18/21fora 400mgQDdose takenfrom(CLEE011X2101)

<div style=\"page-break-after: always\"></div>

Figure 4: Simulated and observed mean pharmacokinetic profiles of ribociclib administered p.o. (left) or i.v. (right) to healthy volunteers. Simulated mean ribociclib concentrations (black line), 5th and 95th percentiles (dashed grey lines), observed mean concentrations (open circles) for ribociclib 600 mg single dose p.o.

<!-- image -->

Figure 5: Simulated (metastatic breast cancer patients) and observed mean pharmacokinetic profiles of ribociclib administered to metastatic breast cancer patients after on day 1 (left) and on day 18 (right)

<!-- image -->

Time(h)

Ribociclib as a perpetrator had been previously qualified (Kisqali iMA). The model in V22 predicted the interaction with CYP3A4 by matching the observed AUC and Cmax ratios for midazolam of 3.75 and 2.05, respectively (predicted AUC ratio: 4.18, Cmax ratio: 2.28, Table 12 ).

The DDI effect of the strong CYP3A4 inhibitor ritonavir was predicted with observed AUC and Cmax ratios of 3.21 and 1.67 and predicted AUC and Cmax ratios of 3.16 and 1.40, respectively ( Table 12 ). Finally, the induction effect of rifampicin on ribociclib was reasonably described. The observed AUC and Cmax ratios were 0.107 and 0.190 and the predicted AUC and Cmax ratios were 0.231 and 0.447, respectively ( Table 12 ).

Table 12: Predicted and observed PK parameters for interactions of midazolam, ribociclib, ritonavir and rifampicin in healthy subjects

<div style=\"page-break-after: always\"></div>

| regimen Perpetrator dose         | Victim dose regimen        | Source              | GeometricMeanCmax bnp (%CV) (ng/mL) of victim Not inh./inh.   | Observed Geometric Mean AUC (%CV) 6np (ng*h/mL) of victim Not inh./inh.   | Victim drug geometricMean Cmax ratio(90% CI)   | Victim drug geometricMean AUC ratio (90% CI)   |
|----------------------------------|----------------------------|---------------------|---------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Ribociclib 400 mg QD for 8 days  | Midazolam 2 mg SD at day 8 | Observed3 Predicted | 7.85 (28.4)/16.1 (22.6) 7.46 (66.6)/17.0 (59.3)               | 17.7 (26.9)/66.4 (33.3) 20.5 (67.3)/85.8 (90.1)                           | 2.05 (1.88, 2.23) 2.28 (2.18, 2.38)            | 3.75 (3.41, 4.11) 4.18 (3.84, 4.55)            |
| Ritonavir 100 mg BID for 13 days | Ribociclib 400 mg SD day 2 | Observed4 Predicted | 357/597 469 (36.0)/657 (31.9)                                 | 5840/18700 5395 (34.6)/17062 (35.4)                                       | 1.67 (1.52, 1.84) 1.40 (1.38, 1.42)            | 3.21 (2.95, 3.49) 3.16 (3.04, 3.29)            |
| Rifampicin600mg QD for 13 days   | Ribociclib 600 mg SD day 5 | Observed4 Predicted | 565/107 671 (35.1)/300 (59.2)                                 | 8940/953 8304 (37.1)/1922 (62.2)                                          | 0.190 (0.164, 0.219) 0.447 (0.422, 0.474)      | 0.107 (0.0945, 0.120) 0.231 (0.214, 0.249)     |

Figure 6: Simulated and observed mean pharmacokinetic profiles of ribociclib administered without and with ritonavir 100 mg b.i.d. to healthy volunteers. Simulated mean ribociclib concentrations with and without ritonavir (black/dashed line), observed mean concentrations with and without ritonavir (open circles/squares) for ribociclib 400 mg single dose p.o.

<!-- image -->

When using the adapted healthy volunteer population file, the plasma concentrations for the time points 2, 4 and 24 h on day 18 of the NATALEE study in early breast cancer were predicted with prediction error (PE) values less than 7% (

Table 13 ,

Figure 7). The simulations using the metastatic breast cancer patient population file overpredicted the plasma concentrations (Figure 8, PE &gt;22%).

<div style=\"page-break-after: always\"></div>

Table 13: Day 18 predicted (healthy subject or metastatic breast cancer population) and observed ribociclib PK after ribociclib 400 mg QD in early breast cancer patients (NATALEE)

| Parameter                            | Observedvalue for 2 h time point   | Predictedvalue for2htimepoint   | Observedvalue for4htimepoint   | Predictedvalue for4htimepoint   | Observedvaluefor 24h timepoint   | Predictedvaluefor 24 h time point   |
|--------------------------------------|------------------------------------|---------------------------------|--------------------------------|---------------------------------|----------------------------------|-------------------------------------|
| Number of includedpatients           | 105                                | 100                             | 113                            | 100                             | 105                              | 100                                 |
| Accurate time (h)                    | 410.08±0.15                        | 409.97                          | 412.07 ± 0.15                  | 411.91                          | 432.00 ±2.01                     | 432.00                              |
| Plasma concentration (ng/mL)         | 815±379                            | HV:871±342 CP:1002±377          | 819±366                        | HV:869±307 CP:1024±333          | 325 ± 272                        | HV:306±183 CP:411±218               |
| Concentration prediction error (% )3 |                                    | HV: 6.87 CP:22.9                |                                | HV: 6.11 CP:25.0                |                                  | HV: -5.85 CP:26.5                   |

CP,cancer patient;HV,healthy volunteer;PE,prediction error; QD,once a day was either the \"adapted healthy volunteer (HV)\" or the “metastatic breast cancer patient\" model. Details of the trial design can be found in Table 3-1.

2Reported AUC values and ratios were AUCinf for ribociclib single dose and AUCtau for ribociclib at steady-state.

3 Prediction error (PE) calculated as PE = (simulated value - observed value) / observed value × 100

Figure 7: Simulated (using the adapted HV population model) PK profiles and observed mean (left) or individual (right) subject concentrations of ribociclib administered to early breast cancer patients (adjuvant therapy) for 18 days. Simulated mean ribociclib concentrations (black line), 5th and 95th percentiles (dashed grey lines), observed individual concentrations (open circles) for ribociclib 400 mg once daily p.o. day 18

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 8: Simulated (using the metastatic breast cancer population model) PK profiles and observed mean (left) or individual (right) subject concentrations of ribociclib administered to early breast cancer patients (adjuvant therapy) for 18 days. Simulated mean ribociclib concentrations (black line), 5th and 95th percentiles (dashed grey lines), observed mean concentrations (open circles) and standard deviation (error bars) for ribociclib 400 mg once daily p.o. on day 18

00OE

<!-- image -->

## Simulations

Numerous scenarios have been simulated using the adapted healthy population file with CYP3A4 inhibitors (Table 14 ) and inducers (In the presence of the strong CYP3A4 inducer rifampicin the AUC and Cmax ratios of ribociclib (400 mg SD) were predicted to be 0.200 and 0.398, respectively, in HV. In the presence of the moderate CYP3A4 inducer efavirenz slightly less DDI was predicted with ribociclib AUC and Cmax ratios of 0.314 and 0.550, respectively.

Table 15) and similarly using the metastatic breast cancer population file ( Table 16 and Table 17 ). Coadministration of the strong CYP3A4 inhibitor ritonavir with 400 mg ribociclib resulted in ribociclib AUC and Cmax ratios of 1.84 and 1.47, respectively. Similar ribociclib AUC was predicted when administered as single dose (18966 ng*h/mL) or at steady-state (19401 ng*h/mL) when co-administered with ritonavir, which was slightly lower than the ribociclib AUC following a 600 mg QD dose at steady-state (23800 ng*h/mL) without ritonavir co-medication. For the moderate CYP3A4 inhibitor erythromycin a ribociclib (400 mg QD) AUC and Cmax increase of 1.23- and 1.13-fold was predicted.

Time (h)

<div style=\"page-break-after: always\"></div>

Table 14: Predicted exposure of ribociclib when administered with CYP3A4 inhibitors - healthy subjects

| Perpetrator                        | Source    | Ribociclib dose regimen 1   | Inhibition status       | Geometric Mean Cmax (%CV) (ng/mL)   | Geometric Mean AUC (%CV) (ng*h/mL)   | Geometric Mean Cmax ratio (90%CI)   | GeometricMeanAuC ratio (90% CI)   |
|------------------------------------|-----------|-----------------------------|-------------------------|-------------------------------------|--------------------------------------|-------------------------------------|-----------------------------------|
| Ritonavir 100 mg BID for 14 days   | simulated | 600 mg SD on day 8          | - inhibitor + inhibitor | 807 (29.3) 1163 (25.2)              | 9646 (35.9) 30250 (38.2)             | 1.44 (1.42, 1.46)                   | 3.14 (3.00, 3.28)                 |
| Ritonavir 100 mg BID for 8 days    | simulated | 600 mg QD for 8 days        | - inhibitor + inhibitor | 1496 (35.2) 1984 (28.9)             | 18696 (46.5) 29114 (35.5)            | 1.33 (1.29, 1.36)                   | 1.56 (1.50, 1.62)                 |
| Ritonavir 100 mg BID for 14 days   | observed  | 400 mg SD on day 2          | - inhibitor + inhibitor | 357 597                             | 5840 18500                           | 1.67 (1.52, 1.84)                   | 3.21 (2.95, 3.49)                 |
| Ritonavir 100 mg BID for 14 days   | simulated | 400 mg SD on day 2          | - inhibitor + inhibitor | 518 (28.6) 769 (24.6)               | 5749 (33.5) 18966 (33.6)             | 1.40(1.38, 1.40)                    | 3.14 (3.03, 3.27)                 |
| Ritonavir 100 mg BID for 8 days    | simulated | 400 mg QD for 8 days        | - inhibitor + inhibitor | 900 (35.5) 1322 (28.9)              | 10523 (47.1) 19401 (35.5)            | 1.47 (1.43, 1.51)                   | 1.84 (1.76, 1.93)                 |
| Ritonavir 100 mg BID for 14 days   | simulated | 200 mg SD on day 2          | - inhibitor + inhibitor | 249 (28.7) 388 (25.3)               | 2641 (32.6) 10079 (38.2)             | 1.56 (1.53, 1.58)                   | 3.82 (3.64, 4.00)                 |
| Ritonavir 100 mg BID for 8days     | simulated | 200 mg QD for 8 days        | - inhibitor + inhibitor | 375 (33.5) 661 (28.9)               | 3855 (42.5) 9696 (35.5)              | 1.76 (1.72, 1.82)                   | 2.51 (2.40, 2.63)                 |
| Erythromycin 500 mg BID for 8 days | simulated | 600 mg SD on day 8          | - inhibitor + inhibitor | 807 (29.3) 987 (28.9)               | 9659 (36.0) 16272 (42.8)             | 1.22 (1.21, 1.24)                   | 1.68 (1.63, 1.74)                 |
| mg BID for 8 days Erythromycin 500 | simulated | for 8 days 600 mg QD        | - inhibitor + inhibitor | 1496 (35.2) 1617 (33.3)             | 21168 (43.0) 18696 (46.5)            | 1.08 (1.07, 1.09)                   | 1.13 (1.12, 1.14)                 |
| Erythromycin 500 mg BID for 8 days | simulated | 400 mg SD on day 8          | - inhibitor + inhibitor | 521 (29.1) 648 (29.0)               | 5862 (34.3) 10285 (42.6)             | 1.24 (1.23, 1.26)                   | 1.75 (1.69, 1.82)                 |
| Erythromycin 500 mg BID for 8 days | simulated | 400 mg QD for 8 days        | - inhibitor             | 900 (35.5)                          | 10523 (47.1)                         | 1.13 (1.12, 1.14)                   | 1.23 (1.21, 1.24)                 |
|                                    |           |                             | + inhibitor             | 1021 (33.7)                         | 12912 (44.0)                         |                                     |                                   |
| Erythromycin 500 mg BID for8days   | simulated | 200 mg SD on day 8          | - inhibitor + inhibitor | 249 (28.7) 317 (29.0)               | 2642 (32.7) 4787 (42.1)              | 1.27 (1.26, 1.29)                   | 1.81 (1.74, 1.88)                 |
| Erythromycin 500 mg BID for 8 days | simulated | 200 mg QD for 8 days        | - inhibitor +inhibitor  | 375 (33.5) 468 (33.5)               | 3855 (42.5) 5593 (43.9)              | 1.25 (1.23, 1.26)                   | 1.45 (1.42, 1.48)                 |

BID, twice a day; Cl, confidence interval; %CV. percent coefficient of variance; QD, once a day; SD, single dose

1 The simulated trials consisted of 10 trials of 10 subjects (n=100) with an age range of 20-55 years, and 100% female. The population model used was the\"adapted healthy volunteer (HV)\" model. Details of the trial design can be found in Table 3-3.

2 Reported AUC values and ratios were AUCinf for ribociclib single dose and AUCtau for ribociclib at steady-state.

3 observed ribociclib Cmax and AUCtau at day 18/21 for a 600 mg QD dose: 1820 ng/mL and 23800 ng*h/mL (CLEE011X2101)

In the presence of the strong CYP3A4 inducer rifampicin the AUC and Cmax ratios of ribociclib (400 mg SD) were predicted to be 0.200 and 0.398, respectively, in HV. In the presence of the moderate CYP3A4 inducer efavirenz slightly less DDI was predicted with ribociclib AUC and Cmax ratios of 0.314 and 0.550, respectively.

Table 15: Predicted exposure of ribociclib when administered with CYP3A4 inducers - healthy subjects

| Perpetrator                    | Source    | Ribociclib regimen 1 dose   | Induction status    | GeometricMean Cmax (%CV) (ng/mL)   | GeometricMean AUC (%CV) (ng*h/mL)   | GeometricMean Cmax ratio (90%CI)   | GeometricMean AUCratio(90%CI)   |
|--------------------------------|-----------|-----------------------------|---------------------|------------------------------------|-------------------------------------|------------------------------------|---------------------------------|
| Rifampicin 600 mg QDfor13days  | observed  | 600 mg SD on day 5          | -inducer + inducer  | 565 107                            | 8940 953                            | 0.190 (0.164,0.219)                | 0.107 (0.0945,0.120)            |
| Rifampicin 600 mg QDfor13days  | simulated | 600 mg SD on day 5          | -inducer + inducer  | 671 (35.1) 300 (59.2)              | 8318 (37.2) 1922 (62.2)             | 0.447 (0.422, 0.474)               | 0.231(0.214,0.249)              |
| Rifampicin600mg QD for 14 days | simulated | 600 mg QD for 14 days       | - inducer +inducer  | 1500 (34.7) 567 (64.7)             | 18607 (46.2) 3646 (93.3)            | 0.378 (0.351, 0.407)               | 0.196 (0.176, 0.218)            |
| Rifampicin 600 mg QDfor14days  | simulated | 400 mg SD on day 12         | - inducer + inducer | 518 (28.6) 206 (53.6)              | 5753 (33.5) 1149 (59.2)             | 0.398 (0.374, 0.423)               | 0.200 (0.185, 0.216)            |
| Rifampicin600 mg QDfor14days   | simulated | 400 mg QD for 14 days       | - inducer + inducer | 911 (35.6) 311 (60.1)              | 10633 (48.2) 1813 (77.8)            | 0.342 (0.318,0.367)                | 0.171 (0.155, 0.188)            |

<div style=\"page-break-after: always\"></div>

| Rifampicin 600 mg QD for 14 days   | simulated   | 200 mg SD on day 12   | -inducer + inducer   | 248 (28.2) 96.1 (54.2)   | 2596 (31.9) 520 (59.4)   | 0.388 (0.364, 0.413)   | 0.200 (0.185, 0.217)   |
|------------------------------------|-------------|-----------------------|----------------------|--------------------------|--------------------------|------------------------|------------------------|
| Rifampicin 600 mg QD for 14 days   | simulated   | 200 mg QD for 14 days | - inducer + inducer  | 383 (34.4) 124 (56.4)    | 3986 (45.6) 660 (65.4)   | 0.324 (0.302, 0.347    | 0.166 (0.151, 0.181)   |
| Efavirenz 600 mg QD for 14 days    | simulated   | 600 mg SD at day 12   | - inducer + inducer  | 807 (29.3) 450 (36.5)    | 9659 (36.0) 2967 (44.3)  | 0.557 (0.537, 0.578)   | 0.307 (0.288, 0.328)   |
| Efavirenz 600 mg QD for 14 days    | simulated   | 600 mg QD for 14 days | - inducer + inducer  | 1549 (36.8) 747 (51.0)   | 19692 (49.4) 5735 (78.7) | 0.483 (0.453, 0.514)   | 0.291 (0.262, 0.324)   |
| Efavirenz 600 mg QD for 14 days    | simulated   | 400 mg SD at day 12   | -inducer + inducer   | 521 (29.1) 286 (36.2)    | 5866 (34.4) 1842 (43.1)  | 0.550 (0.530, 0.571)   | 0.314 (0.295,0.335)    |
| Efavirenz 600mg QD for 14 days     | simulated   | 400 mg QD for 14 days | - inducer + inducer  | 936 (37.2) 421 (47.3)    | 11189 (50.4) 2907 (67.9) | 0.449 (0.424, 0.477)   | 0.260 (0.236, 0.286)   |
| Efavirenz 600mg QD for 14 days     | simulated   | 200 mg SD at day 12   | -inducer + inducer   | 249 (28.7) 135 (35.7)    | 2642 (32.7) 846 (42.1)   | 0.542 (0.521,0.563)    | 0.320 (0.301,0.341)    |
| Efavirenz 600 mg QD for 14 days    | simulated   | 200 mg QD for 14 days | -inducer + inducer   | 390 (35.2) 171 (41.2)    | 4127 (46.3) 1062 (52.6)  | 0.440 (0.418,0.463)    | 0.257 (0.237, 0.279)   |

BID, twice a day; Cl, confidence interval; %CV. percent coefficient of variance; QD, once a day; SD, single dose

1 The simulated trials consisted of 10 trials of 10 subjects (n=100) with an age range of 20-55 years, and 100% female. The population model used was the\"adapted healthy volunteer(HV)\"model.Detailsof the trial design can be found inTable 3-3.

2Reported AUC values and ratios were AUCinf forribociclib single dose and AUCtau for ribociclib at steady-state.

3 observed ribociclib Cmax and AUCinf at day 1 for a 600 mg SD dose taken from (CLEE011A2117)

Table 16: Predicted exposure of ribociclib when administered with CYP3A4 inhibitors - metastatic breast cancer

| Perpetrator                        | Source    | Ribociclib dose regimen 1   | Inhibition status       | Geometric Mean Cmax (%CV) (ng/mL)   | Geometric Mean AUC (%CV) (ng*h/mL)   | Geometric Mean Cmax ratio (90%CI)   | Geometric Mean AUC ratio (90% CI)   |
|------------------------------------|-----------|-----------------------------|-------------------------|-------------------------------------|--------------------------------------|-------------------------------------|-------------------------------------|
| Ritonavir 100 mg BID for 8 days    | simulated | 600 mg QD for 8 days        | - inhibitor + inhibitor | 1685 (32.1) 1990 (28.9)             | 22656 (40.6) 29241 (35.4)            | 1.18 (1.16, 1.20)                   | 1.29 (1.26, 1.32)                   |
| Ritonavir 100 mg BID for8 days     | simulated | 400 mg QD for 8 days        | - inhibitor + inhibitor | 1054 (32.5) 1326 (28.9)             | 13643 (41.5) 19490 (35.4)            | 1.26 (1.24, 1.28)                   | 1.43 (1.39, 1.47)                   |
| Ritonavir 100 mg BID for 14 days   | simulated | 200 mg QD for 8 days        | - inhibitor + inhibitor | 463 (31.8) 663 (28.9)               | 5519 (39.9) 9743 (35.4)              | 1.43 (1.40, 1.46)                   | 1.77 (1.71, 1.83)                   |
| Erythromycin 500 mg BID for 8 days | simulated | 600 mg QD for 8 days        | - inhibitor + inhibitor | 1685 (32.1) 1761 (31.1)             | 22656 (40.6) 24262 (38.8)            | 1.05 (1.04, 1.05)                   | 1.07 (1.06, 1.08)                   |
| Erythromycin 500 mg BID for 8 days | simulated | 400 mg QD for 8 days        | - inhibitor + inhibitor | 1054 (32.5) 1134 (31.3)             | 13643 (41.5) 15318 (39.3)            | 1.08 (1.07, 1.08)                   | 1.12 (1.11, 1.13)                   |
| Erythromycin 500 mg BID for 8days  | simulated | 200 mg QD for 8 days        | - inhibitor + inhibitor | 463 (31.8) 536 (31.2)               | 5519 (39.9) 6983 (39.3)              | 1.16 (1.15, 1.17)                   | 1.27 (1.25, 1.28)                   |

Table 17: Predicted exposure of ribociclib when administered with CYP3A4 inducers - metastatic breast cancer

| Perpetrator                      | Source    | Ribociclib dose regimen 1   | Induction status    | GeometricMean Cmax (%CV) (ng/mL)   | GeometricMean AUC (%CV) (ng*h/mL)   | Geometric Mean Cmax ratio (90%CI)   | Geometric Mean AUC ratio (90% CI)   |
|----------------------------------|-----------|-----------------------------|---------------------|------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Rifampicin 600 mg QD for 14 days | simulated | 600 mg QD for 14 days       | - inducer + inducer | 1678 (31.2) 882 (53.6)             | 22321 (39.3) 7313 (83.3)            | 0.526 (0.496,0.557)                 | 0.328.0.298.0.360)                  |
| Rifampicin 600 mg QD for 14 days | simulated | 400 mg QD for 14 days       | -inducer +inducer   | 1055 (31.9) 494 (52.4)             | 13533 (40.9) 3671 (77.0)            | 0.468 (0.442, 0.497)                | 0.271 (0.248, 0.297)                |
| Rifampicin 600 mg QD for 14 days | simulated | 200 mg QD for 14 days       | - inducer + inducer | 468 (31.9) 196 (48.2)              | 5576 (41.1) 1274 (62.4)             | 0.418(0.395.0.443)                  | 0.229 (0.211,0.248)                 |
| Efavirenz 600 mg QD for 14 days  | simulated | 600 mg QD for14 days        | - inducer + inducer | 1738 (33.6) 1068 (42.9)            | 23686 (43.1) 10366 (64.6)           | 0.615 (0.584,0.646)                 | 0.438 (0.401,0.477)                 |
| Efavirenz 600 mg QD for 14 days  | simulated | 400 mg QD for 14 days       | - inducer + inducer | 1090 (34.1) 611 (42.2)             | 14324 (44.1) 5324 (62.8)            | 0.561(0.533.0.591)                  | 0.372 (0.340, 0.406)                |
| Efavirenz 600 mg QD for 14 days  | simulated | 200 mg QD for14 days        | - inducer + inducer | 481 (33.3) 249 (38.0)              | 5847 (43.0) 1883 (52.1)             | 0.517(0.493,0.542)                  | 0.322 (0.297,0.349)                 |

BID, twice a day; Cl, confidence interval;%CV,percent coefficient of variance;QD,once a day;SD,single dose

1 The simulated trials consisted of 10 trials of 10 subjects (n=100) with an age range of 20-55 years, and 100% female. The population model used was the\"adapted healthy volunteer(HV)\"model.Details of the trial design can be found in Table 3-3.

2Reported AUCvalues and ratios were AUCinf for ribociclib single dose and AUCtau forribociclib at steady-state.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

## Mechanism of action

Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).

## Primary and secondary pharmacology

## 2.3.4. PK/PD modelling

Several PK/PD or exposure-response analyses were performed including a PK-QTc, exposure-efficacy and exposure-neutropenia analyses. However, only the PK-QTc analysis is described below.

## PK-QTc analysis

The objective of this analysis was to characterize the relationship between the QTcF matched ribociclib concentration and the Δ QTcF with or without combination partners (NSAI (letrozole or anastrozole) and fulvestrant).

In the PK-ECG set of pooled studies, 1297 of 1372 patients (94.5%) were female and the remaining were male (75 patients, 5.5%). Overall median age of patients was 58.0 years (range: 22 to 96), with 8.2%, 60.0%, and 31.8% of patients being &lt; 40 years, 40 to &lt; 65 years, and ≥ 65 years, respectively. Overall, patients were predominantly non-Asian (87.0%), and the majority of patients (62.4%) had an ECOG PS of 0. The analysis included 1372 patients in total where 117 were eBC patients from Study OC12301C. Studies A220, E2301, F2301, A2301, X2108, X2107, submitted with previous applications, were also included.

The baseline QTcF are summarized in Table 18.

Table 18 Baseline QTcF (PK-ECG)

| Statistics   | X1101 N=17   | X2101 N=152   | X2107 N=47   | A2301 N=75   | E2301 N=203   | F2301 N=425   | N=336          | A2207O12301Cpatients N=117   | AlI N=1372   |
|--------------|--------------|---------------|--------------|--------------|---------------|---------------|----------------|------------------------------|--------------|
| n            | 17           | 152           | 47           | 75           | 203           | 425           | 336            | 117                          | 1372         |
| Mean         | 417.25       | 411.42        | 415.87       | 414.12       | 415.70        | 415.23        | 407.47         | 420.13                       | 413.38       |
| (SD)         | (19.671)     | (18.805)      | (15.068)     | (15.290)     | (17.232)      |               |                | (17.095) (17.485) (16.154)   | (17.600)     |
| Median       | 415.67       | 410.17        | 416.00       | 413.67       | 415.00        | 415.00        | 406.33         | 419.00                       | 413.00       |
| Q1-Q3        | 405.67-      | 398.00-       | 405.00-      | 402.67-      | 403.67-       |               | 403.33-394.83- | 410.00-                      | 401.67-      |
|              | 430.33       | 425.50        | 429.00       | 424.00       | 429.00        | 427.33        | 419.00         | 434.00                       | 426.33       |
| Min-Max      | 382.7-       | 359.0-        | 378.3-       | 382.3-       | 373.7-        | 362.0-        | 354.3-         | 383.0-                       | 354.3-       |
| Min-Max      | 454.7        | 458.2         | 451.7        | 451.0        | 462.0         | 453.0         | 463.5          | 447.0                        | 463.5        |

A standard workflow and model evaluation for QTcF analysis was applied. The effect of covariates such as patient population (eBC vs non-eBC) on QTcF prolongation was assessed.

Patient population (eBC vs non-eBC patients) was found to be statistically significant (p&lt;0.001). Patients in eBC population were predicted to have lower Δ QTcF (-5.37 ms) than advanced cancer population at the same ribociclib concentration. All the other covariates evaluated in the previous model (M3/7 QT report)

<div style=\"page-break-after: always\"></div>

were retained and the corresponding parameter estimates are consistent between the two models. Using the updated PK-QTcF model, at the geometric mean steady-state Cmax of the ribociclib 400 mg dose in the eBC population with NSAI (letrozole or anastrozole) as combination partner, the estimated mean Δ QTcF was 10.0 ms (90% CI: 8.02, 11.91).

The final model parameters are shown in Table 19.

Table 19 Parameter estimates from PK-QTc model, PK-ECG set

| Parameter                                                                 | Estimate (95% CIl)    | Standard error   |
|---------------------------------------------------------------------------|-----------------------|------------------|
| Baseline QTcF-median baseline QTcF                                        | -0.23 (-0.27, -0.19)  | 0.02             |
| Intercept                                                                 | 1.76 (-0.70, 4.21)    | 1.25             |
| Log(concentration/median concentration+1)                                 | 11.09 (9.51, 12.66)   | 0.80             |
| Log(concentration/median concentration+1)*Fulvestrant                     | 2.87 (0.62, 5.12)     | 1.15             |
| Log(concentration/median concentration+1)*NSAl (letrozole or anastrozole) |                       |                  |
| Log(concentration/median concentration+1)*No combination                  | 4.94 (3.07, 6.80)     | 0.95             |
| Fulvestrant                                                               | -0.60 (-2.86, 1.66)   | 1.15             |
| NSAl (letrozole or anastrozole)                                           |                       |                  |
| No combination                                                            | -7.84 (-10.25, -5.42) | 1.23             |
| Early breast cancer                                                       |                       |                  |
| Non-early breast cancer                                                   | 5.37 (2.85, 7.90)     | 1.29             |

The observed and model-predicted change from baseline vs ribociblib concentration in eBC patients are shown in Figure 9.

Figure 9 PK-QT model and 90% CI (PK-ECG set, with NSAI as combination partner). Note: Blue symbols and curves represent data of early breast cancer patients; black symbols and curves represent data of advanced breast cancer patients; horizontal dotted lines are the reference lines at 30 ms and 60 ms.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology data in support of this application derived from study (CLEE011O12301C (NATALEE) and study A2207 (AMALEE) which were designed to investigate the efficacy and safety of ribociclib treatment in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence.

A population PK approach was conducted to characterize the pharmacokinetics of ribociclib.

The validation of the bioanalytical method for ribociclib and study sample analysis was adequate.

Since the increase in exposure was small in moderate and severe hepatic impairment subjects, no upfront dose adjustment is required in early breast cancer with the 400 mg starting dose if the patient has hepatic impairment. The text in SmPC section 4.2 have been updated to differentiate recommendations for early and metastatic breast cancer with regards to hepatic impairment.

The updated SmPC claims on drug-drug interactions are based on PBPK simulations with CYP3A4 inhibitors or inducers. The remaining parts of the information on interactions are adequate and remain unchanged in the SmPC.

The main update to the existing and accepted PBPK model is the use of an adapted healthy population to represent early cancer patients and a metastatic cancer patient population.

The modelling in the metastatic cancer population was part of variation II-41G and is not reassessed here in this procedure.

In the PBPK model, the early breast cancer population, was actually represented by the Simcyp healthy volunteer population file with a reduced coefficient of variance for the amount of microsomal protein per gram of liver and for the hepatic CYP3A4 abundance. For interaction claims, the mean or geometric mean is typically used, and variability is not considered to a large extent. Therefore, changes to the healthy

<div style=\"page-break-after: always\"></div>

subject population file are not considered to have a substantial impact for the SmPC claims. The update of the healthy subjects population file for the already accepted PBPK model (at time of the initial MAA) is acceptable. The approved SmPC already contains text based on PBPK modelling in healthy subjects, thus the information from 'early breast cancer' simulations is redundant and is not included in the SmPC.

The MAH initially did not propose upfront dose reduction in the case where a strong CYP3A4 inhibitor must be administered with ribociclib. Monitoring and if necessary, dose reduction were proposed instead. In study O12301C, patients receiving strong inhibitors (or inducers) of CYP3A4 were excluded from the study and strong inhibitors were on the list of prohibited medications. Thus, the proposed scenario with no upfront reduction has not been studied. A few patients did still receive strong inhibitors such as ketoconazole, ritonavir/lopinavir. The PBPK model predicts approximately a doubled exposure of ribociclib (400 mg) with a strong CYP3A4 inhibitor, in line with the interaction size being larger at lower ribociclib doses due to its autoinhibition. An upfront dose reduction from 400 mg to 200mg is thus in line with the predictions and it is reflected in the SmPC 4.2

For the moderate CYP3A4 inhibitor erythromycin, the geometric mean ratios of steady-state Cmax and AUC are predicted to be 1.13 and 1.23, respectively, for multiple dosing of 400 mg ribociclib with vs without coadministration of erythromycin, suggesting no apparent effect of moderate CYP3A4 inhibitors on ribociclib PK (see SmPC 4.5).

A moderate CYP3A4 inducer (efavirenz) may decrease steady-state ribociclib Cmax and AUC by 55% and 74%, respectively, at a ribociclib dose of 400 mg, and by 52% and 71%, respectively, at a ribociclib dose of 600 mg. This implies a risk of impaired efficacy, which is reflected in the SmPC.

Study O12301C is the main study with PK sampling in the target population (eBC). Since sparse PK sampling was used in the study, standard non-compartmental analysis (NCA) may not be applicable. The relative low number of samples collected per patient doesn't allow the complete characterization of the ribociclib PK profile, however, the PK of ribociclib was thoroughly characterized in aBC patients and healthy volunteers based on an analysis included in the initial MAA.

The presented PopPK approach represents a reduced model development scheme where only selected parameter(s) were re-estimated based on data from eBC patients. The number of parameters to reestimate was kept to as few as possible, yet the developed model was to give acceptable description of the observed PK data from Study O12301C. Overall, this is considered a plausible strategy to describe PK in eBC patients by still re-using prior information from the previous PopPK model.

The Applicant did not provide a dedicated PopPK report. The previous PopPK model was used as a basis for characterizing the PK in eBC patients, in relation to aBC patients. Based on the provided pcVPC the updated PopPK model gives an acceptable description of the observed PK data in Study O12301C. Overall the updated model is considered acceptable where the re-estimated parameters were CL/F, IIV in absorption and changes to the residual error (going from a proportional model to an additive model). The inclusion of dose on CL explains the non-linear elimination processes that have not been mechanistically explained. A dose-dependency effect (17% higher CL/F) was identified at 400 vs 600 mg. The updated model is considered acceptable to support the general statement in SmPC 5.2 that a lower exposure is expected in eBC than in aBC patients administered with the same dosing regimen. However, due to limitations of the updated PopPK analysis, more detailed are not given in the SmPC. For instance, the implemented dose dependency is considered an empirical relationship which may even be confounded by additional unidentified factors affecting the PK properties of ribociclib. Furthermore, the sparse PK evidence collected in eBC patients is not sufficient for justifying the underlying factors involved in CL/F differences across indications.

<div style=\"page-break-after: always\"></div>

The CL/F was found to be approximately 20% higher in eBC patients compared to aBC patients. This means that the exposure is expected to be lower in eBC patients than aBC patients administered the same dose regimen which is appropriately reflected in the SmPC 5.2.

For the PK-QTc analysis, the eBC data was pooled with the same dataset that was used to develop the previous PK-QTc model. This means that a fairly large database was used to develop the model (1372 patients) although only 117 were eBC patients from Study OC12301C which is a limitation. A standard workflow was used for developing the PK-QTc model which is acceptable in principle, however, the dataset used for model development is considered a critical limitation. Based on the provided documentation,  Study OC12301C is not considered adequately designed for the purpose of performing a robust PK-QTc analysis. Apart from including a general statement from this analysis in SmPC section 5.1, the PK-QTc analysis is not considered acceptable for including specific model-based predictions in the SmPC for eBC patients.

QT prolongation was an important identified risk for ribociclib in the initial MAA where a concentrationdependency in QT prolongation was evident. The current analysis confirms that this trend exists also in eBC patients. Since eBC patients are treated with a lower ribociclib dose (400 mg vs 600 mg), a lower degree of QT prolongation is expected. The identification of eBC patients as a covariate on QT prolongation (indicating a lower QT prolongation of -5.37 ms even after accounting for a lower ribociclib dose in eBC patients) is questioned. This is a data-driven finding with unknown clinical relevance.  Since the PK-QTc model had low impact, any model-based predictions which included this covariate effect is not included in the SmPC.

## 2.3.6. Conclusions on clinical pharmacology

The PK of ribociclib in early breast cancer patients is well characterised and supports the proposed posology.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

Ribociclib is currently indicated in HR-positive, HER2-negative locally advanced or metastatic BC in combination with an Aromatase Inhibitor or fulvestrant, with a dose of 600 mg orally taken once daily for 21 consecutive days followed by seven days off treatment (one treatment cycle is 28 days).

In the current application the intended ribociclib dose is 400 mg orally taken once daily for 21 consecutive days followed by seven days off treatment, with a treatment duration of three years.

The 400 mg dose was selected based on consistent efficacy in post hoc exploratory analyses from the MONALEESA program, a potentially improved safety profile in terms of dose-dependent toxicities such as QTc prolongation and neutropenia as compared to the 600 mg starting dose, and supportive analyses including PK-QTcF and ANC exposure-response modelling, exposure-efficacy, and exploratory progression-free survival (PFS) analysis by dose reduction (See Pharmacology Section).

## 2.4.2. Main study

## Study CLEE11O12301C -NATALEE

The pivotal study CLEE11O12301C, hereafter referred to as study O12301C, is a phase III, multicentre, randomised, open-label trial aiming at evaluating efficacy and safety of ribociclib with an Aromatase

<div style=\"page-break-after: always\"></div>

Inhibitors (AI) vs. AI alone as adjuvant treatment in patients with HR-positive, HER2-negative early BC (eBC). For premenopausal women and for men goserelin was added to the treatment in accordance with current clinical guidelines.

In regard to description of the AI treatment in study O12301C, the abbreviation ET (endocrine therapy letrozole or anastrozole) is used throughout the assessment report.

Figure 10 Study design

<!-- image -->

## Methods

## Study participants

## Selected key inclusion criteria

- Female and male patients ≥18 years of age (with known menopausal status if female)
- Histologically confirmed diagnosis of unilateral ER and/or PR-positive, HER2-negative invasive adenocarcinoma of the breast (patients with multicentric and/or multifocal tumours eligible if all tumours met the pathologic inclusion criteria)
- Stage II-III, regardless of nodal involvement
- For stage IIA without nodal involvement either
- o tumour grade 3 or
- o tumour grade 2 with highrisk genomic profile or Ki67 ≥20% has to be present
- Complete surgical resection with free tumour margins

<div style=\"page-break-after: always\"></div>

- ECOG performance 0-1 and who were deemed eligible for adjuvant ET for at least a 60-month duration
- QTcF interval at screening &lt;450 msec
- Neoadjuvant and/or adjuvant chemotherapy should be completed prior to screening
- Standard neoadjuvant and/or adjuvant ET before study enrolment was allowed, but randomisation should occur within 12 months of the initial start date of ET

## Selected key exclusion criteria

- Prior CDK4/6 inhibitor treatment
- Prior tamoxifen, raloxifene, or AI treatment for risk reduction (`chemoprevention´) of BC
- Concurrent hormone replacement therapy
- Prior anthracycline treatment exceeding specified cumulative doses
- Distant metastases beyond regional lymph nodes (i.e., stage IV) or evidence of recurrence after curative surgery
- Clinically significant, uncontrolled heart disease and/or cardiac repolarisation abnormality (including among others Long QT syndrome and clinically significant cardiac arrythmias)

## Treatments

Patients were randomly assigned to one of the following treatment arms in a 1:1 ratio to either the ribociclib or placebo arm:

- Ribociclib 400 mg days 1-21 of each 28-day cycle plus ET (letrozole 2.5 mg daily or anastrozole 1mg daily) plus goserelin 3.6 mg subcutaneously of each 28-day cycle.
- Placebo plus ET (letrozole or anastrozole) plus goserelin.

Ribociclib and ET (letrozole or anastrozole) were administered orally together at approximately the same time each day with or without food.

Crossover between different types of ETs was not permitted in the study unless intolerable toxicity, patient request, or any other medically important event necessitated a change of ET. Goserelin was administered subcutaneously (premenopausal women and men only).

The scheduled ribociclib treatment duration was 36 months unless treatment was discontinued due to disease recurrence or unacceptable toxicity. ET treatment continued for at least 60 months from randomisation.

Mammography was planned at screening, every 12 months thereafter and as clinically indicated, until confirmation of distant recurrence (unless bilateral mastectomy was performed).

Additional radiologic examinations were planned at screening if clinically indicated and within four weeks of clinical suspicion of any recurrence or second primary non-breast invasive cancer.

<div style=\"page-break-after: always\"></div>

## Objectives

## Outcomes/endpoints

Table 20 Objectives and related endpoints

| Objective                                                                                              | Endpoint                                                                                                                                                             |
|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary                                                                                                |                                                                                                                                                                      |
| To compare iDFS for ribociclib + ET versus ET in patients with HR-positive, HER2-negative, eBC         | iDFS using STEEP criteria, as assessed by Investigator                                                                                                               |
| Secondary                                                                                              |                                                                                                                                                                      |
| To evaluate the 2 treatment arms with respect RFS                                                      | RFS using STEEP criteria                                                                                                                                             |
| To evaluate the 2 treatment arms with respect to DDFS                                                  | DDFS using STEEP criteria                                                                                                                                            |
| To evaluate the 2 treatment arms with respect to OS                                                    | OS defined as time from date of randomization to date of death due to any cause                                                                                      |
| To evaluate PRO for health-related QoL in the 2 treatment arms                                         | Change from baseline in the physical functioning sub- scale score and global healthstatus/ QoL scale score as assessed by EORTC QLQ-C30                              |
| To evaluate safety and tolerability of the treatment regimen                                           | Frequency and severity of AEs, laboratory and ECG abnormalities                                                                                                      |
| To characterize the PK of ribociclib when given in combination with NSAl (and goserelin if applicable) | PK parameters such as Ctrough and other applicable parameters for ribociclib                                                                                         |
| Exploratory                                                                                            |                                                                                                                                                                      |
| To explore the 2 treatment arms with respect to LRRFS                                                  | LRRFS defined as time from date of randomization to date of first event of local invasive breast recurrence, regional invasive recurrence, or death due to any cause |
| To explore use of subsequent anti-neoplastic therapy                                                   | Incidence of subsequent anti-neoplastic therapy and time to first subsequent anti-neoplastic therapy                                                                 |
| To explore healthcare resource utilization                                                             | Number of patients hospitalized, total number of hospitalizations, and length of stay in hospitals, number of patients with Emergency Room and additional visits     |

The primary endpoint invasive disease-free survival (iDFS) was defined as the time from the date of randomisation to the date of the first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, contralateral invasive BC, a second primary non-breast invasive cancer (basal and squamous cell carcinomas of the skin excluded), or death due to any cause. iDFS events were to be assessed locally.

Secondary endpoints relapse-free survival (RFS), distant disease-free survival (DDFS), overall survival (OS), and the exploratory endpoint loco-regional recurrence-free survival (LRRFS) were defined as follows:

RFS - the time from date of randomisation to date of first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, or death due to any cause

DDFS - the time from date of randomisation to date of first event of distant recurrence, second primary non-breast invasive cancer (basal and squamous cell carcinomas of the skin excluded), or death due to any cause

OS - the time from randomisation to date of death due to any cause

LRRFS - the time from date of randomisation to date of first event of local invasive breast recurrence, regional invasive recurrence, or death due to any cause

All endpoints were investigator-assessed.

<div style=\"page-break-after: always\"></div>

Analyses of the primary and secondary endpoints were based on the full analysis set (FAS). iDFS events were assessed locally and the analysis included all data observed up to the cut-off date. Objective confirmation using histological or cytological assessment was required to consider a recurrence an iDFS event. iDFS, RFS, and DDFS were assessed using the STandardised definitions for Efficacy EndPoints (STEEP criteria).

## Sample size

This study was event driven. The assumptions made underlying the sample size estimation was based on the primary endpoint iDFS.

At the planning stage, the expected total sample size needed was approximately 4,000 subjects (randomized 1:1).

The enrolment of patients with Anatomic Stage II was to be capped at 40%.

After the study had started, changes were implemented which affected the assumptions initially made (CSP version 2.0 and CSP version 4.0).

The distribution of Anatomic Stage II and Stage III patients was amended, and it was decided to exclude Anatomic Stage II low risk patients. For patients with node-negative stage IIA tumours to be eligible, they had to be grade 3, or grade 2 with a high Ki67 index ( ≥ 20%) or considered high risk by a validated gene expression test (as defined in inclusion criterion #8).

Based on emergent external data, the total sample size was increased.

A third efficacy interim analysis was added.

Below is the sample size section as described in the latest protocol version (version 4.0) which added another 1,000 patients.

CSP version 4.0 (dated 27 August 2020)

The enrolment of patients was expected to be approximately 40% for the Anatomic Stage II (excluding low risk patients) and 60% for the Anatomic Stage III.

The 5-year iDFS rate for the patients with Anatomic Stage II (excluding low risk patients) was assumed to be approximately 79%.

The 5-year iDFS rate for the patients with Anatomic Stage III was assumed to be approximately 72%.

Given these assumptions, the overall 5-year iDFS of the control arm was assumed to be approximately 74.8%. It was further assumed that the comparison between ribociclib in addition to standard ET and standard ET alone was to result in a hazard ratio (HR) of 0.73.

The power calculation was based on a one-sided log-rank test at an overall 2.5% level of  significance, a randomisation ratio of 1:1, and a 4-look group sequential design with a Lan-DeMets (O'Brien-Fleming) alpha spending function and a Lan-DeMets (O'Brien-Fleming) beta spending function to define a nonbinding futility rule at the interim analyses, using an information fraction of 40% for the first interim analysis (futility only) and an information fraction of 70% and 85% for the second and third interim analyses (efficacy only), respectively.

A total of 500 iDFS events were then to provide a power of approximately 93% and 85% when the overall hazard ratio is 0.73 and 0.76, respectively.

Based on projected enrolment, a total of 5,000 patients were to be randomised to observe the targeted 500 iDFS events at about 44 months after the randomisation date of the first patient.

<div style=\"page-break-after: always\"></div>

Table 21: Update of estimated timelines for interim and final analyses (CSP version 4.0).

|                    | Months after randomisationofthefirst patient(approximation   | jDESevents(information fraction)   | Cumulativepower against a hazard ratio of0.73   |
|--------------------|--------------------------------------------------------------|------------------------------------|-------------------------------------------------|
| Interim analysis 1 | 2627                                                         | 150 200 (40%)                      | 0                                               |
| Interim analysis 2 | 3435                                                         | 263350 (70%)                       | 54.6 68.4%                                      |
| Interimanalysis3   | 42 39                                                        | 375 425 (85%)                      | 84.8%                                           |
| Final analysis     | 44                                                           | 500                                | 85.093.1%                                       |

The final analysis will be performed after approximately 500 iDFS events have been documented.

## Randomisation

Patients were to be assigned to one of the two treatment arms in a ratio of 1:1. Randomisation was to be stratified by the following factors:

- Menopausal status: premenopausal women and men vs. postmenopausal women
- AJCC 8th edition Anatomic Stage Group: Anatomic Stage Group II vs. Anatomic Stage Group III
- Prior neo-/adjuvant chemotherapy: yes vs. no
- Geographical region: North America/Western Europe/Oceania vs. rest of the world (RoW)

To account for the differences in the underlying recurrence rates in the early breast cancer population between the two Anatomic Stages, the number of patients with Anatomic Stage Group II was to be capped. Initially at approximately 40%, per CSP version 2.0 at approximately 50%.

## Blinding (masking)

This is an open label study.

## Statistical methods

The submitted SAP is version 3.0 (Amendment 2, dated 25 August 2022) and contains a version history. With SAP amendment 1 (SAP version 2.0, dated 26 July 2021) changes were implemented to align with CSP version 4.0, 27 August 2020). The first approved SAP version was dated 05 December 2018 which is before the first subject first visit.

The outcome submitted is from a third (added) interim analysis. This is to be considered the primary analysis of the primary endpoint.

## Primary analysis set

The primary analysis was to be based on the Full Analysis Set ( FAS ). FAS was to include all randomised patients. Patients were to be analysed according to the randomised treatment arm and the strata they had been assigned to during the randomisation procedure.

## Primary endpoint definition

The primary efficacy variable of the trial is iDFS (defined above).

The primary iDFS analysis was to include all data observed up-to the cut-off date.

<div style=\"page-break-after: always\"></div>

## Censoring pattern of iDFS

A summary of reasons for iDFS censoring has been provided by treatment arm.

For patients without an iDFS event, the iDFS censoring date is determined as the last assessment before the earliest of the following dates, with the earliest of these also determining the censoring reason (as indicated in parentheses):

1. Analysis cut-off date (censoring reason: 'Ongoing without event'),
2. Date of consent withdrawal (censoring reason: 'Withdrew consent'),

3. Date of Last Contact for patients lost to follow-up at EOT or Date of Visit/contact for patients lost to follow-up during follow-up phase (censoring reason: 'Lost to follow-up').

In addition, the time from iDFS censoring date to data cut-off date was to be summarized by time intervals in months: &lt;3, 3 - &lt; 6, 6 - &lt; 12, 12 - &lt; 18, 18 - &lt;24 and by 12-month intervals thereafter if necessary. The gap time was calculated as ([analysis cut-off date] - [censoring date] + 1)/30.4375.

Recurrence documented after the initiation of new anti-neoplastic therapy was to be considered for the primary analysis provided recurrence assessments had continued after initiation of new cancer therapy.

Discontinuation due to clinical suspicion of recurrence without histological/cytological/imaging confirmation of recurrence was not to be considered as an iDFS event.

## Primary endpoint analyses

The primary hypothesis was to be tested using a stratified log-rank test at an overall one-sided 2.5% level of significance accounting for the randomisation stratification factors: menopausal status, the AJCC 8th edition Anatomic Stage Group, prior neo-/adjuvant chemotherapy, and geographical region.

A stratified Cox regression was used to estimate the hazard ratio (HR) of iDFS along with a 95% confidence interval using the same strata information as the primary efficacy comparison. The iDFS survival distribution was estimated using the Kaplan-Meier method.

The primary efficacy variable was to be analysed at three interim analyses and a final analysis.

The first interim was to allow the trial to stop due to futility.

The second and third interim analyses were to allow the trial to declare superior efficacy.

The study had a group sequential design. iDFS was analysed using a Lan-DeMets (O'Brien-Fleming) alpha spending function and a non-binding Lan-DeMets (O'Brien-Fleming) beta spending function based on the data observed in the FAS up to the cut-off date, according to the treatment arm and strata assigned at randomisation.

## Interim analyses

The statistical properties of the group sequential design are summarized in Table 22 below (CSP version 4.0, 27 August 2020).

<div style=\"page-break-after: always\"></div>

Table 22 Simulated Probabilities to Stop for Efficacy or Futility at the Interim or Final iDFS Analysis

| Scenario                                                                                                   | Look                                                                                                       | #iDFS events                                                                                               | Simulated cumulative probabilities (%)                                                                     | Simulated cumulative probabilities (%)                                                                     | Simulated incremental probabilities (%)                                                                    | Simulated incremental probabilities (%)                                                                    |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
|                                                                                                            |                                                                                                            |                                                                                                            | Stop for efficacy                                                                                          | Stop for futility                                                                                          | Stop for efficacy                                                                                          | Stop for futility                                                                                          |
| Under Ho (HR=1)                                                                                            | Interim 1                                                                                                  | 200                                                                                                        |                                                                                                            | 32.7                                                                                                       |                                                                                                            | 32.7                                                                                                       |
| Under Ho (HR=1)                                                                                            | Interim 2                                                                                                  | 350                                                                                                        | 0.8                                                                                                        |                                                                                                            | 0.8                                                                                                        |                                                                                                            |
| Under Ho (HR=1)                                                                                            | Interim 3                                                                                                  | 425                                                                                                        | 1.5                                                                                                        |                                                                                                            | 0.7                                                                                                        |                                                                                                            |
| Under Ho (HR=1)                                                                                            | Final                                                                                                      | 500                                                                                                        | 2.3                                                                                                        |                                                                                                            | 0.8                                                                                                        |                                                                                                            |
| Under Ha (HR=0.73)                                                                                         | Interim 1                                                                                                  | 200                                                                                                        |                                                                                                            | 0.4                                                                                                        |                                                                                                            | 0.4                                                                                                        |
| Under Ha (HR=0.73)                                                                                         | Interim 2                                                                                                  | 350                                                                                                        | 68.4                                                                                                       |                                                                                                            | 68.4                                                                                                       |                                                                                                            |
| Under Ha (HR=0.73)                                                                                         | Interim 3                                                                                                  | 425                                                                                                        | 84.8                                                                                                       |                                                                                                            | 16.3                                                                                                       |                                                                                                            |
| Under Ha (HR=0.73)                                                                                         | Final                                                                                                      | 500                                                                                                        | 93.1                                                                                                       |                                                                                                            | 8.3                                                                                                        |                                                                                                            |
| Under other Ha (HR=0.76)                                                                                   | Interim 1                                                                                                  | 200                                                                                                        |                                                                                                            | 0.8                                                                                                        |                                                                                                            | 0.8                                                                                                        |
| Under other Ha (HR=0.76)                                                                                   | Interim 2                                                                                                  | 350                                                                                                        | 54.0                                                                                                       |                                                                                                            | 54.0                                                                                                       |                                                                                                            |
| Under other Ha (HR=0.76)                                                                                   | Interim 3                                                                                                  | 425                                                                                                        | 73.3                                                                                                       |                                                                                                            | 19.3                                                                                                       |                                                                                                            |
| Under other Ha (HR=0.76)                                                                                   | Final                                                                                                      | 500                                                                                                        | 85.2                                                                                                       |                                                                                                            | 12.0                                                                                                       |                                                                                                            |
| Under other Ha (HR=0.80)                                                                                   | Interim 1                                                                                                  | 200                                                                                                        |                                                                                                            | 2.1                                                                                                        |                                                                                                            | 2.1                                                                                                        |
| Under other Ha (HR=0.80)                                                                                   | Interim 2                                                                                                  | 350                                                                                                        | 35.3                                                                                                       |                                                                                                            | 35.3                                                                                                       |                                                                                                            |
| Under other Ha (HR=0.80)                                                                                   | Interim 3                                                                                                  | 425                                                                                                        | 53.5                                                                                                       |                                                                                                            | 18.2                                                                                                       |                                                                                                            |
| Under other Ha (HR=0.80)                                                                                   | Final                                                                                                      | 500                                                                                                        | 67.9                                                                                                       |                                                                                                            | 14.4                                                                                                       |                                                                                                            |
| Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 | Note: Simulation is performed in East 6.4 with number of simulations = 10,0o0 and randomization seed = 123 |

The results of the interim analyses were to be provided to the IDMC by the independent statistician who was not to be part of trial management.

The projected timing of interim and final analyses of iDFS is summarized in Table 21.

## Supportive Analyses

As sensitivity analyses performed in the FAS, the hazard ratio and 95% CI for iDFS was to be obtained from:

- An unstratified and covariate unadjusted Cox model.
- A stratified and covariate adjusted Cox model. The covariates to be included will be detailed in the SAP.

iDFS was also to be analysed based on the PPS, using the same analysis conventions as in the primary efficacy analysis, if the FAS and PPS differ and if the primary analysis is significant.

In addition, the following supportive analyses were pre-defined:

· Number of patients and number of events by treatment arm within each stratum were to be presented along with the hazard ratio for treatment effect obtained using the Cox proportional hazards regression with corresponding confidence intervals, provided there was a sufficient number of events within the stratum. No p-values were to be presented for this analysis. Kaplan-Meier plots of survival distributions will be presented by stratum.

- Type of first iDFS event and site of the first iDFS event were to be reported.
- If there was any discrepancy between the strata classifications constructed using the eCRF data and those obtained from the IRT, a sensitivity analysis was to be performed in which a stratified Cox regression model were to be used to estimate the treatment hazard ratio and the associated 95% confidence interval based on the eCRF- derived strata. No other inferential statistics were to be provided.

<div style=\"page-break-after: always\"></div>

- Timing of all recurrence assessments were to be depicted graphically by treatment arm in order to visually assess if the alignment with protocol schedule is similar across the arms.

## Analysis of secondary efficacy endpoints

All secondary efficacy objectives were to be analysed at the primary analysis for iDFS (2nd or 3rd interim analyses if the efficacy boundary was crossed or final iDFS analysis) and at the time of end of trial. Each secondary efficacy endpoint was to be analysed in the FAS population according to the randomized treatment arm and strata assigned at randomisation.

The distributions of the secondary efficacy endpoints RFS, DDFS and OS were estimated using the Kaplan-Meier method and compared between treatment groups using a stratified log-rank test at onesided 2.5% level of significance. The HR for RFS, DDFS and OS were calculated, along with their 95% CI, using a stratified Cox model based on strata assigned at randomisation.

## Results

## Participant flow

Figure 11 Participants' flow chart

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 23 Patient disposition by treatment arm, data at IA3 data cut-off (11 Jan 2023) (FAS)

| Disposition/Reason                                                           | Ribociclib+ET N=2549 n (%)   | ET only N=2552 n (%)   | Total N=5101 n (%)   |
|------------------------------------------------------------------------------|------------------------------|------------------------|----------------------|
| Number of patients randomized                                                | 2549 (100)                   | 2552 (100)             | 5101 (100)           |
| Number of patients randomized but not treated                                | 23 (0.9)                     | 110 (4.3)              | 133 (2.6)            |
| Numberofpatientstreatedwithanytreatment                                      | 2526 (99.1)                  | 2442 (95.7)            | 4968 (97.4)          |
| Number of patients who discontinued all treatment components                 | 542 (21.3)                   | 616 (24.1)             | 1158 (22.7)          |
| Number of patients who discontinued ribociclib*                              | 1377 (54.0)                  | 0                      | 1377 (27.0)          |
| Number of patients who discontinued NSAl                                     | 542 (21.3)                   | 617 (24.2)             | 1159 (22.7)          |
| Numberofpatientsstillontreatment                                             | 1984 (77.8)                  | 1826 (71.6)            | 3810 (74.7)          |
| Primary reason forribociclib discontinuation                                 |                              |                        |                      |
| Adverse event                                                                | 477 (18.7)                   | 0                      | 477 (9.4)            |
| Completed                                                                    | 515 (20.2)                   | 0                      | 515 (10.1)           |
| Death                                                                        | 3 (0.1)                      | 0                      | 3 (0.1)              |
| Disease relapse                                                              | 109 (4.3)                    | 0                      | 109 (2.1)            |
| Endocrine therapy discontinuation                                            | 3 (0.1)                      | 0                      | 3 (0.1)              |
| Lost to follow-up                                                            | 6 (0.2)                      | 0                      | 6 (0.1)              |
| Other                                                                        | 14 (0.5)                     | 0                      | 14 (0.3)             |
| Patient decisiontodiscontinuetreatment                                       | 139 (5.5)                    | 0                      | 139 (2.7)            |
| Physician decision                                                           | 24 (0.9)                     | 0                      | 24 (0.5)             |
| Protocol deviation                                                           | 7 (0.3)                      | 0                      | 7 (0.1)              |
| Withdrawal by subject                                                        | 80 (3.1)                     | 0                      | 80 (1.6)             |
| Number of patients who had their 30-day post- ribociclibsafetyfollow-upvisit | 275 (10.8)                   | 0                      | 275 (5.4)            |
| Primary reason for NsAl discontinuation                                      |                              |                        |                      |
| Adverse event                                                                | 118 (4.6)                    | 105 (4.1)              | 223 (4.4)            |
| Death                                                                        | 5 (0.2)                      | 3 (0.1)                | 8 (0.2)              |
| Disease relapse                                                              | 142 (5.6)                    | 186 (7.3)              | 328 (6.4)            |
| Lost to follow-up                                                            | 8 (0.3)                      | 12 (0.5)               | 20 (0.4)             |
| Other                                                                        | 8 (0.3)                      | 8 (0.3)                | 16 (0.3)             |
| Patient decisionto discontinuetreatment                                      | 123 (4.8)                    | 116 (4.5)              | 239 (4.7)            |
| Physician decision                                                           | 25 (1.0)                     | 26 (1.0)               | 51 (1.0)             |
| Protocol deviation                                                           | 5 (0.2)                      | 7 (0.3)                | 12 (0.2)             |
| Withdrawal by subject                                                        | 108 (4.2)                    | 154 (6.0)              | 262 (5.1)            |
| Number of patients who had their 30-day post-NSAl safetyfollow-upvisit       | 276 (10.8)                   | 336 (13.2)             | 612 (12.0)           |
| Numberofpatientswhohaveenteredthefollow-up phase                             | 276 (10.8)                   | 342 (13.4)             | 618 (12.1)           |
| Number of patientswho discontinued from trial                                | 333 (13.1)                   | 451 (17.7)             | 784 (15.4)           |
| Death                                                                        | 61 (2.4)                     | 73 (2.9)               | 134 (2.6)            |
| Lost to follow-up                                                            | 18 (0.7)                     | 24 (0.9)               | 42 (0.8)             |
| Other                                                                        | 3 (0.1)                      | 2 (0.1)                | 5 (0.1)              |
| Physician decision                                                           | 17 (0.7)                     | 9 (0.4)                | 26 (0.5)             |
| Pregnancy                                                                    | 1 (0.0)                      | 0                      | 1 (0.0)              |
| Protocol deviation                                                           | 4 (0.2)                      | 5 (0.2)                | 9 (0.2)              |
| Withdrawal by subject                                                        | 229 (9.0)                    | 338 (13.2)             | 567 (11.1)           |

*Includes patients who completed the 3-year treatment regimen

In total, 6,068 patients were screened, and 5,101 patients were included in study O12301C, of which 2,549 were randomised to the ribociclib + ET arm and 2,553 patients were randomised to the ET only arm.

At the data cut-off (DCO) of IA3 (11 Jan 2023), 133 the randomised patients had not received the allocated treatment (n=23 [0.9%] in the ribociclib + ET arm, and n=110 [4.3%] in the ET only arm, respectively).

Goserelin was administered for gonadal suppression in premenopausal women and in men. In total, 1,125 patients (44.1%) in the ribociclib + ET arm were premenopausal women and men (n=1,114 women, n=11 men), In the ET only arm, 1,128 patients (44.2%) were premenopausal women and men (n=1,119 women, n=9 men). Goserelin treatment was received by 1,101 patients (43.2%) in the ribociclib + ET arm and 1,066 patients (41.8%) in the ET only arm. Of the patients who were treated with goserelin, 24.7% in the ribociclib + ET arm and 30.1% in the ET only arm had discontinued goserelin treatment as

<div style=\"page-break-after: always\"></div>

of the DCO of IA3. Disease relapse as the reason for goserelin discontinuation was reported for 4.4% of patients in the ribociclib + ET arm and 6.1% of patients in the ET only arm, respectively.

Stratification according to menopausal status (premenopausal women, and men vs. postmenopausal women), AJCC 8th edition Stage (stage II vs. stage III), prior neoadjuvant/adjuvant chemotherapy (yes vs. no), and geographical region (North America/Western Europe/Oceania vs. rest of the world) was incorporated in the randomisation design. There was high concordance between the stratum recorded at the time of randomisation and the actual stratum recorded in the clinical database through the data collected on eCRF and hence, the rate of mis-randomisation due to wrong stratification factors was low.

## Recruitment

Study period

Study initiation date: 7 Dec 2018

Data cut-off date, primary analysis: 11 Jan 2023

Data cut-off date, final iDFS analysis: 21 Jul 2023

Study O12301 is still ongoing.

Study centres

The study was conducted at 393 sites in the following 20 countries: Argentina (1), Australia (2), Austria (3), Belgium (4), Brazil (5), Canada (6), China (7), France (8), Germany (9), Hungary (10), Ireland (11), Italy (12), Republic of Korea (13), Poland (14), Rumania (15), Russia (16), Spain (17), Taiwan (18), United Kingdom (19), and United States (20).

## Conduct of the study

The original study protocol is dated 27 Aug 2018. The protocol has been amended five times, of which two were local amendments for Germany and the USA, respectively. The current protocol version is version 4.0, dated 27 Aug 2020.

Selected key features of amendments are summarised below:

Version 2.0, 20 Jun 2019

- A clarification of which concomitant medications that were allowed vs. not allowed was added.
- A capping rule amendment was included to allow for a better representation of stage II and III patients (50% each).
- After consultation with the EMA, it was decided to include stage II patients with higher risk of recurrence compared to protocol version 1.0. Therefore, the iDFS event rate was expected to increase and therefore the power for the iDFS endpoint was increased from 80% to 85%.

Update of estimated timelines for interim and final analyses

|                    |   Months after randomisation of the first patient (approximation | iDFS events (information fraction)   |   Cumulative power against a hazard ratio of 0.73 |
|--------------------|------------------------------------------------------------------|--------------------------------------|---------------------------------------------------|
| Interim analysis 1 |                                                               26 | 133 150 (40%)                        |                                                 0 |

<div style=\"page-break-after: always\"></div>

| Interim analysis 2   |   34 | 232 263 (70%)   | 47.6 54.6%   |
|----------------------|------|-----------------|--------------|
| Final analysis       |   42 | 332 375         | 80.0 85.0%   |

- Clarification that if the primary efficacy analysis is statistically significant, additional descriptive analyses of iDFS will also be performed approximately two years after the primary iDFS analysis and at end of trial. Consequently, addition of additional OS analysis to coincide with the additional iDFS analysis.

## Version 3.0, 23 Jan 2020

- Concurrent use of hormone replacement therapy was stated explicitly as an exclusion criterion.
- Wording added to provide clear guidance on the management of interstitial lung disease (ILD)/pneumonitis and dose adjustment of ribociclib for ILD/pneumonitis.

## Version 4.0, 27 Aug 2020

- Update made to describe emerging data from other CDK4/6 inhibitor trials indicating a potential greater treatment benefit in stage III patients. Consequently, the sample size was increased to include more stage III patients. The number of stage II patients will be capped at approximately 2,000, out of a total study population of approximately 5,000 patients.
- Update of interim and final analyses due to the increased sample size and update of selected statistical methods. Interim analysis (IA) 1 is a futility analysis, whereas IAs 2 and 3 are intended to declare superior efficacy of the experimental arm.

## Protocol deviations

At least one protocol deviation was reported for 70.2% of the patients. The percentage of patients with deviations was slightly higher in the ribociclib + ET arm compared to that in the ET only arm (73.3% vs. 67.1%). A total of 47 patients (0.9%) were excluded from the per protocol set (PPS) due to major deviations. Forty-six patients (0.9%) were excluded from the PPS due to inclusion/exclusion criteria not being met (n=26 due to not meeting the stage requirement, n=18 due to unavailable HER2 status, and n=2 due to having metastatic disease at study entry). One patient (&lt;0.1%) was excluded from the PPS due to being given a different treatment than originally randomised to; this patient was randomised to the ET only arm but was administered two days of ribociclib treatment (dispensing error) after which ribociclib was recalled and the patient resumed treatment with ET only.

In total, 2,460 patients (48.2%) reported at least one study assessment and procedure protocol deviation and 1,157 patients (22.7%) reported at least one inclusion/exclusion protocol deviation. The most commonly reported study assessment and procedure protocol deviation was mammography not regularly assessed as per protocol (1,062 patients, 20.8%). The most commonly reported inclusion/exclusion protocol deviation was baseline laboratory results criteria (blood salts, i.e., potassium, calcium and magnesium) not met (218 patients, 4.3%).

<div style=\"page-break-after: always\"></div>

Table 24 Protocol deviations (FAS)

| PD Term Deviation                                       | Ribociclib + ET N=2549 n (%)   | ET only N=2552 n (%)   | Total N=5101 n (%)   |
|---------------------------------------------------------|--------------------------------|------------------------|----------------------|
| Number of patients with at least one protocol deviation | 1868 (73.3)                    | 1713 (67.1)            | 3581 (70.2)          |
| IMP/NIMP                                                | 659 (25.9)                     | 370 (14.5)             | 1029 (20.2)          |
| Dosing & Administration                                 | 606 (23.8)                     | 284 (11.1)             | 890 (17.4)           |
| Supply                                                  | 93 (3.6)                       | 97 (3.8)               | 190 (3.7)            |
| Wrong Treatment Administration                          | 3 (0.1)                        | 4 (0.2)                | 7 (0.1)              |
| Informed Consent                                        | 477 (18.7)                     | 480 (18.8)             | 957 (18.8)           |
| Consenting Process                                      | 278 (10.9)                     | 305 (12.0)             | 583 (11.4)           |
| Timing of Consent                                       | 176 (6.9)                      | 161 (6.3)              | 337 (6.6)            |
| Failure to Obtain                                       | 54 (2.1)                       | 38 (1.5)               | 92 (1.8)             |
| Version                                                 | 10 (0.4)                       | 10 (0.4)               | 20 (0.4)             |
| Other                                                   | 9 (0.4)                        | 14 (0.5)               | 23 (0.5)             |
| Protocol Compliance                                     | 1591 (62.4)                    | 1522 (59.6)            | 3113 (61.0)          |
| StudyAssessments&Procedures                             | 1201 (47.1)                    | 1259 (49.3)            | 2460 (48.2)          |
| Inclusion / Exclusion                                   | 586 (23.0)                     | 571 (22.4)             | 1157 (22.7)          |
| Prohibitive Medication or Treatment                     | 304 (11.9)                     | 51 (2.0)               | 355 (7.0)            |
| Other                                                   | 26 (1.0)                       | 11 (0.4)               | 37 (0.7)             |
| Safety                                                  | 39 (1.5)                       | 33 (1.3)               | 72 (1.4)             |
| Late/UnreportedSAE/AESl/Pregnancy                       | 39 (1.5)                       | 33 (1.3)               | 72 (1.4)             |
| Major/Critical Deviation Leading to                     |                                |                        |                      |
| ExclusionfromAnalysis Sets                              | 29 (1.1)                       | 18 (0.7)               | 47 (0.9)             |
| Inclusion / Exclusion                                   | 29 (1.1)                       | 17 (0.7)               | 46 (0.9)             |
| Wrong Treatment Administration                          | 0                              | 1 (0.0)                | 1 (0.0)              |

A patient with multiple protocol deviations within the same PD term is counted only once for this PD term.

Patients may have protocol deviations in more than one PD term.

In total, protocol deviations due to the COVID-19 pandemic were reported in 1,016 patients (19.9%). The number of patients with deviations due to the COVID-19 pandemic was lower in the ribociclib + ET arm compared to that in the ET only arm (16.6% vs. 23.2%). Overall, the most reported protocol deviations due to the COVID-19 pandemic were due to planned visits not done at sites (641 patients, 12.6%) followed by missing visits (377 patients, 7.4%). Protocol deviations due to the COVID-19 pandemic such as changes in drug supply method, treatment not given, patient discontinuation due to COVID-19 situation, and changes in procedures due to COVID-19 were each reported in less than 4.0% of patients.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 25 Demographic characteristics (FAS)

| Characteristic                      | Ribociclib+ET N=2549 n (%)   | ET only N=2552 n (%)   | Total N=5101 n (%)   |
|-------------------------------------|------------------------------|------------------------|----------------------|
| Age group                           |                              |                        |                      |
| <45                                 | 611 (24.0)                   | 591 (23.2)             | 1202 (23.6)          |
| 45 to 54                            | 849 (33.3)                   | 895 (35.1)             | 1744 (34.2)          |
| 55 to 64                            | 682 (26.8)                   | 700 (27.4)             | 1382 (27.1)          |
| >=65                                | 407 (16.0)                   | 366 (14.3)             | 773 (15.2)           |
| Age (years)                         |                              |                        |                      |
| n                                   | 2549                         | 2552                   | 5101                 |
| Mean                                | 52.9                         | 52.7                   | 52.8                 |
| SD                                  | 10.75                        | 10.77                  | 10.76                |
| Min                                 | 24                           | 24                     | 24                   |
| Median                              | 52.0                         | 52.0                   | 52.0                 |
| Max                                 | 90                           | 89                     | 90                   |
| Gender                              |                              |                        |                      |
| Male                                | 11 (0.4)                     | 9 (0.4)                | 20 (0.4)             |
| Female                              | 2538 (99.6)                  | 2543 (99.6)            | 5081 (99.6)          |
| Race                                |                              |                        |                      |
| White                               | 1876 (73.6)                  | 1868 (73.2)            | 3744 (73.4)          |
| BlackorAfricanAmerican              | 42 (1.6)                     | 47 (1.8)               | 89 (1.7)             |
| Asian                               | 341 (13.4)                   | 334 (13.1)             | 675 (13.2)           |
| NativeHawaianorOtherPacificIslander | 3 (0.1)                      | 1 (0.0)                | 4 (0.1)              |
| AmericanIndianorAlaskaNative        | 4 (0.2)                      | 3 (0.1)                | 7 (0.1)              |
| Other                               | 145 (5.7)                    | 172 (6.7)              | 317 (6.2)            |
| Missing                             | 138 (5.4)                    | 127 (5.0)              | 265 (5.2)            |
| Ethnicity                           |                              |                        |                      |
| Hispanic or Latino                  | 212 (8.3)                    | 223 (8.7)              | 435 (8.5)            |
| Not Hispanic or Latino              | 2076 (81.4)                  | 2054 (80.5)            | 4130 (81.0)          |
| Unknown                             | 172 (6.7)                    | 201 (7.9)              | 373 (7.3)            |
| Missing                             | 89 (3.5)                     | 74 (2.9)               | 163 (3.2)            |
| Region                              |                              |                        |                      |
| Asia                                | 281 (11.0)                   | 290 (11.4)             | 571 (11.2)           |
| Europe                              | 1505 (59.0)                  | 1506 (59.0)            | 3011 (59.0)          |
| North America/Australia             | 624 (24.5)                   | 612 (24.0)             | 1236 (24.2)          |
| Latin America                       | 139 (5.5)                    | 144 (5.6)              | 283 (5.5)            |
| ECOGperformance status              |                              |                        |                      |
| 0                                   | 2106 (82.6)                  | 2132 (83.5)            | 4238 (83.1)          |
| 1                                   | 440 (17.3)                   | 418 (16.4)             | 858 (16.8)           |
| Missing                             | 3 (0.1)                      | 2 (0.1)                | 5 (0.1)              |
| Weight (kg)                         |                              |                        |                      |
| n                                   | 2534                         | 2542                   | 5076                 |
| Mean                                | 72.4                         | 72.2                   | 72.3                 |
| SD                                  | 16.20                        | 15.53                  | 15.86                |
| Min                                 | 38                           | 41                     | 38                   |
| Median                              | 70.0                         | 70.0                   | 70.0                 |
| Max                                 | 166                          | 169                    | 169                  |
| Height (cm)                         |                              |                        |                      |
| n                                   | 2523                         | 2522                   | 5045                 |
| Mean                                | 162.9                        | 162.7                  | 162.8                |
| SD                                  | 6.78                         | 6.85                   | 6.81                 |
| Min                                 | 140                          | 140                    | 140                  |
| Median                              | 163.0                        | 163.0                  | 163.0                |
| Max                                 | 198                          | 191                    | 198                  |
| BMI (kg/m2)                         |                              |                        |                      |
| n                                   | 2518                         | 2521                   | 5039                 |
| Mean                                | 27.3                         | 27.3                   | 27.3                 |
| SD                                  | 5.81                         | 5.70                   | 5.76                 |
| Min                                 | 16                           | 15                     | 15                   |
| Median                              | 26.3                         | 26.5                   | 26.4                 |
| Max                                 | 56                           | 59                     | 59                   |

Weight and height are the last non-missing assessments on or before the date of randomization. BMl:bodymassindexiscalculatedbasedonrawdatameasurements.

<div style=\"page-break-after: always\"></div>

Table 26 Disease characteristics (FAS)

|                                                    | Ribociclib+ET N=2549   | ETonly N=2552   | Total N=5101   |
|----------------------------------------------------|------------------------|-----------------|----------------|
| Characteristic Tumor Location                      | n (%)                  | n (%)           | n (%)          |
| Right                                              | 1277 (50.1)            | 1258 (49.3)     | 2535 (49.7)    |
| Left                                               | 1271 (49.9)            | 1287 (50.4)     | 2558 (50.1)    |
| Bilateral                                          | 1 (0.0)                | 7 (0.3)         | 8 (0.2)        |
| Missing                                            | 0                      | 0               | 0              |
| Histopathological grade at diagnosis -n (%)        |                        |                 |                |
| GX                                                 | 30 (1.2)               | 32 (1.3)        | 62 (1.2)       |
| G1                                                 | 218 (8.6)              | 240 (9.4)       | 458 (9.0)      |
| G2                                                 | 1458 (57.2)            | 1451 (56.9)     | 2909 (57.0)    |
| G3                                                 | 521 (20.4)             | 549 (21.5)      | 1070 (21.0)    |
| Not Done                                           | 292 (11.5)             | 258 (10.1)      | 550 (10.8)     |
| Missing                                            | 30 (1.2)               | 22 (0.9)        | 52 (1.0)       |
| T stage at diagnosis -n (%)                        |                        |                 |                |
| X1                                                 | 175 (6.9)              | 173 (6.8)       | 348 (6.8)      |
| TO                                                 | 4 (0.2)                | 7 (0.3)         | 11 (0.2)       |
| Tis                                                | 2 (0.1)                | 3 (0.1)         | 5 (0.1)        |
| T1                                                 | 471 (18.5)             | 442 (17.3)      | 913 (17.9)     |
| T2                                                 | 1181 (46.3)            | 1235 (48.4)     | 2416 (47.4)    |
| T3                                                 | 471 (18.5)             | 472 (18.5)      | 943 (18.5)     |
| T4                                                 | 200 (7.8)              | 184 (7.2)       | 384 (7.5)      |
| Missing                                            | 45 (1.8)               | 36 (1.4)        | 81 (1.6)       |
| N stage at diagnosis -n (%)                        |                        |                 |                |
| NX                                                 | 272 (10.7)             | 264 (10.3)      | 536 (10.5)     |
| NO                                                 | 694 (27.2)             | 737 (28.9)      | 1431 (28.1)    |
| N1                                                 | 1050 (41.2)            | 1049 (41.1)     | 2099 (41.1)    |
| N2                                                 | 332 (13.0)             | 292 (11.4)      | 624 (12.2)     |
| N3                                                 | 151 (5.9)              | 175 (6.9)       | 326 (6.4)      |
| Missing                                            | 50 (2.0)               | 35 (1.4)        | 85 (1.7)       |
| Ki67scoreatinitialdiagnosis                        |                        |                 |                |
| n                                                  | 1861                   | 1908            | 3769           |
| Mean                                               | 27.1                   | 27.1            | 27.1           |
| SD                                                 | 19.88                  | 19.50           | 19.69          |
| Min                                                | 0                      | 0               | 0              |
| Median Max                                         | 20.0 66                | 20.5 100        | 20.0 100       |
| Ki67 category atinitial diagnosis                  |                        |                 |                |
| <=14%                                              | 508 (19.9)             | 508 (19.9)      | 1016 (19.9)    |
| >14%                                               | 1353 (53.1)            | 1400 (54.9)     | 2753 (54.0)    |
| <=20%                                              | 938 (36.8)             | 954 (37.4)      | 1892 (37.1)    |
|                                                    |                        |                 | 1877 (36.8)    |
| >20%                                               | 923 (36.2)             | 954 (37.4)      |                |
| Missing Histopathologicalgrade onsurgical specimen | 688 (27.0)             | 644 (25.2)      | 1332 (26.1)    |
| - n (%)                                            | 32 (1.3)               | 30 (1.2)        | 62 (1.2)       |
| GX G1                                              | 213 (8.4)              | 217 (8.5)       | 430 (8.4)      |
| G2                                                 | 1460 (57.3)            | 1432 (56.1)     | 2892 (56.7)    |
| G3                                                 | 684 (26.8)             | 702 (27.5)      | 1386 (27.2)    |
| Not Done                                           |                        | 168 (6.6)       | 327 (6.4)      |
| Missing                                            | 159 (6.2) 1 (0.0)      | 3 (0.1)         | 4 (0.1)        |
| T stage on surgical specimen - n (%)               |                        |                 |                |
| X1                                                 | 20 (0.8)               | 9 (0.4)         | 29 (0.6)       |
| TO                                                 | 56 (2.2)               | 52 (2.0)        | 108 (2.1)      |
| S!1                                                | 16 (0.6)               | 19 (0.7)        | 35 (0.7)       |
| T1                                                 | 774 (30.4)             | 761 (29.8)      | 1535 (30.1)    |
| T2                                                 | 1162 (45.6)            | 1198 (46.9)     | 2360 (46.3)    |
| T3                                                 | 427 (16.8)             | 422 (16.5)      | 849 (16.6)     |
|                                                    | 92 (3.6)               | 91 (3.6)        | 183 (3.6)      |
| T4                                                 |                        | 0               | 2 (0.0)        |
| Missing N stage on surgical specimen - n (%)       | 2 (0.1)                |                 |                |
| NX                                                 | 2 (0.1)                | 5 (0.2)         | 7 (0.1)        |
| NO                                                 | 378 (14.8)             | 418 (16.4)      | 796 (15.6)     |
| N1                                                 | 1062 (41.7)            | 1039 (40.7)     | 2101 (41.2)    |
| N2                                                 | 733 (28.8)             | 690 (27.0)      | 1423 (27.9)    |
| N3                                                 | 372 (14.6)             | 399 (15.6)      | 771 (15.1)     |
| Missing Ki67score on surgical specimen1            | 2 (0.1)                | 1 (0.0)         | 3 (0.1)        |
| n                                                  | 1269                   | 1332            | 2601           |
| Mean                                               | 20.6                   | 20.9            | 20.7           |
| SD                                                 | 17.82                  | 18.15           | 17.99          |
| Min                                                | 0                      | 0               | 0              |
| Median Max                                         | 15.0 66                | 15.0 98         | 15.0 66        |

<div style=\"page-break-after: always\"></div>

|                                                                 | Ribociclib+ET      | ET only            | Total              |
|-----------------------------------------------------------------|--------------------|--------------------|--------------------|
| Characteristic                                                  | N=2549 n (%)       | N=2552 n (%)       | N=5101 n (%)       |
| Ki67 category on surgical specimen                              |                    |                    |                    |
| <=14%                                                           | 541 (21.2)         | 577 (22.6)         | 1118 (21.9)        |
| >14%                                                            | 728 (28.6)         | 755 (29.6)         | 1483 (29.1)        |
| <=20%                                                           | 817 (32.1)         | 864 (33.9)         | 1681 (33.0)        |
| >20%                                                            | 452 (17.7)         | 468 (18.3)         | 920 (18.0)         |
| Missing                                                         | 1280 (50.2)        | 1220 (47.8)        | 2500 (49.0)        |
| Time since initial diagnosis (months)                           |                    |                    |                    |
| n                                                               | 2517               | 2528               | 5045               |
| Mean                                                            | 11.8               | 11.8               | 11.8               |
| SD                                                              | 3.53               | 3.58               | 3.55               |
| Min Median                                                      | 1 11.7             | 1 11.7             | 1 11.7             |
| Max                                                             | 23                 | 27                 | 27                 |
| Predominant histology-n(%)                                      |                    |                    |                    |
| Invasiveductal carcinomaNOS                                     | 1857 (72.9)        | 1881 (73.7)        | 3738 (73.3)        |
| Invasivelobular                                                 | 455 (17.9)         | 450 (17.6)         | 905 (17.7)         |
| Carcinoma medullary                                             | 1 (0.0)            | 1 (0.0)            | 2 (0.0)            |
| Mucinous                                                        | 17 (0.7)           | 16 (0.6)           | 33 (0.6) 30 (0.6)  |
| Papillary                                                       | 18 (0.7) 5 (0.2)   | 12 (0.5) 3 (0.1)   | 8 (0.2)            |
| Tubular                                                         | 1 (0.0)            | 0                  | 1 (0.0)            |
| Ductal Carcinoma In Situ LobularCarcinoma InSitu                | 0                  | 0                  | 0                  |
| Other                                                           |                    |                    |                    |
| Missing                                                         | 194 (7.6)          | 189 (7.4) 0        | 383 (7.5) 1 (0.0)  |
| Prior surgery -n (%)                                            | 1 (0.0)            |                    |                    |
| Mastectomy                                                      | 1664 (65.3)        | 1691 (66.3)        | 3355 (65.8)        |
| Breastconservingsurgery                                         | 978 (38.4)         | 963 (37.7)         | 1941 (38.1)        |
| Axillarylymphnodedissection                                     | 2165 (84.9)        | 2149 (84.2)        | 4314 (84.6)        |
| Sentinel lymph node biopsy                                      | 926 (36.3)         | 920 (36.1)         | 1846 (36.2)        |
| Other                                                           | 143 (5.6)          | 162 (6.3)          | 305 (6.0)          |
| Missing                                                         | 0                  | 0                  | 0                  |
| HER2ISH result prior to surgery (reported                       |                    |                    |                    |
| onlyifperformed)-n(%) Amplification                             | 4 (0.2)            | 7 (0.3)            | 11 (0.2)           |
| Non-Amplification                                               | 612 (24.0)         | 653 (25.6)         | 1265 (24.8)        |
| Equivocal                                                       | 19 (0.7)           | 13 (0.5)           | 32 (0.6)           |
| Unknown                                                         | 6 (0.2)            | 11 (0.4)           | 17 (0.3)           |
| HER2ISHresultfrom the surgical specimen                         |                    |                    |                    |
| (reportedonlyifperformed)-n(%)                                  | 2 (0.1)            | 1 (0.0)            | 3 (0.1)            |
| Amplification Non-Amplification                                 | 417 (16.4)         | 423 (16.6)         | 840 (16.5)         |
| Equivocal                                                       | 1 (0.0)            | 1 (0.0)            | 2 (0.0)            |
| Unknown                                                         | 2 (0.1)            | 2 (0.1)            | 4 (0.1)            |
| HER2IHC score prior to surgery (reported onlyif performed)-n(%) |                    |                    |                    |
| 0                                                               | 856 (33.6)         | 881 (34.5)         | 1737 (34.1)        |
| 1+                                                              | 862 (33.8)         | 813 (31.9)         | 1675 (32.8)        |
| 2+                                                              | 464 (18.2)         | 480 (18.8)         | 944 (18.5)         |
| 3+                                                              | 5 (0.2)            | 5 (0.2)            | 10 (0.2)           |
| Unknown HER2IHCscorefrom thesurgical specimen                   | 21 (0.8)           | 21 (0.8)           | 42 (0.8)           |
| (reported only if performed)-n (%) 0                            | 625 (24.5)         | 610 (23.9)         | 1235 (24.2)        |
| 1+                                                              | 513 (20.1)         | 516 (20.2)         | 1029 (20.2)        |
| 2+                                                              | 235 (9.2)          | 262 (10.3)         | 497 (9.7)          |
| 3+                                                              | 1 (0.0)            | 3 (0.1)            | 4 (0.1)            |
| Unknown                                                         | 6 (0.2)            | 10 (0.4)           | 16 (0.3)           |
| ER/PR combination statuses-n(%)                                 |                    |                    |                    |
| ER+/PR+                                                         | 2172 (85.2)        | 2132 (83.5)        | 4304 (84.4)        |
| ER+/PR-                                                         | 359 (14.1)         | 392 (15.4)         | 751 (14.7)         |
| ER-/PR+                                                         | 3 (0.1)            | 12 (0.5)           | 15 (0.3)           |
| ER+/UNK                                                         | 10 (0.4)           | 13 (0.5) 2 (0.1)   | 23 (0.5)           |
| UNK/PR+                                                         | 2 (0.1)            |                    | 4 (0.1)            |
| UNK/PR- UNK/UNK                                                 | 1 (0.0)            | 1 (0.0) 0          | 2 (0.0)            |
| AJCC 8thed.anatomic stage-n(%)                                  | 2 (0.1)            |                    | 2 (0.0)            |
| Stage 0                                                         | 0                  | 0                  | 0                  |
| Stage I                                                         | 9 (0.4)            | 5 (0.2)            | 14 (0.3)           |
| Stage II                                                        | 1011 (39.7)        | 1034 (40.5)        | 2045 (40.1)        |
| Stage IlI                                                       | 1528 (59.9)        | 1512 (59.2)        | 3040 (59.6)        |
| Stage IV                                                        | 0                  | 0                  | 0 2 (0.0)          |
| Missing Genomic test                                            | 1 (0.0)            | 1 (0.0)            |                    |
| Endopredict                                                     | 23 (0.9)           | 28 (1.1)           | 51 (1.0)           |
| Mammaprint                                                      | 46 (1.8)           | 51 (2.0)           | 97 (1.9)           |
| Oncotype DX                                                     | 120 (4.7) 38 (1.5) | 129 (5.1) 29 (1.1) | 249 (4.9) 67 (1.3) |
| Pam50 Other                                                     | 109 (4.3)          | 103 (4.0)          | 212 (4.2)          |

<div style=\"page-break-after: always\"></div>

| Characteristic                                        | Ribociclib+ET N=2549 n (%)   | ETonly N=2552 n (%)   | Total N=5101 n (%)   |
|-------------------------------------------------------|------------------------------|-----------------------|----------------------|
| NstatusforsubgroupanalysisusedinAJcc Stagederivation2 |                              |                       |                      |
| NO                                                    | 285 (11.2)                   | 328 (12.9)            | 613 (12.0)           |
| N1-N3                                                 | 2261 (88.7)                  | 2219 (87.0)           | 4480 (87.8)          |
| >N3                                                   | 0                            | 0                     | 0                    |
| Missing                                               | 3 (0.1)                      | 5 (0.2)               | 8 (0.2)              |

Patientsmayhavehadmore thanonepriorsurgerybutareonlycountedoncepercategory.

T stage categoryT1 collectsT1mi,T1a,T1b,and T1c.CategoryT4 collectsT4a,T4b,T4c,andT4d.

N stage category N0 collects N0 and N0(i+). Category N1 collects N1, N1a, N1c, and N1mi. Category

N2 collects N2a,N2b,andN2c.CategoryN3collectsN3a,N3b,and N3c.

patientshavingnotreceivedneo-/adjuvanttreatment,orasworststagederived usingTNMatdiagnosisandTNMfromsurgeryforpatientshavingreceivedneo-/adjuvanttreatment. PatientsmayhavehadmorethanoneGenomictest typebutareonlycountedoncepertype.

1Ki67persurgical specimen(if available,otherwise at diagnosis)was used forsubgroup iDFSanalysis.

2 Included in missing category are patients having Nx. These patients are either unable to be staged orhavebeenstagedwithNxandT4(x)asStageIlIB

## Baseline data

## Prior and concomitant therapy

Overall, 44.6% and 84.5% of patients had received prior antineoplastic medications in the neoadjuvant and adjuvant settings, respectively, prior to study entry. In total, 2,249 patients (88.2%) in the ribociclib + ET arm and 2,245 patients (88.0%) in the ET only arm had received prior chemotherapy, of which taxanes were the most common (84.2% of the patients in the ribociclib + ET arm and 83.5% in the ET only arm). Per protocol, patients were allowed to initiate adjuvant ET up to 12 months before randomisation and a total of 1,824 patients (71.6%) in the ribociclib + ET arm and 1,801 patients (70.6%) in the ET only arm had received prior ET. AIs were the most common prior ET in both treatment arms (62.8% in the ribociclib + ET arm, 62.4% in the ET only arm). The median duration of prior ET was 2.8 months (range 0-16) in the ribociclib + ET arm and 2.9 months (range 0-54) in the ET only arm.

Prior radiotherapy due to breast cancer was received by 2,292 patients (89.9%) in the ribociclib + ET arm and by 2,302 patients (90.2%) in the ET only arm. The median time since end of last radiotherapy was 2.3 months (range 0-14) in both treatment arms. All but one patient in the ribociclib + ET arm and all patients in the ET only arm had received prior breast cancer surgery with a median time since last surgery 7.9 months (range 0-18) in the ribociclib + ET arm and 7.8 months (range 0-21) in the ET only arm.

## Numbers analysed

Table 27 Analysis set (all randomised patients)

| Analysisset                | Ribociclib+ET N=2549 n (%)   | ET only N=2552 n (%)   | Total N=5101 n (%)   |
|----------------------------|------------------------------|------------------------|----------------------|
| Full analysis set          | 2549 (100)                   | 2552 (100)             | 5101 (100)           |
| Safety analysis set        | 2524 (99.0)                  | 2444 (95.8)            | 4968 (97.4)          |
| Per-protocol set           | 2496 (97.9)                  | 2424 (95.0)            | 4920 (96.5)          |
| Pharmacokineticanalysisset | 108 (4.2)                    |                        | 108 (2.1)            |

Note:DenominatorforpercentaaesisbasedonthenumberofpatientsintheFullanalvsisset.

In total, 5,101 patients were randomised 1:1 to the two treatment arms between 10 Jan 2019 and 20 April 2021 and constituted the full analysis set (FAS), which was used for efficacy analyses.

All patients who received at least one dose of ribociclib or ET were included in the safety analysis set, which in total comprised 97.4% of all patients. All patients who received at least one dose of ribociclib and had at least on evaluable post-dose concentration measurement were included in the pharmacokinetic analysis set.

<div style=\"page-break-after: always\"></div>

Furthermore, the patients in the FAS who were compliant with requirements of the protocol (i.e., received study treatment and were not excluded due to major protocol deviations) were included in the per protocol set (PPS). In total, 133 patients who did not receive any treatment, 47 patients with major protocol deviations, and one patient who by mistake received the wrong study treatment (ET only instead of ribociclib + ET) and withdrew consent for the study were excluded from the PPS. In the study protocol it is stated that sensitivity analyses of the primary endpoint iDFS may be performed using data from the PPS if the FAS and PPS differ and if the primary analysis is significant.

## Outcomes and estimation

## Primary endpoint iDFS

The primary analysis is based on data from the IA3 as of DCO 11 Jan 2023, with 426 iDFS events and median follow-up 27.7 months (range 0-45 months). Of the 426 investigator-assessed iDFS events, seven did not have a protocol-specified method of validation to support the event and were documented as protocol deviations.

At DCO for IA3, 515 (20.2%) patients in the ribociclib + ET arm had completed the full 36 months of ribociclib treatment, and 1,449 patients (57.4%) had completed 24 months of ribociclib treatment. Based on the third interim analysis, it is estimated that the maximum possible number of patients to complete 3-year treatment with ribociclib plus ET will be approximately 75.0%.

The hazard ratio (HR) of the primary endpoint iDFS was 0.748 (95% confidence interval [CI] 0.618, 0.906, 1-sided p-value=0.0014) in favour of the ribociclib + ET arm. The median time to iDFS was not reached (NR) in any of the treatment arms but in general, the iDFS event-free probability remained higher in the ribociclib + ET arm.

The 3-year iDFS rates were 90.4% (95% CI 88.6, 91.9) in the ribociclib + ET arm and 87.1% (95% CI 85.3, 88.8) in the ET only arm, reflecting a 3.3% absolute benefit favouring ribociclib + ET.

Final iDFS data as of DCO 21 Jul 2023 were consistent with the primary analysis with HR=0.749 (95% CI 0.628, 0.892, 1-sided p-value 0.0006). The median time to iDFS was NR in both treatment arms. At the final analysis, a total of 509 iDFS events had occurred (n=226 in the ribociclib + ET arm vs. n=283 in the ET only arm, respectively). The median follow-up at final iDFS analysis was 33.3 months (range 0-51 months), 6.3 months longer compared to at IA3.

At the final iDFS analysis (DCO 21 Jul 2023), an additional 576 patients had completed the full 3-year ribociclib treatment duration since the IA3 analysis. In total, 1,996 (78.3%) patients in the ribociclib + ET arm had then discontinued ribociclib; 1,091 (42.8%) of the patients had completed the 3-year ribociclib treatment, 498 (19.5%) discontinued due to AEs, 135 (5.3%) due to patient decision to discontinue, and 122 (4.8%) due to disease recurrence.

<div style=\"page-break-after: always\"></div>

Figure 12 Kaplan-Meier plot for iDFS  (final iDFS analysis, 21 Jul 2023 data cut-off) (FAS)

<!-- image -->

p-value from stratified loq-rank test is one-sided.

Table 28 Kaplan-Meier estimates for iDFS (final iDFS analysis, 21 Jul 2023 data cut-off) (FAS)

<!-- image -->

| ET+ribociclib N=2549   |                  | ET only N=2552   | KM%estimate 95%CI   |
|------------------------|------------------|------------------|---------------------|
| Month6                 | 98.9(98.4,99.2)  | Month6           | 97.9 (97.3, 98.4)   |
| Month12                | 97.3 (96.5,97.9) | Month12          | 96.3 (95.4,97.0)    |
| Month 18               | 95.4(94.5,96.2)  | Month 18         | 94.0(93.0,94.9)     |
| Month 24               | 93.5(92.4,94.4)  | Month 24         | 92.0 (90.8,93.0)    |
| Month30                | 92.1(90.9,93.1)  | Month30          | 89.7 (88.3,90.9)    |
| Month36                | 90.7(89.3,91.8)  | Month36          | 87.6 (86.1,88.9)    |
| Month 42               | 88.3(86.4,89.9)  | Month 42         | 84.8(82.8,86.6)     |
| Month48                | 86.2(83.5,88.5)  | Month48          | 79.5(71.4,85.5)     |
| Month54                | NE (NE, NE)      | Month54          | NE (NE, NE)         |
| NE=Notestimable        | NE=Notestimable  |                  |                     |

As shown in the table above, the 3-year iDFS rates at DCO for final iDFS analysis were 90.7% (95% CI 89.3, 91.8) in the ribociclib + ET arm and 87.6% (95% CI 86.1, 88.9) in the ET only arm, reflecting a 3.1% absolute benefit favouring ribociclib + ET.

Key baseline factors included age, ER/PR status, and ET type.

<div style=\"page-break-after: always\"></div>

Table 29 Cox regression model for iDFS stratified by randomisation factors and adjusted for key baseline and prognostic factors (final iDFS analysis 21 Jul 2023 data cut-off) (FAS)

<!-- image -->

The most common type of first IDFS event in both treatment arms was distant recurrence. In total, 4.7% distance recurrence iDFS events were reported in the ribociclib + ET arm compared to 6.7% in the ET only arm.

Table 30 Type and site of first iDFS event (final iDFS analysis 21 Jul 2023 data cut-off) (FAS)

<!-- image -->

At DCO for the final analysis, the total proportion of patients censored for iDFS was comparable between the ribociclib plus ET arm and the ET only arm (91.1% vs. 88.9%). The predominant censoring reason in both treatment arms was `ongoing without event´.

<div style=\"page-break-after: always\"></div>

Table 31 iDFS censoring by treatment arm (final iDFS analysis, 21 Jul 2023 data cut-off) (FAS)

|                                    | Number of patients N=5101 n (%)   |
|------------------------------------|-----------------------------------|
| Ribociclib +ET (N=2549)            |                                   |
| Number of patients with iDFS event | 226 (8.9)                         |
| Number of patients censored        | 2323 (91.1)                       |
| Reasonfor censoring                |                                   |
| Ongoing without event              | 2073 (81.3)                       |
| Withdrew consent                   | 233 (9.1)                         |
| Lost to follow-up                  | 17 (0.7)                          |
| ET only (N=2552)                   |                                   |
| NumberofpatientswithiDFSevent      | 283 (11.1)                        |
| Numberofpatientscensored           | 2269 (88.9)                       |
| Reason for censoring               |                                   |
| Ongoing without event              | 1901 (74.5)                       |
| Withdrew consent                   | 343 (13.4)                        |
| Lost to follow-up                  | 25 (1.0)                          |

## Secondary endpoints

## Relapse-free survival (RFS)

As of DCO for the final iDFS analysis, HR for the secondary endpoint RFS was 0.727 (95% CI 0.602, 0.887, nominal 1-sided p-value=0.0004) in favour of the ribociclib + ET arm. At DCO for the final iDFS analysis, 7.5% (192/2549) of the patients in the ribociclib + ET arm and 9.7% (248/2552) of the patients in the ET only arm had had an RFS event. The estimated 3-year RFS rates were 92.1% (95% CI 90.9, 93.2) in the ribociclib + ET arm and 89.1% (95% CI 87.6, 90.4) in the ET only arm, translating into an absolute risk reduction of 3.0% in favour of ribociclib + ET treatment. This is in line with the primary analysis. The proportion of patients censored for RFS was comparable between the two treatment arms (92.5% [2,357/2,549 patients] in the ribociclib + ET arm vs. 90.2% [2,304/2,552 patients] in the ET only arm).

## Distant disease-free survival (DDFS)

As of DCO for the final iDFS HR for the secondary endpoint DDFS was 0.749 (95% CI 0.623, 0.900, nominal 1-sided p-value=0.0010) in favour of the ribociclib + ET arm. At DCO for the final iDFS analysis, 8.0% (204/2549) of the patients in the ribociclib + ET arm compared to 10.0% (256/2552) of the patients in the ET only arm had had an DDFS event. The estimated 3-year DDFS rates were 91.5% (95% CI 90.2, 92.7) and 88.9% (95% CI 87.4, 90.2) in the ribociclib + ET arm and the ET only arm, respectively. This translates into an absolute risk reduction of 2.6% in favour of ribociclib + ET treatment and is in line with the iDFS results of the primary analysis. As for RFS, the proportion of patients censored for DDFS was comparable between the two treatment arms (92.0% [2,345/2,549 patients] vs. 90.0% [2,296/2,552 patients] in the ribociclib + ET arm vs. the ET only arm).

## Overall survival (OS)

At DCO for the final iDFS analysis, the median follow-up for the secondary endpoint OS was 35.9 months (range 0-52 months). At this time point, only 84 (3.3%) OS events had occurred in the ribociclib + ET arm compared to 88 (3.4%) OS events in the ET only arm. There was a trend for prolonged OS in the ribociclib + ET arm vs. the ET only arm, with HR=0.892 (95% CI 0.661, 1.203, nominal 1-sided pvalue=0.2263). The 3-year OS rate was 97.0% (95% CI 96.2, 97.6) in the ribociclib + ET arm vs. 96.1% (95% CI 95.1, 96.9) in the ET only arm, respectively, translating into an absolute risk reduction of 0.9%. The total proportion of patients censored for OS was comparable between the ribociclib + ET arm and the ET only arm (96.7% [2,466/2,549 patients] vs. 96.5% [2,464/2,553 patients]).

## Patient reported outcomes (PROs)

<div style=\"page-break-after: always\"></div>

As regards the secondary endpoints PROs , the physical functioning sub-scale score of the EORTC QLQC30 was the primary PRO variable of interest. Secondary PRO variables were the Global health status/quality of life (QoL), emotional functioning and social functioning sub-scale scores of the EORTC QLQ-C30, the breast cancer symptoms scale of the EORTC QLQ-BR23, the VAS scores of the EQ-5D-5L, and the anxiety domain and depression domain scores of HADS.

Overall, treatment with ribociclib + ET maintained PRO scores over time and completion rates for PRO questionnaires during the treatment period were comparable between both treatment arms. At baseline, PRO data was collected from 2,495 patients (97.9%) in the ribociclib + ET arm vs. 2,483 patients (97.3%) in the ET only arm. Among those patients, 84.5% of patients in the ribociclib + ET arm vs. 84.1% in the ET only arm partially completed the questionnaires at IA3. As of the DCO for IA3, data were collected for 469/544 patients (86.2%) in the ribociclib + ET arm vs. 502/610 patients (82.3%) in the ET only arm with a completed end of treatment visit. Of those patients with end of treatment PRO data, 67.7% of patients in the ribociclib + ET arm partially completed vs. 68.2% in the ET only arm at IA3.

Data regarding physical functioning using the EORTC QLQ-C30 were obtained at baseline, every 12 weeks during the first 24 months, every 24 weeks thereafter until confirmation of distant recurrence, at end of treatment, at confirmation of first recurrence and at confirmation of distant recurrence (if first recurrence was not distant), and every 12 weeks after distant recurrence for 12 months. Missing information were to be handled according to scoring manuals for each respective questionnaire. If &gt;50% of the items were missing in a scale or subscale, the score for this scale/subscale would be considered missing for this assessment. Otherwise, the average of the non-missing items in the scale/subscale would be used to impute for the missing items when calculate the score for the scale/subscale.

Mean baseline physical functioning scores were well balanced between the treatment arms: 85.0 (on a scale of 0 to 100) in both the ribociclib plus ET and ET only arms. Physical functioning scores were generally similar between the two treatment arms throughout the study

## Exploratory endpoints

## Distant recurrence-free survival (DRFS)

A stratified Cox regression model was used to estimate the HR of the exploratory endpoint DRFS , a composite time to event endpoint of any distant recurrence or death) in a post-hoc analysis. At DCO for the final iDFS analysis, HR for DRFS was 0.738, (95% CI 0.606, 0.898, one-sided nominal pvalue=0.0012), in favour of ribociclib + ET treatment. The DRFS distribution was estimated using the Kaplan-Meier method. There were 178 events in the ribociclib + ET arm vs. 227 events in the ET only arm.

## Loco-regional recurrence-free survival (LRRFS)

At the DCO for IA3, HR for the exploratory endpoint LRRFS was 0.722 (95% CI 0.541, 0.962), 3.3% of the patients in the ribociclib + ET arm and 4.2% of the patients in the ET only arm had an LRRFS event. The 3-year LRRFS rates were 96.0% (95% CI 95.0, 96.8) in the ribociclib + ET arm and 93.0% (95% CI 91.2, 94.4) in the ET only arm.

At DCO for the final iDFS analysis, 612 patients (24.0%) in the ribociclib + ET arm and 693 patients (27.2%) in the ET only arm had discontinued all treatment components.

## Post-treatment antineoplastic therapy

The proportion of patients who received at least one post-treatment antineoplastic medication was lower in the ribociclib + ET arm compared to the ET only arm (13.1% vs. 17.3%). The subsequent antineoplastic therapies included e.g., chemotherapy, ETs, EGFR and VEFGR inhibitors, HER2 inhibitors, mTOR inhibitors, PD-1/PD-L1 inhibitors, and investigational compounds. The only treatments

<div style=\"page-break-after: always\"></div>

(summarised by treatment groups) received by &gt;2% of the patients in any treatment arm were antioestrogens (.50% in the ribociclib + ET arm vs. 8.6% in the ET only arm), AIs (6.6% vs. 7.3%), CDK inhibitors (1.9% vs. 6.5%), GnRH analogues (1.4% vs. 2.6%), taxanes (1.5% vs. 2.5%), and pyrimidine analogues such as e.g., capecitabine and gemcitabine (2.5% vs. 3.1%). The frequency of use of posttreatment CDK4/6 inhibitors was 1.9% in the ribociclib + ET arm vs. 6.5% in the ET only group.

## Health care resource utilisation

Regarding the exploratory endpoint healthcare resource utilisation, hospitalisation was reported for 14.7% of the patients in the ribociclib + ET arm (14.2% during on-treatment, 0.5% during follow-up) compared to 11.1% of the patients in the ET only arm (10.9% during on-treatment, 0.2% during followup). The median duration of on-treatment hospitalisation was five days in both treatment arms and two vs. one days for hospitalisation during follow-up for the ribociclib + ET arm vs. the ET only arm. (Data as of DCO for IA3.)

## Ancillary analyses

## Sensitivity analysis, primary endpoint iDFS

At DCO 11 Jan 2023 (IA3) an unstratified Cox regression model supported the result of the stratified model, with HR=0.759 (95% CI 0.627, 0.919) in favour of the ribociclib + ET arm. Results of the iDFS analysis based on the PPS were also consistent with the primary analysis based on the FAS (HR=0.749 [95% CI 0.618, 0.907], 1-sided p-value 0.0015).

Sensitivity analyses based on excluding missing iDFS assessment, backdating iDFS, new anti-cancer therapy, clinical recurrence, and death due to COVID-19, were supportive of the primary analysis results.

Table 32 Sensitivity analyses for iDFS assessment (data at IA3)

| Sensitivity analysis                                    | Treatment               | n/N               |   p-value | Hazard ratio (95% CI)   |
|---------------------------------------------------------|-------------------------|-------------------|-----------|-------------------------|
| Primary analysis                                        | Ribociclib + ET ET only | 189/2549 237/2552 |    0.0014 | 0.748 (0.618, 0.906)    |
| Primary analysis (PPS)                                  | Ribociclib +ET ET only  | 187/2496 235/2424 |    0.0015 | 0.749 (0.618, 0.907)    |
| Primary analysis per CRF                                | Ribociclib + ET ET only | 189/2549 237/2552 |    0.0012 | 0.744 (0.614, 0.901)    |
| Unstratified log-rank test and Coxmodel                 | Ribociclib + ET ET only | 189/2549 237/2552 |    0.0023 | 0.759 (0.627, 0.919)    |
| StratifiedCoxmodel adjusting for baseline covariates[a] | Ribociclib + ET ET only | 189/2549 237/2552 |    0.0018 | 0.752 (0.621, 0.911)    |
| Actual event [b]                                        | Ribociclib + ET ET only | 186/2549 232/2552 |    0.0019 | 0.752 (0.620, 0.912)    |
| Backdating [c]                                          | Ribociclib + ET ET only | 189/2549 237/2552 |    0.0014 | 0.748 (0.618, 0.906)    |
| Censoringfor antineoplastic therapy [d]                 | Ribociclib + ET ET only | 186/2549 226/2552 |    0.0031 | 0.763 (0.629, 0.927)    |
| Clinical recurrence [e]                                 | Ribociclib +ET ET only  | 189/2549 237/2552 |    0.0014 | 0.748 (0.618, 0.906)    |
| CensoringCoVIDdeath[]                                   | Ribociclib + ET ET only | 183/2549 236/2552 |    0.0006 | 0.727 (0.600, 0.882)    |

<div style=\"page-break-after: always\"></div>

## Subgroup analysis, primary endpoint iDFS

The primary efficacy endpoint iDFS was summarised by the following subgroups provided that the primary efficacy analysis based on the FAS was statistically significant:

- Stratification factor(s) (based on eCRF)
- Anatomic stages IIA, IIB, IIIA, IIIB, and IIIC (derived from eCRF data)
- Gender (women vs. men)
- Prior adjuvant chemotherapy (yes vs. no)
- Prior neoadjuvant chemotherapy (yes vs. no)
- Prior endocrine therapy (yes vs. no)
- Prior mastectomy (yes vs. no)
- Race (Asian vs. Non-Asian)
- Region (Europe, North America/Australia, Asia, Latin America)
- Age category 1 (&lt;45 vs. 45-54 vs. 5564 vs. ≥65)
- Age category 2 (&lt;median vs. ≥median)
- Type of AI at randomisation (letrozole vs. anastrozole)
- ER+PR+ vs. ER-PR+ vs. ER+PR-
- Nodal status: N0 vs. N1-N3
- Tumour category: T0 vs. T1-T3 vs. &gt; T3
- Histological grade at time of surgery: grade 1 vs. grade 2 vs. grade 3
- Ki67 status from surgical specimen: ≤20% vs. &gt;20%. If the Ki67 score was missing from surgical specimen, the Ki67 score at initial diagnosis was considered.
- Histological subtype: ductal, lobular, other
- BMI at screening: ≥ 25 vs. &lt; 25

<div style=\"page-break-after: always\"></div>

Figure 13 Forest Plot of iDFS - subgroup analysis (final iDFS analysis, 21 Jul 2023 data cut-off) (FAS)

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

*-Hazard rate in group ribociclib + ET versus hazard rate in group ET only is computed using the Cox proportional hazards model with treatment as a single covariate and premenopausal women and men vs. postmenopausal North America/Western Europe/Oceania vs.rest of world as stratification factors.The group ET only is the referenceinthehazardratiocalculation.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## OS sensitivity analysis

Table 33 Sensitivity analyses of OS (final iDFS analysis, 21 Jul 2023 data cut-off) (FAS)

| Sensitivity analysis                                  | Treatment             | n/N             |   p-value | Hazard ratio (95% CI)   |
|-------------------------------------------------------|-----------------------|-----------------|-----------|-------------------------|
| Stratified analysis                                   | ET+Ribociclib ET only | 84/2549 88/2552 |    0.2263 | 0.892 (0.661, 1.203)    |
| Stratified analysis(PPS)                              | ET+Ribociclib ET only | 83/2496 88/2423 |    0.207  | 0.882 (0.654, 1.191)    |
| StratifiedanalysisperCRF                              | ET+Ribociclib ET only | 84/2549 88/2552 |    0.1908 | 0.875 (0.648, 1.181)    |
| Unstratifiedlog-ranktest andCox model                 | ET+Ribociclib ET only | 84/2549 88/2552 |    0.2687 | 0.910 (0.675, 1.227)    |
| StratifiedCoxmodeladjustingfor baseline covariates[a] | ET+Ribociclib ET only | 84/2549 88/2552 |    0.2567 | 0.905 (0.670, 1.221)    |
| CensoringCoviDdeath[]                                 | ET+Ribociclib ET only | 78/2549 87/2552 |    0.1262 | 0.837 (0.616, 1.136)    |

## Summary of main study

The following table summarise the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 34 Summary of Efficacy for trial NATALEE, O12301C

| Title: NATALEE, a phase III, open-label, randomised trial of ribociclib + ET versus ET only as adjuvant treatment of adult patients with HR-positive, HER2-negative, stage II or stage III early breast cancer, irrespective of nodal status.   | Title: NATALEE, a phase III, open-label, randomised trial of ribociclib + ET versus ET only as adjuvant treatment of adult patients with HR-positive, HER2-negative, stage II or stage III early breast cancer, irrespective of nodal status.                                                                                                               | Title: NATALEE, a phase III, open-label, randomised trial of ribociclib + ET versus ET only as adjuvant treatment of adult patients with HR-positive, HER2-negative, stage II or stage III early breast cancer, irrespective of nodal status.                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                | CLEE011O12301C EudraCT number 2018-002998-21 ClinicalTrials.gov identifier NCT03701334                                                                                                                                                                                                                                                                      | CLEE011O12301C EudraCT number 2018-002998-21 ClinicalTrials.gov identifier NCT03701334                                                                                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                                          | Open-label, randomised, multi-centre phase III study. Patients were stratified for: • menopausal status (premenopausal women, and men vs. postmenopausal women) • AJCC 8th edition stage (stage II vs. stage III) • prior neoadjuvant/adjuvant chemotherapy (yes vs. no) • geographical region (North America/Western Europe/Oceania vs. rest of the world) | Open-label, randomised, multi-centre phase III study. Patients were stratified for: • menopausal status (premenopausal women, and men vs. postmenopausal women) • AJCC 8th edition stage (stage II vs. stage III) • prior neoadjuvant/adjuvant chemotherapy (yes vs. no) • geographical region (North America/Western Europe/Oceania vs. rest of the world) |
|                                                                                                                                                                                                                                                 | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                                              | 7 Dec 2018 - ongoing not applicable not applicable                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Hypothesis                | Superiority of ribociclib + ET over ET only Statistical hypothesis: H 01 : Ө 1 >1 vs. H A1 : Ө 1 <1 Ө 1 = iDFS HR (ricocilib + ET vs. ET only)   | Superiority of ribociclib + ET over ET only Statistical hypothesis: H 01 : Ө 1 >1 vs. H A1 : Ө 1 <1 Ө 1 = iDFS HR (ricocilib + ET vs. ET only)   | Superiority of ribociclib + ET over ET only Statistical hypothesis: H 01 : Ө 1 >1 vs. H A1 : Ө 1 <1 Ө 1 = iDFS HR (ricocilib + ET vs. ET only)                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups         | Ribociclib + ET arm                                                                                                                              | Ribociclib + ET arm                                                                                                                              | Ribociclib 400 mg (flat-fixed dose) was administered orally once daily on days 1-21 in each 28-day cycle. ET (letrozole or anastrozole) was administered orally once daily consecutively. Goserelin was administered subcutaneously on day 1+3 of each 28-day cycle to premenopausal women and to men for gonadal suppression. The ribociclib treatment duration was 36 months, unless discontinued earlier due to disease recurrence or intolerable toxicity. The ET treatment duration was 60 months. N=2,549 patients were randomised to receive ribociclib + ET. |
|                           | ET only arm                                                                                                                                      | ET only arm                                                                                                                                      | ET (letrozole or anastrozole) was administered orally once daily consecutively. Goserelin was administered subcutaneously on day 1+3 of each 28-day cycle to premenopausal women and to men for gonadal suppression. The ET treatment duration was 60 months. N=2,552 patients were randomised to receive ribociclib + ET.                                                                                                                                                                                                                                           |
| Endpoints and definitions | Primary endpoint: invasive Disease-Free Survival                                                                                                 | iDFS                                                                                                                                             | The time from the date of randomisation to the date of the first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, contralateral invasive BC, a second primary non-breast invasive cancer (basal and squamous cell carcinomas of the skin excluded), or death due to any cause.                                                                                                                                                                                                                                           |
|                           | Secondary endpoint, other: Relapse-Free Survival                                                                                                 | RFS                                                                                                                                              | The time from date of randomisation to date of first event of local invasive breast recurrence, regional invasive recurrence, distant recurrence, or death due to any cause.                                                                                                                                                                                                                                                                                                                                                                                         |
|                           | Secondary endpoint, other: Distant Disease- Free Survival                                                                                        | DDFS                                                                                                                                             | The time from date of randomisation to date of first event of distant recurrence, second primary non-breast invasive cancer (basal and squamous cell carcinomas of the skin excluded), or death due to any cause.                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                                | Secondary endpoint, other: Overall Survival                                                                                                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                                                                                                                                          | The time from randomisation to date of death due to any cause.                                                                                                                                                                                                                                                                                                                                              | The time from randomisation to date of death due to any cause.                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                  | IA3 11 Jan 2023, final iDFS analysis 21 Jul 2023                                                                                                                                                                                                                                                                                                                                                            | IA3 11 Jan 2023, final iDFS analysis 21 Jul 2023                                                                                                                                                                                                                                                                                                                                                            | IA3 11 Jan 2023, final iDFS analysis 21 Jul 2023                                                                                                                                                                                                                                                                                                                                                            | IA3 11 Jan 2023, final iDFS analysis 21 Jul 2023                                                                                                                                                                                                                                                                                                                                                            |
| Results and Analysis                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis population and time point description | The primary population for efficacy analyses was the full analysis set (FAS), comprising all patients to whom study treatment had been assigned by randomisation regardless of whether treatment was administered or not. The primary analysis was conducted when approximately 426 iDFS events were observed. The primary endpoint iDFS was alpha protected. P-values for secondary endpoints are nominal. | The primary population for efficacy analyses was the full analysis set (FAS), comprising all patients to whom study treatment had been assigned by randomisation regardless of whether treatment was administered or not. The primary analysis was conducted when approximately 426 iDFS events were observed. The primary endpoint iDFS was alpha protected. P-values for secondary endpoints are nominal. | The primary population for efficacy analyses was the full analysis set (FAS), comprising all patients to whom study treatment had been assigned by randomisation regardless of whether treatment was administered or not. The primary analysis was conducted when approximately 426 iDFS events were observed. The primary endpoint iDFS was alpha protected. P-values for secondary endpoints are nominal. | The primary population for efficacy analyses was the full analysis set (FAS), comprising all patients to whom study treatment had been assigned by randomisation regardless of whether treatment was administered or not. The primary analysis was conducted when approximately 426 iDFS events were observed. The primary endpoint iDFS was alpha protected. P-values for secondary endpoints are nominal. |
| Effect estimates per comparison                | Primary endpoint iDFS, data at IA3 (inferential analysis)                                                                                                                                                                                                                                                                                                                                                   | Ribociclib + ET vs. ET                                                                                                                                                                                                                                                                                                                                                                                      | Ribociclib + ET vs. ET                                                                                                                                                                                                                                                                                                                                                                                      | N=2,549 patients in the ribociclib + ET arm N=2,552 patients in the ET only arm                                                                                                                                                                                                                                                                                                                             |
| Effect estimates per comparison                | Primary endpoint iDFS, data at IA3 (inferential analysis)                                                                                                                                                                                                                                                                                                                                                   | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | HR=0.748                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimates per comparison                | Primary endpoint iDFS, data at IA3 (inferential analysis)                                                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 0.618, 0.906                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimates per comparison                | Primary endpoint iDFS, data at IA3 (inferential analysis)                                                                                                                                                                                                                                                                                                                                                   | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | 0.0014                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimates per comparison                | Primary endpoint iDFS, final iDFS analysis                                                                                                                                                                                                                                                                                                                                                                  | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimates per comparison                | Primary endpoint iDFS, final iDFS analysis                                                                                                                                                                                                                                                                                                                                                                  | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | 0.749                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimates per comparison                | Primary endpoint iDFS, final iDFS analysis                                                                                                                                                                                                                                                                                                                                                                  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 0.628, 0.892                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimates per comparison                | Primary endpoint iDFS, final iDFS analysis                                                                                                                                                                                                                                                                                                                                                                  | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | 0.0006                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimates per comparison                | Secondary endpoint RFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                        | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimates per comparison                | Secondary endpoint RFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                        | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | HR=0.727                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimates per comparison                | Secondary endpoint RFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                        | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                      | 0.602, 0.887                                                                                                                                                                                                                                                                                                                                                                                                |
| Effect estimates per comparison                | Secondary endpoint RFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                        | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | P-value 1-sided, Log-Rank test                                                                                                                                                                                                                                                                                                                                                                              | 0.0004                                                                                                                                                                                                                                                                                                                                                                                                      |
| Effect estimates per comparison                | Secondary endpoint DDFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                       | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 | Ribociclib + ET vs. ET only                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                             |
| Effect estimates per comparison                | Secondary endpoint DDFS (data at final iDFS analysis)                                                                                                                                                                                                                                                                                                                                                       | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | Cox regression                                                                                                                                                                                                                                                                                                                                                                                              | HR=0.79                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                                     | 95% CI                         | 0.602, 0.900                         |
|-----------------------------------------------------|--------------------------------|--------------------------------------|
|                                                     | P-value 1-sided, Log-Rank test | 0.0010 (Not type 1 error controlled) |
| Secondary endpoint OS (data at final iDFS analysis) | Ribociclib + ET vs. ET only    |                                      |
|                                                     | Cox regression                 | HR=0.892                             |
|                                                     | 95% CI                         | 0.661, 1.203                         |
|                                                     | P-value 1-sided, Log-Rank test | 0.2263 (Not type 1 error controlled) |

## Clinical studies in special populations

|                                                              | Controlled trials CLEE011O12301C (NATALEE), Safety set   |
|--------------------------------------------------------------|----------------------------------------------------------|
| Renal impairment* patients (Subjects number/total number)    | 23/4967                                                  |
| Hepatic impairment** patients (Subjects number/total number) | 109/4967                                                 |
| Paediatric patients <18 years (Subjects number/total number) | Not Applicable                                           |
| Age 65-74 (Subjects number/total number)                     | 634/4967                                                 |
| Age 75-84 (Subjects number/total number)                     | 116/4967                                                 |
| Age 85+ (Subjects number/total number)                       | 3/4697                                                   |

## 2.4.1. Discussion on clinical efficacy

## 2.4.1.1. Design and conduct of clinical study

Data to support the current application are derived from the multi-centre, open-label, phase III study CLEE011O12301C (NATALEE), conducted in 393 centres across 20 countries world-wide.

Overall, the study entry criteria in the pivotal study define an appropriate population for the proposed treatment. The comparator arm contains a standard of care AI for the indicated population. The openlabel design is considered appropriate since it would be functionally difficult to blind a study where the

<div style=\"page-break-after: always\"></div>

add-on treatment in the experimental arm has a fundamentally different toxicity profile than the treatment in the comparator arm. A justification of the decision to the open-label design of the trial was added to the CSP version 2.0 (20 June 2019) following a scientific advice received from CHMP.

Patients were randomised to receive either ribociclib + an aromatase inhibitor (AI) (hereafter ET [endocrine therapy]) or ET only. Ribociclib + ET or ET only were administered orally with or without food. Ribociclib was administered as a flat-fixed dose of 400 mg orally on days 1-21 in each 28-day cycle. ETs (letrozole or anastrozole) were administered orally once daily continuously. Men and premenopausal women also received the GnRH agonist goserelin for gonadal suppression.

Randomisation used an allocation ratio 1:1 and was stratified by menopausal status, AJCC 8th edition Anatomic Stage Group, prior neo-/adjuvant chemotherapy, and geographical region. The proposed (and maintained) stratified randomisation was supported in a CHMP scientific advice.

Ribociclib treatment was scheduled for 36 months, unless discontinued earlier due to disease recurrence or unacceptable toxicity. ET treatment was scheduled for at least 60 months from randomisation, but adjuvant ET was allowed up to 12 months before study enrolment. Hence, ET treatment in both treatment arms could begin prior to ribociclib treatment.

The primary endpoint was iDFS (alpha protected) and secondary endpoints included RFS, DDFS, and OS (not alpha protected). All endpoints were investigator-assessed. The endpoints are considered relevant time-dependent endpoints in a Randomized Clinical Trial. Other secondary endpoints were PROs.

After the study had started, the assumptions and expectations underlying the sample size estimation were changed twice (CSP version 2.0, 20 June 2019 and CSP version 4.0, 27 August 2020). The rationale for a minor change in expected Anatomic stage distribution and a decision to exclude Anatomic Stage II low risk patients (with CSP version 2.0) and discussions concerning the heterogeneity of the study population was addressed in the CHMP scientific advice This change is considered to have been implemented early in the study (approximately 5 months after randomisation of the first patient) and given the background, is not objected to. However, this also had an impact on study power, targeted number of iDFS event as well as primary analysis time-point.With CSP version 4.0, a decision was made to randomise an additional 1,000 Stage III patients implying that the total sample size was increased from initial 4,000 to 5,000.

Patients were randomised between 10 January 2019 and 20 April 2021. The projected proportion of Stage II patients as per CSP version 2.0 (approximately 50%) had already been reached when it was decided to increase the number of Stage III patients. This explains why the distribution of Anatomic Stage II and Stage III patients ended up as had been initially planned (40%/60%).

The applicant's justification for increasing the number of Stage III patients was emergent external data. The applicant referred to new data from PALLAS and MonarchE trials, where preliminary results indicated that patients with stage III early BC may have an increased treatment benefit from CDK4/6 inhibitors compared to patients with Stage II early BC. This is acknowledged.

Further, a third interim analysis (IA) was added and the number of iDFS events for the final analysis was at the same time increased from 375 to 500. It would have been preferred to delete the second/altering the timing of the already planned second efficacy IA instead of only adding a third IA. The number of IAs to be performed in a study should always be kept at a minimum.

Based on sufficiently convincing statistical evidence in the primary analysis and a justification based on external data, there are no specific concerns regarding the risk for study integrity damage and loss of type I error control.

The first IA had a futility objective only and can be accepted. IAs 2 and 3 were both intended to declare superior efficacy of the experimental arm.

<div style=\"page-break-after: always\"></div>

IA 3 was planned to occur at 85% information fraction and was performed after 426 iDFS events. Based on the outcome, the independent DMC concluded that the study met its primary endpoint. This is the analysis presented within this submission as the primary efficacy endpoint analysis.

Regarding secondary endpoints and multiplicity considerations, no multiple testing procedure had been planned except for the considerations made in relation to the multiple analysis over time of the primary endpoint. In this respect it is endorsed that no additional claims besides for the primary endpoint are included in the SmPC.

The primary analysis was based on FAS (all randomised patients). The primary testing and estimation were based on a stratified log rank test and an adjusted Cox proportional hazard regression model, both test and estimation accounting for the stratification factors used at randomisation. The primary analysis of the primary endpoint is thus endorsed. Censoring rules were appropriate.

All endpoints were investigator-assessed. As stated in the scientific advice in 2016, this was not agreed upon. All efforts must be made to keep the strictest parallelism in the assessments between arms to minimise the risk of bias when the study is not double-blinded. However, the majority of recurrence events were histologically or cytologically confirmed, thus providing objective confirmation of the events. This is acknowledged.

## 2.4.1.2. Efficacy data and additional analyses

In total, 6,068 patients were screened, and 5,101 patients (84.0%) were included in study O12301C.

Of the 5,101 patients included, 2,549 and 2,552 patients were randomised to receive ribociclib + ET vs. ET only treatment, respectively. Overall, the proportion of patients receiving the allocated treatments were equally high, 99.1% and 95.7% in the ribociclib + ET arm vs. the ET only arm, respectively.

At DCO for IA3, 542 patients (21.3%) in the ribociclib + ET arm and 616 patients (24.1%) in the ET only arm had discontinued all treatment, respectively. Disease relapse as reason for treatment discontinuation was low in both treatment arms (4.3% and 5.6% discontinuations of ribociclib and ET treatments, respectively, in the ribociclib + ET arm vs. 7.3% ET discontinuations in the ET only arm).

At DCO for IA3, 1,984 patients (77.8%) in the ribociclib + ET arm and 1,826 patients (71.6%) in the ET only arm were still on study treatment. This difference between the treatment arms is expected, provided that the add-on treatment in the experimental arm is effective. Consequently, study discontinuation due to death was infrequent in both treatment arms (2.4% and 2.9%, respectively). Furthermore, at DCO, 20.2% patients in the ribociclib + ET arm had completed three years of ribociclib treatment and 57.4% had completed two years of treatment.

As of DCO of final iDFS analysis, with an additional median 6.3 months follow-up, in total 1,996 patients (78.3%) in the ribociclib + ET arm had discontinued ribociclib, of which 1,091 patients (42.8%) had completed the 3-year treatment duration and 905 patients (35.5%) had discontinued ribociclib prematurely. The main reason for early discontinuation was AE (19.5%).

In total, at least one protocol deviation was reported for 70.2% of the patients. The percentage of patients with deviations was slightly higher in the ribociclib + ET arm compared to that in the ET only arm (73.3% vs. 67.1%). The difference between treatment arms was mainly due to a higher number of dosing and administration errors in the ribociclib + ET arm compared to the ET only arm (25.9% vs. 14.5%). This could be understood given that the ribociclib + ET arm consisted of two different medications, of which ribociclib was administered during a 3 weeks on/1 week off schedule, and the ET only arm consisted of only one medication administered continuously. Overall, only 47 patients (0.9%) were excluded from the PPS due to major deviations. A numerical imbalance between the treatment arms was, however, also noted for protocol deviations due to prohibitive medication/treatment, with 304

<div style=\"page-break-after: always\"></div>

(11.9%) such reported deviations in the ribociclib + ET arm vs. 51 (2.0%) in the ET only arm. The Applicant confirmed that there were more protocol-defined prohibited medications with ribociclib than with ET, explaining the noted imbalance between the study arms. The duration of the prohibited concomitant medication was generally less than seven days and without noticeable imbalance between the study arms, indicating that there was no impact on the supportive iDFS. This explanation is accepted.

There was a slight imbalance in COVID-19 pandemic-related deviations, with fewer such deviations being reported in the ribociclib + ET arm (16.6%) compared to the ET only arm (23.2%). The Applicant has not provided any reasons for this, but regardless of treatment arm the main pandemic-related deviation was due to `planned visits not being done at sites´, which is acknowledged.

Overall, the baseline demographic and disease characteristics were well balanced between the two treatment arms. The median age (52.0 years) and gender distribution (99.6% women, 0.4% men) were identical in the treatment arms. Per protocol, patients were followed until distant recurrence event even if the patient initiated a new anti-neoplastic treatment.

Previous cancer therapies, including prior chemotherapy, ET, radiotherapy, and surgery were comparable between the treatment arms.

The study met its primary endpoint, demonstrating a statistically significant improvement of iDFS in favour of ribociclib + ET treatment, with HR=0.748 (95% CI 0.618, 0.906, 1-sided p-value=0.0014) in favour of ribociclib + ET treatment. When it regards adjuvant treatment of a patient population with an overall favourable prognosis (long expected OS) it may be more relevant to compare the absolute difference between treatment arms rather than medians. In the current study, the absolute iDFS improvement with ribociclib + ET treatment at 3-years was 3.3% (3-year iDFS rates 90.4% [95% CI 88.6, 91.9] in the ribociclib + ET arm and 87.1% [95% CI 85.3, 88.8] in the ET only arm). This is in line with what is normally accepted in adjuvant trials. Due to the limited number of patients that had completed three years of ribociclib treatment, though, the 3-year iDFS improvement must be interpreted with caution.

Although only 42.8% of the patients had completed the intended 3-year ribociclib treatment and 20.7% of the patients were still on ribociclib treatment, in total almost 80% had discontinued ribociclib and there were no signs of a rebound peak with relapses shortly after end of treatment. Apart from completion of the intended 3-year treatment, the most common reason for ribociclib discontinuation was AEs (19.5%).

Overall, the sensitivity analyses were supportive of the primary analysis results. For the subgroup analyses, the objective was to demonstrate homogeneity of treatment effect, but no formal statistical hypothesis testing was performed. It is noted that the upper boundary of the confidence interval was crossing 1.0 for several subgroups (e.g., several substages, age categories 45-54 and 55-64 years, ER+/PR- tumours, &gt;T3, and grade 1) but the number of events in all these subgroups were very limited. The HR point estimates were all &lt;1.0. The subgroup analyses should be interpreted with caution, but the data do not raise any concerns regarding a detrimental effect of ribociclib in any subgroup.

Inclusion of stage II patients was capped at 40% in line with scientific advice received in 2018 where it was highlighted that consistent responses across stages would be crucial to justify that the observed study results can be generalised to the overall patient population outside clinical trials. Although subgroup analyses of stages II and III revealed that the upper boundary of the confidence interval was crossing 1.0 for stages IIB, IIIA, and IIIB, it did not for stages IIA and IIIC. In light of the HR point estimates being &lt;1.0 and the limited number of events in all substages, there is no concern about a detrimental effect of ribociclib in any substage. Overall, no obvious difference in response to ribociclib between stages II and III was noted.

Improvements of the secondary endpoints RFS (HR=0.727 [95% CI 0.602, 0.887], nominal 1-sided pvalue=0.0004) and DDFS (HR=0.749 [95% CI 0.602, 0.900], nominal 1-sided p-value=0.0010) at DCO

<div style=\"page-break-after: always\"></div>

for final iDFS analysis imply a potential clinical relevance, supported by absolute 3-year risk reductions of 3.0%, for RFS and 2.26 for DDFS, respectively, in favour of ribociclib + ET treatment. This is in line with the primary analysis. It is, however, noted that none of the secondary endpoints were type I error controlled.

OS data were immature at DCO for final iDFS analysis, with only 3.3% and 3.4% events (n=84 and n=88 patients) in the ribociclib + ET arm and the ET only arm, respectively. Data indicated a trend for prolonged OS in the ribociclib + ET arm vs. the ET only arm, with HR=0.892 (95% CI 0.661, 1.203, nominal 1-sided p-value=0.2263). The 3-year OS rates indicate an absolute risk reduction of 0.9% for ribociclib + ET over ET only.

To better characterize the efficacy profile of ribociclib in the current indication the MAH has committed to submit 5-year iDFS and OS data as a post approval measure (PAES Annex IID condition) according to delegated act: (a) an initial efficacy assessment that is based on surrogate endpoints, which requires verification of the impact of the intervention on clinical outcome or disease progression or confirmation of previous efficacy assumptions

Overall, treatment with ribociclib + ET maintained PRO scores over time. PRO data should, however, be interpreted with caution due to the open-label study design, due to the PRO endpoints not being type 1 error controlled, and the fact that the patients answered the PRO questionnaires on day one of every third treatment cycle (i.e., after one week off ribociclib).

At DCO of the final iDFS analysis, 13.1% of the patients in the ribociclib + ET arm compared to 17.3% of the patients in the ET only arm had received at least on post-treatment antineoplastic therapy. The range of subsequent antineoplastic therapies was wide, with only few patients reported to have received the different treatments.

Following the CHMP review of this extension of indication application, the agreed indication is:

Kisqali in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence (see section 5.1 for selection criteria).

## 2.4.2. Conclusions on the clinical efficacy

The initial study protocol included stage II and stage III eBC, however, as the protocol was eventually modified to exclude patients with low risk of recurrence stage II, the actually studied population can be considered reflecting a high-risk of recurrence population, which is reflected in the agreed indication.

A statistically significant effect on iDFS has been shown for ribociclib + ET in the intended patient population, supported by RFS and DDFS results.

With a median follow-up of 33.3 months, a 3.1% absolute improvement in iDFS at three years, no signs of a relapse peak shortly after treatment discontinuation but rather iDFS curves that continue to separate over time, the treatment effect on iDFS is considered robust and the remaining uncertainty pertaining to an effect on OS is considered acceptable. However more mature OS and IDFS data are considered critical to characterize the long-term benefit of ribociclib.

Therefore, the applicant has committed to submit 5-year follow-up for efficacy and safety including OS data in the final study report for the NATALEE study.

This has been reflected in the RMP and Annex II:  Post-authorisation efficacy study (PAES): In order to further characterise the efficacy of Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2

<div style=\"page-break-after: always\"></div>

(HER2)-negative early breast cancer at high risk of recurrence, the MAH should submit a 5-year follow-up of iDFS and OS in the NATALEE study.

## 2.5. Clinical safety

## 2.5.1. Introduction

The most common ADRs that have previously been established for ribociclib include those related to bone marrow suppression (notably neutropenia), infections, GI-disorders, alopecia, hepatotoxicity and the risk of QT-prolongation.

The safety specification in the RMP (version 8.0) include myelosuppression, hepatobiliary toxicity, QT interval prolongation and reproductive toxicity as important identified risks and renal toxicity as an important potential risk.

The safety data presented in this report derive from study CLEE011O12301C (acronym NATALEE) and are based on an updated data cut-off date of 21-Jul-2023 unless otherwise indicated. The Safety set included all randomized patients who received any study treatment (i.e., at least one dose of ribociclib or ET). Patients were analyzed according to the study treatment received.

The evaluation is based on safety data from 2525 patients exposed to a starting dose of 400 mg ribociclib once daily on Day 1 to Day 21 of each 28-day cycle in combination with ET (letrozole or anastrozole [NSAI]) and 2444 patients exposed to ET only (plus goserelin, if applicable, in both groups).

## 2.5.2. Patient exposure

In the NATALEE study, 400 mg ribociclib was to be administered once daily on Day 1 to Day 21 in each 28-day cycle for a 3-year treatment duration. ET was to be administered for at least a 5-year treatment duration in both the ribociclib + ET and ET only groups.

There were 1752 patients (69.4%) who completed at least two years of ribociclib treatment. Of these, 1091 patients (43.2%) had at least three years of ribociclib. In detail, the following exposure data by drug component were observed:

- The median duration of exposure to ribociclib was 32.9 months (range: 0 to 37)
- The median duration of exposure to NSAI was 36.0 months (range: 0 to 54) in the ribociclib plus ET group and the ET only group, 35.9 months (0 to 54)
- The median duration of exposure to goserelin was 33.8 months (range: 0 to 52) in the ribociclib plus ET group and in ET only group, 31.3 months (0 to 52)
- The median RDI for ribociclib was 94.0% (range: 14 to 132)
- The median RDI for NSAI was 100.0% in both treatment groups (ribociclib plus ET, range: 21 to 127; ET only, range: 4 to 105)
- The median RDI for goserelin was 99.7% in both treatment groups (ribociclib plus ET, range: 34 to 1395; ET only, range: 48 to 399)

<div style=\"page-break-after: always\"></div>

Table 35. Duration of exposure and adherence by drug component (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                | NSAI Goserelin    | NSAI Goserelin            | NSAI Goserelin   | NSAI Goserelin            | NSAI Goserelin   |
|--------------------------------|-------------------|---------------------------|------------------|---------------------------|------------------|
| Study treatment adherence      | Ribociclib N=2525 | Ribociclib plus ET N=2525 | ET only N=2442   | Ribociclib plus ET N=1102 | ET only N=1066   |
| Duration of exposure: (n (96)) |                   |                           |                  |                           |                  |
| 0 to 3 months                  | 305 (12.1)        | 126 (5.0)                 | 170 (7.0)        | 70 (6.4)                  | 89 (8.3)         |
| 3 to 6 months                  | 164 (6.5)         | 85 (3.4)                  | 77 (3.2)         | 46 (4.2)                  | 51 (4.8)         |
| 6 to 9 months                  | 89 (3.5)          | 58 (2.2)                  | 51 (2.1)         | 31 (2.8)                  | 29 (2.7)         |
| 9 to 12 months                 | 51 (2.0)          | 47 (1.9)                  | 55 (2.3)         | 25 (2.3)                  | 33 (3.1)         |
| 12 to 15 months                | 47 (1.9)          | 39 (1.5)                  | 44 (1.8)         | 24 (2.2)                  | 26 (2.4)         |
| 15 to 18 months                | 37 (1.5)          | 38 (1.4)                  | 47 (1.9)         | 24 (2.2)                  | 37 (3.5)         |
| 18 to 21 months                | 44 (1.7)          | 44 (1.7)                  | 58 (2.3)         | 24 (2.2)                  | 37 (3.5)         |
| 21 to 24 months                | 36 (1.4)          | 35 (1.4)                  | 31 (1.3)         | 35 (3.2)                  | 27 (2.5)         |
| 24 to 27 months                | 46 (1.8)          | 26 (1.0)                  | 28 (1.1)         | 47 (4.3)                  | 32 (3.0)         |
| 27 to 30 months                | 267 (10.6)        | 293 (11.6)                | 267 (10.9)       | 125 (11.3)                | 126 (11.8)       |
| 30 to 33 months                | 211 (8.4)         | 113 (4.5)                 | 119 (4.9)        | 70 (6.4)                  | 68 (6.4)         |
| 33 to 38 months                | 1205 (47.7)       | 345 (13.7)                | 301 (12.3)       | 172 (15.6)                | 134 (12.8)       |
| 36 to 39 months                | 23 (0.9)          | 232 (9.2) NSAI            | 205 (8.4)        | 112 (10.2) Goserelin      | 95 (8.9)         |
| Study treatment adherence      | Ribociclib        | Ribociclib plus ET        | ET only          | Ribociclib plus ET        | ET only          |
|                                | N=2525            | N=2525                    | N=2442           | N=1102                    | N=1066           |
| 39 to 42 months                | 0                 | 441 (17.5)                | 411 (16.8)       | 129 (11.7)                | 116 (10.9)       |
| 42 to 45 months                | 0                 | 387 (14.5)                | 341 (14.0)       | 104 (9.4)                 | 113 (10.6)       |
| 45 to 48 months                | 0                 | 187 (7.8)                 | 191 (7.8)        | 56 (5.1)                  | 45 (4.2)         |
| 48 to 51 months                | 0                 | 34 (1.3)                  | 39 (1.6)         | 7 (0.6)                   | 5 (0.5)          |
| 51 to 54 months                | 0                 | 9 (0.4)                   | 8 (0.3)          | 1 (0.1)                   | 3 (0.3)          |
| 54 to 57 months                | 0                 | 0                         | 1 (≤ 0.1)        | 0                         | 0                |
| Duration of exposure (months)  |                   |                           |                  |                           |                  |
| n                              | 2525              | 2525                      | 2442             | 1102                      | 1066             |
| Mean                           | 25.4              | 32.7                      | 31.8             | 29.7                      | 28.1             |
| SD                             | 13.16             | 12.86                     | 13.68            | 13.13                     | 13.93            |
| Min                            | 0                 | 0                         | 0                | 0                         | 0                |
| Median                         | 32.9              | 36.0                      | 35.9             | 33.8                      | 31.3             |
| Max                            | 37                | 54                        | 54               | 52                        | 52               |
| Cumulative dose (mg)           |                   |                           |                  |                           |                  |
| n                              | 2525              | 2525                      | 2442             | 1102                      | 1068             |
| Mean                           | 201813.3          | 2021.8                    | 1987.5           | 114.9                     | 108.7            |
| SD                             | 116021.77         | 1077.53                   | 1104.01          | 51.24                     | 54.18            |
| Min                            | 400               | 1                         | 1                | 4                         | 4                |
| Median                         | 238400.0          | 2202.5                    | 2190.0           | 129.6                     | 122.4            |
| Max                            | 858000            | 4085                      | 5410             | 202                       | 198              |
| Dose intensity (mg/day)        |                   |                           |                  |                           |                  |
| n                              | 2525              | NA                        | NA               | 1102                      | 1068             |
| Mean                           | 333.7             | NA                        | NA               | 0.1                       | 0.1              |
| SD                             | 78.74             | NA                        | NA               | 0.06                      | 0.02             |
| Min                            | 56                | NA                        | NA               | 0                         | 0                |
| Median                         | 375.8             | NA                        | NA.              | 0.1                       | 0.1              |
| Max                            | 527               | NA                        | NA               | 2                         | 1                |
| Relative dose intensity (%6)   |                   |                           |                  |                           |                  |
| n                              | 2525              | 2525                      | 2442             | 1102                      | 1066             |
| Mean                           | 83.4              | 99.0                      | 99.2             | 101.6                     | 100.4            |
| SD                             | 19.69             | 3.57                      | 3.84             | 45.62                     | 18.29            |
| Min                            | 14                | 21                        | 4                | 34                        | 48               |
| Median                         | 94.0              | 100.0                     | 100.0            | 98.7                      | 99.7             |
| Max                            | 132               | 127                       | 105              | 1395                      | 398              |
| Average daily dose (mg)        |                   |                           |                  |                           |                  |
| n                              | 2525              | 2525                      | 2442             | 1102                      | 1068             |
| Mean                           | 366.0             | 2.0                       | 2.1              | 3.6                       | 3.6              |
| SD                             | 66.35             | 0.68                      | 0.67             | 0                         | 0                |
| Min                            | 201               | 1                         | 1                | 4                         | 4                |
| Median Max                     | 400.0 438         | 2.5 3                     | 2.5 3            | 3.6 4                     | 3.6 4            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## 2.5.3. Adverse events

## 2.5.3.1. Overview of adverse events

Table 36. Overall summary of deaths and adverse events (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                  | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | ET only N=2442   |               |               |               |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------|---------------|---------------|---------------|
| AE category                      | All grades n (%)            | Grade 3 n (%)               | Grade 4 n (%)               | Grade 5 n (%)               | All grades n (%) | Grade 3 n (%) | Grade 4 n (%) | Grade 5 n (%) |
| All deaths'                      | 83 (3.3)                    |                             |                             |                             | 89 (3.6)         |               |               |               |
| On-treatment deaths2             | 20 (0.8)                    |                             |                             |                             | 9 (0.4)          |               |               |               |
| Adverse events                   | 2474 (98.0)                 | 1463 (57.9)                 | 133 (5.3)                   | 11 (0.4)                    | 2145 (87.8)      | 425 (17.4)    | 40 (1.6)      | 4 (0.2)       |
| Suspected to be drug-related     | 2368 (93.8)                 | 1284 (50.9)                 | 101 (4.0)                   | 1 (≤ 0.1)                   | 1566 (64.1)      | 97 (4.0)      | 6 (0.3)       | 0             |
| Serious adverse events           | 357 (14.1)                  | 252 (10.0)                  | 44 (1.7)                    | 11 (0.4)                    | 256 (10.5)       | 192 (7.9)     | 26 (1.1)      | 4 (0.2)       |
| Suspected to be drug-related     | 68 (2.7)                    | 39 (1.5)                    | 17 (0.7)                    | 1 (≤ 0.1)                   | 13 (0.5)         | 9 (0.4)       | 0             | 0             |
| AEs leading to discontinuation   | 524 (20.8)                  | 201 (8.0)                   | 36 (1.4)                    | 2 (0.1)                     | 134 (5.5)        | 38 (1.6)      | 5 (0.2)       | 3 (0.1)       |
| Suspected to be drug-related     | 435 (17.2)                  | 165 (6.5)                   | 26 (1.0)                    | 0                           | 94 (3.9)         | 18 (0.7)      | 0             | 0             |
| AEs requiring dose interruption  | 1858 (73.6)                 | 1226 (48.6)                 | 87 (3.5)                    | 0                           | 199 (8.2)        | 67 (2.7)      | 8 (0.3)       | 0             |
| Suspected to be drug-related     | 1635 (64.8)                 | 1156 (45.8)                 | 70 (2.8)                    | 0                           | 99 (4.1)         | 27 (1.1)      | 3 (0.1)       | 0             |
| AEs requiring dose adjustment    | 586 (23.2)                  | 338 (13.4)                  | 36 (1.4)                    | 0                           |                  |               |               |               |
| Suspected to be drug-related     | 561 (22.2)                  | 330 (13.1)                  | 36 (1.4)                    | 0                           |                  |               |               |               |
| AEs requiring additional therapy | 1962 (77.7)                 | 499 (19.8)                  | 61 (2.4)                    | 2 (0.1)                     | 1627 (66.6)      | 297 (12.2)    | 28 (1.2)      | 1 (≤ 0.1)     |
| Suspected to be drug-related     | 1225 (48.5)                 | 240 (9.5)                   | 32 (1.3)                    | 0                           | 696 (28.5)       | 58 (2.4)      | 3 (0.1)       | 0             |
| AEs of special interest          | 2183 (86.5)                 | 1291 (51.1)                 | 114 (4.5)                   | 7 (0.3)                     | 1179 (48.3)      | 168 (6.9)     | 15 (0.6)      | 2 (0.1)       |
| Suspected to be drug-related     | 1886 (74.7)                 | 1188 (47.1)                 | 100 (4.0)                   | 0                           | 203 (8.3)        | 17 (0.7)      | 2 (0.1)       | 0             |

Discontinuation refers to discontinuation of any treatment component.

Patients are counted once / cateqory at worst toxicity qrade in the main cateqory rows and once per cateqory per toxicity in the related rows.

A total of 98 % of patients in the ribociclib + ET group and 87.8% of patients in the ET only group experienced at least one AE during the study.

In terms of All Deaths, 83 (3.3%) and 89 (3.6%) died in the test-arm and control arm, respectively. Corresponding numbers for On-treatment Deaths (defined as deaths occurring on or after treatment start date and up to 30 days after 36 months of treatment or earlier treatment discontinuation and include deaths with cause other than AE), were 20 patients (0. 7%) in the ribociclib + ET group and nine patients (0.4%), respectively.

<div style=\"page-break-after: always\"></div>

Table 37. Adverse events by primary system organ class and maximum grade, irrespective of causality (final iDFS analysis, 21-Jul-2023) data cut-off (Safety set)

|                                                                     | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | ET only // N=2442   | ET only // N=2442   | ET only // N=2442   | ET only // N=2442   |
|---------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|---------------------|---------------------|---------------------|---------------------|
| System organ class                                                  | All grades n (%)               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)                  | All grades n (%)    | Grade 3 n (%)       | Grade 4 n (%)       | Grade 5 n (%)       |
| Total no. patients with at least 1 TEAE                             | 2474 (98.0)                    | 1463 (57.9) 133 (5.3)          |                                | 11 (0.4)                       | 2145 (87.8)         | 425 (17.4)          | 40 (1.6)            | 4 (0.2)             |
| Investigations                                                      | 1634 (64.7)                    | 640 (25.3)                     | 67 (2.7)                       | 口                              | 795 (32.6)          | 72 (2.9)            | 10 (0.4)            | 0                   |
| Musculoskeletal and connective tissue disorders                     | 1539 (61.0)                    | 60 (2.4)                       | 1 (≤ 0.1)                      | 0                              | 1567 (64.2)         | 56 (2.3)            | 0                   | 0                   |
| General disorders and administration site conditions                | 1386 (54.9)                    | 55 (2.2)                       | 0                              | 0                              | 902 (36.9)          | 22 (0.9)            | 0                   | 0                   |
| Gastrointestinal disorders                                          | 1321 (52.3)                    | 59 (2.3)                       | 1 (≤ 0.1)                      | 0                              | 724 (29.6)          | 32 (1.3)            | 0                   | 0                   |
| Infections and infestations                                         | 1249 (49.5)                    | 124 (4.9)                      | 8 (0.3)                        | 6 (0.2)                        | 878 (36.0)          | 72 (2.9)            | 3 (0.1)             | 2 (0.1)             |
| Blood and lymphatic system disorders                                | 1217 (48.2)                    | 707 (28.0)                     | 35 (1.4)                       | 0                              | 217 (8.9)           | 23 (0.9)            | 3 (0.1)             | 0                   |
| Nervous system disorders                                            | 1013 (40.1)                    | 53 (2.1)                       | 5 (0.2)                        | 1 (≤ 0.1)                      | 788 (32.3)          | 40 (1.6)            | 4 (0.2)             | 0                   |
| Skin and subcutaneous tissue disorders                              | 942 (37.3)                     | 12 (0.5)                       | 1 (≤ 0.1)                      | 0                              | 495 (20.3)          | 10 (0.4)            | 0                   | 0                   |
| Vascular disorders                                                  | 832 (33.0)                     | 72 (2.9)                       | 0                              | 0                              | 818 (33.5)          | 67 (2.7)            | 1 (≤ 0.1)           | 0                   |
| Metabolism and nutrition disorders                                  | 755 (29.9)                     | 34 (1.3)                       | 2 (0.1)                        | 0                              | 367 (15.0)          | 24 (1.0)            | 4 (0.2)             | 0                   |
| Respiratory, thoracic and mediastinal disorders                     | 733 (29.0)                     | 41 (1.6)                       | 4 (0.2)                        | 2 (0.1)                        | 432 (17.7)          | 25 (1.0)            | 3 (0.1)             | 1 (≤ 0.1)           |
| Psychiatric disorders                                               | 616 (24.4)                     | 12 (0.5)                       | 4 (0.2)                        | 0                              | 571 (23.4)          | 10 (0.4)            | 7 (0.3)             | 0                   |
| Injury, poisoning and procedural complications                      | 375 (14.9)                     | 44 (1.7)                       | 1 (≤ 0.1)                      | 1 (≤ 0.1)                      | 301 (12.3)          | 37 (1.5)            | 0                   | 0                   |
| Reproductive system and breast disorders                            | 357 (14.1)                     | 19 (0.8)                       | 1 (≤± 0.1)                     | 0                              | 403 (16.5)          | 15 (0.6)            | 0                   | 0                   |
| Eye disorders                                                       | 313 (12.4)                     | 10 (0.4)                       | 1 (≤ 0.1)                      | 0                              | 172 (7.0)           | 10 (0.4)            | 0                   | 0                   |
| Cardiac disorders                                                   | 197 (7.8)                      | 18 (0.7)                       | 3 (0.1)                        | 2 (0.1)                        | 156 (6.4)           | 19 (0.8)            | 1 (≤ 0.1)           | 2 (0.1)             |
| Renal and urinary disorders                                         | 176 (7.0)                      | 12 (0.5)                       | 1 (≤ 0.1)                      | 0                              | 124 (5.1)           | 4 (0.2)             | 0                   | 0                   |
| Ear and labyrinth disorders                                         | 154 (6.1)                      | 5 (0.2)                        | 0                              | 0                              | 91 (3.7)            | 4 (0.2)             | 1 (≤ 0.1)           | 0                   |
| Hepatobiliary disorders                                             | 124 (4.9)                      | 25 (1.0)                       | 11 (0.4)                       | 0                              | 77 (3.2)            | 9 (0.4)             | 0                   | 0                   |
| Neoplasms benign, malignant and unspecified (incl cysts (sdAjod pue | 113 (4.5)                      | 30 (1.2)                       | 4 (0.2)                        | 0                              | 115 (4.7)           | 24 (1.0)            | 8 (0.3)             | 0                   |
| Endocrine disorders                                                 | 56 (2.2)                       | 1 (≤ 0.1)                      | 0                              | 0                              | 71 (2.9)            | 1 (≤ 0.1)           | 1 (≤ 0.1)           | 0                   |
| Immune system disorders                                             | 43 (1.7)                       | 2 (0.1)                        | 0                              | 0                              | 32 (1.3)            | 2 (0.1)             | 0                   | 0                   |
| Product issues                                                      | 3 (0.1)                        | 2 (0.1)                        | 0                              | 0                              | 4 (0.2)             | 1 (≤ 0.1)           | 0                   | 0                   |
|                                                                     | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | ET only // N=2442   | ET only // N=2442   | ET only // N=2442   | ET only // N=2442   |
| System organ class                                                  | All grades n (%)               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)                  | All grades n (%)    | Grade 3 n (%)       | Grade 4 n (%)       | Grade 5 n (%)       |
| Congenital, familial and genetic disorders                          | 3 (0.1)                        | 1 (≤ 0.1)                      | 0                              | 0                              | 4 (0.2)             | 1 (≤ 0.1)           | 0                   | 0                   |
| Social circumstances                                                | 0                              | 0                              | 0                              | 0                              | 2 (0.1)             | 0                   | 0                   | 0                   |

System organ classes are sorted in descending frequency based on frequency in ribociclib plus ET group. MedDRA Version 26.0 has been used for reporting

<div style=\"page-break-after: always\"></div>

Table 38. Adverse events by preferred term and maximum grade (all grades ≥ 2% / either group), irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                      | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | ET only // N=2442    | ET only // N=2442   | ET only // N=2442   | ET only // N=2442   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------|---------------------|---------------------|---------------------|
| Preferred term                       | All grades n (%)               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)                  | All grades n (%)     | Grade 3 n (%)       | Grade 4 n (%)       | Grade 5 n (%)       |
| Neutropenia                          | 1047 (41.5)                    | 673 (26.7)                     | 34 (1.3)                       | 0                              | 73 (3.0)             | 13 (0.5)            | 1 (≤ 0.1)           | 0                   |
| Arthralgia                           | 942 (37.3)                     | 25 (1.0)                       | 0                              | 0                              | 1058 (43.3) 31 (1.3) |                     | 0                   | 0                   |
| Neutrophil count decreased           | 609 (24.1)                     | 429 (17.0)                     | 19 (0.8)                       | 0                              | 41 (1.7)             | 6 (0.2)             | 2 (0.1)             | 0                   |
| Nausea                               | 588 (23.3)                     | 6 (0.2)                        | 0                              | 0                              | 190 (7.8)            | 1 (≤ 0.1)           | 0                   | 0                   |
| Headache                             | 575 (22.8)                     | 11 (0.4)                       | 0                              | 0                              | 415 (17.0)           | 4 (0.2)             | 0                   | 0                   |
| Fatigue                              | 564 (22.3)                     | 19 (0.8)                       | 0                              | 0                              | 322 (13.2)           | 4 (0.2)             | 0                   | 0                   |
| COVID-19                             | 537 (21.3)                     | 18 (0.7)                       | 0                              | 3 (0.1)                        | 345 (14.1)           | 11 (0.5)            | 0                   | 1 (≤ 0.1)           |
| SARS-CoV-2 test positive             | 532 (21.1)                     | 0                              | 0                              | 0                              | 332 (13.6)           | 0                   | 0                   | 0                   |
| Alanine aminotransferase increased   | 492 (19.5)                     | 159 (6.3)                      | 33 (1.3)                       | 0                              | 136 (5.6)            | 16 (0.7)            | 1 (≤ 0.1)           | 0                   |
| Hot flush                            | 486 (19.2)                     | 6 (0.2)                        | 0                              | 0                              | 489 (20.0)           | 3 (0.1)             | 0                   | 0                   |
| Asthenia                             | 428 (17.0)                     | 14 (0.6)                       | 0                              | 0                              | 291 (11.9)           | 3 (0.1)             | 0                   | 0                   |
| Aspartate aminotransferase increased | 426 (16.9)                     | 100 (4.0)                      | 18 (0.7)                       | 0                              | 139 (5.7)            | 13 (0.5)            | 0                   | 0                   |
| Alopecia                             | 380 (15.0)                     | 0                              | 0                              | 0                              | 109 (4.5)            | 0                   | 0                   | 0                   |
| Diarrhoea                            | 366 (14.5)                     | 16 (0.6)                       | 0                              | 0                              | 135 (5.5)            | 3 (0.1)             | 0                   | 0                   |
| Leukopenia                           | 337 (13.3)                     | 94 (3.7)                       | 0                              | 0                              | 50 (2.0)             | 2 (0.1)             | 0                   | 0                   |
| Constipation                         | 335 (13.3)                     | 5 (0.2)                        | 0                              | 0                              | 123 (5.0)            | 0                   | 0                   | 0                   |
| Cough                                | 332 (13.1)                     | 3 (0.1)                        | 0                              | 0                              | 201 (8.2)            | 2 (0.1)             | 0                   | 0                   |
| Insomnia                             | 292 (11.6)                     | 1 (± 0.1)                      | 0                              | 0                              | 281 (11.5)           | 6 (0.2)             | 0                   | 0                   |
| Pyrexia                              | 280 (11.1)                     | 5 (0.2)                        | 0                              | 0                              | 147 (6.0)            | 2 (0.1)             | 0                   | 0                   |
| Back pain                            | 272 (10.8)                     | 5 (0.2)                        | 0                              | 0                              | 247 (10.1)           | 2 (0.1)             | 0                   | 0                   |
| Pain in extremity                    | 261 (10.3)                     | 3 (0.1)                        | 0                              | 0                              | 219 (9.0)            | 1 (≤ 0.1)           | 0                   | 0                   |
| White blood cell count decreased     | 246 (9.7)                      | 93 (3.7)                       | 1 (≤0.1)                       | 0                              | 38 (1.6)             | 5 (0.2)             | 1 (≤ 0.1)           | 0                   |
| Dizziness                            | 225 (8.9)                      | 5 (0.2)                        | 0                              | 0                              | 112 (4.6)            | 2 (0.1)             | 0                   | 0                   |
| Hypertension                         | 212 (8.4)                      | 54 (2.1)                       | 0                              | 0                              | 185 (7.6)            | 59 (2.4)            | 0                   | 0                   |

|                                     | Ribociclib plus ET / N=2525   | Ribociclib plus ET / N=2525   | Ribociclib plus ET / N=2525   |               | ET only // N=2442   | ET only // N=2442   |               |               |
|-------------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------|---------------------|---------------------|---------------|---------------|
| Preferred term                      | All grades n (%)              | Grade 3 n (%)                 | Grade 4 n (%)                 | Grade 5 n (%) | All grades n (%)    | Grade 3 n (%)       | Grade 4 n (%) | Grade 5 n (%) |
| Anaemia                             | 211 (8.4)                     | 8 (0.3)                       | 0                             | 0             | 73 (3.0)            | 6 (0.2)             | 1 (≤0.1)      | 0             |
| Rash                                | 202 (8.0)                     | 4 (0.2)                       | 0                             | 0             | 69 (2.8)            | 3 (0.1)             | 0             | 0             |
| Myalgia                             | 199 (7.9)                     | 2 (0.1)                       | 0                             | 0             | 182 (7.5)           | 8 (0.3)             | 0             | 0             |
| Vomiting                            | 198 (7.8)                     | 10 (0.4)                      | 0                             | 0             | 96 (3.9)            | 1 (≤ 0.1)           | 0             | 0             |
| Pruritus                            | 188 (7.4)                     | 2 (0.1)                       | 0                             | 0             | 77 (3.2)            | 1 (≤ 0.1)           | 0             | 0             |
| Lymphoedema                         | 170 (6.7)                     | 4 (0.2)                       | 0                             | 0             | 186 (7.6)           | 3 (0.1)             | 0             | 0             |
| Dyspnoea                            | 166 (6.6)                     | 13 (0.5)                      | 0                             | 0             | 102 (4.2)           | 10 (0.4)            | 0             | 0             |
| Urinary tract infection             | 164 (6.5)                     | 10 (0.4)                      | 0                             | 0             | 125 (5.1)           | 5 (0.2)             | 0             | 0             |
| Abdominal pain                      | 159 (6.3)                     | 9 (0.4)                       | 0                             | 0             | 100 (4.1)           | 8 (0.3)             | 0             | 0             |
| Hypomagnesaemia                     | 155 (6.1)                     | 0                             | 1 (≤ 0.1)                     | 0             | 39 (1.6)            | 0                   | 0             | 0             |
| Oropharyngeal pain                  | 154 (6.1)                     | 0                             | 0                             | 0             | 81 (3.3)            | 0                   | 0             | 0             |
| SARS-CoV-2 test negative            | 146 (5.8)                     | 0                             | 0                             | 0             | 82 (3.4)            |                     | 0             | 0             |
| Anxiety                             | 145 (5.7)                     | 2 (0.1)                       | 0                             | 0             | 125 (5.1)           | 1 (≤ 0.1)           | 0             | 0             |
| Nasopharyngilis                     | 139 (5.5)                     | 0                             | 0                             | 0             | 94 (3.8)            | 0                   | 0             | 0             |
| Abdominal pain upper                | 137 (5.4)                     | 3 (0.1)                       | 0                             | 0             | 85 (3.5)            | 1 (≤ 0.1)           | 0             | 0             |
| Oedema peripheral                   | 136 (5.4)                     | 1 (≤ 0.1)                     | 0                             | 0             | 77 (3.2)            | 0                   | 0             | 0             |
| Upper respiratory tract infection   | 123 (4.9)                     | 2 (0.1)                       | 0                             | 0             | 63 (2.6)            | 0                   | 0             | 0             |
| Decreased appetite                  | 120 (4.8)                     | 1 (≤ 0.1)                     | 0                             | 0             | 47 (1.9)            | 0                   | 0             |               |
| Gamma-glutamyltransferase increased | 119 (4.7)                     | 23 (0.9)                      | 3 (0.1)                       | 0             | 67 (2.7)            | 22 (0.9)            | 0             | D             |
| Dyspepsia                           | 118 (4.7)                     | 0                             | 0                             | 0             | 73 (3.0)            | 0                   | 0             | 0             |
| Depression                          | 116 (4.6)                     | 5 (0.2)                       | 0                             | 0             | 101 (4.1)           | 4 (0.2)             | 2 (0.1)       | 0             |
| Hyperkalaemia                       | 114 (4.5)                     | 3 (0.1)                       | 0                             | 0             | 26 (1.1)            | 2 (0.1)             | 0             | 0             |
| Thrombocytopenia                    | 110 (4.4)                     | 5 (0.2)                       | 0                             | 0             | 45 (1.8)            | 0                   | 1 (± 0.1)     | 0             |
| Hypocalcaemia                       | 110 (4.4)                     | 1 (≤ 0.1)                     | 0                             | 0             | 14 (0.6)            | 0                   | 0             | 0             |
| Electrocardiogram QT prolonged      | 109 (4.3)                     | 7 (0.3)                       | 0                             | 0             | 18 (0.7)            | 1 (≤ 0.1)           | 0             | 0             |
| Breast pain                         | 109 (4.3)                     | 2 (0.1)                       | 0                             | 0             | 125 (5.1)           | 2 (0.1)             | 0             | 0             |
| Vulvovaginal dryness                | 107 (4.2)                     | 1 (≤ 0.1)                     | 0                             | 0             | 134 (5.5)           | 5 (0.2)             | 0             | 0             |

<div style=\"page-break-after: always\"></div>

|                                       | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   | Ribociclib plus ET // N=2525   |                             | ET only // N=2442   | ET only // N=2442   |                   |                   |
|---------------------------------------|--------------------------------|--------------------------------|--------------------------------|-----------------------------|---------------------|---------------------|-------------------|-------------------|
| Preferred term                        | All grades n (%)               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)               | All grades n (%)    | Grade 3 n (%)       | Grade 4 n (%)     | Grade 5 n (%)     |
| Hypokalaemia                          | 104 (4.1)                      | 8 (0.3)                        | 0                              | 0                           | 35 (1.4)            | 7 (0.3)             | 0                 | 0                 |
| Bone pain                             | 104 (4.1)                      | 5 (0.2)                        | 0                              | 0                           | 104 (4.3)           | 2 (0.1)             | 0                 | 0                 |
| Dry mouth                             | 102 (4.0)                      | 0                              | 0                              | 0                           | 58 (2.4)            |                     | 0                 | 0                 |
| Influenza like illness                | 101 (4.0)                      | 0                              | 0                              | 0                           | 43 (1.8)            | 0                   | 0                 | 0                 |
| Blood creatinine increased            | 98 (3.9)                       | 3 (0.1)                        | 0                              | 0                           | 22 (0.9)            | 0                   | 0                 | 0                 |
| Dry eye                               | 96 (3.8)                       | 0                              | 0                              | 0                           | 37 (1.5)            | 0                   | 0                 | 0                 |
| Musculoskeletal pain                  | 93 (3.7)                       | 0                              | 0                              | 0                           | 85 (3.5)            | 2 (0.1)             |                   | 0                 |
| Dry skin                              | 91 (3.6)                       | 0                              | 0                              | 0                           | 31 (1.3)            |                     | 0                 | 0                 |
| Hyperglycaemia                        | 88 (3.5)                       | 4 (0.2)                        | 0                              | 0                           | 76 (3.1)            | 4 (0.2)             | 0                 | 0                 |
| Muscle spasms                         | 87 (3.4)                       | 1 (± 0.1)                      | 0                              | 0                           | 62 (2.5)            | 0                   | 0                 | 0                 |
| Palpitations                          | 87 (3.4)                       | 0                              | 0                              | 0                           | 37 (1.5)            | 0                   | 0                 | 0                 |
| Gastrooesophageal reflux disease      | 85 (3.4)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 52 (2.1)            | 0                   | 0                 | 0                 |
| Stomatitis                            | 84 (3.3)                       | 0                              | 0                              | 0                           | 16 (0.7)            |                     | 0                 | 0                 |
| Weight increased                      | 81 (3.2)                       | 11 (0.4)                       | 0                              | 0                           | 69 (2.8)            | 5 (0.2)             | 0                 | 0                 |
| Mucosal inflammation                  | 81 (3.2)                       | 2 (0.1)                        | 0                              | 0                           | 9 (0.4)             | 0                   | 0                 | 0                 |
| Musculoskeletal chest pain            | 81 (3.2)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 75 (3.1)            | 1 (≤ 0.1)           | 0                 | 0                 |
| Blood magnesium decreased             | 80 (3.2)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 31 (1.3)            | 0                   | 0                 | 0                 |
| Pain                                  | 77 (3.0)                       | 3 (0.1)                        | 0                              | 0                           | 53 (2.2)            | 3 (0.1)             | 0                 | 0                 |
| Blood alkaline phosphatase increased  | 76 (3.0)                       | 2 (0.1)                        | 0                              | 0                           | 62 (2.5)            | 2 (0.1)             | 0                 | 0                 |
| Osteopenia                            | 76 (3.0)                       | 0                              | 0                              | 0                           | 76 (3.1)            | 1 (≤ 0.1)           | 0                 | 0                 |
| Rhinorrhoea                           | 73 (2.9)                       | 0                              | 0                              | 0                           | 27 (1.1)            | 0                   | 0                 | 0                 |
| Vertigo                               | 72 (2.9)                       | 2 (0.1)                        | 0                              | 0                           | 43 (1.8)            | 2 (0.1)             | 0                 | 0                 |
| Osteoporosis                          | 71 (2.8)                       | 3 (0.1)                        | 0                              | 0                           | 91 (3.7)            | 0                   | 0                 | 0                 |
| Neck pain                             | 71 (2.8)                       | 0                              | 0                              | 0                           | 47 (1.9)            | 1 (≤ 0.1)           | 0                 | 0                 |
| Lacrimation increased                 | 71 (2.8)                       | 0                              | 0                              | 0                           | 15 (0.6)            | 0                   | 0                 | 0                 |
| Lymphopenia                           | 69 (2.7)                       | 11 (0.4)                       | 1 (≤ 0.1)                      | 0                           | 16 (0.7)            | 0                   | 0                 | 0                 |
| Sinusitis                             | 67 (2.7)                       | 0                              | 0                              | 0                           | 41 (1.7)            | 0                   | 0                 | 0                 |
|                                       | Ribociclib plusET // N=2525    | Ribociclib plusET // N=2525    | Ribociclib plusET // N=2525    | Ribociclib plusET // N=2525 | ET only I/ N=2442   | ET only I/ N=2442   | ET only I/ N=2442 | ET only I/ N=2442 |
| Preferred term                        | All grades n (%)               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 5 n (%)               | All grades n (%)    | Grade 3 n (%)       | Grade 4 n (%)     | Grade 5 n (%)     |
| Blood bilirubin increased             | 66 (2.6)                       | 4 (0.2)                        | 1 (≤ 0.1)                      | 0                           | 28 (1.1)            | 1 (≤ 0.1)           | 0                 | 0                 |
| Paraesthesia                          | 65 (2.6)                       |                                | 0                              | 0                           | 57 (2.3)            | 0                   | 0                 | 0                 |
| Joint stiffness                       | 64 (2.5)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 70 (2.9)            | 0                   | 0                 | 0                 |
| Procedural pain                       | 64 (2.5)                       | 0                              | 0                              | 0                           | 65 (2.7)            | 0                   | 0                 | 0                 |
| Herpes zoster                         | 62 (2.5)                       | 3 (0.1)                        | 0                              | 0                           | 53 (2.2)            | 2 (0.1)             | 0                 | 0                 |
| Lymphocyte count decreased            | 60 (2.4)                       | 17 (0.7)                       | 2 (0.1)                        | 0                           | 24 (1.0)            | 2 (0.1)             |                   | 0                 |
| Lipase increased                      | 58 (2.3)                       | 18 (0.7)                       | 7 (0.3)                        | 0                           | 33 (1.4)            | 6 (0.2)             | 6 (0.2)           | 0                 |
| Chest pain                            | 58 (2.3)                       | 1 (≤0.1)                       | 0                              | 0                           | 50 (2.0)            | 3 (0.1)             | 0                 | 0                 |
| Weight decreased                      | 58 (2.3)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 40 (1.6)            | 2 (0.1)             | 0                 | 0                 |
| Nasal congestion                      | 58 (2.3)                       | 0                              | 0                              | 0                           | 26 (1.1)            | 0                   | 0                 | 0                 |
| Non-cardiac chest pain                | 57 (2.3)                       | 2 (0.1)                        | 0                              | 0                           | 28 (1.1)            | 2 (0.1)             | 0                 | 0                 |
| Blood lactate dehydrogenase increased | 55 (2.2)                       | 0                              | 1 (≤ 0.1)                      | 0                           | 33 (1.4)            | 0                   | 0                 | 0                 |
| Neuropathy peripheral                 | 54 (2.1)                       | 0                              | 1 (≤ 0.1)                      | 0                           | 55 (2.3)            | 1 (≤ 0.1)           | 0                 | 0                 |
| Dysgeusia                             | 54 (2.1)                       | 0                              | 0                              | 0                           | 14 (0.6)            | 0                   | 0                 | 0                 |
| Osteoarthritis                        | 53 (2.1)                       | 5 (0.2)                        | 0                              | 0                           | 49 (2.0)            | 5 (0.2)             | 0                 | 0                 |
| Platelet count decreased              | 53 (2.1)                       | 1 (≤ 0.1)                      | 0                              | 0                           | 11 (0.5)            | 2 (0.1)             | 0                 | 0                 |
| Peripheral swelling                   | 53 (2.1)                       | 0                              | 0                              | 0                           | 48 (2.0)            | 0                   | 0                 | 0                 |
| Axillary pain                         | 52 (2.1)                       | 0                              | 0                              | 0                           | 37 (1.5)            | 1 (≤ 0.1)           | 0                 | 0                 |

Preferred terms are sorted in descending frequency based on frequency in ribociclib plus ET group. MedDRA Version 26.0 has been used for reportinq.

Adverse events where a higher proportion of ribociclib plus ET-treated patients reported events, all grades, with a ≥ 10% relative difference to the ET only group, included:

Neutropenia: +38.5%; Decreased neutrophil count: +22.4%; Nausea: +15.5%; ALT increased: +13.9%; Leukopenia: +11.3%;  AST increased: +11.2%; Alopecia: +10.6% and Arthralgia (43.3%). Hot flush (20.0%) were the only PTs reported in ≥ 20% of patients in the ET only group.

The number of patients reported with COVID-19 (21.3% vs. 14.1%) or a positive SARS-CoV-2 test (21.1% vs. 13.6%) was higher in the ribociclib plus ET group, compared with the ET only group.

<div style=\"page-break-after: always\"></div>

## 2.5.3.2. Adverse events of grade 3-5 severity

Table 39. Common adverse events, grade ≥ 3, by preferred term and maximum grade (≥ 1% / either group), irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                      | Rlboclcllbplue ET N=2525   | Rlboclcllbplue ET N=2525   | Rlboclcllbplue ET N=2525   | Rlboclcllbplue ET N=2525   | ET only N=2442   | ET only N=2442   | ET only N=2442   | ET only N=2442   |
|--------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|------------------|------------------|------------------|------------------|
| Preferredterm                        | Grade3 n(96)               | Grade3 n(96)               | Grade 4 n (86)             | Grade5 0 (36)              | Grade3 n6)       | Grade3 n(96)     | Grade 4 n (66)   | Grade5 n (86)    |
| Total no.patlentewlthat leaat 1 TEAE | 1607 (63.6)                | 1463 (57.9)                | 133 (5.3)                  | 11 (0.4)                   | 469 (19.2)       | 425 (17.4)       | 40 (1.6)         | 4 (0.2)          |
| Neutropenla                          | 707 (28.0)                 | 673 (26.7]                 | 34 (1.3)                   | D                          | 14 (0.6)         | 13 (0.5)         | 1 (± 0.1)        |                  |
| Neutrophll count decreased           | 448 (17.7)                 | 429 (17.0)                 | 19 (0.8)                   | 0                          | 8 (0.3)          | 6(0.2)           | 2 (0.1)          |                  |
| Alanlne amlnotransterase Increased   | 192 (7.6)                  | 159 (6.3)                  | 33 (1.3)                   | 口                          | 17 (0.7)         | 16 (0.7)         | 1 (± 0.1)        | D                |
| AepartateamnotransferaseIncreaeed    | 118 (4.7)                  | 100 (4.0)                  | 18 (0.7)                   | D                          | 13 (0.5)         | 13 (0.5)         | 0                | 0                |
| Whlte blood cell count decreased     | 94 (3.7)                   | 93 (3.7)                   | 1 (- 0.1)                  | 0                          | 6 (0.2)          | 5 (0.2)          | 1 (± 0.1)        | 0                |
| Leukopenla                           | 94 (3.7)                   | 94 (3.7)                   | 0                          |                            | 2 (0.1)          | 2 (0.1)          | 0                |                  |
| Hypertenslon                         | 54 (2.1)                   | 54 (2.1)                   | 0                          | D                          | 59 (2.4)         | 59 (2.4)         | 0                |                  |
| Gamma-glutamyltransferaseInereased   | 26 (1.0)                   | 23 (0.9)                   | 3 (0.1)                    | 0                          | 22 (0.9)         | 22 (0.9)         | 0                | D                |
| Arthralgla                           | 25 (1.0)                   | 25 (1.0)                   | 0                          | D                          | 31 (1.3)         | 31 (1.3)         | 0                | 0                |

MedDRA Verslon 26.0 has been used for reporting.

The most common grade ≥ 3 AEs in the ribociclib + ET arm were neutropenia (28.0%), neutrophil count decreased (17.7%), ALT increased (7.6%), AST increased 4.7%), WBC decreased (3.7%), and leukopenia (3.7%).

Grade 3 AEs were reported in 57.9% of patients in the ribociclib + ET group (mainly neutropenia, neutrophil count decreased, and ALT increased) and 17.4% of patients in the ET only group.

Grade 4 AEs were reported in 5.3% of patients in the ribociclib + ET group and 1.6% of patients in the ET only group. Neutropenia (1.3%) and ALT increased (1.3%) were the most frequently reported grade 4 AE (with incidences ≥ 1.0%) in the ribociclib + ET group.

In 11 patients (0.4%) a grade 5 event (AE with fatal outcome) were reported in the ribociclib + ET group. Amongst causes were cardiac arrest, cardiogenic shock, concurrent brain oedema and epilepsy, pneumonia, pulmonary embolism, and road traffic accident.

## 2.5.3.3. Adverse events suspected to be study treatment related

Overall, 93.8% of patients treated in the ribociclib + ET group had AEs suspected to be study treatment related.

## 2.5.3.4. Adverse drug reactions

## Methodology for selection of ADRs

ADR candidates include two types of events namely 'pre-qualified candidate ADRs' and 'other candidate ADRs' identified through numerical screening rule. Ribociclib ADRs identified in advanced mBC were considered as 'pre-qualified candidate ADRs' for the adjuvant eBC setting.

'Other ADR candidates' are events for which a higher incidence versus comparator in the O12301C clinical database is observed. These have be identified using a numerical screening rule, i.e. algorithmically, based on all treatment emergent AEs.

ADR screening selection in the O12301C clinical database following the strategy, as follows:

1. Any AE (MedDRA PT) with ≥ 2% difference in AE incidence between ET + ribociclib vs ET only.
2. Any AE (MedDRA PT) with ≥ 5% incidence in ET + ribociclib group.

<div style=\"page-break-after: always\"></div>

3. Any AE (MedDRA PT) from MedDRA SMQ (as per approved SMQs in RMP) with ≥ 2% in ET + ribociclib group.
4. Any AE (MedDRA PT) from SMQ (as per approved SMQs in RMP) with ≥ 5% difference in AE incidences between ET + ribociclib vs ET only.
5. Any Grade ≥ 3 AE with an absolute frequency ≥ 2 with no reports or lower reports on ET only group.
6. AEs and SAEs leading to discontinuation of ribociclib if occurrence at least 0.5% in ET + ribociclib group for Study O12301C.
7. Laboratory abnormalities with ≥ 5% difference in incidence between ET + ribociclib vs ET only.

In addition, the MAH´s safety database has been included in the screening for ADR candidates and has been used as an internal control against the clinical database. The purpose of this internal control is to identify those reported AEs that have not been identified in the clinical database before (ADR candidates arising from the MAH´s safety database only).

Identification of ADRs for ribociclib that considered the safety information from Study O12301C was performed based on the MAH´s 3-step process:

- (1) selection of pre-qualified ADR candidates based on prior evidence of causality;
- (2) statistical screening of the pivotal clinical study data for ADRs;
- (3) medical evaluation of ADR candidates identified during Step 1 and/or Step 2.

To abridge the DCO of 11-Jan-2023, the ADR selection process included MedDRA Version 26.0 and eCRS as of 25-May-2023. As all other safety analyses being described in the SCS for Study O12301C were based on MedDRA Version 25.1 and eCRS as of 16-Dec-2022, coding changes between versions are detailed in SCS Study O12301C Appendix 2-Listing 14.6-1.2.

## Summary of adverse drug reactions

Table 40 . Adverse drug reactions reported in the phase III clinical studies and during post -marketing experience

ET + Ribociclib N=2525 ET Only N=2442

| Adverse drug reaction   | Preferred term             | SAE n (%)   | Grade >=3 n (%)   | Frequency n (%)   | Freq. category   | SAE n (%)   | Grade >=3 n (%)   | Frequency n (%)   | Freq. category   |
|-------------------------|----------------------------|-------------|-------------------|-------------------|------------------|-------------|-------------------|-------------------|------------------|
| Neutropenia             | Total                      | 1 (<0.1)    | 1113 (44.1)       | 1577 (62.5)       | Very common      | 0           | 22 (0.9)          | 113 (4.6)         | Common           |
| Neutropenia             | Neutropenia                | 0           | 707 (28.0)        | 1047 (41.5)       |                  | 0           | 14 (0.6)          | 73 (3.0)          |                  |
| Neutropenia             | Neutrophil count decreased | 1 (<0.1)    | 448 (17.7)        | 609 (24.1)        |                  | 0           | 8 (0.3)           | 41 (1.7)          |                  |
| Neutropenia             | Granulocytopenia           | 0           | 0                 | 4 (0.2)           |                  | 0           | 0                 | 0                 |                  |
| Infections              | Total                      | 42 (1.7)    | 49 (1.9)          | 917 (36.3)        | Very common      | 26 (1.1)    | 23 (0.9)          | 642 (26.3)        | Very common      |
| Infections              | COVID-19                   | 20 (0.8)    | 21 (0.8)          | 537 (21.3)        |                  | 13 (0.5)    | 12 (0.5)          | 345 (14.1)        |                  |
| Infections              | Urinary tract infection    | 6 (0.2)     | 10 (0.4)          | 164 (6.5)         |                  | 3 (0.1)     | 5 (0.2)           | 125 (5.1)         |                  |
| Infections              | Nasopharyngitis            | 0           | 0                 | 139 (5.5)         |                  | 0           | 0                 | 94 (3.8)          |                  |

<div style=\"page-break-after: always\"></div>

|                               | Upper respiratory tract infection                   | 1 (<0.1) 2                                          | (0.1)                                               | 123 (4.9)   |             | 0                | 0                | 63 (2.6)   |             |
|-------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------|-------------|------------------|------------------|------------|-------------|
|                               | Sinusitis                                           | 0                                                   | 0                                                   | 67 (2.7)    |             | 0                | 0                | 41 (1.7)   |             |
|                               | Pneumonia                                           | 14 (0.6)                                            | 12 (0.5)                                            | 40 (1.6)    |             | 9 (0.4)          | 8 (0.3)          | 22 (0.9)   |             |
|                               | Bronchitis                                          | 1 (<0.1) 1 (<0.1)                                   | 1 (<0.1) 1 (<0.1)                                   | 34 (1.3)    |             | 1 (<0.1)0        | 1 (<0.1)0        | 31 (1.3)   |             |
|                               | Cystitis                                            | 0                                                   | 0                                                   | 34 (1.3)    |             | 1 (<0.1)0        | 1 (<0.1)0        | 26 (1.1)   |             |
|                               | Pharyngitis                                         | 0                                                   | 0                                                   | 23 (0.9)    |             | 0 0              | 0 0              | 23 (0.9)   |             |
|                               | Respiratory tract infection                         | 0                                                   | 0                                                   | 23 (0.9)    |             | 1 (<0.1)1        | (<0.1)           | 18 (0.7)   |             |
|                               | Rhinitis                                            | 0                                                   | 0                                                   | 23 (0.9)    |             | 0                | 0                | 16 (0.7)   |             |
|                               | Lower respiratory tract infection                   | 0                                                   | 1 (<0.1)                                            | 11 (0.4)    |             | 0                | 0                | 12 (0.5)   |             |
|                               | Tracheitis                                          | 0                                                   | 0                                                   | 10 (0.4)    |             | 0                | 0                | 8 (0.3)    |             |
|                               | Viral upper respiratory tract infection             | 1 (<0.1)1 (<0.1)                                    | 1 (<0.1)1 (<0.1)                                    | 8 (0.3)     |             | 0                | 0                | 1 (<0.1)   |             |
|                               | Laryngitis                                          | 0                                                   | 0                                                   | 6 (0.2)     |             | 0                | 0                | 8 (0.3)    |             |
|                               | Acute sinusitis                                     | 0                                                   | 0                                                   | 3 (0.1)     |             | 0                | 0                | 1 (<0.1)   |             |
|                               | Urosepsis                                           | 3 (0.1)                                             | 3 (0.1)                                             | 3 (0.1)     |             | 1 (<0.1)1        | (<0.1)           | 1 (<0.1)   |             |
|                               | Escherichia urinary tract infection 1 (<0.1)2 (0.1) | Escherichia urinary tract infection 1 (<0.1)2 (0.1) | Escherichia urinary tract infection 1 (<0.1)2 (0.1) | 2 (0.1)     |             | 0                | 0                | 0          |             |
|                               | Atypical pneumonia                                  | 0                                                   | 0                                                   | 1 (<0.1)    |             | 0                | 0                | 0          |             |
|                               | Viral sinusitis                                     | 0                                                   | 0                                                   | 1 (<0.1)    |             | 0                | 0                | 0          |             |
| Nausea                        | Total                                               | 2 (0.1)                                             | 6 (0.2)                                             | 588 (23.3)  | Very common | 1 (<0.1)1 (<0.1) | 1 (<0.1)1 (<0.1) | 190 (7.8)  | Common      |
|                               | Nausea                                              | 2 (0.1)                                             | 6 (0.2)                                             | 588 (23.3)  |             | 1 (<0.1)1 (<0.1) | 1 (<0.1)1 (<0.1) | 190 (7.8)  |             |
| Headache                      | Total                                               | 0                                                   | 11 (0.4)                                            | 580 (23.0)  | Very common | 2 (0.1)          | 4 (0.2)          | 417 (17.1) | Very common |
|                               | Headache                                            | 0                                                   | 11 (0.4)                                            | 575 (22.8)  |             | 2 (0.1)          | 4 (0.2)          | 415 (17.0) |             |
|                               | Tension headache                                    | 0                                                   | 0                                                   | 7 (0.3)     |             | 0                | 0                | 4 (0.2)    |             |
| Fatigue                       | Total                                               | 1 (<0.1)19 (0.8)                                    | 1 (<0.1)19 (0.8)                                    | 564 (22.3)  | Very common | 0                | 4 (0.2)          | 322 (13.2) | Very common |
|                               | Fatigue                                             | 1 (<0.1)19 (0.8)                                    | 1 (<0.1)19 (0.8)                                    | 564 (22.3)  |             | 0                | 4 (0.2)          | 322 (13.2) |             |
| Leukopenia                    | Total                                               | 0                                                   | 184 (7.3)                                           | 564 (22.3)  | Very common | 0                | 8 (0.3)          | 88 (3.6)   | Common      |
|                               | Leukopenia                                          | 0                                                   | 94 (3.7)                                            | 337 (13.3)  |             | 0                | 2 (0.1)          | 50 (2.0)   |             |
|                               | White blood cell count decreased                    | 0                                                   | 94 (3.7)                                            | 246 (9.7)   |             | 0                | 6 (0.2)          | 38 (1.6)   |             |
| Abnormal liver function tests | Total                                               | 9 (0.4)                                             | 197 (7.8)                                           | 563 (22.3)  | Very common | 0                | 25 (1.0)         | 186 (7.6)  | Common      |
|                               | Alanine aminotransferase increased                  | 9 (0.4)                                             | 192 (7.6)                                           | 492 (19.5)  |             | 0                | 17 (0.7)         | 136 (5.6)  |             |

<div style=\"page-break-after: always\"></div>

| Aspartate aminotransferase increased   |   5 (0.2) | 118 (4.7)   | 426 (16.9)   |   0 | 13 (0.5)   | 139 (5.7)   |
|----------------------------------------|-----------|-------------|--------------|-----|------------|-------------|
| Blood bilirubin increased              |         0 | 5 (0.2)     | 66 (2.6)     |   0 | 1 (<0.1)   | 28 (1.1)    |

|                | Blood bilirubin       | 0        | 5 (0.2)   | 66 (2.6)   |             | 0                | 1 (<0.1)         | 28 (1.1)   |             |
|----------------|-----------------------|----------|-----------|------------|-------------|------------------|------------------|------------|-------------|
| Asthenia       | Total                 | 1 (<0.1) | 14 (0.6)  | 428 (17.0) | Very common | 1 (<0.1)3        | (0.1)            | 291 (11.9) | Very common |
|                | Asthenia              | 1 (<0.1) | 14 (0.6)  | 428 (17.0) |             | 1 (<0.1)3        | (0.1)            | 291 (11.9) |             |
| Alopecia       | Total                 | 0        | 0         | 380 (15.0) | Very common | 0                | 0                | 109 (4.5)  | Common      |
|                | Alopecia              | 0        | 0         | 380 (15.0) |             | 0                | 0                | 109 (4.5)  |             |
| Diarrhoea      | Total                 | 5 (0.2)  | 16 (0.6)  | 366 (14.5) | Very common | 0                | 3 (0.1)          | 135 (5.5)  | Common      |
|                | Diarrhoea             | 5 (0.2)  | 16 (0.6)  | 366 (14.5) |             | 0                | 3 (0.1)          | 135 (5.5)  |             |
| Constipation   | Total                 | 3 (0.1)  | 5 (0.2)   | 335 (13.3) | Very common | 0                | 0                | 123 (5.0)  | Common      |
|                | Constipation          | 3 (0.1)  | 5 (0.2)   | 335 (13.3) |             | 0                | 0                | 123 (5.0)  |             |
| Cough          | Total                 | 0        | 3 (0.1)   | 332 (13.1) | Very common | 0                | 2 (0.1)          | 201 (8.2)  | Common      |
|                | Cough                 | 0        | 3 (0.1)   | 332 (13.1) |             | 0                | 2 (0.1)          | 201 (8.2)  |             |
| Pyrexia        | Total                 | 7 (0.3)  | 5 (0.2)   | 280 (11.1) | Very common | 1 (<0.1)2        | (0.1)            | 147 (6.0)  | Common      |
|                | Pyrexia               | 7 (0.3)  | 5 (0.2)   | 280 (11.1) |             | 1 (<0.1)2        | (0.1)            | 147 (6.0)  |             |
| Abdominal pain | Total                 | 1 (<0.1) | 12 (0.5)  | 277 (11.0) | Very common | 4 (0.2)          | 9 (0.4)          | 179 (7.3)  | Common      |
|                | Abdominal pain        | 1 (<0.1) | 9 (0.4)   | 159 (6.3)  |             | 3 (0.1)          | 8 (0.3)          | 100 (4.1)  |             |
|                | Abdominal pain upper  | 0        | 3 (0.1)   | 137 (5.4)  |             | 1 (<0.1)1        | (<0.1)           | 85 (3.5)   |             |
| Rash           | Total                 | 0        | 4 (0.2)   | 233 (9.2)  | Common      | 0                | 3 (0.1)          | 85 (3.5)   | Common      |
| Rash           | Rash                  | 0        | 4 (0.2)   | 202 (8.0)  |             | 0                | 3 (0.1)          | 69 (2.8)   |             |
|                | Rash maculo-papular   | 0        | 0         | 27 (1.1)   |             | 0                | 0                | 9 (0.4)    |             |
|                | Rash pruritic         | 0        | 0         | 16 (0.6)   |             | 0                | 0                | 8 (0.3)    |             |
| Dizziness      | Total                 | 2 (0.1)  | 5 (0.2)   | 225 (8.9)  | Common      | 1 (<0.1)2        | (0.1)            | 112 (4.6)  | Common      |
|                | Dizziness             | 2 (0.1)  | 5 (0.2)   | 225 (8.9)  |             | 1 (<0.1)2        | (0.1)            | 112 (4.6)  |             |
| Anaemia        | Total                 | 3 (0.1)  | 8 (0.3)   | 215 (8.5)  | Common      | 2 (0.1)          | 7 (0.3)          | 75 (3.1)   | Common      |
|                | Anaemia               | 3 (0.1)  | 8 (0.3)   | 211 (8.4)  |             | 2 (0.1)          | 7 (0.3)          | 73 (3.0)   |             |
|                | Haemoglobin decreased | 0        | 0         | 3 (0.1)    |             | 0                | 0                | 1 (<0.1)   |             |
|                | Microcytic anaemia0   |          | 0         | 1 (<0.1)   |             | 0                | 0                | 1 (<0.1)   |             |
|                | Haematocrit decreased | 0        | 0         | 1 (<0.1)   |             | 0                | 0                | 0          |             |
| Vomiting       | Total                 | 2 (0.1)  | 10 (0.4)  | 198 (7.8)  | Common      | 1 (<0.1)1        | (<0.1)           | 96 (3.9)   | Common      |
|                | Vomiting              | 2 (0.1)  | 10 (0.4)  | 198 (7.8)  |             | 1 (<0.1)1 (<0.1) | 1 (<0.1)1 (<0.1) | 96 (3.9)   |             |

<div style=\"page-break-after: always\"></div>

| Pruritus                       | Total                          | 0          | 2 (0.1)       | 188 (7.4)   | Common   | 0         | 1 (<0.1)   | 77 (3.2)   | Common   |
|--------------------------------|--------------------------------|------------|---------------|-------------|----------|-----------|------------|------------|----------|
|                                | Pruritus                       | 0          | 2 (0.1)       | 188 (7.4)   |          | 0         | 1 (<0.1)   | 77 (3.2)   |          |
| Peripheral oedema              | Total                          | 0          | 1 (<0.1)      | 183 (7.2)   | Common   | 0         | 0          | 121 (5.0)  | Common   |
|                                | Oedema peripheral              | 0          | 1 (<0.1)      | 136 (5.4)   |          | 0         | 0          | 77 (3.2)   |          |
|                                | Peripheral swelling            | 0          | 0             | 53 (2.1)    |          | 0         | 0          | 48 (2.0)   |          |
| Dyspnoea                       | Total                          | 12 (0.5)13 | (0.5)         | 166 (6.6)   | Common   | 5 (0.2)   | 10 (0.4)   | 102 (4.2)  | Common   |
|                                | Dyspnoea                       | 12         | (0.5)13 (0.5) | 166 (6.6)   |          | 5 (0.2)   | 10 (0.4)   | 102 (4.2)  |          |
| Thrombocytopeni a              | Total                          | 0          | 6 (0.2)       | 162 (6.4)   | Common   | 0         | 3 (0.1)    | 56 (2.3)   | Common   |
|                                | Thrombocytopenia0              |            | 5 (0.2)       | 110 (4.4)   |          | 0         | 1 (<0.1)   | 45 (1.8)   |          |
|                                | Platelet count decreased       | 0          | 1 (<0.1)      | 53 (2.1)    |          | 0         | 2 (0.1)    | 11 (0.5)   |          |
| Oropharyngeal pain             | Total                          | 0          | 0             | 154 (6.1)   | Common   | 0         | 0          | 81 (3.3)   | Common   |
|                                | Oropharyngeal pain             | 0          | 0             | 154 (6.1)   |          | 0         | 0          | 81 (3.3)   |          |
| Stomatitis                     | Total                          | 0          | 2 (0.1)       | 154 (6.1)   | Common   | 0         | 0          | 24 (1.0)   | Uncommon |
|                                | Stomatitis                     | 0          | 0             | 84 (3.3)    |          | 0         | 0          | 16 (0.7)   |          |
|                                | Mucosal inflammation           | 0          | 2 (0.1)       | 81 (3.2)    |          | 0         | 0          | 9 (0.4)    |          |
| Hypocalcaemia                  | Total                          | 0          | 1 (<0.1)      | 134 (5.3)   | Common   | 1 (<0.1)0 |            | 26 (1.1)   | Common   |
|                                | Hypocalcaemia                  | 0          | 1 (<0.1)      | 110 (4.4)   |          | 1 (<0.1)0 |            | 14 (0.6)   |          |
|                                | Blood calcium decreased        | 0          | 0             | 30 (1.2)    |          | 0         | 0          | 13 (0.5)   |          |
| Lymphopenia                    | Total                          | 0          | 30 (1.2)      | 124 (4.9)   | Common   | 0         | 2 (0.1)    | 39 (1.6)   | Common   |
|                                | Lymphopenia                    | 0          | 12 (0.5)      | 69 (2.7)    |          | 0         | 0          | 16 (0.7)   |          |
|                                | Lymphocyte count decreased     | 0          | 19 (0.8)      | 60 (2.4)    |          | 0         | 2 (0.1)    | 24 (1.0)   |          |
| Hypokalaemia                   | Total                          | 3 (0.1)    | 8 (0.3)       | 121 (4.8)   | Common   | 0         | 7 (0.3)    | 41 (1.7)   | Common   |
|                                | Hypokalaemia                   | 3 (0.1)    | 8 (0.3)       | 104 (4.1)   |          | 0         | 7 (0.3)    | 35 (1.4)   |          |
|                                | Blood potassium decreased      | 0          | 0             | 20 (0.8)    |          | 0         | 0          | 6 (0.2)    |          |
| Decreased apetite              | Total                          | 0          | 1 (<0.1)      | 120 (4.8)   | Common   | 0         | 0          | 47 (1.9)   | Common   |
|                                | Decreased appetite             | 0          | 1 (<0.1)      | 120 (4.8)   |          | 0         | 0          | 47 (1.9)   |          |
| Electrocardiogra m prolonged   | Total                          | 0          | 7 (0.3)       | 109 (4.3)   | Common   | 0         | 1 (<0.1)   | 18 (0.7)   | Uncommon |
| Electrocardiogram QT prolonged | Electrocardiogram QT prolonged | 0          | 7 (0.3)       | 109 (4.3)   |          | 0         | 1 (<0.1)   | 18 (0.7)   |          |
| Blood creatinine Total         | Blood creatinine Total         | 1 (<0.1)3  | (0.1)         | 98 (3.9)    | Common   | 0         | 0          | 22 (0.9)   | Uncommon |

<div style=\"page-break-after: always\"></div>

Blood creatinine increased

Hepatotoxicity Total

1 (&lt;0.1)  3 (0.1)

13 (0.5) 16 (0.6)

98 (3.9)

36 (1.4)

0

0

Common  1 (&lt;0.1) 1 (&lt;0.1)

22 (0.9)

13 (0.5)

Uncommon

| Hepatotoxicity             | 5 (0.2) 7 (0.3)   | 15       | (0.6)     | 0       | 0      | 1 (<0.1)   |
|----------------------------|-------------------|----------|-----------|---------|--------|------------|
| Hepatic cytolysis          | 1 (<0.1)3 (0.1)   | 11 (0.4) | 1         | (<0.1)1 | (<0.1) | 12 (0.5)   |
| Drug-induced liver injury6 | (0.2) 5 (0.2)     | 9 (0.4)  | 0         | 0       | 0      |            |
| Autoimmune hepatitis       | 1 (<0.1)1 (<0.1)  | 1 (<0.1) | 0         | 0       | 0      |            |
| Febrile neutropeniaTotal   | 1 (<0.1)7 (0.3)   | 7 (0.3)  | Uncommon0 | 0       | 0      |            |
| Febrile neutropenia        | 1 (<0.1)7 (0.3)   | 7 (0.3)  | 0         | 0       | 0      |            |

Numbers (n) represent counts of subjects. MedDRA version 26.0, CTCAE version 4.03. Frequency category is based on the following convention: very common (&gt;=1/10); common (&gt;=1/100 to &lt;1/10); uncommon (&gt;=1/1,000 to &lt;1/100); rare (&gt;=1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000)

## 2.5.3.5. Adverse event of special interest (AESI)

Table 41. Adverse events of special interest by grouping, irrespective of causality (final iDFS analysis, 21Jul-2023 data cut-off) (Safety set)

| AESI grouping               | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|-----------------------------|-----------------------------------|------------------------|
| Myelosuppression AESl       |                                   |                        |
| Neutropenia                 | 1579 (62.5)                       | 113 (4.6)              |
| Leukopenia                  | 595 (23.6)                        | 111 (4.5)              |
| Anemia                      | 216 (8.6)                         | 78 (3.2)               |
| Thrombocytopenia            | 162 (6.4)                         | 56 (2.3)               |
| Other                       | 0                                 | 1 (≤0.1)               |
| Non-myelosuppression AESl   |                                   |                        |
| Infections                  | 1253 (49.6)                       | 884 (36.2)             |
| Hepatobiliary toxicity      | 687 (26.4)                        | 273 (11.2)             |
| Renal toxicity              | 152 (6.0)                         | 58 (2.4)               |
| QT interval prolongation    | 134 (5.3)                         | 34 (1.4)               |
| Second primary malignancies | 48 (1.9)                          | 49 (2.0)               |
| ILD / Pneumonitis           | 39 (1.5)                          | 22 (0.9)               |
| Reproductive toxicity       | 32 (1.3)                          | 27 (1.1)               |

AESl grouping terms are presented by AESl grouping in descending frequency. 3s reported in the ribociclib plus ET group.

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

MedDRA. Version 26.0 has been used for reporting.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

## 2.5.3.5.1. Myelosuppressive AESIs

## Neutropenia

Table 42. Clinical impact of Neutropenia AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

<div style=\"page-break-after: always\"></div>

| Myelosuppression - Neutropenia Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%6)   |
|-------------------------------------------------|-----------------------------------|-------------------------|
| AllAEs                                          | 1579 (62.5)                       | 113 (4.6)               |
| Neutropenia                                     | 1047 (41.5)                       | 73 (3.0)                |
| Neutrophil count decressed                      | 609 (24.1)                        | 41 (1.7)                |
| Febrile neutropenia                             | 7 (0.3)                           | 0                       |
| Granulocytopenia                                | 4 (0.2)                           | 0                       |
| CTCAE grade23 AEs                               | 1118 (44.3)                       | 22 (0.9)                |
| Neutropenia                                     | 707 (28.0)                        | 14 (0.6)                |
| Neutrophil count decreased                      | 448 (17.7)                        | 8 (0.3)                 |
| Febrile neutropenia                             | 7 (0.3)                           | 0                       |
| SAEs                                            | 2 (0.1)                           | 0                       |
| Febrile neutropenia                             | 1 (≤ 0.1)                         | 0                       |
| Neutrophil count decreased                      | 1 (≤ 0.1)                         | 0                       |
| AEs leading to discontinuation                  | 28 (1.1)                          | 0                       |
| Neutropenia                                     | 19 (0.8)                          | 0                       |
| Neutrophil count decreased                      | 7 (0.3)                           | 0                       |
| Myelosuppression- Neutropenia Preferred term    | Ribociclib plus ET N=2525 n (9)   | ET only N=2442 n (96)   |
| Febrile neutropenia                             | 2 (0.1)                           | 0                       |
| AEs leading to dose adjustment                  | 358 (14.2)                        | 0                       |
| Neutropenia                                     | 215 (8.5)                         | 0                       |
| Neutrophil count decreased                      | 141 (5.6)                         | 0                       |
| Febrile neutropenia                             | 2 (0.1)                           | 0                       |
| AEs leading to dose interruption                | 1093 (43.3)                       | 3 (0.1)                 |
| Neutropenia                                     | 683 (27.0)                        | 1 (≤ 0.1)               |
| Neutrophil count decressed                      | 441 (17.5)                        | 2 (0.1)                 |
| Febrile neutropenia                             | 4 (0.2)                           | 0                       |

Patients with multiple events in a grouping are counted only once in the grouping. Patients with events in more than 1 category within a grouping are counted once in each of those categories. frequency. as reported in the ribociclib plus ET group. MedDRA Version 26.0 has been used for reporting. AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

<div style=\"page-break-after: always\"></div>

Figure 14. Kaplan-Meier plot of neutropenia, grade 2 or higher, as time-to-first occurrence by treatment group in Study O12301C (Safety set based on cut-off date 11-Jan-2023)

<!-- image -->

Based on neutrophil counts.

N=total number of patienis included in the analysis. Patients meeting the criteria for an event at baseline and patients with missing baseline are excluded from the analysis. n=number of patients with event. NE=not evaluable.

Table 43. Side-by-side comparison of Neutropenia AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset         |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|----------------------------|
| Myelosupression - Neutropenia    | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% C1 | PBO+ET N=818 n (%): 95% CI |
| Total no. patients               | 1568 (62.1): 60.2, 64.0                 | 110 (4.5): 3.7, 5.4          | 806 (75.7): 73.0, 78.2               | 56 (6.8): 5.2, 8.8         |
| Grade ≥ 3                        | 1106 (43.8): 41.9.45.8                  | 20 (0.8): 0.5. 1.3           | 666 (62.5): 59.5. 65.5               | 20 (2.4): 1.5.3.8          |
| SAEs                             | 2 (0.1): 0.0,0.3                        | 0                            | 26 (2.4): 1.6.3.6                    | 1 (0.1): 0.0, 0.7          |
| AEs with fatal outcome           | 0 32 (1.3):                             | 0 0                          | 0 11 (1.0):                          | 0 0                        |
| AEs leading to discontinuation   | 0.9, 1.8 317 (12.6):                    |                              | 0.5. 1.8 275 (25.8):                 | 2 (0.2):                   |
| AEs leading to dose adjustment   | 11.3, 13.9 1080 (42.8):                 | 0                            | 23.2.28.6                            | 0.0,0.9                    |
| AEs leading to dose interruption |                                         | 3 (0.1):                     | 605 (56.8):                          | 11 (1.3):                  |
|                                  | 40.8,44.7                               | 0.0.0.4                      | 53.8.59.8                            | 0.7.2.4                    |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## Leukopenia

Table 44 Clinical impact of Leukopenia AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Myelosuppression - Leukopenia Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|------------------------------------------------|-----------------------------------|------------------------|
| All AEs                                        | 595 (23.6)                        | 111 (4.5)              |
| Leukopenia                                     | 337 (13.3)                        | 50 (2.0)               |
| Vhite blood cell count decressed               | 246 (9.7)                         | 38 (1.6)               |
| Lymphopenia                                    | 69 (2.7)                          | 16 (0.7)               |
| Lymphocyte count decreased                     | 60 (2.4)                          | 24 (1.0)               |
| CTCAE grade 2 3 AEs                            | 202 (8.0)                         | 10 (0.4)               |
| Leukopenia                                     | 94 (3.7)                          | 2 (0.1)                |
| White blood cell count decreased               | 84 (3.7)                          | 6 (0.2)                |
| Lymphocyte count decreased                     | 19 (0.8)                          | 2 (0.1)                |
| Lymphopenia                                    | 12 (0.5)                          |                        |
| AEs leading to discontinuation                 | 6 (0.2)                           | D                      |
| Leukopenia                                     | 2(0.1)                            | 0                      |
| White blood cell count decreased               | 2 (0.1)                           | 0                      |
| Lymphocyte count decressed                     | 1 (≤ 0.1)                         |                        |
| Lymphopenia                                    | 1 (≤ 0.1)                         | 0                      |
| Myelosuppression - Leukopenia Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
| AEs leading to dose adjustment                 | 45 (1.8)                          | 0                      |
| White blood cell count decre3sed               | 26 (1.0)                          | 0                      |
| Leukopenia                                     | 17 (0.7)                          | 0                      |
| Lymphocyte count decre3sed                     | 1 (≤ 0.1)                         | 0                      |
| Lymphopenia                                    | 1 (≤ 0.1)                         | 0                      |
| AEs leading to dose interruption               | 160 (6.3)                         | 0                      |
| Leukopenia                                     | 81 (3.2)                          | 0                      |
| White blood cell count decressed               | 70 (2.8)                          | 0                      |
| Lymphocyte count decressed                     | 12 (0.5)                          | 0                      |
| Lymphopenia                                    | 7 (0.3)                           | 0                      |

Patienis with multiple events in a grouping are counted only once in the grouping.

AESl grouping terms are presented by preferred terms as sorted within the AEsl grouping in descending

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

frequency. as reported in the ribociclib plus ET group.

AESl groupings per eCRS released by Novartis dated 28-Aug-2023.

MedDRA Version 26.0 has. been used for reporting.

<div style=\"page-break-after: always\"></div>

Table 45. Side-byside comparison of Leukopenia AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset          |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|-----------------------------|
| Myelosupression-Leukopenia       | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% CI | PBO +ET N=818 n (%): 95% Cl |
| Total no. patients               | 583 (23.1): 21.5, 24.8                  | 110 (4.5): 3.7,5.4           | 372 (34.9) (32.1, 37.9)              | 38 (4.6) (3.3, 6.3)         |
| Grade 2 3                        | 197 (7.8): 6'8 89                       | 9 (0.4): 0.2,0.7             | 210 (19.7) (17.4, 22.2)              | 9 (1.1) (0.5, 2.1)          |
| SAEs                             | 0                                       | 0                            | 3 (0.3) (0.1, 0.8)                   | 0                           |
| AEs with fatal outcome           | 0                                       | 0                            | 0                                    | 0                           |
| AEsleading to discontinuation    | 7 (0.3): 0.1,0.6                        | 0                            | 1(0.1) (0.0, 0.5)                    | 0                           |
| AEs leading to dose adjustment   | 37 (1.5): 1.0, 2.0                      | 0                            | 26 (2.4) (1.6, 3.6)                  | 0                           |
| AEs leading to dose interruption | 155 (6.1): 5.2, 7.1                     | 0                            | 116 (10.9) (9.1. 12.9)               | 1 (0.1) (0.0, 0.7)          |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

## Anaemia

Table 46. Clinical impact of Anemia AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Myelosuppression - Anemia Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|--------------------------------------------|-----------------------------------|------------------------|
| All AEs                                    | 216 (8.6)                         | 78 (3.2)               |
| Anaemia                                    | 211 (8.4)                         | 73 (3.0)               |
| Haemoglobin decreased                      | 3 (0.1)                           | 1 (≤ 0.1)              |
| Red blood cell count decreased             | 3 (0.1)                           | 2 (0.1)                |
| Haematocrit decreased                      | 1 (≤ 0.1)                         | 0                      |
| Microcytic anaemia                         | 1 (≤ 0.1)                         | 1 (≤ 0.1)              |
| Normocytic snaemia                         | D                                 | 1 (≤0.1)               |
| CTCAE grade 3 AEs                          | 8 (0.3)                           | 8 (0.3)                |
| Anaemia                                    | 8 (0.3)                           | 7 (0.3)                |
| Red blood cell count decreased             | 0                                 | 1 (≤0.1)               |
| SAEs                                       | 3 (0.1)                           | 3 (0.1)                |
| Anaemia                                    | 3 (0.1)                           | 2 (0.1)                |
| Red blood cell count decreased             | D                                 | 1 (≤0.1)               |
| AEs leading to discontinuation             | 2 (0.1)                           | 0                      |
| Anaemia                                    | 2 (0.1)                           | 0                      |
| Myelosuppression - Anemia Preferred term   | Ribociclib plus ET N=2525 n(%)    | ET only N=2442 n (96)  |
| AEs leading to dose adjustment             | 1 (≤ 0.1)                         | 0                      |
| Anaemia                                    | 1 (≤ 0.1)                         | 0                      |
| AEs leading to dose interruption           | 10 (0.4)                          | 1 (≤ 0.1)              |
| Anaemia                                    | 10 (0.4)                          | 1 (≤ 0.1)              |

Patients with multiple events in a grouping are counted only once in the grouping. Patienis with events in more than 1 category within a grouping are counted once in each of those categories. AESI grouping terms are presented by prefered terms as sorted within the AESl grouping in descending frequency. as reported in the ribociclib plus ET group. MedDRA Version 26.0 has been used for reporting.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

<div style=\"page-break-after: always\"></div>

Table 47. Side-by-side comparison of Anemia AESI by AE catergories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset           |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|------------------------------|
| Myelosupression-Anemia           | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% CI | PBO + ET N=818 n (%): 95% CI |
| Total no. patients               | 209 (8.3): 7.2, 9.4                     | 74 (3.0): 2.4, 3.8           | 228 (21.4):                          | 69 (8.4):                    |
|                                  |                                         |                              | 19.0, 24.0                           | 6.6, 10.6                    |
| Grade ≥ 3                        | 7 (0.3):                                | 6 (0.2):                     | 41 (3.8):                            | 18 (2.2):                    |
|                                  | 0.1, 0.6                                | 0.1, 0.5                     | 2.8,5.2                              | 1.3.3.5                      |
| SAEs                             | 3 (0.1):                                | 1 (≤ 0.1):                   | 12 (1.1):                            | 3 (0.4):                     |
| AEs with fatal outcome           | 0.0,0.3 0                               | 0.0, 0.2 0                   | 0.6, 2.0                             | 0.1, 1.1 0                   |
|                                  | 2 (0.1): 0.0,0.3                        | 0                            | 0 0                                  | 0                            |
| AEs leading to discontinuation   | 1 (≤ 0.1):                              | 0                            | 5 (0.5):                             |                              |
| AEs leading to dose adjustment   | 0.0,0.2                                 |                              | 0.2, 1.1                             | 0                            |
| AEs leading to dose interruption | 12 (0.5): 0.2.0.8                       | 1 (= 0.1): 0.0.0.2           | 28 (2.6): 1.8,3.8                    | 7 (0.9): 0.3.1.8             |

For Study O12301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

## Thrombocytopenia

Table 48 Clinical impact of Thrombocytopenia AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Myelosuppression - Thrombocytopenia Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|------------------------------------------------------|-----------------------------------|------------------------|
| All AEs                                              | 162 (6.4)                         | 56 (2.3)               |
| Thrombocytopenia                                     | 110 (4.4)                         | 45 (1.8)               |
| Platelet count decreased                             | 53 (2.1)                          | 11 (0.5)               |
| CTCAE grade ≥3 AEs                                   | 6 (0.2)                           | 3 (0.1)                |
| Thrombocytopenia                                     | 5 (0.2)                           | 1 (≤ 0.1)              |
| Platelet count decreased                             | 1 (≤0.1)                          | 2 (0.1)                |
| AEs leading to discontinuation                       | 1 (≤ 0.1)                         | 0                      |
| Thrombocytopenia                                     | 1(≤0.1)                           | 0                      |
| AEs leading to dose adjustment                       | 2 (0.1)                           | 0                      |
| Platelet count decreased                             | 1 (≤0.1)                          |                        |
| Thrombocytopenia                                     | 1 (≤ 0.1)                         | 0                      |
| AEs leading to dose interruption                     | 20 (0.8)                          | 1 (≤ 0.1)              |
| Thrombocytopenia                                     | 12 (0.5)                          | 0                      |
| Platelet count decreased                             | 9 (0.4)                           | 1 (≤ 0.1)              |
| Myelosuppression- Thrombocytopenia Preferred term    | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |

Patients with multiple events in a grouping are counted only once in the grouping.

AESl grouping terms are presented by preferred terms as sorted within the AESl grouping in descending

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

frequency. as reported in the ribociclib plus ET group.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

MedDRA Version 26.0 has been used for reporting.

<div style=\"page-break-after: always\"></div>

Table 49. Side-by-side comparison of Thrombocytopenia AESI by AE categories of Study O12301C vs. Pooled aBC (Safety set based on cut-off date 11-Jan-2023)

|                                   | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset          |
|-----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|-----------------------------|
| Myelosupression- Thrombocytopenia | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% CI | PBO +ET N=818 n (%): 95% CI |
| Total no. patients                | 161 (6.4): 5.5, 7.4                     | 53 (2.2): 1.6, 2.8           | 105 (9.9): 8.1, 11.8                 | 15 (1.8): 1.0, 3.0          |
|                                   | 6 (0.2): 0.1,0.5                        | 3 (0.1): 0.0.0.4             | 9 (0.8): 0.4, 1.6                    | 2 (0.2): 0.0,0.9            |
| Grade ≥ 3 SAEs                    | 0                                       | 0                            | 5 (0.5): 0.2, 1.1                    | 1 (0.1): 0.0,0.7            |
| AEs with fatal outcome            | 0                                       | 0                            | 0                                    | 0                           |
| AEs leading to discontinuation    | 1 (≤0.1): 0.0,0.2                       | 0                            | 0                                    | 1 (0.1): 0.0, 0.7           |
| AEs leading to dose adjustment    | 2 (0.1): 0.0,0.3                        | 0                            | 7 (0.7): 0.3, 1.3                    | 0                           |
|                                   | 20 (0.8):                               | 1 (≤ 0.1):                   | 17 (1.6):                            | 0                           |
| AEs leading to dose interruption  | 0.5.1.2                                 | 0.0,0.2                      | 0.9, 2.5                             |                             |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## 2.5.3.5.2. Non-myelosuppressive AESI

## Infections

Clinical impact of Infections AESI by preferred term, irrespective of causality ( ≥ 3 patients / either group) (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Infections Preferred term         | Ribociclib plus ET N=2525 n (96)   | ET only N=2442 n(%)   |
|-----------------------------------|------------------------------------|-----------------------|
| AllAEs                            | 1253 (49.6)                        | 884 (36.2)            |
| COVID-19                          | 537 (21.3)                         | 345 (14.1)            |
| Urinary tract infection           | 164 (6.5)                          | 125 (5.1)             |
| Nasopharyngitis                   | 139 (5.5)                          | 94 (3.8)              |
| Upper respiratory tract infection | 123 (4.9)                          | 63 (2.6)              |
| Sinusitis                         | 67 (2.7)                           | 41 (1.7)              |
| Herpes zoster                     | 62 (2.5)                           | 53 (2.2)              |
| Suspected COv1D-19                | 47 (1.9)                           | 24 (1.0)              |
| Pneumonia                         | 40 (1.6)                           | 22 (0.8)              |
| Oral herpes                       | 37 (1.5)                           | 13 (0.5)              |
| Cellulitis.                       | 35 (1.4)                           | 18 (0.7)              |
| Bronchitis                        | 34 (1.3)                           | 31 (1.3)              |
| Cystitis                          | 34 (1.3)                           | 28 (1.1)              |
| Influenza                         | 34 (1.3)                           | 22 (0.9)              |
| Gastroenteritis                   | 31 (1.2)                           | 19 (0.8)              |
| Respiratory tract infection viral | 30 (1.2)                           | 29 (1.2)              |
| Tooth infection                   | 30 (1.2)                           | 19 (0.8)              |
| Conjunctivitis                    | 29 (1.1)                           | 13 (0.5)              |
| Mastitis.                         | 27 (1.1)                           | 19 (0.8)              |
| Pharyngitis                       | 23 (0.9)                           | 23 (0.9)              |
| Respiratory tract infection       | 23 (0.9)                           | 18 (0.7)              |
| Rhinitis                          | 23 (0.9)                           | 16 (0.7)              |
| Ear infection                     | 19 (0.8)                           | 13 (0.5)              |
| Skin infection                    | 19 (0.8)                           | 15 (0.6)              |
| Pneumonia viral                   | 16 (0.6)                           | 7 (0.3)               |
| Breast cellulitis                 | 15 (0.6)                           | 5 (0.2)               |

<div style=\"page-break-after: always\"></div>

| Infections Preferred term               | Ribociclib plus ET N=2525 n (%%)   | ET only N=2442 n (%)   |
|-----------------------------------------|------------------------------------|------------------------|
| Gastroenteritis viral                   | 15 (0.6)                           | 9 (0.4)                |
| Chronic gastritis                       | 14 (0.6)                           | 7 (0.3)                |
| Tonsillitis                             | 13 (0.5)                           | 8 (0.3)                |
| COV10-19 pneumonia                      | 12 (0.5)                           | 7 (0.3)                |
| Erysipelas                              | 12 (0.5)                           | 9 (0.4)                |
| Fungal infection                        | 12 (0.5)                           | 10 (0.4)               |
| Hordeolum                               | 12 (0.5)                           | 4 (0.2)                |
| Periodontitis                           | 12 (0.5)                           | 4 (0.2)                |
| Postoperative wound infection           | 12 (0.5)                           | 5 (0.2)                |
| Gingivilis                              | 11 (0.4)                           | 4 (0.2)                |
| Lower respiratory tract infection       | 11 (0.4)                           | 12 (0.5)               |
| Tooth abscess                           | 11 (0.4)                           | 4 (0.2)                |
| Wound infection                         | 11 (0.4)                           | 5 (0.2)                |
| Oral candidiasis                        | 10 (0.4)                           | 5 (0.2)                |
| Tracheitis                              | 10 (0.4)                           | 8 (0.3)                |
| Viral infection                         | 10 (0.4)                           | 11 (0.5)               |
| Diverticulitis                          | 9(0.4)                             | 7 (0.3)                |
| Eye infection                           | 9(0.4)                             | 5 (0.2)                |
| Pulpilis dental                         | 9 (0.4)                            | 2 (0.1)                |
| Pyelonephritis                          | 9(0.4)                             | 4 (0.2)                |
| Vulvovaginal candidiasis                | 9(0.4)                             | 5 (0.2)                |
| Food poisoning                          | 8 (0.3)                            | 3 (0.1)                |
| Gastrointestinal infection              | 8 (0.3)                            | 3 (0.1)                |
| Localised infection                     | 8 (0.3)                            | 5 (0.2)                |
| Viral upper respiratory tract infection | 8 (0.3)                            | 1 (≤ 0.1)              |
| Candida infection                       | 7 (0.3)                            | 4 (0.2)                |
| Herpes simplex                          | 7 (0.3)                            | 3 (0.1)                |
| Vaginal infection                       | 7 (0.3)                            | 13 (0.5)               |
| Vulvovaginal mycotic infection          | 7 (0.3)                            | 2 (0.1)                |
| Acarodematitis                          | 6 (0.2)                            | 0                      |
| Laryngitis                              | 6 (0.2)                            | 8 (0.3)                |
| Onychomycosis                           | 6 (0.2)                            | 5 (0.2)                |
| Oral infection                          | 6 (0.2)                            | 0                      |
| Paronychia                              | 6 (0.2)                            | 4 (0.2)                |
| Device related infection                | 5 (0.2)                            | 5 (0.2)                |
| Helicobacter infection                  | 5 (0.2)                            | 5 (0.2)                |
| Post procedural infection               | 5 (0.2)                            | 6 (0.2)                |
| Rash pustular                           | 5 (0.2)                            | 1 (≤ 0.1)              |
| Tinea pedis                             | 5 (0.2)                            | 1 (≤ 0.1)              |
| Appendicitis                            | 4(0.2)                             | 3 (0.1)                |
| Bacteraemia                             | 4 (0.2)                            | 0                      |
| Furuncle                                | 4 (0.2)                            | 2 (0.1)                |
| Herpes virus infection Infected bite    | 4 (0.2) 4(0.2)                     | 1 (≤ 0.1) 0            |

<div style=\"page-break-after: always\"></div>

| Infections Preferred term     | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|-------------------------------|-----------------------------------|------------------------|
| Infected seroma               | 4 (0.2)                           | 1 (≤ 0.1)              |
| Pyelonephritis chronic        | 4 (0.2)                           | 4 (0.2)                |
| Skin papilloma                | 4 (0.2)                           | 4 (0.2)                |
| Acute sinusitis               | 3 (0.1)                           | 1 (≤ 0.1)              |
| Bacterial vaginosis           | 3 (0.1)                           | 3 (0.1)                |
| Carbuncle                     | 3 (0.1)                           | 0                      |
| Coronavirus infection         | 3 (0.1)                           | 2 (0.1)                |
| Folliculitis                  | 3 (0.1)                           | 3 (0.1)                |
| Fungal skin infection         | 3 (0.1)                           | 7 (0.3)                |
| Herpes simplex reactivation   | 3 (0.1)                           | 1 (≤ 0.1)              |
| Infected cyst                 | 3 (0.1)                           | 1 (<≤0.1)              |
| Labyrinthitis                 | 3 (0.1)                           | 3 (0.1)                |
| Nasal herpes                  | 3 (0.1)                           | 0                      |
| Otitis extema                 | 3 (0.1)                           | 2 (0.1)                |
| Post procedural cellulitis    | 3 (0.1)                           | 0                      |
| Pustule                       | 3 (0.1)                           | 0                      |
| Pyelonephritis acute          | 3 (0.1)                           | 0                      |
| Sialoadenitis                 | 3 (0.1)                           | 1 (≤ 0.1)              |
| Urosepsis                     | 3 (0.1)                           | 1 (≤0.1)               |
| Breast abscess                | 2 (0.1)                           | 3 (0.1)                |
| Lymphangitis                  | 2 (0.1)                           | 3 (0.1)                |
| Oral fungal infection         | 2 (0.1)                           | 4 (0.2)                |
| Subcutaneous abscess          | 2 (0.1)                           | 5 (0.2)                |
| Pharyngotonsillitis           | 1 (≤ 0.1)                         | 3 (0.1)                |
| Sepsis                        | 1 (≤ 0.1)                         | 3 (0.1)                |
| Vestibular neuronilis         | 1(≤ 0.1)                          | 3 (0.1)                |
| Cervicitis                    | 0                                 | 4 (0.2)                |
| CTCAE grade23 AEs             | 138 (5.5)                         | 77 (3.2)               |
| COVID-19                      | 21 (0.8)                          | 12 (0.5)               |
|                               | 12 (0.5)                          | 8 (0.3)                |
| Celluliis                     | 11 (0.4)                          | 8 (0.3)                |
| Urinary tract infection       | 10 (0.4)                          | 5 (0.2)                |
| Breast cellulitis             | 9 (0.4)                           | 3 (0.1)                |
| COV1D-19 pneumonia            | 9 (0.4)                           | 5 (0.2)                |
| Mastitis                      | 7 (0.3)                           | 5 (0.2)                |
| Postoperative wound infection | 5 (0.2)                           | 2 (0.1)                |
| Appendicitis                  | 4 (0.2)                           | 3 (0.1)                |
| Pyelonephritis                | 4 (0.2)                           | 2 (0.1)                |
| Bacteraemia                   | 3 (0.1)                           | 0                      |
| Device related infection      | 3 (0.1)                           | 5 (0.2)                |
| Herpes zoster                 | 3 (0.1)                           | 2 (0.1)                |
| Urosepsis                     | 3 (0.1)                           | 1 (≤ 0.1)              |
| Wound infection Erysipelas    | 3 (0.1) 2 (0.1)                   | 3 (0.1) 3 (0.1)        |

<div style=\"page-break-after: always\"></div>

| Infections Preferred term                                     | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|---------------------------------------------------------------|-----------------------------------|------------------------|
| Post procedural infection                                     | 2 (0.1)                           | 3 (0.1)                |
| Sepsis                                                        | 1 (≤ 0.1)                         | 3(0.1)                 |
| SAEs                                                          | 126 (5.0)                         | 73 (3.0)               |
| COV1D-19                                                      | 20 (0.8)                          | 13 (0.5)               |
| Pneumonia                                                     | 14 (0.6)                          | 9(0.4)                 |
| Breast cellulitis                                             | 9 (0.4)                           | 3 (0.1)                |
| COV10-19 pneumonia                                            | 9(0.4)                            | 5 (0.2)                |
| Cellulitis                                                    | 7 (0.3)                           | 6 (0.2)                |
| Urinary tract infection                                       | 6 (0.2)                           | 3 (0.1)                |
| Postoperative wound infection                                 | 5 (0.2)                           | 2 (0.1)                |
| Appendicitis                                                  | 4 (0.2)                           | 2 (0.1)                |
| Erysipelas                                                    | 4 (0.2)                           | 3 (0.1)                |
| Masitis                                                       | 4 (0.2)                           | 2 (0.1)                |
| Pneumonia viral                                               | 4 (0.2)                           | 3 (0.1)                |
| Suspected COVID-19                                            | 4 (0.2)                           | 1 (≤ 0.1)              |
| Bacteraemia                                                   | 3 (0.1)                           | 0                      |
| Pyelonephritis                                                | 3 (0.1)                           | 2 (0.1)                |
| Urosepsis                                                     | 3 (0.1)                           | 1 (≤ 0.1)              |
| Device related infection                                      | 2(0.1)                            | 3 (0.1)                |
| Post procedural infection                                     | 2 (0.1)                           | 3 (0.1)                |
| Sepsis                                                        | 1 (≤ 0.1)                         | 3 (0.1)                |
| AEs leading to discontinuation                                | 20 (0.8)                          | 3 (0.1)                |
| COVID-19                                                      | 8 (0.3)                           | 1 ( 0.1)               |
| AEs leading to dose adjustment                                | 11 (0.4)                          | 0                      |
| AEs leading to dose interruption                              | 455 (18.0)                        | 35 (1.4)               |
| COVID-19                                                      | 228 (9.0)                         | 20 (0.8)               |
| Upper respiratory tract infection                             | 27 (1.1)                          | 1 (≤ 0.1)              |
| Nasopharyngitis                                               | 26 (1.0)                          | 1(≤ 0.1)               |
| Herpes zoster                                                 | 20 (0.8)                          | 0                      |
| Cellulitis                                                    | 18 (0.7)                          | 0                      |
| Suspected COVID-19                                            | 14 (0.6)                          | 4 (0.2)                |
| Urinary tract infection                                       | 14 (0.6)                          | 0                      |
| Influenza                                                     | 13 (0.5)                          | 0                      |
| Mastitis                                                      | 12 (0.5)                          | 1 (± 0.1)              |
| Pneumonia                                                     | 12 (0.5)                          | 0                      |
| Gastroenteritis                                               | 11 (0.4)                          | 1 (≤ 0.1)              |
| Bresst cellulitis                                             | 10 (0.4)                          | 0                      |
| Postoperative wound infection                                 | 8 (0.3)                           | 0                      |
| Tooth infection                                               | 8 (0.3)                           | 0                      |
| COV10-19 pneumonia                                            | 7 (0.3)                           | 2 (0.1)                |
| Erysipelas                                                    | 7 (0.3)                           | 1 (≤ 0.1)              |
| Sinusitis                                                     | 7 (0.3)                           | 0                      |
| Gastroenteritis viral Viral upper respiratory tract infection | 6 (0.2) 5 (0.2)                   | 0 0                    |

<div style=\"page-break-after: always\"></div>

Table 50. Side-by-side comparison of Infections AESI by AE catergories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           |                              | Pooled aBC Dataset                   | Pooled aBC Dataset           |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|------------------------------|
| Infections                       | Ribociclib plus ET N=2524 n (%): 95% CI | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% CI | PBO + ET N=818 n (%): 95% C1 |
| Total no. patients               | 1199 (47.5): 45.5, 49.5                 | 836 (34.2): 32.3, 36.1       | 624 (58.6): 55.6, 61.6               | 388 (47.4): 44.0, 50.9       |
| Grade23                          | 131 (5.2): 4.4, 6.1                     | 72 (2.9): 2.3.3.7            | 82 (7.7): 6.2.9.5                    | 29 (3.5): 2.4, 5.1           |
| SAEs                             | 120 (4.8): 4.0,5.7                      | 70 (2.9): 2.2, 3.6           | 80 (7.5): 6.0,9.3                    | 31 (3.8): 2.6, 5.3           |
| AEswithfatal outcome             | 7 (0.3): 0.1, 0.6                       | 2 (0.1): 0.0,0.3             | 4 (0.4): 0.1, 1.0                    | 0                            |
| AEs leading to discontinuation   | 17 (0.7):                               | 2 (0.1): 0.0, 0.3            | 5 (0.5): 0.2, 1.1                    | 1 (0.1): 0.0, 0.7            |
| AEs leading to dose              | 0.4, 1.1                                |                              | 4 (0.4):                             | 1 (0.1):                     |
| adjustment                       | 10 (0.4): 0.2,0.7                       | 0                            | 0.1, 1.0                             | 0.0, 0.7                     |
|                                  |                                         |                              | 122 (11.5):                          | 29 (3.5):                    |
| AEs leading to dose interruption | 419 (16.6): 15.2, 18.1                  | 27 (1.1): 0.7, 1.6           | 9.6. 13.5                            | 2.4, 5.1                     |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## Hepatobiliary toxicity

Table 51. Incidence, severity, and clinical impact of Hepatobiliary toxicity AESI by preferred term in Study O12301C (Safety set)

Clinical impact of Hepatobiliary toxicity AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Hepatobiliary toxicity Preferred term   | Ribociclib plus ET N=2525 n(%6)   | ET only N=2442 n (%)   |
|-----------------------------------------|-----------------------------------|------------------------|
| All AEs                                 | 667 (26.4)                        | 273 (11.2)             |
| Alanine aminotransferase increased      | 492 (19.5)                        | 136 (5.6)              |
| Aspartate aminotransferase increased    | 426 (16.9)                        | 139 (5.7)              |
| Gamma-glutamyltransfersse incressed     | 119 (4.7)                         | 67 (2.7)               |
| Blood alkaline phosphatase increased    | 76 (3.0)                          | 62 (2.5)               |
| Blood bilinubin increased               | 66 (2.6)                          | 28 (1.1)               |
| Hepatic steatosis                       | 22 (0.9)                          | 13 (0.5)               |
| Bilirubin conjugated increased          | 19 (0.8)                          | 11 (0.5)               |
| Hepatotoxicity                          | 15 (0.6)                          | 1 (≤ 0.1)              |
| Hyperbilirubinaemia                     | 12 (0.5)                          | 3 (0.1)                |
| Hypertransaminasaemia                   | 12 (0.5)                          | 5 (0.2)                |
| Hepatic cytolysis                       | 11 (0.4)                          | 12 (0.5)               |
| Drug-induced liver injury               | 9(0.4)                            | 0                      |
| Liver disorder                          | 8 (0.3)                           | 10 (0.4)               |
| Transsminases increased                 | 8(0.3)                            | 3 (0.1)                |
| Hypoalbuminaemia                        | 7 (0.3)                           | 5 (0.2)                |
| Hepatic cyst                            | 4 (0.2)                           | 7 (0.3)                |
| Blood bilinubin unconjugated increased  | 3 (0.1)                           | 0                      |
| Non-alcoholic steatohepatitis           | 3 (0.1)                           | 1(≤0.1)                |
| Ascites                                 | 2 (0.1)                           | 6 (0.2)                |
| Cholestasis                             | 2 (0.1)                           | 2 (0.1)                |
| Hepatic calcification                   | 2(0.1)                            | 0                      |
| Hepatic enzyme increased                | 2 (0.1)                           | 2 (0.1)                |
| Hepatic function abnormal               | 2 (0.1)                           | 1 (≤0.1)               |
| Hepatitis toxic                         | 2 (0.1)                           | 0                      |
| Autoimmune hepatitis                    | 1 (≤ 0.1)                         | 0                      |
| Hepatic mass                            | 1 (≤0.1)                          | 0                      |
| Hepatic pain                            | 1 (≤ 0.1)                         | 4 (0.2)                |
| Hepatobiliary disease                   | 1 (≤0.1)                          | 0                      |
| Hepatomegaly                            | 1 (±0.1)                          | 0                      |
| Jaundice                                | 1 (≤ 0.1)                         | 0                      |
| Jaundice cholestatic                    | 1 (± 0.1)                         | 1 (≤0.1)               |
| Liver injury                            | 1 (≤0.1)                          | 0                      |
| Haemangioma of liver                    | 0                                 | 2 (0.1)                |
| Hepatic encephalopathy                  | 0                                 | 1 (≤0.1)               |
| Liver function test increased           | 0                                 | 1 (≤0.1)               |

<div style=\"page-break-after: always\"></div>

| Hepatobiliary toxicity Preferred term               | Ribociclib plus ET N=2525 n (96)   | ET only N=2442 n(96)   |
|-----------------------------------------------------|------------------------------------|------------------------|
| Liver scan abnormal                                 | 0                                  | 1 (≤ 0.1)              |
| CTCAE grade ≥ 3 AEs                                 | 217 (8.6)                          | 42 (1.7)               |
| Alanine aminotransferase increased                  | 192 (7.6)                          | 17 (0.7)               |
| Aspartate aminotransferase increased                | 118 (4.7)                          | 13 (0.5)               |
| Gamma-glutamyltransfersse incressed                 | 26 (1.0)                           | 22 (0.9)               |
| Hepatotoxicity                                      | 7 (0.3)                            | 0                      |
| Blood bilirubin increased                           | 5 (0.2)                            | 1 (≤ 0.1)              |
| Drug-induced liver injury                           | 5 (0.2)                            | 0                      |
| Hepatic cytolysis                                   | 3 (0.1)                            | 1 (≤ 0.1)              |
| Blood alkaline phosphatase increased                | 2 (0.1)                            | 2 (0.1)                |
| Hepatic function abnormal                           | 2 (0.1)                            | 0                      |
| Ascites                                             | 1 (≤ 0.1)                          | 1 (≤ 0.1)              |
| Autoimmune hepatitis                                | 1 (± 0.1)                          | 0                      |
| Bilirubin conjugated increased                      | 1 (≤ 0.1)                          | 0                      |
| Hepatitis toxic                                     | 1 (≤ 0.1)                          | 0                      |
| Hepatobiliary disease                               | 1 (± 0.1)                          | 0                      |
| Hypertransaminasaemia                               | 1 (≤ 0.1)                          | 0                      |
| Jaundice cholestatic                                | 1 (≤ 0.1)                          | 1 (≤ 0.1)              |
| Liver injury                                        | 1 (≤ 0.1)                          | 0                      |
| Hepatic cyst                                        | 0                                  | 1 (≤ 0.1)              |
| Hepatic encephalopathy                              | 0                                  | 1 (≤ 0.1)              |
| SAEs                                                | 26 (1.0)                           | 5 (0.2)                |
| Alanine aminotransferase increased                  | 9(0.4)                             | 0                      |
| Drug-induced liver injury                           | 6 (0.2)                            | 0                      |
| Aspartate aminotransferase increased                | 5 (0.2)                            | 0                      |
| Hepatotoxicity                                      | 5 (0.2)                            | 0                      |
| Ascites                                             | 1 (≤0.1)                           | 1 (≤ 0.1)              |
| Autoimmune hepatitis                                | 1 (≤ 0.1)                          | 0                      |
| Hepatic cytolysis                                   | 1 (≤ 0.1)                          | 1 (≤ 0.1)              |
| Hepatic function sbnormal                           | 1 (≤ 0.1)                          | 0                      |
| Hepatobiliary disease                               | 1 (≤± 0.1)                         | 0                      |
| Jaundice cholestatic                                | 1 (± 0.1)                          | 1 (≤ 0.1)              |
| Liver injury                                        | 1 (± 0.1)                          | 0                      |
| Non-alcoholic steatohepatitis                       | 1 (≤ 0.1)                          | 0                      |
| Hepatic cyst                                        | 0                                  | 1 (≤0.1)               |
| Hepatic encephalopathy                              | 0                                  | 1 (≤ 0.1)              |
| Liver function test increased                       | 0                                  | 1 (≤ 0.1)              |
| AEs leading to discontinuation                      | 225 (8.9)                          | 3 (0.1)                |
| Alanine 3sminotransferase increased                 | 180 (7.1)                          | 2 (0.1)                |
| Aspariate aminotransferase increased                | 71 (2.8)                           | 0                      |
| Hepatotoxicity                                      | 7 (0.3)                            | 0                      |
| Hypertransaminasaemia                               | 4 (0.2)                            | 0                      |
| Blood bilirubin inereased Drug-induced liver injury | 3 (0.1) 3 (0.1)                    | 0                      |

<div style=\"page-break-after: always\"></div>

| Hepatobiliary toxicity Preferred term   | Ribociclib plus ET N=2525 n (9)   | ET only N=2442 n (%)   |
|-----------------------------------------|-----------------------------------|------------------------|
| Gamma-glutamyltransferase increased     | 3 (0.1)                           | 0                      |
| Hepatic cytolysis                       | 2 (0.1)                           | 0                      |
| Bilirubin conjugated increased          | 1 (≤ 0.1)                         | 0                      |
| Hepatic function abnormal               | 1 (≤ 0.1)                         | 0                      |
| Dxol SedeH                              | 1 (≤ 0.1)                         | 0                      |
| Hepatobiliary disease                   | 1 (≤ 0.1)                         | 0                      |
| Hyperbilirubinaemia                     | 1 (≤ 0.1)                         | 1 (≤0.1)               |
| Non-alcoholic steatohepatitis           | 1 (≤ 0.1)                         | 0                      |
| Transaminases increased                 | 1 (≤±0.1)                         | 0                      |
| Hepatic enzyme increased                | D                                 | 1 (≤ 0.1)              |
| AEs leading to dose adjustment          | 66 (2.6)                          | 0                      |
| Alanine aminotransferase increased      | 49 (1.9)                          | 0                      |
| Aspartate aminotransferase increased    | 16 (0.6)                          | 0                      |
| Gamma-glutamyltransferase incre3sed     | 5 (0.2)                           | 0                      |
| Blood bilirubin increased               | 3 (0.1)                           | 0                      |
| Blood alkaline phosphatase increased    | 1 (≤ 0.1)                         | 0                      |
| Hyperbilirubinaemia                     | 1 (≤ 0.1)                         | 0                      |
| Hypertransaminasaemis                   | 1 (≤ 0.1)                         | 0                      |
| AEs leading to dose interruption        | 313 (12.4)                        | 10 (0.4)               |
| Alanine aminotransferase increased      | 255 (10.1)                        | 7 (0.3)                |
| Aspartate aminotransferase increased    | 171 (6.8)                         | 7 (0.3)                |
| Gamma-glutamyltransferase increased     | 17 (0.7)                          | 3 (0.1)                |
| Blood bilirubin inereased               | 15 (0.6)                          | 0                      |
| Hepatotoxicity                          | 7 (0.3)                           | 0                      |
| Blood alkaline phosphatase increased    | 5 (0.2)                           | 2 (0.1)                |
| Drug-induced liver injury               | 5 (0.2)                           | 0                      |
| Hepatic cytolysis                       | 5 (0.2)                           | 0                      |
| Hypertransaminasaemia                   | 5 (0.2)                           | 0                      |
| Hyperbilirubinaemia                     | 3 (0.1)                           | 0                      |
| Bilirubin conjugated increased          | 2 (0.1)                           | 0                      |
| Hepatitis toxic                         | 2 (0.1)                           | 0                      |
| Autoimmune hepatitis                    | 1 (≤ 0.1)                         | 0                      |
| Hepatic function abnormal               | 1 (≤ 0.1)                         | 0                      |
| Hepatobiliary disease                   | 1 (≤ 0.1)                         | 0                      |
| Non-alcoholic steatohepatitis           | 1 (≤ 0.1)                         | 0                      |

Patients with multiple events in a grouping are counted only once in the grouping. Patients with events in more than 1 category within a grouping are counted once in each of those categories. AESl grouping terms are presented by preferred terms as sorted within the AESl grouping in descending frequency. as reported in the ribociclib plus ET group. MedDRA Version 26.0 has been used for reporting. AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

<div style=\"page-break-after: always\"></div>

Figure 15. Kaplan-Meier plot of ALT/AST, grade 2 or higher, as time-of-first occurrence by treatment group in Study O12301C (Safety set based on cut-off date 11-Jan-2023)

<!-- image -->

Table 52. Side-by side comparison of Hepatobiliary toxicity AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset          |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|-----------------------------|
| Hepatobiliary toxicity           | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% C1 | PBO +ET N=818 n (%): 95% C1 |
| Total no. patients               | 641 (25.4): 23.7, 27.1                  | 260 (10.6): 9.4, 11.9        | 291 (27.3): 24.7, 30.1               | 160 (19.6): 16.9, 22.4      |
| Grade 2 3                        | 209 (8.3): 7.2.9.4                      | 37 (1.5): 1.1, 2.1           | 141 (13.2): 11.3.15.4                | 50 (6.1): 4.6,8.0           |
| SAEs                             | 27 (1.1): 0.7, 1.6 0                    | 4 (0.2): 0.0,0.4 0           | 30 (2.8): 1.9,4.0 3 (0.3):           | 7 (0.9): 0.3. 1.8 3(0.4):   |
| AEs with fatal outcome           |                                         |                              | 0.1, 0.8                             | 0.1, 1.1                    |
| AEs leading to discontinuation   | 225 (8.9): 7.8, 10.1                    | 3 (0.1): 0.0, 0.4            | 69 (6.5): 5.1,8.1                    | 12 (1.5): 0.8,2.5           |
| AEs leading to dose adjustment   | 62 (2.5): 1.9, 3.1                      | 0                            | 36 (3.4): 2.4,4.6                    | 10 (1.2): 0.6,2.2           |
| AEs leading to dose interruption | 303 (12.0): 10.8.13.3                   | 7 (0.3): 0.1, 0.6            | 121(11.4): 9.5,13.4                  | 36 (4.4): 3.1, 6.0          |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

Hepatobiliary toxicity AESI were reported more frequently in the ribociclib plus ET group (all grades, 26.4% and grade ≥ 3, 8.6%) relative to the ET only group (11.2% and 1.7%, respectively). Most of these events were increased ALT (all grades: 19.5% vs. 5.6%) and increased AST (16.9% vs. 5.7%).

The ALT/AST increased events were managed with protocol dose management guidance specific for hepatotoxicity. Few of these presented as SAE (increased ALT: 0.4% vs. 0; increased AST: 0.2% vs. 0).

<div style=\"page-break-after: always\"></div>

Discontinuation of study treatment due to hepatobiliary toxicity events occurred in 8.9% of patients in the ribociclib plus ET group; predominantly due to increased ALT (7.1%) and increased AST (2.8%). In the ribociclib plus ET group, study treatment dose adjustments and dose interruptions were required for 66 patients (2.6%) and 313 patients (12.4%), respectively; again, primarily due to AEs of ALT increased and AST increased.

There were 9 patients (0.4%) in the ribociclib plus ET group who presented DILI. Of these 9, 6 patients (0.2%) were considered to have experienced serious DILI events and 5 patients (0.2%) had ≥ grade 3. Five patients had study treatment with ribociclib plus ET interrupted due to DILI, and 3 patients (0.1%) ultimately discontinued treatment due to DILI. As of DCO (21-Jul-2023), the reported DILI events were resolved in all patients, excluding 1 patient.

## Renal toxicity

Table 53. Clinical impact of Renal toxicity AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Renal toxicity Preferred term        | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|--------------------------------------|-----------------------------------|------------------------|
| All AEs                              | 152 (6.0)                         | 58 (2.4)               |
| Blood creatinine increased           | 98 (3.9)                          | 22 (0.9)               |
| Glomerular filtration rate decreased | 42 (1.7)                          | 11 (0.5)               |
| Blood urea increased                 | 27 (1.1)                          | 28 (1.1)               |
| Acute kidney injury                  | 7 (0.3)                           | 3 (0.1)                |
| Renal impairment                     | 6 (0.2)                           | 1 (≤ 0.1)              |
| Renal failure                        | 4(0.2)                            | 4 (0.2)                |
| Creatinine renal clearance decreased | 2 (0.1)                           | 0                      |
| Azotaemia                            | 1 (≤ 0.1)                         | 0                      |
| Nephritis                            | 1(≤ 0.1)                          | 0                      |
| Oliguria                             | 1 (≤ 0.1)                         | 0                      |
| Prerenal failure:                    | 1 (≤0.1)                          | 口                      |
| Proteinunia                          | 1 (≤ 0.1)                         | 0                      |
| Tubulointerstitial nephritis         | 1 (≤0.1)                          | 0                      |
| Blood creatinine sbnormal            | 0                                 | 1 (≤ 0.1)              |
| Hypercreatininaemia                  | D                                 | 2 (0.1)                |
| CTCAE grade 2 3 AEs                  | 7 (0.3)                           | 0                      |
| Blood creatinine increased           | 3 (0.1)                           | 口                      |
| Acute kidney injury                  | 2 (0.1)                           | 0                      |
| Glomerular filtration rate decreased | 2 (0.1)                           | 0                      |
| SAEs                                 | 2 (0.1)                           | 1 (≤ 0.1)              |
| Acute kidney injury                  | 1 (≤ 0.1)                         | 1 (≤ 0.1)              |
| Blood creatinine increased           | 1 (≤ 0.1)                         | 0                      |
| AEs leading to discontinuation       | 9 (0.4)                           | 0                      |
| Blood creatinine increased           | 8 (0.3)                           | 0                      |
| Glomerular filtration rate decreased | 1 (≤ 0.1)                         | 0                      |

<div style=\"page-break-after: always\"></div>

| Renal toxicity Preferred term        | Ribociclib plus ET N=2525 n (%6)   | ET only N=2442 n(96)   |
|--------------------------------------|------------------------------------|------------------------|
| AEs leading to dose adjustment       | 4 (0.2)                            | 0                      |
| Blood crestinine increased           | 2 (0.1)                            |                        |
| Glomerular filtration rate decreased | 1 (≤ 0.1)                          |                        |
| Renal impairment                     | 1 (≤ 0.1)                          | 0                      |
| AEs leading to dose interruption     | 22 (0.9)                           | 0                      |
| Blood creatinine increased           | 13 (0.5)                           | 0                      |
| Glomerular filtration rate decreased | 5 (0.2)                            | 0                      |
| Renal impairment                     | 2 (0.1)                            | 0                      |
| Aoute kidney injury                  | 1 (≤ 0.1)                          | 0                      |
| Prerenal failure                     | 1 (≤ 0.1)                          | 0                      |
| Renal failure                        | 1 (≤ 0.1)                          |                        |

Patients with multiple events in a grouping are counted only once in the grouping. Patients with events in more than 1 category within a grouping are counted once in each of those categories. AESl grouping terms are presented by preferred terms as sorted within the AESl grouping in descending frequency. as reported in the ribociclib plus ET group. MedDRA Version 26.0 has. been used for reporting. AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

Table 54. Side0by-side comparison of Renal toxicity AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                  | Pooled aBC Dataset         |
|----------------------------------|-----------------------------------------|------------------------------|-------------------------------------|----------------------------|
| Renal toxicity                   | Ribociclib plus ET N=2524 n (%): 95% CI | ET only N=2444 n (%): 95% CI | Ribociclib +ET N=1065 n (%): 95% CI | PBO+ET N=818 n (%): 95% CI |
| Total no. patients               | 144 (5.7): 4.8, 6.7                     | 49 (2.0): 1.5, 2.6           | 122 (11.5): 9.6, 13.5               | 34 (4.2): 2.9,5.8          |
| Grade ≥3                         | 7 (0.3): 0.1, 0.6                       | 0                            | 14 (1.3): 0.7, 2.2                  | 7 (0.9): 0.3, 1.8          |
| SAEs                             | 3 (0.1): 0.0, 0.3                       | 0                            | 16 (1.5): 0.9.2.4                   | 5 (0.6): 0.2.1.4           |
| AEs with fatal outcome           | 0                                       | 0                            | 0                                   | 0                          |
| AEs leading to discontinuation   | 7 (0.3): 0.1, 0.6                       | 0                            | 7 (0.7): 0.3, 1.3                   | 1 (0.1): 0.0, 0.7          |
| AEs leading to dose adjustment   | 3 (0.1): 0.0,0.3                        | 0                            | 7 (0.7): 0.3.1.3                    | 2 (0.2): 0.0.0.9           |
| AEs leading to dose interruption | 23 (0.9): 0.6,1.4                       | 0                            | 24 (2.3): 1.4, 3.3                  | 8 (1.0): 0.4,1.9           |

For Study O12301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## QT interval prolongation

Table 55. Clinical impact of QT interval prolongation AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off)

| QT interval prolongation Preferred term      | Ribociclib plus ET N=2525 n (96)   | ET only N=2442 n (%)   |
|----------------------------------------------|------------------------------------|------------------------|
| AllAEs                                       | 134 (5.3)                          | 34 (1.4)               |
| Electrocardiogram QT prolonged               | 109 (4.3)                          | 18 (0.7)               |
| Syncope                                      | 17 (0.7)                           | 14 (0.6)               |
| Loss of consciousness                        | 4 (0.2)                            | 1 (≤ 0.1)              |
| Cardiac arrest                               | 1 (± 0.1)                          | 0                      |
| Electrocardiogram repolarisation abnommality | 1 (≤ 0.1)                          | 1 (≤ 0.1)              |
| Long QT syndrome                             | 1 (± 0.1)                          | 0                      |
| Ventricular tachycardia                      | 1 (≤ 0.1)                          | 0                      |
| CTCAE grade23 AEs                            | 26 (1.0)                           | 15 (0.6)               |
| Syncope                                      | 17 (0.7)                           | 14 (0.6)               |
| Electrocardiogram QT prolonged               | 7 (0.3)                            | 1 (≤ 0.1)              |
| Cardiac arrest                               | 1 (≤ 0.1)                          | 0                      |
| Loss of consciousness                        | 1(≤ 0.1)                           | 0                      |
| SAEs                                         | 5 (0.2)                            | 2 (0.1)                |
| Syncope                                      | 4 (0.2)                            | 2 (0.1)                |
| Cardiac arrest                               | 1 (±0.1)                           | 0                      |
| AEs leading to discontinuation               | 10 (0.4)                           | 0                      |
| Electrocardiogram QT prolonged               | 7 (0.3)                            | 0                      |
| Syncope                                      | 2 (0.1)                            | 0                      |
| Ventricular tachycardia                      | 1 (± 0.1)                          | 0                      |
| AEs leading to dose adjustment               | 3 (0.1)                            | 0                      |
| Electrocardiogram QT prolonged               | 3 (0.1)                            | 0                      |
| AEs leading to dose interruption             | 28 (1.1)                           | 0                      |
| Electrocardiogram QT prolonged               | 21 (0.8)                           | 0                      |
| Syncope                                      | 7 (0.3)                            | 0                      |
| AEs leading to death                         | 1 (≤ 0.1)                          | 0                      |
| Cardiac arrest                               | 1 (≤ 0.1)                          | 0                      |

Patients with multiple events in a grouping are counted only once in the grouping.

MedDRA Version 26.0 has been used for reporting.

Patients with events in more than 1 category within a grouping are counted once in each of those categories. AESl grouping terms are presented by preferred tems as sorted within the AEsl grouping in descending frequency. 3s reported in the ribociclib plus ET group.

AESl crouoinos Der eCRS released bv Novartis dated 26-Auo-2023.

<div style=\"page-break-after: always\"></div>

Table 56. Notable ECG values (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Notable laboratory category    | Ribociclib plus ET N=2525 n/m (%)   | ET only N=2442 n/m (%)   | Total N=4967 n/m (%6)   |
|--------------------------------|-------------------------------------|--------------------------|-------------------------|
| QTcF                           |                                     |                          |                         |
| New value > 450                | 240/2477 (9.7)                      | 87/2365 (2.8)            | 307/4842 (6.3)          |
| New value ? 480                | 10/2493 (0.4)                       | 4/2378 (0.2)             | 14/4871 (0.3)           |
| New value >500                 | 3/2493 (0.1)                        | 1/2378 (0.1)             | 4/4871 (0.1)            |
| Increase from baseline of>30   | 466/2493 (18.7)                     | 167/2378 (7.0)           | 833/4871 (13.0)         |
| Increase from baseline: of *60 | 19/2493 (0.8)                       | 2/2378 (0.1)             | 21/4871 (0.4)           |

Patienis are counted based on any notable ECG post-baseline value.

EcG sssessments based on central laboratory resulis only.

Baseline is defined as the last assessment on or before start of study treatment. For anyreplicate/triplicate ECGs per time point, the average of these measurements would be calculated for baseline.

n=Number of patients who meet the designated criterion.

m=Number of patienis at risk for 3 specific category. For new abnormality post-baseline, this is the number of patienis with both baseline and post-baseline evaluations, and baseline not meeting the criteria. For abnormal change from baseline, it is the number of patients with both baseline and post-baseline evaluations.

N=Total number of patients in the treatment group in this analysis set.

Table 57. Side-by-side comparison of QT interval prolongation AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset         |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|----------------------------|
| QT interval prolongation         | Ribociclib plus ET N=2524 n (%): 95% CI | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% CI | PBO+ET N=818 n (%): 95% CI |
| Total no. patients               | 132 (5.2): 4.4,6.2                      | 30 (1.2): 0.8, 1.7           | 99 (9.3): 7.6,11.2                   | 29 (3.5): 2.4, 5.1         |
| Grade ≥3                         | 25 (1.0): 0.6, 1.5                      | 13 (0.5): 0.3, 0.9           | 34 (3.2): 2.2,4.4                    | 11 (1.3): 0.7,2.4          |
| SAEs                             | 6 (0.2): 0.1, 0.5                       | 1 (< 0.1): 0.0,0.2           | 13 (1.2): 0.7, 2.1                   | 3 (0.4): 0.1, 1.1          |
| AEs with fatal outcome           | 1(≤0.1): 0.0, 0.2                       | 0                            | 3 (0.3): 0.1.0.8                     | 0                          |
| AEs leading to discontinuation   | 11 (0.4) 0.2,0.8                        | 0                            | 5 (0.5): 0.2, 1.1                    | 3 (0.4): 0.1, 1.1          |
| AEs leading to dose adjustment   | 3 (0.1): 0.0, 0.3                       | 0                            | 15 (1.4): 0.8,2.3                    | 2 (0.2) 0.0, 0.9           |
| AEs leading to dose interruption | 28 (1.1): 0.7, 1.6                      | 0                            | 20 (1.9): 1.2,2.9                    | 3 (0.4): 0.1, 1.1          |

For Study O12301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reportinq and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## 2.5.3.5.3. Second primary malignancies

Table 58. Clinical impact of Second primary malignancies AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Second primary malignancies Preferred term   | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n(%)   |
|----------------------------------------------|-----------------------------------|-----------------------|
| AllAEs                                       | 48 (1.9)                          | 49 (2.0)              |
| Meningioma                                   | 5 (0.2)                           | 1 (≤ 0.1)             |
| Papillary thyroid cancer                     | 5 (0.2)                           | 2 (0.1)               |
| Malignant melanoma in situ                   | 4 (0.2)                           | 1 (≤ 0.1)             |
| Malignant melanoma                           | 3 (0.1)                           | 0                     |
| Intraductal proliferative: breast lesion     | 2 (0.1)                           | 2 (0.1)               |
| Aoute myeloid leukaemia                      | 1 (≤ 0.1)                         | 3 (0.1)               |
| Adenocsrcinoma of colon                      | 1 (± 0.1)                         | 2 (0.1)               |
| Basal cell carcinoma                         | 1 (≤ 0.1)                         | 7 (0.3)               |
| Benign lymph node neoplasm                   | 1 (± 0.1)                         | 0                     |
| Bladder transitional cell carcinoma          | 1 (± 0.1)                         | 3 (0.1)               |
| Bowen's disease                              | 1 (≤0.1)                          | 1 (≤ 0.1)             |
| Breast neoplasm                              | 1 (± 0.1)                         |                       |
| Clear cell renal cell carcinoma              | 1 (≤ 0.1)                         | 0                     |
| Colon cancer stage 0                         | 1 (≤ 0.1)                         | 0                     |
| Colon cancer stage l                         | 1 (± 0.1)                         | 0                     |
| Colorectal cancer stage l                    | 1 (≤ 0.1)                         | 0                     |
| Colorectal carcinoma stage 0                 | 1 (± 0.1)                         | 0                     |
| Ductal adenocarcinoma of pancre3s            | 1 (≤ 0.1)                         | 0                     |
| Endometrial stromal sarcoma                  | 1 (≤ 0.1)                         | 0                     |
| Fallopian tube cancer                        | 1 (≤ 0.1)                         | 0                     |
| Glioblastoma                                 | 1 (≤ 0.1)                         | 0                     |
| Glioma                                       | 1 (≤ 0.1)                         | 0                     |
| Lip andlor oral cavity cancer recurrent      | 1 (≤± 0.1)                        | 0                     |
| Malignant sweat gland neoplasm               | 1(≤ 0.1)                          | 0                     |
| Medullary thyroid cancer                     | 1 (≤ 0.1)                         | 0                     |
| Mucinous sdenocarcinoma of appendix          | 1 (≤ 0.1)                         | 0                     |
| Nasopharyngeal cancer                        | 1 (± 0.1)                         |                       |
| Neuroendocrine tumour                        | 1 (≤ 0.1)                         | 0                     |
| Ovarian epithelial cancer                    | 1 (± 0.1)                         |                       |
| Ovarian neoplasm                             | 1 (≤ 0.1)                         | 0                     |
| Pancreatic carcinoma                         | 1 (≤ 0.1)                         | 0                     |
| Rectal adenocarcinoma                        | 1 (± 0.1)                         | 1 (≤ 0.1)             |
| Rectosigmoid cancer                          | 1 (≤ 0.1)                         | 0                     |
| Renal cancer                                 | 1(≤ 0.1)                          | 1 (≤ 0.1)             |

<div style=\"page-break-after: always\"></div>

| Second primary malignancies Preferred term       | Ribociclib plus ET N=2525 n (96)   | ET only N=2442 n (%)   |
|--------------------------------------------------|------------------------------------|------------------------|
| Squamous cell carcinoma                          | 1 (≤ 0.1)                          | 0                      |
| Squamous cell carcinoma of skin                  | 1 (≤ 0.1)                          | 0                      |
| Squamous cell carcinoma of the cervix            | 1 (≤ 0.1)                          | 0                      |
| Acute promyelocytic leukaemia                    | 0                                  | 1(≤ 0.1)               |
| Adenocarcinoma gastric                           | 0                                  | 1 (≤ 0.1)              |
| Cervix carcinoma stage 0                         |                                    | 1 (≤ 0.1)              |
| Chromophobe renal cell carcinoma                 | 0                                  | 1 (≤0.1)               |
| Colon cancer                                     | 0                                  | 1 (≤ 0.1)              |
| Colon cancer stage ll                            |                                    | 1 (< 0.1)              |
| Cutaneous lymphoma                               | 0                                  | 1 (≤ 0.1)              |
| Endometrial cancer                               | 0                                  | 1 (± 0.1)              |
| Exiramammary Paget's disease                     | 0                                  | 1 (≤ 0.1)              |
| Gastric cancer                                   | 0                                  | 1 (≤0.1)               |
| Gastrointestinal stromal tumour                  | 0                                  | 1 (≤ 0.1)              |
| Invasive ductal breast carcinoma                 |                                    | 1 (≤ 0.1)              |
| Lung adenocarcinoma                              | 0                                  | 1 (≤ 0.1)              |
| Malignant melanoma stage I                       |                                    | 1 (≤ 0.1)              |
| Myelodysplastic syndrome                         | 0                                  | 3 (0.1)                |
| Oesophageal adenocarcinoma                       | 0                                  | 1(≤0.1)                |
| Owarian cancer                                   |                                    | 1 (<≤0.1)              |
| Ovarian clear cell carcinoma                     | 0                                  | 1(≤ 0.1)               |
| Plasma cell myeloma                              | 0                                  | 1(≤ 0.1)               |
| Recial cancer                                    |                                    | 1 (≤± 0.1)             |
| Renal cell carcinoma                             | 0                                  | 1 (≤ 0.1)              |
| Squamous cell carcinoma of lung                  | 0                                  | 1 (≤0.1)               |
| Superficial spreading melanoma stage unspecified |                                    | 2 (0.1)                |
| CTCAE grade2 3 AEs                               | 30 (1.2)                           | 30 (1.2)               |
| SAEs                                             | 33 (1.3)                           | 34 (1.4)               |
| AEs leading to discontinuation                   | 25 (1.0)                           | 17 (0.7)               |
| AEs leading to dose interruption                 | 11 (0.4)                           | 9 (0.4)                |

Patients with multiple events in a grouping are counted only once in the grouping.

AESl grouping terms are presented by preferred terms as sorted within the AESl grouping in descending

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

frequency. as reported in the ribociclib plus ET group.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

MedDRA Version 26.0 has been used for reporting.

<div style=\"page-break-after: always\"></div>

## 2.5.3.5.4. ILD / pneumonitis

Table 59. Clinical impact of ILD / Pneumonitis AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set )

|                                  | Ribociclib plus ETET only   | Ribociclib plus ETET only   |
|----------------------------------|-----------------------------|-----------------------------|
| ILD/Pneumonitis Preferred term   | N=2525 n (%)                | N=2442 n (%)                |
| All AEs                          | 39 (1.5)                    | 22 (0.9)                    |
| Pneumonitis                      | 16 (0.6)                    | 9 (0.4)                     |
| Pulmonary fibrosis               | 7 (0.3)                     | 7 (0.3)                     |
| Radiation pneumonitis            | 6 (0.2)                     | 2 (0.1)                     |
| Lung opacity                     | 3 (0.1)                     | 0                           |
| Lung infiltration                | 2 (0.1)                     | 0                           |
| Bronchiolitis                    | 1 (≤ 0.1)                   | 1 (≤ 0.1)                   |
| Cystic lung disease              | 1 (≤ 0.1)                   | 2 (0.1)                     |
| Interstitial lung disease        | 1 (± 0.1)                   | 0                           |
| Pulmonary radiation injury       | 1 (≤ 0.1)                   | 1 (≤ 0.1)                   |
| Pulmonary sarcoidosis            | 1 (≤ 0.1)                   | 0                           |
| Radiation fibrosis - lung        | 1 (≤± 0.1)                  | 1 (≤0.1)                    |
| Sarcoidosis                      | 0                           | 1 (≤ 0.1)                   |
| CTCAE grade23AEs                 | 0                           | 2 (0.1)                     |
| Pneumonitis                      | 0                           | 1 (≤ 0.1)                   |
| Pulmonary radiation injury       | 0                           | 1 (≤± 0.1)                  |
| Radiation fibrosis - lung        | 0                           | 1 (≤ 0.1)                   |
| SAEs                             | 1 (≤ 0.1)                   | 1 (≤0.1)                    |
| Pneumonitis                      | 1 (≤ 0.1)                   | 0                           |
| Pulmonary radiation injury       | 0                           | 1 (≤ 0.1)                   |
| Radiation fibrosis - lung        | 0                           | 1 (≤0.1)                    |
| AEsleading to discontinuation    | 6 (0.2)                     | 0                           |
| Pneumonitis                      | 5 (0.2)                     | 0                           |
| Radiation pneumonitis            | 1 (≤ 0.1)                   | 0                           |
| AEs leading to dose interruption | 4 (0.2)                     | 0                           |
| Bronchiolitis                    | 1 (≤± 0.1)                  | 0                           |
| Pneumonitis                      | 1 (± 0.1)                   | 0                           |
| Pulmonary fibrosis               | 1 (≤ 0.1)                   | 0                           |
| Radiation pneumonitis            | 1 (≤ 0.1)                   | 0                           |
|                                  | Ribociclib plus ET ET only  | Ribociclib plus ET ET only  |
| ILD/ Pneumonitis                 | N=2525                      | N=2442                      |
| Preferred term                   | n (%)                       | n (%)                       |

Patients with multiple events in a grouping are counted only once in the grouping.

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

AESl grouping terms are presented by preferred terms as sorted within the AESl grouping in descending frequency, as reported in the ribociclib plus ET group.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

MedDRA Version 26.0 has been used for reporting.

<div style=\"page-break-after: always\"></div>

Table 60. Side-by-side comparison of ILD/pneumonitis AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                 | Pooled aBC Dataset                   | Pooled aBC Dataset          |
|----------------------------------|-----------------------------------------|-------------------------------|--------------------------------------|-----------------------------|
| ILD / pneumonitis                | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%6): 95% C1 | Ribociclib + ET N=1065 n (%): 95% C1 | PBO +ET N=818 n (%): 95% CI |
| Total no. patients               | 39 (1.5): 1.1, 2.1                      | 19 (0.8): 0.5, 1.2            | 17 (1.6): 0.9, 2.5                   | 5 (0.6): 0.2, 1.4           |
| Grade ≥ 3                        | 0                                       | 2(0.1): 0.0,0.3               | 4 (0.4): 0.1, 1.0                    | 0                           |
| SAEs                             | 1 (≤ 0.1): 0.0.0.2                      | 1 (≤ 0.1): 0.0,0.2            | 1 (0.1): 0.0,0.5                     | 0                           |
| AEswithfatal outcome             | 0                                       | 0                             | 1 (0.1): 0.0,0.5                     | 0                           |
| AEs leading to discontinuation   | 6 (0.2): 0.1.0.5                        | 0                             | 5 (0.5): 0.2, 1.1                    | 0                           |
| AEs leading to dose adjustment   | 0                                       | 0                             | 1 (0.1): 0.0,0.5                     | 0                           |
| AEs leading to dose interruption | 3 (0.1): 0.0,0.3                        | 0                             | 3 (0.3): 0.1.0.8                     | 1 (0.1): 0.0,0.7            |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

## 2.5.3.5.5. Reproductive toxicity

Table 61. Clinical impact of Reproductive toxicity AESI by preferred term, irrespective of causality (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

| Reproductive toxicity Preferred term   | Ribociclib plus ET N=2525 n196)   | ET only N=2442 n (%)   |
|----------------------------------------|-----------------------------------|------------------------|
| All AEs                                | 32 (1.3)                          | 27 (1.1)               |
| Mastitis.                              | 27 (1.1)                          | 19 (0.8)               |
| Aocessory spleen                       | 1 (≤ 0.1)                         | 0                      |
| Dermoid cyst                           | 1(≤ 0.1)                          | 0                      |
| Omphalitis                             | 1(≤0.1)                           | 1 (≤ 0.1)              |
| Polycystic liver disease               | 1 (≤ 0.1)                         | 0                      |
| Retracted nipple                       | 1(≤0.1)                           | 1 (± 0.1)              |
| Sacralisation                          | 1 (≤ 0.1)                         | 0                      |
| BRCA1 gene mutation                    | D                                 | 1 (≤ 0.1)              |
| BRCA2 gene mutation                    | 0                                 | 1(≤ 0.1)               |
| Failure to thrive                      | D                                 | 1 (<0.1)               |
| Fibrous dysplasia of bone              | 0                                 | 1 (≤ 0.1)              |
| Human chorionic gonadotropin increased | 0                                 | 1 (≤ 0.1)              |
| Neurofibromatosis                      | 0                                 | 1 (± 0.1)              |
| Nipple infection                       | 0                                 | 1 (≤0.1)               |
| Renal arteriovenous malformation       | 0                                 | 1 (± 0.1)              |
| CTCAE grade 2 3 AEs                    | 8 (0.3)                           | 7 (0.3)                |
| Mastitis                               | 7 (0.3)                           | 5 (0.2)                |
| Polycystic liver disease               | 1 (≤0.1)                          | 0                      |
| Failure to thrive                      | 0                                 | 1 (≤ 0.1)              |
| Renal arteriovenous malformation       | 0                                 | 1 (≤ 0.1)              |
| SAEs                                   | 5 (0.2)                           | 5 (0.2)                |
| Mastitis                               | 4 (0.2)                           | 2 (0.1)                |
| Polycystic liver disease               | 1 (≤ 0.1)                         | 0                      |

<div style=\"page-break-after: always\"></div>

| Reproductive toxicity Preferred term   | Ribociclib plus ET N=2525 n(%)   | ET only N=2442 n (96)   |
|----------------------------------------|----------------------------------|-------------------------|
| BRCA1 gene mutation                    | 0                                | 1 (≤ 0.1)               |
| BRCA2 gene mutation                    | 0                                | 1 (≤ 0.1)               |
| Failure to thrive                      | 0                                | 1 (≤ 0.1)               |
| Renal arteriovenous malformation       | 0                                | 1 (± 0.1)               |
| AEs leading to discontinuation         | 2 (0.1)                          | 1 (<0.1)                |
| Mastitis                               | 2 (0.1)                          | 0                       |
| BRCA1 gene mutation                    | 0                                | 0.1)]                   |
| BRCA2 gene mutation                    | 0                                | 1 (±0.1)                |
| AEs leading to dose interruption       | 12 (0.5)                         | 1 (≤ 0.1)               |
| Mastitis                               | 12 (0.5)                         | 1 (≤0.1)                |

Budnobi ay ui aouo Auo paunoo aie buidnob e ui sjuana aldnnw yw siuaed

Patients with events in more than 1 category within a grouping are counted once in each of those categories.

frequency. as reported in the ribociclib plus ET group.

AESl groupings per eCRS released by Novartis dated 26-Aug-2023.

MedDRA Version 26.0 has been used for reporting.

Table 62. Side-by-side comparison of Reproductive toxicity AESI by AE categories of Study O12301C vs. Pooled aBC Dataset (Safety set based on cut-off date 11-Jan-2023)

|                                  | Study 012301C                           | Study 012301C                | Pooled aBC Dataset                   | Pooled aBC Dataset           |
|----------------------------------|-----------------------------------------|------------------------------|--------------------------------------|------------------------------|
| Reproductive toxicity            | Ribociclib plus ET N=2524 n (%): 95% C1 | ET only N=2444 n (%): 95% CI | Ribociclib + ET N=1065 n (%): 95% C1 | PBO + ET N=818 n (%): 95% CI |
| Total no. patients               | 32 (1.3): 0.9, 1.8                      | 25 (1.0): 0.7, 1.5           | 6 (0.6): 0.2, 1.2                    | 6 (0.7): 0.3, 1.6            |
| Grade 2 3                        | 8(0.3): 0.1.0.6                         | 5 (0.2): 0.1, 0.5            | 1 (0.1): 0.0,0.5                     | 0                            |
| SAEs                             | 5 (0.2): 0.1.0.5                        | 4 (0.2): 0.0.0.4             | 0                                    |                              |
| AEs with fatal outcome           | 0                                       | 0                            | 0                                    | 0                            |
| AEs leading to discontinuation   | 2 (0.1): 0.0,0.3                        | 1 (≤0.1): 0.0,0.2            | 0                                    | 0                            |
| AEs leading to dose adjustment   | 0                                       | 0                            | 0                                    | 0                            |
|                                  | 12 (0.5):                               | 1 (≤ 0.1):                   | 1 (0.1):                             | 0                            |
| AEs leading to dose interruption | 0.2.0.8                                 | 0.0.0.2                      | 0.0,0.5                              |                              |

For Study 012301C MedDRA Version 25.1 is used for reporting and eCRS dated 16-Dec-2022. For the Pooled aBC Dataset, MedDRA Version 24.0 is used for reporting and eCRS dated 16-Jun-2021.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Serious adverse event/deaths/other significant events

## 2.5.4.1. Serious adverse events

Table 63. Serious adverse events by preferred term, irrespective of causality ( ≥ 3 patients / either group) (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                        | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | ET only N=2442    | ET only N=2442   | ET only N=2442   | ET only N=2442   |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------|------------------|------------------|------------------|
| Preferred term                         | All grades n (%)            | Grade 3 n (%)               | Grade 4 n (%)               | Grade 5 n (%)               | All grades n (9%) | Grade 3 n (%)    | Grade 4 n (%)    | Grade 5 n (%)    |
| No. patients with at least 1 TEAE      | 357 (14.1)                  | 252 (10.0)                  | 44 (1.7)                    | 11 (0.4)                    | 256 (10.5)        | 192 (7.9)        | 26 (1.1)         | 4 (0.2)          |
| COVID-19                               | 20 (0.8)                    | 13 (0.5)                    | 0                           | 3 (0.1)                     | 13 (0.5)          | 9 (0.4)          | 0                | 1 (≤0.1)         |
| Pulmonary embolism                     | 15 (0.6)                    | 11 (0.4)                    | 1 (±0.1)                    | 2 (0.1)                     | 5 (0.2)           | 5 (0.2)          | 0                | 0                |
| Pneumonia                              | 14 (0.6)                    | 12 (0.5)                    | 0                           | 0                           | 9 (0.4)           | 7 (0.3)          | 0                | 0                |
| Dyspnoea                               | 12 (0.5)                    | 9(0.4)                      | 0                           | 0                           | 5 (0.2)           | 3 (0.1)          | 0                | 0                |
| COVID-19 pneumonia                     | 9 (0.4)                     | 5 (0.2)                     | 0                           | 3 (0.1)                     | 5 (0.2)           | 4 (0.2)          | 1 (≤0.1)         | 0                |
| Breast cellulitis                      | 9(0.4)                      | 9(0.4)                      | 0                           | 0                           | 3 (0.1)           | 3 (0.1)          | 0                | 0                |
| Alanine aminotransferase increased     | 9(0.4)                      | 1 (≤ 0.1)                   | 7 (0.3)                     | 0                           | 0                 | 0                | 0                | 0                |
| Humerus fracture                       | 8 (0.3)                     | 7 (0.3)                     | 0                           | 0                           | 4 (0.2)           | 3 (0.1)          | 0                | 0                |
| Atrial fibrillation                    | 7 (0.3)                     | 5 (0.2)                     | 1 (≤ 0.1)                   | 0                           | 8 (0.3)           | 7 (0.3)          | 0                |                  |
| Celluliftis                            | 7 (0.3)                     | 7 (0.3)                     | 0                           | 0                           | 6 (0.2)           | 6 (0.2)          | 0                | 0                |
| Cholelithiasis                         | 7 (0.3)                     | 6 (0.2)                     | 1 (±0.1)                    | 0                           | 5 (0.2)           | 5 (0.2)          | 0                | 0                |
| Pyrexia                                | 7 (0.3)                     | 2 (0.1)                     | 0                           | 0                           | 1 (≤ 0.1)         | 1 (≤ 0.1)        | 0                | 0                |
| Urinary tract infection                | 6 (0.2)                     | 6 (0.2)                     | 0                           | 0                           | 3 (0.1)           | 3 (0.1)          | 0                | 0                |
| Drug-induced liver injury              | 6 (0.2)                     | 2 (0.1)                     | 3 (0.1)                     | 0                           | 0                 | 0                | 0                | 0                |
| Papillary thyroid cancer               | 5 (0.2)                     | 5 (0.2)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Postoperative wound infection          | 5 (0.2)                     | 5 (0.2)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Aspartate aminotransferase increased   | 5 (0.2)                     | 2 (0.1)                     | 3 (0.1)                     | 0                           | 0                 | 0                | 0                | 0                |
| Hepatotoxicity                         | 5 (0.2)                     | 3 (0.1)                     | 2 (0.1)                     | 0                           | 0                 | 0                | 0                | 0                |
| Cerebrovascular accident               | 5 (0.2)                     | 2 (0.1)                     | 0                           | 0                           | 1 (≤ 0.1)         | 0                | 1 (≤ 0.1)        | 0                |
| Diarrhoea                              | 5 (0.2)                     | 3 (0.1)                     | 0                           | 0                           | 0                 | 0                | 0                | 0                |
| Osteoarthritis                         | 4 (0.2)                     | 4 (0.2)                     | 0                           | 0                           | 4 (0.2)           | 4 (0.2)          | 0                | 0                |
| Appendicitis                           | 4 (0.2)                     | 3 (0.1)                     | 1 (± 0.1)                   | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Syncope                                | 4 (0.2)                     | 4 (0.2)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
|                                        | Ribociclib plus ET          | Ribociclib plus ET          | Ribociclib plus ET          | Ribociclib plus ET          | ET only           | ET only          | ET only          | ET only          |
|                                        | N=2525                      | N=2525                      | N=2525                      | N=2525                      | N=2442            | N=2442           | N=2442           | N=2442           |
| Preferred term                         | All grades n (%)            | Grade 3 n (9%)              | Grade 4 n (%)               | Grade 5 n (%6)              | All grades n (%)  | Grade 3 n (%)    | Grade 4 n (96)   | Grade 5 n (9%)   |
| Acute myocardial infarction            | 4 (0.2)                     | 1 (≤0.1)                    | 3 (0.1)                     | 0                           | 0                 | 0                | 0                | 0                |
| Erysipelas                             | 4 (0.2)                     | 2 (0.1)                     | 0                           | 0                           | 3 (0.1)           | 2 (0.1)          | 0                | 0                |
| Mastitis                               | 4 (0.2)                     | 2 (0.1)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Pneumonia viral                        | 4 (0.2)                     | 0                           | 0                           | 0                           | 3 (0.1)           | 1 (≤ 0.1)        | 0                | 0                |
| Suspected COVID-19                     | 4 (0.2)                     | 0                           | 0                           | 0                           | 1 (≤0.1)          | 0                | 0                | 0                |
| Lymphoedema                            | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                |                  |
| Pyelonephritis                         | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Radius fracture                        | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 2 (0.1)           | 2 (0.1)          | 0                | 0                |
| Breast fibrosis                        | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 1 (≤±0.1)         | 1 (≤ 0.1)        | 0                | 0                |
| Cholecystitis acute                    | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 1 (<0.1)          | 1 (≤ 0.1)        | 0                | 0                |
| Urosepsis                              | 3 (0.1)                     | 2 (0.1)                     | 1 (≤ 0.1)                   | 0                           | 1 (≤0.1)          | 1 (≤ 0.1)        | 0                | 0                |
| Anaemia                                | 3 (0.1)                     | 1 (≤ 0.1)                   | 0                           | 0                           | 2 (0.1)           | 1 (≤ 0.1)        | 1 (≤ 0.1)        | 0                |
| Bacteraemia                            | 3 (0.1)                     | 1 (<0.1)                    | 2 (0.1)                     | 0                           | 0                 | 0                | 0                |                  |
| Cholecystilis chronic                  | 3 (0.1)                     | 2 (0.1)                     | 1 (± 0.1)                   | 0                           | 0                 | 0                | 0                | 0                |
| Constipation                           | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 0                 | 0                | 0                | 0                |
| Hypokalaemia                           | 3 (0.1)                     | 3 (0.1)                     | 0                           | 0                           | 0                 | 0                | 0                | 0                |
| Spinal compression fracture            | 3 (0.1)                     | 2 (0.1)                     | 1 (≤ 0.1)                   | 0                           | 0                 | 0                | 0                | 0                |
| Spinal cord compression                | 3 (0.1)                     | 1 (<0.1)                    | 2 (0.1)                     | 0                           | 0                 | 0                | 0                | 0                |
| Malignant melanoma                     | 3(0.1)                      | 2 (0.1)                     | 0                           | 0                           | 0                 | 0                | 0                | 0                |
|                                        | 3 (0.1)                     |                             |                             |                             |                   |                  | 0                |                  |
| Myocardial ischaemia                   |                             | 1 (< 0.1)                   | 0                           | 0                           | 1 (≤ 0.1)         | 1 (≤0.1)         |                  | 0                |
| Foot fracture Device related infection | 3(0.1) 2 (0.1)              | 1 (≤0.1) 1(≤0.1)            | 0 1 (≤± 0.1)                | 0 0                         | 0 3 (0.1)         | 0 3 (0.1)        | 0 0              | 0 0              |
| Post procedural infection              | 2 (0.1)                     | 2 (0.1)                     | 0                           | 0                           | 3 (0.1)           | 3 (0.1)          | 0                | 0                |
| Respiratory failure                    | 2 (0.1)                     | 0                           | 2 (0.1)                     | 0                           | 3 (0.1)           | 0                | 2 (0.1)          | 1 (≤0.1)         |
| Hypertension                           | 2 (0.1)                     | 1 (≤ 0.1)                   | 0                           | 0                           | 3 (0.1)           | 2 (0.1)          | 0                | 0                |
| Cataract                               | 2 (0.1)                     | 0                           | 0                           | 0                           |                   | 2 (0.1)          | 0                | 0                |
| Abdominal pain                         | 1 (≤ 0.1)                   | 1 (≤0.1)                    | 0                           | 0                           | 3 (0.1) 3 (0.1)   | 3 (0.1)          | 0                | 0                |

<div style=\"page-break-after: always\"></div>

|                             | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   |               |               | ET only N=2442   |               |                |              |
|-----------------------------|-----------------------------|-----------------------------|---------------|---------------|------------------|---------------|----------------|--------------|
| Preferred term              | Allgrades n (%)             | Grade 3 n (%)               | Grade 4 n (%) | Grade 5 n (%) | All grades n(%)  | Grade 3 n (%) | Grade 4 n (%6) | Grade5 n (%) |
| Acutemyeloid leukaemia      | 1 (≤0.1)                    | 0                           | 1 (≤ 0.1)     | 0             | 3 (0.1)          | 1 (≤ 0.1)     | 2 (0.1)        | 0            |
| Cardiacfailure congestive   | 1 (≤0.1)                    | 1 (≤ 0.1)                   | 0             | 0             | 3 (0.1)          | 2 (0.1)       | 0              | 1 (≤± 0.1)   |
| Myocardial infarction       | 1 (≤ 0.1)                   | 1 (≤ 0.1)                   | 0             | 0             | 3 (0.1)          | 2 (0.1)       | 0              | 1 (≤ 0.1)    |
| Sepsis                      | 1 (≤ 0.1)                   | 0                           | 1 (≤ 0.1)     | 0             | 3 (0.1)          | 0             | 2 (0.1)        | 1 (≤ 0.1)    |
| Small intestinalobstruction | 1 (<≤ 0.1)                  | 1 (≤ 0.1)                   | 0             | 0             | 3 (0.1)          | 3 (0.1)       | 0              | 0            |
| Depression                  | 0                           | 0                           | 0             | 0             | 3 (0.1)          | 1 (≤ 0.1)     | 2 (0.1)        | 0            |
| Fall                        | 0                           | 0                           | 0             | 0             | 3 (0.1)          | 3 (0.1)       | 0              | 0            |
| Myelodysplastic syndrome    | 0                           | 0                           | 0             | 0             | 3 (0.1)          | 0             | 3 (0.1)        | 0            |

Preferred terms are sorted in descending frequency based on frequency in ribociclib plus ET group.

MedDRA. Version 26.0 has been used for reporting.

## 2.5.4.2. Deaths

Table 64. All deaths by primary reason for death and preferred term (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set

| All death Reason for death             | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n1%)   | Total N=4967 n (%)   |
|----------------------------------------|-----------------------------------|-----------------------|----------------------|
| Total no. of patients who died overall | 83 (3.3)                          | 89 (3.6)              | 172 (3.5)            |
| Primary reason of death                |                                   |                       |                      |
| Diseaserecurrencelprogression          | 58 (2.3)                          | 73 (3.0)              | 131 (2.6)            |
| Adverse event                          | 16 (0.6)                          | 4 (0.2)               | 20 (0.4)             |
| COVID-19                               | 3 (0.1)                           | 1 (≤0.1)              | 4 (0.1)              |
| Cov10-19 pneumonia                     | 3 (0.1)                           | 0                     | 3 (0.1)              |
| Pulmonary embolism                     | 2 (0.1)                           | 0                     | 2 (± 0.1)            |
| Aoute myocardial infarction            | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Brain oedema                           | 1 (≤0.1)                          | 0                     | 1 (≤ 0.1)            |
| Cardiac arrest                         | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Cardio-respiratory arrest              | 1 (≤0.1)                          | 0                     | 1 (≤ 0.1)            |
| Cardiogenic shock                      | 1 (±0.1)                          | 0                     | 1 (≤ 0.1)            |
| Cardiovascular insufficiency           | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Pneumonia                              | 1 (≤0.1)                          | 0                     | 1 (≤ 0.1)            |
| Road traffic accident                  | 1 (≤0.1)                          | 0                     | 1 (≤ 0.1)            |
| Cardiac failure congestive             | 0                                 | 1 (≤0.1)              | 1 (≤ 0.1)            |
| Myocardial infarction                  | 0                                 | 1 (≤0.1)              | 1 (≤ 0.1)            |
| Sepsis                                 | 0                                 | 1 (≤0.1)              | 1 (≤ 0.1)            |
| All death Reason for death             | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)  | Total N=4967 n (%)   |
| Other                                  | 9(0.4)                            | 12 (0.5)              | 21 (0.4)             |
| Acute myeloid leukaemia                | 1 (≤± 0.1)                        | 1 (≤± 0.1)            | 2 (≤ 0.1)            |
| Death                                  | 1 (± 0.1)                         | 6 (0.2)               | 7 (0.1)              |
| General physical health deterioration  | 1 (± 0.1)                         | 1 (≤0.1)              | 2(≤ 0.1)             |
| Lower respiratory tract infeclion      | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Lung neoplasm malignant                | 1 (≤0.1)                          | 0                     | 1 (≤ 0.1)            |
| Malignant melanoma                     | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Pancreatic carcinoma                   | 1 (± 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Pulmonary embolism                     | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Rectosigmoid cancer                    | 1 (≤ 0.1)                         | 0                     | 1 (≤ 0.1)            |
| Adenocarcinoma gastric                 |                                   | 1 (≤ 0.1)             | 1 ( 0.1)             |
| Cardiac arrest                         | 0                                 | 1 (≤ 0.1)             | 1 (≤ 0.1)            |
| Fungal sepsis                          | 0                                 | 1 (≤± 0.1)            | 1 (≤ 0.1)            |
| Sepsis                                 |                                   | 1 (≤ 0.1)             | 1 (≤ 0.1)            |

Other as per-protocol are defined as SAEs collected after 36 months + 30 days and not related to study treatment.

As of the data cut-off date of 21-Jul- 2023, a total of 83 (3.3%) and 89 (3.6%) patients died during the study in the ribociclib + ET and ET only groups, respectively. The main cause of death during the study in

<div style=\"page-break-after: always\"></div>

both the ribociclib + ET and ET only treatment groups, was disease recurrence/progression (2.3 % vs. 3.0%). Deaths due to AEs in the ribociclib + ET arm was 0.6%.

Nine patients (0.4%) in the ribociclib + ET group and 12 patients (0.5%) in the ET only group died due to reasons 'other' than disease recurrence/progression or AE. The reasons for the 'other' deaths reported in the ribociclib + ET arm were (one patient each): acute myeloid leukaemia, lung neoplasm malignant, malignant melanoma and rectosigmoid cancer, and pulmonary embolism.

Table 65. On-treatment deaths (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set

| On-treatment death Reason for death      | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   | Total N=4967 n (%)   |
|------------------------------------------|-----------------------------------|------------------------|----------------------|
| Total no. patients who died on treatment | 20 (0.8)                          | 9 (0.4)                | 29 (0.6)             |
| Primary reason of death                  |                                   |                        |                      |
| Disease recurrencelprogression           | 9 (0.4)                           | 4 (0.2)                | 13 (0.3)             |
| Adverse event                            | 11 (0.4)                          | 4 (0.2)                | 15 (0.3)             |
| COVID-19                                 | 3 (0.1)                           | 1 (≤0.1)               | 4 (0.1)              |
| CoV10-19 pneumonia                       | 3 (0.1)                           | 0                      | 3 (0.1)              |
| Pulmonary embolism                       | 2 (0.1)                           | 0                      | 2 (± 0.1)            |
| Brain oedema                             | 1 (≤0.1)                          | 0                      | 1 (≤ 0.1)            |
| Cardiac arrest                           | 1 (±0.1)                          | 0                      | 1 (≤ 0.1)            |
| Road traffic accident                    | 1 (≤0.1)                          | 0                      | 1 (≤ 0.1)            |
| Cardiac failure congestive               | 0                                 | 1(≤0.1)                | 1 (≤ 0.1)            |
| Myocardial infarction                    | 0                                 | 1 (≤0.1)               | 1 (≤ 0.1)            |
| Sepsis                                   | 0                                 | 1 (≤0.1)               | 1 (≤ 0.1)            |
| Other                                    | 0                                 | 1 (≤ 0.1)              | 1 ( 0.1)             |
| Death                                    | 0                                 | 1 (≤ 0.1)              | 1 (≤ 0.1)            |

'On-treatment deaths are defined ss occurring on or after treatment start date and up to 30 days after 38 months of treatment or earlier treatment discontinuation.

A total of 20 patients (0.8%) in the ribociclib + ET group and nine patients (0.4%) in the ET only group died within 36 months of treatment plus 30 days of safety follow-up.

In the ribociclib + ET group 10 (0.4%) on-treatment deaths occurred during the ribociclib treatment period. The remaining seven (0.3%) occurred &gt; 30 days from the discontinuation of ribociclib, whilst continuing to receive treatment with ET.

On-treatment death due to AE was reported for 11 patients (0.4%) in the ribociclib + ET group and for four patients (0.2%) in the ET only group.

On-treatment death due to disease recurrence/progression occurred in 9 patients (0.4%) in the ribociclib + ET group vs. 4 patients (0.2%) in the ET only group.

## 2.5.5. Laboratory findings

## 2.5.5.1. Haematology

The most common worst-post-baseline grade 1 / 2 haematological abnormalities in the ribociclib plus ET group ( ≥ 10.0% difference relative to ET only group) were: decreased leukocytes (+23.3%), decreased hemoglobin (+21.3%), decreased platelets (+15.1%), and decreased neutrophils (+15.0%).

Grade 3 haematological abnormalities in the ribociclib plus ET group ( ≥ 10.0% difference relative to ET only group) were: decreased neutrophils (+41.5%), decreased leukocytes (+26.8%), and decrease lymphocytes (+12.4%). The highest number of patients (in both treatment groups) with grade-4 hematological abnormalities were decreased lymphocytes (2.7% of ribociclib plus ET patients and 2.3% of ET only patients).

<div style=\"page-break-after: always\"></div>

Table 66 Worst post-baseline hematology value (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set)

|                                                         | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | Ribociclib plus ET N=2525   | ET only N=2442   | ET only N=2442   | ET only N=2442   |
|---------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|------------------|------------------|------------------|
| Notable laboratory category                             | Grade 1/ 2 n(%)             | Grade 3 n (%)               | Grade 4 n (%)               | Grade 1/2 n(%)   | Grade 3 n (96)   | Grade 4 n (%6)   |
| Activated partial thromboplastin time (sec) Hyper Grade | 11 (0.4)                    | 0                           | 0                           | 8 (0.3)          | 0                | 0                |
| Hemoglobin (g/L) Hyper Grade                            | 91(3.6)                     | 3 (0.1)                     | 0                           | 182 (6.6)        | 4 (0.2)          | 0                |
| Hemoglobin (g/dL) Hypo Grade                            | 1178 (46.7)                 | 14 (0.6)                    | 0                           | 619 (25.4)       | 8 (0.3)          | 0                |
| Leukocytes (10E9/L) Hyper Grade                         | 0                           | 4 (0.2)                     | 0                           | 0                | 1 (≤ 0.1)        | 0                |
| Leukocytes (10E9/L) Hypo Grade                          | 1714 (67.9)                 | 688 (27.3)                  | 5 (0.2)                     | 1089 (44.6)      | 12 (0.5)         | 2 (0.1)          |
| Lymphocytes (10E9/L) Hyper Grade                        | 24 (1.0)                    | 10 (0.4)                    | 0                           | 49 (2.0)         | 6 (0.3)          | 0                |
| Lymphocytes (10E9/L) Hypo Grade                         | 1980 (78.4)                 | 413 (16.4)                  | 67 (2.7)                    | 1998 (81.8)      | 98 (4.0)         | 55 (2.3)         |
| Neutrophils (10E9/L) Hypo Grade                         | 1225 (48.5)                 | 1083 (42.9)                 | 55 (2.2)                    | 818 (33.5)       | 35 (1.4)         | 6 (0.3)          |
| Platelets (10E9/L) Hypo Grade                           | 705 (27.9)                  | 9 (0.4)                     | 1 (≤ 0.1)                   | 312 (12.8)       | 7 (0.3)          | 1 (≤ 0.1)        |
| Prothrombin intl. normalized ratio (sec) Hyper Grade    | 5 (0.2)                     | 1 (≤ 0.1)                   | 0                           | 3 (0.1)          | 2 (0.1)          | 0                |

Baseline is defined as the last non-missing value prior to the start date of study treatment.

Percentages are based on N.

Patients are counted only for the worst grade observed post-baseline.

Laboratory assessments performed after on-treatment period are not summarized.

CTCAE Version 4.03 is used for reporting.

## 2.5.5.2. Clinical chemistry

Grade 1 / 2 increased creatinine (+20.9%) were the only clinical chemistry parameter reported in a higher proportion of patients (difference ≥ 10%) who received ribociclib plus ET, compared with patients who received ET only. The frequency of remaining post-baseline biochemical abnormalities was similar by group. There were no grade 3 clinical chemistry abnormalities in ribociclib plus ET group with a ≥ 10% difference relative to ET only group.

The most common grade 4 clinical chemistry abnormalities (with incidences ≥ 1.0%) reported in ribociclib plus ET group were increased ALT (1.5% vs. &lt; 0.1%) and increased urate (1.5% vs. 1.8%).

## 2.5.5.3. Intrinsic factors

## 2.5.5.3.1. AESI by sex and menopausal status

Table 67. AESI by sex and menopausal status in Study O12301C (safety set based on cut-off date 11Jan-2023)

|                                   | PremenopausalWomen      | PremenopausalWomen   | PostmenopausalWomen     | PostmenopausalWomen   | Men                   | Men         |
|-----------------------------------|-------------------------|----------------------|-------------------------|-----------------------|-----------------------|-------------|
| AESl grouping -n (%)              | RibociclibplusET N=1106 | ET only N=1072       | RibociclibplusET N=1408 | ET only N=1363        | RibociclibplusET N=10 | ET only N=9 |
| Myelosuppression-Neutropenia      | 733 (66.3)              | 66 (6.2)             | 832 (59.1)              | 44 (3.2)              | 4 (40.0)              | 1 (11.1)    |
| Myelosuppression-Leukopenia       | 248 (22.4)              | 67 (6.3)             | 334 (23.7)              | 44 (3.2)              | 2 (20.0)              | 0           |
| Myelosuppression-Anaemia          | 79 (7.1)                | 32 (3.0)             | 131 (9.3)               | 41 (3.0)              | 0                     | 1 (11.1)    |
| Myelosuppression-Thrombocytopenia | 57 (5.2)                | 25 (2.3)             | 104 (7.4)               | 27 (2.0)              | 1 (10.0)              | 1 (11.1)    |
| Infections                        | 543 (49.1)              | 388 (36.2)           | 659 (46.8)              | 449 (32.9)            | 2 (20.0)              | 2 (22.2)    |
| Hepatobiliarytoxicity             | 253 (22.9)              | 113 (10.5)           | 387 (27.5)              | 145 (10.6)            | 2 (20.0)              | 2 (22.2)    |
| Renal toxicity                    | 31 (2.8)                | 9 (0.8)              | 111 (7.9)               | 40 (2.9)              | 2 (20.0)              | 0           |
| QTintervalprolongation            | 62 (5.6)                | 18 (1.7)             | 69 (4.9)                | 12 (0.9)              | 1 (10.0)              | 0           |
| Secondprimaryalignancies          | 18 (1.6)                | 16 (1.5)             | 28 (2.0)                | 29 (2.1)              | 0                     | 0           |
| ILD/pneumonitis                   | 15 (1.4)                | 5 (0.5)              | 24 (1.7)                | 14 (1.0)              | 0                     | 0           |
| Reproductivetoxicity              | 17 (1.5)                | 12 (1.1)             | 15 (1.1)                | 13 (1.0)              | 0                     | 0           |

<div style=\"page-break-after: always\"></div>

## 2.5.5.3.2. AESI by age

Table 68. AESI by sex and menopausal status in Study O12301C (Safety set based on cut-off date 11Jan-2023)

|                                   | 65Years                   | 65Years        | ≥65Years               | ≥65Years      |
|-----------------------------------|---------------------------|----------------|------------------------|---------------|
| AESIgrouping-n(%)                 | Ribociclib plus ET N=2122 | ET only N=2093 | RibociclibplusET N=402 | ET only N=351 |
| Myelosuppression-Neutropenia      | 1338 (63.1)               | 102 (4.9)      | 231 (57.5)             | 9 (2.6)       |
| Myelosuppression-Leukopenia       | 481 (22.7)                | 97 (4.6)       | 103 (25.6)             | 14 (4.0)      |
| Myelosuppression-Anaemia          | 148 (7.0)                 | 55 (2.6)       | 62 (15.4)              | 19 (5.4)      |
| Myelosuppression-Thrombocytopenia | 120 (5.7)                 | 46 (2.2)       | 42 (10.4)              | 7 (2.0)       |
| Infections                        | 1024 (48.3)               | 729 (34.8)     | 180 (44.8)             | 110 (31.3)    |
| Hepatobiliary toxicity            | 528 (24.9)                | 216 (10.3)     | 114 (28.4)             | 44 (12.5)     |
| Renal toxicily                    | 96 (4.5)                  | 30 (1.4)       | 48 (11.9)              | 19 (5.4)      |
| QTintervalprolongation            | 107 (5.0)                 | 26 (1.2)       | 25 (6.2)               | 4 (1.1)       |
| Secondprimarymalignancies         | 39 (1.8)                  | 31 (1.5)       | 7 (1.7)                | 14 (4.0)      |
| ILD/pneumonitis                   | 32 (1.5)                  | 16 (0.8)       | 7 (1.7)                | 3 (0.9)       |
| Reproductivetoxicity              | 30 (1.4)                  | 23 (1.1)       | 2 (0.5)                | 2 (0.6)       |

Anaemia, thrombocytopenia and renal toxicity were more frequently reported in patients ≥65 years compared to patients &lt;65 years.

<div style=\"page-break-after: always\"></div>

## 2.5.5.3.3. Adverse events by age range (CLEE011O12301C safety set)

Table 69. Adverse events by age range (CLEE011O12301C Safety set based on cut-off date 11-Jan-2023)

|                                                      | ET + Ribocielib     | ET + Ribocielib      | ET + Ribocielib     | ET + Ribocielib   | ET alone            | ET alone                                   | ET alone   | ET alone   |
|------------------------------------------------------|---------------------|----------------------|---------------------|-------------------|---------------------|--------------------------------------------|------------|------------|
| MedDRA Terms                                         | Age <65 N=2123 n[%] | Age 65-74 N=346 n[%] | Age 75-84 N=53 n(%) | Age 85+ N=3 n[%]  | N=2091 (%%]u        | Age<65 Age65-74 Age75-84 Age85+ N=288 n[%] | N=63 n[%]  | N=0 n[%]   |
| Total AEs                                            | 2081 (98.0)         | 338 (97.7)           | 52 (98.1)           | 3 (100)           |                     | 1843 (68.1) 252 (87.5)                     | 50 (79.4)  |            |
| Serious AEs - Total                                  | 277 (13.0)          | 66 (19.1)            | 13 (24.5)           | 1 (33.3)          | 204 (9.8)           | 39 (13.5)                                  | 13 (20.6)  | 0          |
| - Fatal                                              | 7 (0.3)             | 4(1.2)               | 0                   | 0                 | 3 (0.1)             | 1 (0.3)                                    | 0          | 0          |
| - Hospitalizstion/prolong existing                   | 247 (11.6)          | 60 (17.3)            | 12 (22.6)           | 1(33.3)           | 189 (9.0)           | 37 (12.8)                                  | 13 (20.6)  |            |
| . Life-threatening                                   | 14 (0.7)            | 5(1.4)               | 0                   | D                 | 11 (0.5)            | 1 (0.3)                                    | 1(1.6)     | 0          |
| - Disability/incapacity                              | 5 (0.2)             | 2 (0.6)              | 0                   | D                 | 2 (0.1)             | 2 (0.7)                                    | 0          | 0          |
| - Other (medieally signifieant)                      | 47 (2.2)            | 9 (2.6)              | 2(3.8]              | 0                 | 23 (1.1)            | 5 (1.7)                                    | 2(3.2)     | 0          |
| AE leading to discontinuation (Ribociclib and/or ET) | 409 (19.3)          | 92 (26.6)            | 21 (39.6)           | 2 (66.7)          | 111 (5.3)           | 20 (6.9)                                   | 3(4.8)     |            |
| Psychiatric disorders                                | 534 (25.15)         | 69 (19.94)           | 13 (24.53)          |                   |                     | 514 (24.58) 45 (15.63)                     | 12 (19.05) | 0          |
| Nervous system disorders                             | 856 (40.32)         | 135 (39.02)          | 21 (39.62)          | 1(33.33)          |                     | 685 (32.76) 84 (29.17)                     | 19 (30.16) | 0          |
| Accidents and injuries                               | 203 (9.56)          | 43 (12.43)           | 8 (15.09)           | 0                 | 161 (7.70)          | 30 (10.42)                                 | 8 (12.70)  | 0          |
| Cardiac disorders                                    | 149 (7.02)          | 41 (11.85)           | 7 (13.21)           | D                 | 132 (6.31)18 (6.25) |                                            | 6 (9.52)   | 0          |

ET + Ribocielib

ET alone

| MedDRA Terms                                                                          | Age <65 N=2123 n[%]   | Age 65-74 N=346 n[%]   | Age 75-84 N=53 n(%)   | Age 85+ N=3 n[%)   | N=2091 n[%]         | N=288 n[%]              | Age <65 Age 65-74 Age 75-84 Age 85+ N=63 n[%]   | N=0 n[%]   |
|---------------------------------------------------------------------------------------|-----------------------|------------------------|-----------------------|--------------------|---------------------|-------------------------|-------------------------------------------------|------------|
| Vascular disorders                                                                    | 707 (33.30)           | 101 (29.19)            | 23 (43.40)            | 1 (33.33)          |                     | 725 (34.67]) 75 (26.04) | 18 (28.57)                                      | 0          |
| Cerebrovascular disorders                                                             | 26 (1.22)             | 13 (3.76)              | 3 (5.66)              | 0                  | 27 (1.29)           | 10 (3.47)               | 2 (3.17)                                        | 0          |
| Infections and infestations                                                           | 1064 (50.12)          | 160 (46.24)            | 24 (45.28)            | 1 (33.33)          |                     | 762 (36.44] 94 (32.64)  | 20 (31.75)                                      | 0          |
| Anticholinergic syndrome                                                              | 567 (26.71)           | 90 (26.01)             | 12 (22.64)            | 1 (33.33)          |                     | 354 (16.93] 37 (12.85]  | 8 (12.70)                                       |            |
| Quality af life daerensed?                                                            | NA                    | NA                     | NA                    | NA                 | NA                  | NA                      | NA                                              | NA         |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 220 (10.36)           | 45 (13.01)             | 7 (13.21)             |                    | 138 (6.60)21 (7.29) |                         | 4 (6.35)                                        |            |

<div style=\"page-break-after: always\"></div>

## 2.5.5.3.4. By disease stages

Table 70. AESI by AJCC Anatomic Stage Group in Study O12301C (Safety set based on cut-off date 11Jan-2023)

|                                   | AJCCAnatomicStageGroupIl   | AJCCAnatomicStageGroupIl   | AJCCAnatomicStageGroupIll   | AJCCAnatomicStageGroupIll   |
|-----------------------------------|----------------------------|----------------------------|-----------------------------|-----------------------------|
| AESIgrouping-n(%)                 | RibociclibplusET N=996     | ET only N=1007             | RibociclibplusET N=1518     | ET only N=1431              |
| Myelosuppression-Neutropenia      | 591 (59.3)                 | 41 (4.1)                   | 971 (64.0)                  | 70 (4.9)                    |
| Myelosuppression-Leukopenia       | 202 (20.3)                 | 38 (3.8)                   | 380 (25.0)                  | 73 (5.1)                    |
| Myelosuppression-Anaemia          | 76 (7.6)                   | 36 (3.6)                   | 132 (8.7)                   | 38 (2.7)                    |
| Myelosuppression-Thrombocytopenia | 62 (6.2)                   | 24 (2.4)                   | 99 (6.5)                    | 29 (2.0)                    |
| Infections                        | 461 (46.3)                 | 357 (35.5)                 | 738 (48.6)                  | 481 (33.6)                  |
| Hepatobiliarytoxicity             | 271 (27.2)                 | 105 (10.4)                 | 368 (24.2)                  | 155 (10.8)                  |
| Renal toxicity                    | 64 (6.4)                   | 20 (2.0)                   | 80 (5.3)                    | 29 (2.0)                    |
| QTintervalprolongation            | 49 (4.9)                   | 11 (1.1)                   | 83 (5.5)                    | 19 (1.3)                    |
| Secondprimarymalignancies         | 17 (1.7)                   | 17 (1.7)                   | 28 (1.8)                    | 28 (2.0)                    |
| ILD/pneumonitis                   | 12 (1.2)                   | 6 (0.6)                    | 27 (1.8)                    | 13 (0.9)                    |
| Reproductive toxicity             | 14 (1.4)                   | 8 (0.8)                    | 18 (1.2)                    | 17 (1.2)                    |

## 2.5.6. Safety in special populations

## 2.5.6.1. Renal impairment

Table 71. Renal impairment, as normal, mild, moderate vs. severe (based on cut-off date 11-Jan-2023)

|                                   | Normalrenalfunction     | Normalrenalfunction   | Mildrenalimpairment     | Mildrenalimpairment   | Moderaterenalimpairment   | Moderaterenalimpairment   |
|-----------------------------------|-------------------------|-----------------------|-------------------------|-----------------------|---------------------------|---------------------------|
| AESl grouping-n(%)                | RibociclibplusET N=1434 | ETonly N=1385         | RibociclibplusET N=1009 | ETonly N=973          | Ribociclibplus ET N=72    | ETonly N=81               |
| Myelosuppression-Neutropenia      | 925 (64.5)              | 70 (5.1)              | 608 (60.3)              | 37 (3.8)              | 31 (43.1)                 | 4 (4.9)                   |
| Myelosuppression-Leukopenia       | 326 (22.7)              | 70 (5.1)              | 236 (23.4)              | 35 (3.6)              | 20 (27.8)                 | 6 (7.4)                   |
| Myelosuppression-Anaemia          | 114 (7.9)               | 31 (2.2)              | 81 (8.0)                | 35 (3.6)              | 13 (18.1)                 | 8 (9.9)                   |
| Myelosuppression-Thrombocytopenia | 86 (6.0)                | 29 (2.1)              | 67 (6.6)                | 20 (2.1)              | 7 (9.7)                   | 4 (4.9)                   |
| Infections                        | 680 (47.4)              | 486 (35.1)            | 482 (47.8)              | 329 (33.8)            | 40 (55.6)                 | 23 (28.4)                 |
| Hepatobiliarytoxicity             | 379 (26.4)              | 144 (10.4)            | 240 (23.8)              | 107 (11.0)            | 21 (29.2)                 | 9 (11.1)                  |
| Renal toxicity                    | 29 (2.0)                | 17 (1.2)              | 93 (9.2)                | 23 (2.4)              | 22 (30.6)                 | 9 (11.1)                  |
| QTintervalprolongation            | 79 (5.5)                | 12 (0.9)              | 50 (5.0)                | 18 (1.8)              | 3 (4.2)                   | 0                         |
| Secondprimarymalignancies         | 21 (1.5)                | 28 (2.0)              | 25 (2.5)                | 15 (1.5)              | 0                         | 2 (2.5)                   |
| ILD/pneumonitis                   | 18 (1.3)                | 10 (0.7)              | 20 (2.0)                | 8 (0.8)               | 1 (1.4)                   | 1 (1.2)                   |
| Reproductivetoxicity              | 18 (1.3)                | 13 (0.9)              | 13 (1.3)                | 12 (1.2)              | 1 (1.4)                   | 0                         |

<div style=\"page-break-after: always\"></div>

## 2.5.6.2. Hepatic impairment

Table 72. AESI by baseline hepatic impairment in Study O12301C (Safety set (based on cut-off date 11Jan-2023)

|                                   | Normalhepaticfunction   | Normalhepaticfunction   | Mildhepaticimpairment   | Mildhepaticimpairment   | Moderatehepaticimpairment   | Moderatehepaticimpairment   |
|-----------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|
| AESIgrouping-n(%)                 | RibociclibplusET N=2290 | ET only N=2202          | RibociclibplusET N=221  | ET only N=229           | RibociclibplusET N=3        | ET only N=9                 |
| Myelosuppression-Neutropenia      | 1422 (62.1)             | 99 (4.5)                | 140 (63.3)              | 11 (4.8)                | 2 (66.7)                    | 0                           |
| Myelosuppression-Leukopenia       | 514 (22.4)              | 101 (4.6)               | 66 (29.9)               | 10 (4.4)                | 1 (33.3)                    | 0                           |
| Myelosuppression-Anaemia          | 197 (8.6)               | 69 (3.1)                | 11 (5.0)                | 5 (2.2)                 | 0                           | 0                           |
| Myelosuppression-Thrombocytopenia | 146 (6.4)               | 48 (2.2)                | 15 (6.8)                | 5 (2.2)                 | 0                           | 0                           |
| Infections                        | 1094 (47.8)             | 760 (34.5)              | 101 (45.7)              | 73 (31.9)               | 2 (66.7)                    | 5 (55.6)                    |
| Hepatobiliarytoxicity             | 548 (23.9)              | 205 (9.3)               | 91 (41.2)               | 55 (24.0)               | 1 (33.3)                    | 0                           |
| Renal toxicily                    | 134 (5.9)               | 44 (2.0)                | 9 (4.1)                 | 5 (2.2)                 | 0                           | 0                           |
| QTintervalprolongation            | 120 (5.2)               | 28 (1.3)                | 12 (5.4)                | 2 (0.9)                 | 0                           | 0                           |
| Secondprimarymalignancies         | 38 (1.7)                | 41 (1.9)                | 7 (3.2)                 | 4 (1.7)                 | 0                           | 0                           |
| ILD/pneumonitis                   | 34 (1.5)                | 18 (0.8)                | 5 (2.3)                 | 1 (0.4)                 | 0                           |                             |
| Reproductivetoxicity              | 29 (1.3)                | 21 (1.0)                | 3 (1.4)                 | 3 (1.3)                 | 0                           | 1 (11.1)                    |

## 2.5.7. Discontinuation due to adverse events

Table 73. Adverse events leading to discontinuation irrespective of causality, by preferred term and maximum grade (in greater than or equal to 3 patients in either group) (safety set based on cut-off date 11-Jan-2023)

|                                      |                  | Ribociclib +ET N=2524   | Ribociclib +ET N=2524   |               |                  | ET only N=2444   | ET only N=2444   |               |
|--------------------------------------|------------------|-------------------------|-------------------------|---------------|------------------|------------------|------------------|---------------|
| PreferredTerm                        | All Grades n (%) | Grade 3 n (%)           | Grade 4 n (%)           | Grade 5 n (%) | All Grades n (%) | Grade 3 n (%)    | Grade 4 n (%)    | Grade 5 n (%) |
| Numberofpatientswith atleastone TEAE | 523 (20.7)       | 202 (8.0)               | 35 (1.4)                | 6 (0.2)       | 129 (5.3)        | 35 (1.4)         | 5 (0.2)          | 3 (0.1)       |
| Alanineaminotransferaseincreased     | 176 (7.0)        | 77 (3.1)                | 19 (0.8)                | 0             | 2 (0.1)          | 1(0.0)           | 0                | 0             |
| Aspartate aminotransferaseincreased  | 71 (2.8)         | 29 (1.1)                | 7 (0.3)                 | 0             | 0                | 0                | 0                | 0             |
| Arthralgia                           | 34 (1.3)         | 4 (0.2)                 | 0                       | 0             | 46 (1.9)         | 9 (0.4)          | 0                | 0             |
| Fatigue                              | 24 (1.0)         | 5 (0.2)                 | 0                       | 0             | 2 (0.1)          | 0                | 0                | 0             |
| Neutropenia                          | 16 (0.6)         | 13 (0.5)                | 2 (0.1)                 | 0             | 0                | 0                | 0                | 0             |
| Neutrophil count decreased           | 14 (0.6)         | 12 (0.5)                | 0                       | 0             | 0                | 0                | 0                | 0             |
| Nausea                               | 13 (0.5)         | 1 (0.0)                 | 0                       | 0             | 2 (0.1)          | 0                | 0                | 0             |
| Hepatotoxicity                       | 8 (0.3)          | 4 (0.2)                 | 2 (0.1)                 | 0             | 0                | 0                | 0                | 0             |
| Asthenia                             | 8 (0.3)          | 4 (0.2)                 | 0                       | 0             | 1 (0.0)          | 0                | 0                | 0             |
| Rash                                 | 8 (0.3)          | 2 (0.1)                 | 0                       | 0             | 2 (0.1)          | 0                | 0                | 0             |
| Headache                             | 7 (0.3)          | 2 (0.1)                 | 0                       | 0             | 5 (0.2)          | 0                | 0                | 0             |
| Bloodmagnesium decreased             | 7 (0.3)          | 0                       | 0                       | 0             | 0                | 0                | 0                | 0             |
| COVID-19                             | 6 (0.2)          | 2 (0.1)                 | 1 (0.0)                 | 2 (0.1)       | 1 (0.0)          | 0                | 1 (0.0)          | 0             |
| Diarrhoea                            | 6 (0.2)          | 2 (0.1)                 | 0                       | 0             | 2 (0.1)          | 0                | 0                | 0             |
| Electrocardiogram QTprolonged        | 6 (0.2)          | 1 (0.0)                 | 0                       | 0             | 0                | 0                | 0                | 0             |
| Blood creatinine increased           | 6 (0.2)          | 0                       | 0                       | 0             | 0                | 0                | 0                | 0             |
| Hypomagnesaemia                      | 6 (0.2)          | 0                       | 0                       | 0             | 0                | 0                | 0                | 0             |
| Pulmonary embolism                   | 5 (0.2)          | 3 (0.1)                 | 1 (0.0)                 | 1 (0.0)       | 1 (0.0)          | 1 (0.0)          | 0                | 0             |
| Alopecia                             | 5 (0.2)          | 0                       | 0                       | 0             | 0                | 0                | 0                | 0             |
| Pneumonitis                          | 5 (0.2)          | 0                       | 0                       | 0             | 0                | 0                | 0                | 0             |

<div style=\"page-break-after: always\"></div>

|                                     | Ribociclib +ET N=2524   | Ribociclib +ET N=2524   | Ribociclib +ET N=2524   | Ribociclib +ET N=2524   |                  |               |               |               |
|-------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------|---------------|---------------|---------------|
| PreferredTerm                       | All Grades n (%)        | Grade 3 n (%)           | Grade 4 n (%)           | Grade 5 n (%)           | All Grades n (%) | Grade 3 n (%) | Grade 4 n (%) | Grade 5 n (%) |
| Papillary thyroid cancer            | 4 (0.2)                 | 4 (0.2)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Gamma-glutamyltransferase increased | 4 (0.2)                 | 3 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Anxiety                             | 4 (0.2)                 | 1 (0.0)                 | 0                       | 0                       | 1 (0.0)          | 0             | 0             | 0             |
| Hyperkalaemia                       | 4 (0.2)                 | 1 (0.0)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Hypertransaminasaemia               | 4 (0.2)                 | 1 (0.0)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Acute myocardial infarction         | 3 (0.1)                 | 1 (0.0)                 | 2 (0.1)                 | 0                       | 0                | 0             | 0             | 0             |
| COVID-19 pneumonia                  | 3 (0.1)                 | 1 (0.0)                 | 1 (0.0)                 | 1 (0.0)                 | 0                | 0             | 0             | 0             |
| Syncope                             | 3 (0.1)                 | 3 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Depression                          | 3 (0.1)                 | 2 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Drug-induced liver injury           | 3 (0.1)                 | 2 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Malignant melanoma                  | 3 (0.1)                 | 2 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Whiteblood cell count decreased     | 3 (0.1)                 | 2 (0.1)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Blood bilirubin increased           | 3 (0.1)                 | 1 (0.0)                 | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Dyspnoea                            | 3 (0.1)                 | 0                       | 0                       | 0                       | 2 (0.1)          | 1 (0.0)       | 0             | 0             |
| Hypercalcaemia                      | 3 (0.1)                 | 0                       | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Pyrexia                             | 3 (0.1)                 | 0                       | 0                       | 0                       | 0                | 0             | 0             | 0             |
| Myalgia                             | 2 (0.1)                 | 1 (0.0)                 | 0                       | 0                       | 6 (0.2)          | 2 (0.1)       | 0             | 0             |
| Acute myeloid leukaemia             | 1 (0.0)                 | 0                       | 1 (0.0)                 | 0                       | 3 (0.1)          | 1 (0.0)       | 2 (0.1)       | 0             |
| Osteoporosis                        | 0                       | 0                       | 0                       | 0                       | 3 (0.1)          | 0             | 0             | 0             |

Preferred terms are sorted in descending frequency based on frequency in ribociclib + ET arm. MedDRA Version 25.1 has been used for reporting.

AEs leading to study treatment discontinuation were reported more commonly in the ribociclib + ET group (20.7%) compared to the ET only group (5.3%). The most commonly reported AEs leading to study treatment drug discontinuation in the ribociclib + plus ET group were ALT increased (7.0%), AST increased (2.8%), arthralgia (1.3%), fatigue (1.0%), neutropenia (0.6%), neutrophil count decreased (0.6%), and nausea (0.5%).

## 2.5.7.1. Dose modification

Table 74. Study treatment modifications (final iDFS analysis, 21-Jul-2023 data cut-off) (Safety set

| Modification Reasonformodification      | Ribociclib plus ET N=2525 n (96)   | ET only N=2442 n(%)   |
|-----------------------------------------|------------------------------------|-----------------------|
| Ribociclib                              |                                    |                       |
| No. patients who have dose reduction    | 875 (26.7)                         |                       |
| Adverse event                           | 576 (22.8)                         |                       |
| Dosing error                            | 89 (3.5)                           |                       |
| Technicalproblem                        | 4 (0.2)                            |                       |
| Physician decision                      | 15 (0.6)                           |                       |
| Other                                   | 7 (0.3)                            |                       |
| No. patients who have dose interruption | 2173 (86.1)                        |                       |
| Adverse event                           | 1871 (66.2)                        |                       |

<div style=\"page-break-after: always\"></div>

| Modification Reason formodification      | Ribociclib plus ET N=2525 n (%)   | ET only N=2442 n (%)   |
|------------------------------------------|-----------------------------------|------------------------|
| Dosing error                             | 1189 (47.1)                       |                        |
| Dispensing error                         | 96 (3.8)                          |                        |
| Technical problem                        | 90 (3.6)                          |                        |
| Physician decision                       | 306 (12.1)                        |                        |
| Logistical issue                         | 724 (28.7)                        |                        |
| Other                                    | 531 (21.0)                        |                        |
| NSAI                                     |                                   |                        |
| No. patients who have dose interruption  | 1123 (44.5)                       | 872 (35.7)             |
| Adverse event                            | 281 (11.1)                        | 134 (5.5)              |
| Dosing error                             | 881 (34.9)                        | 705 (28.9)             |
| Dispensing error                         | 57 (2.3)                          | 40 (1.8)               |
| Technical problem                        | 15 (0.6)                          | 16 (0.7)               |
| Physicisn decision                       | 70 (2.8)                          | 40 (1.8)               |
| Logistical issue                         | 61 (2.4)                          | 55 (2.3)               |
| Other                                    | 137 (5.4)                         | 110 (4.5)              |
| Missing                                  | 2 (0.1)                           | 0                      |
| No. patients who switched NSAl treatment | 99 (3.9)                          | 122 (5.0)              |

400 mg to 200 mg is permilted to allow the patient to continue study treatment.

For patients who did not tolerate the protocol-specified dosing schedule, a single dose reduction of ribociclib from

Mulliple entries for interruption on consecutive days with different reasons will be counted 3s separate interruptions.

## 2.5.8. Post marketing experience

The cumulative exposure is estimated to approximately 127,528 PTY (Kisqali PSUR 2023).

Cumulatively, since the time of the first marketing authorisation approval of Kisqali (in 2017), two new safety signals were identified (interstitial lung disease [ILD]/pneumonitis and toxic epidermal necrolysis [TEN]).

## 2.5.9. Discussion on clinical safety

The safety data base is considered of an acceptable magnitude for detecting any changes to the already known safety characterisation of ribociclib and/or identifying new safety concerns including those potentially related to this new patient population.

The median duration of exposure to ribociclib in the NATALEE study was 33 months, with 69.4% patients exposed for &gt;24 months and 42.8% patients exposed for &gt;36 months.

Overall, the presented data on patient exposure evoked no concern and the methodology for selection of ADRs was considered acceptable.

Observations on the overall safety data are in line with the known safety profile of ribociclib. A clear difference relative the comparator in terms of frequency of AE reports is noted in regard to e.g.  SAEs (14.1% and 10.5%, respectively), severity (Grade 3 and 4), AEs leading to discontinuations and dose interruptions.

Neutropenia was the most frequently reported adverse reaction (62.5%) and a grade 3 or 4 decrease in neutrophil counts (based on laboratory findings) was reported in 45.1% of patients receiving Kisqali plus aromatase inhibitor (AI). As expected with the lower starting dose of ribociclib 400 mg QD, less overall incidences and incidences of grade ≥ 3 Neutropenia AESI were observed compared to that in the pooled aBC dataset treated with 600 mg QD. Events of neutropenia leading to treatment discontinuation are considered acceptable for the ribociclib + ET arm. It has previously been concluded when ribociclib was initially approved in patients with aBC, that the risk of neutropenia is not regarded as any major concern since it is considered to be manageable with the risk minimisation measures laid out in the SmPC. This

<div style=\"page-break-after: always\"></div>

conclusion is applicable also for the eBC population. No new concern is evoked based on the submitted data. The risk of neutropenia is substantially addressed in sections 4.2, 4.4 and 4.8 of the Kisqali SmPC. Myelosuppression is included in the safety specification of the RMP as an important identified risk.

Events in the Anaemia AESI were 8.6% in the ribociclib + ET group vs. 3.2% in the ET only group. The vast majority of events by PT were anaemia (8.4% vs. 3.0%, respectively). Events of Grade ≥ 3 were similar between the two arms (0.3% in both arms). In three patients in each arm, anaemia events were considered SAEs (0.3%). There were two patients (0.1%) who discontinued study treatment in the ribociclib + ET group due to anaemia.

Events in the Thrombocytopenia AESI were 6.4% in the ribociclib + ET group vs. 2.3% in the ET only group. By PT, these were limited to thrombocytopenia (4.4% vs. 1.8%) and decreased platelet count (2.1% vs. 0.5%). Events of Grade ≥ 3) were reported with a similar proportion (0.2% and 0.1%, respectively). There were no SAEs reported. In one patient who had a Grade ≥3 event of thrombocytopenia, a vitreous haemorrhage occurred which were not assessed as related by the investigator. One patient (&lt; 0.1%) discontinued study treatment in the ribociclib + ET group due to thrombocytopenia.

Events of Infections AESI were 49.6% in the ribociclib + ET group vs. 36.2% in the ET only group. The majority were reported for COVID-19 infection (21.3% vs. 14.1%, respectively). Following in frequency, the next most frequent reported infection was UTI (6.5% vs. 5.1%). The remaining PTs presented infrequently, and no obvious pattern can be identified. Infections are a known ADR to ribociclib and included in the ADR table (with frequency `Very common´). The following infections are detailed: urinary tract infections, respiratory tract infections, gastroenteritis and sepsis.

Hepatobiliary toxicity AESI were reported more frequently in the ribociclib plus ET group (all grades, 26.4% and grade ≥ 3, 8.6%) as compared to the ET only group (11.2% and 1.7%, respectively). The majority of event were increased ALT (all grades: 19.5% vs. 5.6%) and increased AST (16.9% vs. 5.7%).

Few of these presented as SAE (increased ALT: 0.4% vs. 0; increased AST: 0.2% vs. 0).

Discontinuation of study treatment due to hepatobiliary toxicity events occurred in 8.9% of patients in the ribociclib plus ET group; predominantly due to increased ALT (7.1%) and increased AST (2.8%). In the ribociclib plus ET group, study treatment dose adjustments and dose interruptions were required for 66 patients (2.6%) and 313 patients (12.4%), respectively; again, primarily due to AEs of ALT increased and AST increased.

There were 9 patients (0.4%) in the ribociclib plus ET group who presented DILI. Of these 9, 6 patients (0.2%) were considered to have experienced serious DILI events and 5 patients (0.2%) had ≥ grade 3. Five patients had study treatment with ribociclib plus ET interrupted due to DILI, and 3 patients (0.1%) ultimately discontinued treatment due to DILI. As of the data cut-off (21-Jul-2023), the reported DILI events were resolved in all but one patient.

Hepatobiliary toxicity is addressed in sections 4.2, 4.4 and 4.8 of the Kisqali SmPC and it is considered that the risk minimisation measures currently included in the SmPC pertaining to the aBC population (dose modifications, monitoring of liver function tests and management of events of hepatobiliary toxicities) are considered also sufficiently applicable to the eBC population.

Events in the Renal toxicity AESI were 6.0% in the ribociclib + ET group vs. 2.4% in the ET only group, consisting mainly of reports by PT of `increased blood creatinine´ (3.9% vs. 0.9%). Decreased glomerular filtration rate was more frequent in the ribociclib plus ET group (1.7% vs. 0.5%). In the ribociclib + ET arm, one patient (&lt;0.1%) had an SAE of AKI and one patient (&lt; 0.1%) had an SAE of increased blood creatinine. Out of seven (0.3%) Renal toxicity AESI grade ≥ 3 in ribociclib + ET arm, three events were increased blood creatinine, two were decreased glomerular filtration rate, and twowere

<div style=\"page-break-after: always\"></div>

AKI.  AEs of renal toxicity leading to treatment discontinuation was acceptable (0.4% in the ribociclib + ET arm).

Based on the submitted data no new concern has been evoked. Renal toxicity is adequately addressed in sections 4.2 (renal impairment, 4.4 (Blood creatinine increase and Renal impairment) and included in Table 7 in section 4.8 (SOC Investigations: Blood creatinine increase). In addition, Renal toxicity is an important potential risk already included in the safety specifications.

Overall, in the NATALEE study QT interval prolongation AESI were more commonly reported in the ribociclib + ET group compared with the ET only group (5.3% vs. 1.4%). The most frequently reported in both the ribociclib + ET and ET only treatment groups were ECG QT prolonged (4.3% and 0.7% respectively). The incidences of ≥ grade 3 QT interval prolongation AESI were 1.0% in the ribociclib + ET and 0.6% ET only group. The most common ≥ grade 3 QT prolongation event reported in both the ribociclib + ET group (in 0.7% of patients) and ET only group (in 0.6% of patients) was syncope. Study treatment was discontinued for 10 patients (0.4%) in the ribociclib + ET group due to ECG QT prolonged; for 4 patients (0.2%) due to syncope; and for 1 patient (&lt; 0.1%) each due to cardiac arrest. A total of four patients (0.2%) had an SAE of syncope, and one patient (&lt;0.1%) had an SAE of cardiac arrest. There were no cardiac sudden deaths or TdP reported. The known risk of QT interval prolongation is extensively addressed in sections 4.2, 4.4, 4.8 and 5.1 of the Kisqali SmPC, and already included in the safety specifications as an important identified risk. ECG should be assessed before initiating treatment. Treatment with Kisqali should be initiated only in patients with QTcF values less than 450 msec. ECG should be repeated at approximately day 14 of the first cycle, then as clinically indicated (see sections 4.2, 4.4 and 4.8 of the SmPC). In patients with early breast cancer, appropriate monitoring of serum electrolytes (including potassium, calcium, phosphorus and magnesium) should be performed before initiating treatment, at the beginning of the first 6 cycles and then as clinically indicated. Any abnormality should be corrected before initiating treatment with Kisqali and during treatment with Kisqali. Based on the observed QT prolongation during treatment, treatment with Kisqali may have to be interrupted, reduced or discontinued (see sections 4.2, 4.4, 4.8 and 5.2 of the SmPC).

The overall proportion of patients with ILD / pneumonitis AESI was 1.5% vs. 0.9% in the ribociclib + ET arm vs. the ET only arm. The majority were events of pneumonitis (0.6% vs. 0.4%, respectively). There were no events of Grade ≥3 and one SAE reported in the ribociclib + ET arm. The proportion of events of ILD/pneumonitis leading to treatment discontinuation is acceptable (0.2%). ILD/pneumonitis is adequately addressed in section 4.2 and 4.4 of the Kisqali SmPC and the table in section 4.8 has now been updated with `ILD/pneumonitis´ also for the eBC population. Two new safety signals were identified (interstitial lung disease [ILD]/pneumonitis and toxic epidermal necrolysis [TEN]) that eventually were added as postmarketing ADRs in the Kisqali prescribing information with communication within the Warning and precaution section 4.4. Further to the post marketing setting assessment, section 4.4 and 4.8 have been updated with ILD/Pneumonitis and TEN for the aBC population (with a frequency of `Common´ and `Not known´, respectively).

Events in the Reproductive toxicity AESI were reported in 1.3% in the R + ET arm and 1.1% in the ET only arm, including Grade ≥3 (0.3% in both arms) and SAEs (0.2% in both arms). The proportion of AEs leading to discontinuation was low (0.1%). The observed increase in reports of reproductive toxicity in the eBC population compared to the pooled aBC population (1.3% vs. 0.6%) including Grade ≥3 (0.3% vs. 0.1%) and SAEs (0.2% vs. 0%), is however noted. Upon further review, the incidence of the events appears to be driven primarily by the PT 'mastitis' with the incidence of all grades 27 (1.1%) vs 3 (0.3%) in eBC and aBC patients, respectively. In the NATALEE study `Mastitis´ was reported in 27 patients (1.1%) in the ribociclib + ET arm compared to 17 patients (0.7%) in the control arm (see Table 61. ). The observed incidence of mastitis in the eBC population could be explained by factors such as patients with eBC start ribociclib treatment in adjuvant setting, meaning they have recently had neoadjuvant

<div style=\"page-break-after: always\"></div>

chemotherapy, surgery and radiation. Moreover, it does not appear that mastitis occurred in the context of myelosuppression (i.e. neutropenia). It is concluded that a causal association between ribociclib and `mastitis´ cannot be established at this point. Reproductive toxicity is addressed in sections 4.4, 4.6 and 5.3. In addition, Reproductive toxicity is an important identified risk already included in the safety specification and will be monitored.

Overall, no new concerns have been identified in relation to the AESIs.

Dose reduction due to adverse events, regardless of causality, occurred in 22.8% of patients receiving Kisqali plus AI in the phase III clinical study. Permanent discontinuation was reported in 19.7% of patients receiving Kisqali plus AI in the phase III clinical study.

## 2.5.10. Conclusions on clinical safety

The safety profile as characterised in the pivotal study is mainly in line with what has previously been established for ribociclib in combination with ET in aBC patients, despite differences in safety profiles due to differences in the study designs, patient populations and disease setting, background therapies, comorbidities, risk factors, starting dose and duration of exposure. Moreover, no new safety concerns have been identified. The safety profile is acceptable for the proposed use.

## 2.5.11. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version 8.2 with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 8.2 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 8.2 with the following content:

## Safety concerns

No changes were proposed by the MAH to the summary of safety concerns. The summary of safety concerns is as follows:

Table 75: Summary of the Safety Concerns

| Important identified risks   | Myelosuppression Hepatobiliary toxicity QT interval prolongation Reproductive toxicity   |
|------------------------------|------------------------------------------------------------------------------------------|
| Important potential risks    | Renal toxicity                                                                           |
| Missing information          | Safety in Japanese patients                                                              |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

There are no additional pharmacovigilance activities.

## Risk minimisation measures

Table 76 Summary of pharmacovigilance activities and risk minimization activities by safety concerns

| Safety concern              | Risk minimization measures                                                                                       | Pharmacovigilance activities                                                                                                                                                 |
|-----------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Myelosuppression            | Section 4.2, Section 4.4 and Section 4.8 of the SmPC and Section 2 of PL.                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                             |
| Hepatobiliary toxicity      | Section 4.2, Section 4.4, Section 4.8, and Section 5.3 of the SmPC and Section 2 of PL.                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance activities: None |
| QT interval prolongation    | Section 4.2, Section 4.4, Section 4.5, Section 4.8, Section 5.1 and Section 5.3 of the SmPC and Section 2 of PL. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted follow-up questionnaire Additional pharmacovigilance activities: None |
| Reproductive Toxicity       | Section 4.4, Section 4.6 and Section 5.3 of the SmPC and Section 2 of PL.                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                             |
| Renal toxicity              | Section 4.2, Section 4.8 and Section 5.2 of the SmPC                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                             |
| Safety in Japanese patients | Currently available data are limited and do not support the need for risk minimization.                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                             |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated as well as the Annex IID. The Package Leaflet has been updated accordingly.

In addition, the list of local representatives in the PL has been revised to amend contact details for the

<div style=\"page-break-after: always\"></div>

representative(s) of the Netherlands.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

A consultation with the target patient population regarding the readability of the Package Leaflet (PL) for Kisqali was conducted as part of the original Marketing Authorisation Application. The new information proposed in the PL included in this type II variation maintain the currently approved layout and format and are not considered to require further consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The final approved indication is:

Kisqali in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence (see SmPC section 5.1 for selection criteria).

## 3.1.2. Available therapies and unmet medical need

According to current ESMO and NCCN 2024 clinical guidelines (Loibl S, Ann Oncol. 2024) pre- and postmenopausal women with HR-positive eBC are recommended adjuvant ET, consisting of tamoxifen or an AI + an LHRH for men and premenopausal women and either an AI or tamoxifen, alone or as sequential treatment, for postmenopausal women.

In 2022, Verzenios was approved for use in patients with early breast cancer at `high risk of recurrence´. High risk of recurrence is defined by clinical and pathological features: either &gt;4 pALN (positive axillary lymph nodes), or 1-3 pALN and at least one of the following criteria: tumour size &gt;5 cm or histological grade 3 (Verzenios-H-C-004302-II-0013).

Despite adjuvant therapies, which are normally considered for patients at risk for recurrence, approximately 30-60% of patients with stage II and III BC still relapse. The risk of recurrence in patients with HR-positive, HER-2 negative eBC is highest during the first 5 years after diagnosis, but &gt;50% of those who recur will recur ≥ 5 years from diagn osis (Pan et al 2017). Therefore, there is a need to further improve outcomes in this patient population with new treatment options that can prevent recurrence and, eventually, death.

## 3.1.3. Main clinical studies

This new indication is supported by a randomised, open-label, multi-centre, phase III study CLEE11O12301C (O12301C) with adjuvant treatment with ribociclib + ET vs. ET only in adult women and men with Stage II (excluding low risk of recurrence) and stage III eBC. In total, 5,101 patients entered the study and were randomised 1:1 to ribociclib + ET (n=2,549) or ET only (n=2,552).

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

Primary analysis results are derived from the third interim analysis (IA3) as of DCO 11 Jan 2023, with 426 PFS events and median duration from randomisation 34.0 months (range 21-48 months). At DCO, 515 (20.2%) patients in the ribociclib + ET arm had completed the full 36 months of ribociclib treatment.

HR for iDFS at the inferential IA3 was 0.748 (95% CI 0.618, 0.906, 1-sided p-value 0.0014) in favour of ribociclib + ET treatment. Median iDFS was not reached for any of the treatment arms. The 3-year iDFS rates were 90.4% (95% CI 88.6, 91.9) in the ribociclib + ET arm and 87.1% (95% CI 85.3, 88.8) in the ET only arm.

At the DCO of final iDFS analysis (DCO 21 Jul 2023), the HR for iDFS was 0.749 (95% CI 0.628, 0.892, 1sided p-value 0.0006) in favour of ribociclib + ET treatment. The median time to iDFS was NR in both treatment arms. The 3-year iDFS rates were 90.7% (95% CI 89.3, 91.8) in the ribociclib + ET arm and 87.6% (95% CI 86.1, 88.9) in the ET only arm. HR for secondary endpoint RFS (not type 1 error controlled) at DCO for final iDFS analysis was 0.727 (95% CI 0.602, 0.887) in favour of the ribociclib + ET arm. The 3-year iDFS rate for RFS was 92.1% (95% CI 90.9, 93.2) in the ribociclib + ET arm and 89.1% (95% CI 87.6, 90.4) in the ET only arm, in line with the primary analysis.

HR for secondary endpoint DDFS (not type 1 error controlled) at DCO for final iDFS analysis was 0.749 (95% CI 0.623, 0.900), in favour of the ribociclib + ET treatment. The 3-year iDFS rate for DDFS was 91.5% (95% CI 90.2, 92.7) for the ribociclib + ET arm vs. 88.9% (95% CI 87.4, 90.2) for the ET only arm. This was in line with the primary analysis.

OS data were immature at DCO for the final iDFS analysis, with in total 172 (3.4%) events. HR for OS (not type 1 error controlled) was 0.892 (95% CI 0.661, 1.203)). Median OS was not reached for any of the treatment arms. The estimated 3-year OS rates were 97.0% (95% CI 96.2, 97.6) in the ribociclib + ET arm and 96.1% (95% CI 95.1, 96.9) in the ET only arm.

At the time of the most updated iDFS analysis, 78.3% of the patients had finished treatment with ribociclib. In total, 42.8% had completed the 3-year ribociclib treatment and 35.5% discontinued prematurely, mainly due to AEs (19.5%).

## 3.3. Uncertainties and limitations about favourable effects

At DCO for the final iDFS analysis only 42.8% of the patients had completed the full three years of ribociclib treatment and almost 80% of the patients had discontinued ribociclib with 35.5% of the patients discontinuing ribociclib early. The iDFS Kaplan-Meier curves continue to separate over time, indicating a sustained effect even after ribociclib discontinuation. While there are no signs of a detrimental effect on OS in ribociclib exposed patients, the OS data are still immature.

To further characterize the long-term benefit of ribociclib in this patient population more mature OS and iDFS data are considered relevant.

The following measures are considered necessary to address issues related to efficacy and safety:

Post-authorisation efficacy study (PAES): In order to further characterise the efficacy of Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence, the MAH should submit a 5-year follow-up of iDFS and OS in the NATALEE study.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The safety evaluation is based on data from 2524 patients exposed to a starting dose of 400 mg ribociclib QD in combination with ET, and 2444 patients exposed to ET only.

The median duration of exposure to ribociclib across the study was 32.0 months, with 69.4% patients exposed for &gt;24 months, and 42.8% patients completing the 36-month ribociclib regimen. Adverse events where a higher proportion of ribociclib plus ET-treated patients reported events, all grades, with a ≥ 10% relative difference to the ET only group, included:

Neutropenia: +38.5%; Decreased neutrophil count: +22.4%; Nausea: +15.5%; ALT increased: +13.9%; Leukopenia: +11.3%;  AST increased: +11.2%; Alopecia: +10.6% and Arthralgia (43.3%). Hot flush (20.0%) were the only PTs reported in ≥ 20% of patients in the ET only group

The most common grade ≥ 3 AEs in the ribociclib + ET arm were neutropenia (28.0%), neutrophil count decreased (17.7%), ALT increased (7.6%), AST increased 4.7%), WBC decreased (3.7%), and leukopenia (3.7%).

Grade 3 AEs were reported in 57.9% of patients in the ribociclib + ET group (mainly neutropenia, neutrophil count decreased, and ALT increased) and 17.4% of patients in the ET only group.

Grade 4 AEs were reported in 5.3% of patients in the ribociclib + ET group and 1.6% of patients in the ET only group. Neutropenia (1.3%) and ALT increased (1.3%) were the most frequently reported grade 4 AE (with incidences ≥ 1.0%) in the ribociclib + ET group.

In 11 patients (0.4%) a grade 5 event (AE with fatal outcome) was reported in the ribociclib + ET group. Amongst causes were cardiac arrest, cardiogenic shock, concurrent brain oedema and epilepsy, pneumonia, pulmonary embolism, and road traffic accident.

SAEs were reported in 14.1% in the ribociclib + ET arm vs. 10.5% in the ET only group. The most commonly reported SAEs (in ≥ 10 patients) in the ribociclib + ET group were COVID-19 (0.8%), pneumonia (0.6%), pulmonary embolism (0.6%) and dyspnoea (0.5%).

A total of 83 (3.3%) and 89 (3.6%) patients died during the study in the ribociclib + ET and ET only groups, respectively. The main cause of death during the study in both the ribociclib + ET and ET only treatment groups, was disease recurrence/progression (2.3% vs. 3.0%). Deaths due to AEs in the ribociclib + ET arm was 0.6% with deaths related to COVID-19 accounting for about 0.1%.

AEs leading to study treatment discontinuation were reported more commonly in the ribociclib + ET group (20.8%) compared to the ET only group (5.5%).

Since this new patient population consists of patients presumed cured after their initial treatment for eBC, the risk of QT-prolongation and hepatobiliary toxicity warranted further consideration:

## QT-prolongation

Overall, QT interval prolongation AESI were more commonly reported in the ribociclib + ET group compared with the ET only group (5.3% vs. 1.4%). The most frequently reported in both the ribociclib + ET and ET only treatment groups were ECG QT prolonged (4.3% and 0.7% respectively). The incidences of ≥ grade 3 QT interval prolongation AESI were 1.0% in the ribociclib + ET and 0.6% ET only group. The most common ≥ grade 3 QT prolongation event reported in both the ribociclib + ET group (in 0.7% of patients) and ET only group (in 0.6% of patients) was syncope.

## Hepatobiliary toxicity

Events in the Hepatobiliary toxicity AESI were reported in 26.4% in the ribociclib + ET group vs. 11.2% in the ET only group and the majority by PT being increased ALT and AST. Events of Grade ≥ 3 were

<div style=\"page-break-after: always\"></div>

reported in 8.6% and 1.7%, respectively. Hepatobiliary toxicity is addressed in sections 4.2, 4.4 and 4.8 of the SmPC.

## 3.5. Uncertainties and limitations about unfavourable effects

None

## 3.6. Effects Table

Table 77 Effects Table for study O12301C in early breast cancer (data cut-off: 11 Jan 2023)

| Effect                                        | Short description                                   | Unit                                          | Treatment                                     | Control                                       | Uncertaintie s / Strength of evidence                                   | Referen ces                                   |
|-----------------------------------------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------|
| Favourable Effects                            | Favourable Effects                                  | Favourable Effects                            | Favourable Effects                            | Favourable Effects                            | Favourable Effects                                                      | Favourable Effects                            |
| Full analysis set (FAS), n=5,101 participants | Full analysis set (FAS), n=5,101 participants       | Full analysis set (FAS), n=5,101 participants | Full analysis set (FAS), n=5,101 participants | Full analysis set (FAS), n=5,101 participants | Full analysis set (FAS), n=5,101 participants                           | Full analysis set (FAS), n=5,101 participants |
|                                               |                                                     |                                               | Ribociclib + ET N=2,549                       | ET only N=2,552                               |                                                                         |                                               |
| iDFS (primary endpoint)                       | Invasive disease-free survival                      | HR (95% CI) p-value                           | 0.748 (0.618-0.906) p=0.0014 (1-sided)        | 0.748 (0.618-0.906) p=0.0014 (1-sided)        | Final iDFS analysis HR (95% CI) 0.749 (0.628-0.892) p=0.0006 (1- sided) | Data at DCO for IA3 and Final iDFS analysis   |
| OS (secondary endpoint)                       | Overall survival                                    | Median, months HR                             | Not reached                                   | Not reached                                   | OS data immature (3.4%) Final data requested as PAES                    | Final iDFS analysis                           |
| OS (secondary endpoint)                       | Overall survival                                    | (95% CI)                                      | 0.892 (0.661-1.203)                           | 0.892 (0.661-1.203)                           | OS data immature (3.4%) Final data requested as PAES                    | Final iDFS analysis                           |
| Unfavourable Effects n=2524 participants      | Unfavourable Effects n=2524 participants            | Unfavourable Effects n=2524 participants      | Unfavourable Effects n=2524 participants      | Unfavourable Effects n=2524 participants      | Unfavourable Effects n=2524 participants                                | Unfavourable Effects n=2524 participants      |
| TEAEs                                         | Neutropenia Arthralgia Nausea Fatigue ALT increased | %                                             | 41.0 36.5 23.0 21.9 18.9                      | 2.9 42.5 7.5 12.7 5.2                         |                                                                         |                                               |
| Grade 3 and 4                                 | Any                                                 | %                                             | 56.9 and 5.2                                  | 16.1 and 1.6                                  |                                                                         |                                               |
| SAEs                                          | Any                                                 | %                                             | 13.3                                          | 9.9                                           |                                                                         |                                               |
| TEAEs                                         | Any                                                 | %                                             | 20.7 7.0                                      | 5.3 0.1 0                                     |                                                                         |                                               |
| leading to discont.                           | ALT increased                                       |                                               | 2.8                                           |                                               |                                                                         |                                               |
| Deaths                                        | AST increased Due to AEs                            | %                                             | 0.5                                           | 0.2                                           |                                                                         |                                               |

Abbreviations: ET=endocrine therapy (letrozole, anastrozole); PD Disease recurrence/progression

Notes: All endpoints were investigator-assessed. Only iDFS was type 1 error controlled.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

A statistically significant increase in iDFS with ribociclib + ET vs. ET only is shown in the intended population. The relative risk reduction with ribociclib + ET is 25.2%, whereas the absolute 3-years iDFS improvement is 3.3% (data at IA3). The final iDFS analysis confirmed these data. At the final iDFS analysis, almost 80% of the patients had discontinued ribociclib. Although only approximately half of them had completed the intended three years of ribociclib treatment and one fourth discontinued ribociclib prematurely due to AEs, the iDFS curves continued to separate over time. This indicates a sustained treatment effect even after ribociclib discontinuation. As expected in this early breast cancer setting, OS data are still immature but there are no signs of a detrimental effect on OS.

Given the approximately 3% absolute iDFS benefit at three years, a median of &gt;30 months follow-up, a manageable toxicity with a relatively low proportion of on-treatment deaths (n=6 in the ribociclib + ET arm, n=4 in the ET only arm), and comparable proportions of patients who discontinued all treatment components (21.3% in the ribociclib + ET arm, 24.1% in the ET only arm, data at IA3), an effect of ribociclib as add-on to ET is considered established. The remaining uncertainty pertaining to a potential overall survival benefit is considered acceptable, however, to further characterize the long-term benefit of ribociclib in this patient population more mature OS and iDFS data are considered relevant.

These data will be provided as a post approval measure (PAES Annex IID condition) by June 2027.

Given the reduced dose recommended (400 mg QD) in this new patient population, an improved overall safety profile is recognised. The safety profile as characterised in the pivotal study is mainly in line with what has previously been established for ribociclib in combination with ET in aBC patients and no new safety concerns were identified. Given the established benefit, the safety profile is acceptable for the proposed use.

## 3.7.2. Balance of benefits and risks

Efficacy has been established with an acceptable safety profile. Therefore, the benefit/risk is considered positive for this new indication.

## Third party intervention during the evaluation of Kisqali

On 19 October 2023, the CHMP received correspondence from a participant (hereafter referred to as 'third party') in one of the MAH supported ribociclib studies. The third party expressed concerns about the efficacy and safety profile of Kisqali in the adjuvant treatment of breast cancer.

The CHMP considered the interventions and concluded that the concerns put forward by the third party were already addressed in the ongoing assessment and did not impact the CHMP conclusions.

## 3.7.3. Additional considerations on the benefit-risk balance

The current extension of indication application aims to treat early breast cancer in an adjuvant setting and would need to follow ICH M7 guidance for non-clinical development. The non-clinical development supporting the initial MA was conducted according to ICH S9 as ribociclib was intended for the treatment of advanced breast cancer. The N-nitrosoribociclib impurity (N-NRib) is present in trace amounts in ribociclib succinate drug substance and in Ribociclib 200 mg film-coated tablet. N-NRib was tested in three separate Ames tests, all concluding that N-NRib did not induce mutations under the test conditions.

<div style=\"page-break-after: always\"></div>

However, N-NRib was determined to be mutagenic in an in vivo transgenic rodent (TGR) gene mutation assay (Muta™Mouse study). N-NRib limits need to be controlled using the carcinogenic potency categorization approach (CPCA) by applying a maximum acceptable intake (AI) of 400 ng/day (category 3). The applicant proposed changes to the quality module to include measures to minimize the formation of the N-NRib impurity and to ensure control of N-NRib in compliance with the acceptable intake of 400 ng/day throughout the product shelf-life and considering a Maximum Daily Dose (MDD) of 400 mg for the proposed early breast cancer indication.

A type II quality variation to amend the control strategy for the product, including more restrictive storage conditions and a shorter shelf-life has been submitted in Kisqali EMEA/H/C/004213/II/0054 procedure and adopted by CHMP on 17 October 2024. The proposed storage conditions have been proven to keep the levels of N-NRib below the established acceptable intake throughout the product shelf-life. The revised storage conditions are included in the SmPC and disseminated via a DHPC to inform the relevant stakeholders of the changes.

## 3.8. Conclusions

The Benefit Risk balance of Kisqali is positive.

The following measures are considered necessary to address issues related to efficacy:

In order to further evaluate the efficacy of Kisqali for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer, in combination with an aromatase inhibitor, the MAH should submit a 5-year follow-up of iDFS and OS in the NATALEE study. (Annex II.D)

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

The indication is based on study CLEE011O12301C (NATALEE); This is a global, Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with ET versus ET alone as adjuvant treatment in patients with HR-positive, HER2-negative, early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated as well as Annex II.D. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted. In addition,

<div style=\"page-break-after: always\"></div>

the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

This recommendation is subject to the following new condition.

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures.

The measure is a post-authorisation efficacy study (PAES) in accordance with the Commission Delegated Regulation (EU) No 357/2014.

| Description                                                                                                                                                                                                                                                                                                                                                                                                     | Due date   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Post-authorisation efficacy study (PAES): In order to further characterise the efficacy of Kisqali in combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence, the MAH should submit a 5-year follow-up of iDFS and OS in the NATALEE study | June 2027  |